

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>C12N 9/00</b>	<b>A2</b>	<b>(11) International Publication Number:</b> <b>WO 00/52147</b> <b>(43) International Publication Date:</b> 8 September 2000 (08.09.00)
<b>(21) International Application Number:</b> PCT/US00/05551 <b>(22) International Filing Date:</b> 3 March 2000 (03.03.00) <b>(30) Priority Data:</b> 60/123,148 5 March 1999 (05.03.99) US <b>(71) Applicant:</b> UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. [US/US]; 632 Boyd Graduate Studies, Athens, GA 30602-7411 (US). <b>(71)(72) Applicants and Inventors:</b> TRAVIS, James [US/US]; 825 Riverbend Parkway, Athens, GA 30605 (US). POTEPA, Jan [US/US]; Apt. #102, 170 Barrington Drive, Athens, GA 30605 (US). BANBULA, Agnieszka [US/US]; Apt. #E13, 280 Picadilly Square, Athens, GA 30605 (US). <b>(74) Agent:</b> MUETING, Ann, M.; Mueeting, Raasch, Gebhardt, P.A., P.O. Box 581415, Minneapolis, MN 55458-1415 (US).		<b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>
<b>(54) Title:</b> PROLYL PEPTIDASES AND METHODS OF USE  <b>(57) Abstract</b>  The present invention provides isolated polypeptides, prolyl tripeptidyl-peptidases, and active analogs, active fragments or active modifications thereof, having amidolytic activity for cleavage of a peptide bond present in a target peptide having at least 30 amino acids. Isolated nucleic acid fragments encoding isolated prolyl tripeptidyl-peptidases are also provided, as are methods of reducing growth of a bacterium by inhibiting a prolyl tripeptidyl-peptidase.		

BEST AVAILABLE COPY

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## PROLYL PEPTIDASES AND METHODS OF USE

### CONTINUING APPLICATION DATA

This patent application claims the benefit of U.S. provisional patent application No. 60/123,148, filed March 5, 1999, which is incorporated by reference herein.

### GOVERNMENT FUNDING

The present invention was made with government support under Grant No. DE 09761, awarded by the National Institutes of Health. The Government may have certain rights in this invention.

### BACKGROUND OF THE INVENTION

*Porphyromonas gingivalis* (formerly *Bacteroides gingivalis*) is an obligately anaerobic bacterium which is implicated in periodontal disease. *P. gingivalis* produces several distinct proteolytic enzymes, many of which are recognized as important virulence factors. A number of physiologically significant proteins, including collagen, fibronectin, immunoglobulins, complement factors C3, C4, C5, and B, lysozyme, iron-binding proteins, plasma proteinase inhibitors, fibrin and fibrinogen, and factors of the plasma coagulation cascade system, are hydrolyzed by *P. gingivalis* proteases. Broad proteolytic activity plays a role in the evasion of host defense mechanisms and the destruction of gingival connective tissue in progressive periodontitis.

Progressive periodontitis is characterized by acute tissue degradation promoted by collagen digestion and a vigorous inflammatory response characterized by excessive neutrophil infiltration. Gingival crevicular fluid accumulates in periodontitis as periodontal tissue erosion progresses at the foci of the infection, and numerous plasma proteins are exposed to proteinases expressed by the bacteria at the injury site. Neutrophils are recruited to the gingiva, in part, by the humoral chemotactic factor C5a. The complement components C3 and C5 are activated by complex plasma proteases with "trypsin-like" specificities called convertases. The human plasma convertases

cleave the  $\alpha$ -chains of C3 and C5 at a specific site generating biologically active factors known as anaphylatoxins (i.e. C3a and C5a). The anaphylatoxins are potent proinflammatory factors exhibiting chemotactic and/or spasmogenic activities as well as promoting increased vascular permeability. The larger products from C3 and C5 cleavage (i.e. C3b and C5b) participate in functions including complement cascade activation, opsonization, and lytic complex formation.

Recent studies have indicated that this periodontopathogen produces at least seven different enzymes belonging to the cysteine and serine catalytic classes of peptidases, among which three cysteine proteinases (gingipains) are predominant (Potempa, J., et al. (1995) *Prospect. Drug Discovery and Design* 2, 445-458). The gingipains are the best characterized group of *P. gingivalis* enzymes as their structure, function, enzymatic properties and pathological significance are known. From *in vitro* studies it is apparent that two gingipains R (also referred to generally as "Arg-gingipains" and more specifically as RgpA and RgpB), enzymes specific for cleavage at Arg-Xaa peptide bonds, have a significant potential to contribute to the development and/or maintenance of a pathological inflammatory state in infected periodontal pockets through: (i) activation of the kallikrein-kinin cascade, (ii) the release of neutrophil chemotactic activity from native and oxidized C5 of the complement pathway, and (iii) activation of factor X. In addition, gingipain K (also referred to as "Lys-gingipain"), an enzyme which cleaves Lys-Xaa peptide bonds, degrades fibrinogen. This may add to a bleeding on probing tendency associated with periodontitis. Finally, the presence of a hemagglutinin/adhesion domain in the non covalent multiprotein complexes of RgpA and gingipain K suggests participation of these enzymes in the binding of *P. gingivalis* to extracellular matrix proteins which may facilitate tissue invasion by this pathogen.

In comparison to the gingipains, relatively little is known about other cysteine proteinases produced by *P. gingivalis*. Two genes, referred to as *tp*r and *p*rtT have been cloned and sequenced and although they encode a putative papain-like and streptopain-like cysteine proteinases, respectively, neither has been purified and characterized.



The presence of serine proteinase activity in cultures of *P. gingivalis* has been known for several years; however, only limited information is available about such enzymes. Indeed, a serine endopeptidase has been isolated from culture media, although it was only superficially characterized (Hinode D., et al.,  
5 (1993) *Infect. Immun.* 59, 3060-3068). On the other hand, an enzyme referred to as glycylprolyl peptidase (DPP IV) was found to be associated with bacterial surfaces and two molecular mass forms of this peptidase have been described. This enzyme has also been shown to possess the ability to hydrolyze partially degraded type I collagen, releasing the Gly-Pro dipeptide, and it was suggested  
10 that, in collaboration with collagenase, glycylprolyl peptidase may contribute to the destruction of the periodontal ligament (Abiko, Y., et al. (1985) *J.Dent. Res.* 64, 106-111). In addition to this potential pathological function, glycylprolyl peptidase may also play a vital role in providing *P. gingivalis* with dipeptides which can be transported inside the cell and serve as a source of carbon,  
15 nitrogen, and energy for this asaccharolytic organism. Recently, a gene encoding glycylprolyl peptidase in *P. gingivalis* has been cloned and sequenced, and it is now apparent that this enzyme is homologous to dipeptidyl-peptidase IV (DPP-IV) from other organisms (Kiyama, M., et al. (1998) 1396, 39-46). The nucleotide sequence of the genome of this bacterium is currently being  
20 determined by The Institute for Genomic Research, and is available at [www.tigr.org](http://www.tigr.org).

### SUMMARY OF THE INVENTION

The present invention is directed to an isolated prolyl tripeptidyl-  
25 peptidase, active analog, active fragment, or active modification thereof having amidolytic activity for cleavage of a peptide bond present in a target polypeptide having at least 4 amino acids. Alternatively, the isolated prolyl tripeptidyl-peptidase, active analog, active fragment, or active modification thereof is isolated from *P. gingivalis*. Typically, amidolytic activity is determined with a  
30 prolyl tripeptidyl-peptidase:target polypeptide ratio of at least about 1:1 to no greater than about 1:10,000,000 in about 200 mM HEPES, about pH 7.5 at 37°C for at least about 3 hours. The peptide cleaved by the isolated prolyl tripeptidyl-peptidase can include the sequence of SEQ ID NO:1, SEQ ID NO:2, SEQ ID

NO:7, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:11, H-Ala-Arg-Pro-Ala-D-Lys-amide, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:25, or SEQ ID NO:37. The amino acid sequence of the isolated prolyl tripeptidyl-peptidase can include the amino acid sequence GXSTXXG (SEQ ID NO:39), the amino acid sequence GXSTXGG (SEQ ID NO:40), or the amino acid sequence of SEQ ID NO:30.

Another aspect of the invention is an isolated polypeptide, active analog, active fragment, or active modification thereof having amidolytic activity for cleavage of a peptide bond present in a target polypeptide having at least 4 amino acids. Typically, the polypeptide:target polypeptide ratio of at least about 1:1 to no greater than about 1:10,000,000 in about 200 mM HEPES, about pH 7.5 at 37°C for at least about 3 hours.

The invention is also directed to an isolated polypeptide comprising an amino acid sequence having a percentage amino acid identity of greater than 35 % with SEQ ID NO:30.

An alternative aspect of the invention is an isolated nucleic acid fragment encoding a prolyl-tripeptidyl peptidase, active analog, active fragment, or active modification thereof, having amidolytic activity for cleavage of a peptide bond present in a target polypeptide having at least 4 amino acids. Typically, the prolyl tripeptidyl-peptidase:target polypeptide ratio of at least about 1:1 to no greater than about 1:10,000,000 in about 200 mM HEPES, about pH 7.5 at 37°C for at least about 3 hours. The nucleic acid fragment can have a nucleotide sequence comprising SEQ ID NO:38. A complement of the nucleic acid fragment can hybridize to SEQ ID NO:38 under hybridization conditions of 0.5 M phosphate buffer, pH 7.2, 7 % SDS, 10 mM EDTA, at 68°C, followed by three for 20 minutes washes in 2x SSC, and 0.1 % SDS, at 65°C, wherein at least about 20 nucleotides of the complement hybridize.

Another aspect of the invention is an isolated nucleic acid fragment encoding a polypeptide that includes an amino acid sequence having a percentage amino acid identity of greater than 35 % with SEQ ID NO:30.

The invention is also directed at a method of identifying an inhibitor of a prolyl-tripeptidyl peptidase, active analog, active fragment, or active modification thereof, including identifying a molecule that inhibits the

amidolytic activity of the prolyl-tripeptidyl peptidase. The inhibitor is identified by incubating the prolyl-tripeptidyl peptidase with the molecule under conditions that promote amidolytic activity of the prolyl-tripeptidyl peptidase and determining if the amidolytic activity of the prolyl-tripeptidyl peptidase is inhibited relative to the amidolytic activity in the absence of molecule.

An aspect of the invention is a method of reducing growth of a bacterium. This method includes inhibiting a prolyl tripeptidyl-peptidase, active analog, active fragment, or active modification thereof, or a prolyl dipeptidyl-peptidase, active analog, active fragment, or active modification thereof. The method includes contacting the prolyl tripeptidyl-peptidase with an inhibitor of the prolyl tripeptidyl-peptidase. The method can be used to protect an animal from a periodontal disease caused by *P. gingivalis* including administering to the animal the inhibitor. The disease can be selected from the group consisting of gingivitis and periodontitis. The inhibitor can be administered by a method selected from the group consisting of subgingival application and controlled release delivery.

Another aspect of the invention is an immunogenic composition including an isolated prolyl tripeptidyl-peptidase, or an antigenic analog, antigenic fragment, or antigenic modification thereof, the prolyl tripeptidyl-peptidase having amidolytic activity for cleavage of a peptide bond present in a target peptide having at least 4 amino acids. Typically, the prolyl tripeptidyl-peptidase:target polypeptide ratio is at least about 1:1 to no greater than about 1:10,000,000 in about 200 mM HEPES, about pH 7.5 at 37°C for at least about 3 hours. The immunogenic composition can include an adjuvant.

The invention is also directed to a composition including an inhibitor of an isolated prolyl tripeptidyl-peptidase and a pharmaceutically acceptable carrier.

Additional aspects of the invention include a dipeptidyl peptidase having an amino acid sequence including SEQ ID NO:43, SEQ ID NO:44, or SEQ ID NO:45.

### Definitions

“Polypeptide” as used herein refers to a polymer of amino acids and does not refer to a specific length of a polymer of amino acids. Thus, for example, the terms peptide, oligopeptide, protein, and enzyme are included within the definition of polypeptide. This term also includes post-expression modifications of the polypeptide, for example, glycosylations, acetylations, phosphorylations, and the like. A polypeptide can be produced by an organism, or produced using recombinant techniques, or chemically or enzymatically synthesized.

“Peptidase,” “proteinase,” and “protease” all refer to enzymes that catalyze the hydrolysis of peptide bonds in a polypeptide. A “peptide bond” or “amide bond” is a covalent bond between the alpha-amino group of one amino acid and the alpha-carboxyl group of another amino acid. “Peptidase inhibitor,” “proteinase inhibitor,” “protease inhibitor,” and “inhibitor” all refer to molecules that inhibit a peptidase that catalyzes the hydrolysis of peptide bonds in a polypeptide.

As used herein, the term “isolated” means that a polypeptide or a nucleic acid fragment has been either removed from its natural environment, produced using recombinant techniques, or chemically or enzymatically synthesized. Preferably, the polypeptide or nucleic acid fragment is purified, i.e., essentially free from any other polypeptides or nucleic acid fragments and associated cellular products or other impurities.

“Amidolytic activity” refers to the ability of a polypeptide to catalyze the hydrolysis of at least one peptide bond in a polypeptide. The term “cleavage” can also be used to refer to the hydrolysis of a peptide bond in a polypeptide. “Prolyl-tripeptidyl peptidase” and “PTP” refer to a polypeptide having a particular “amidolytic activity”. A “prolyl-tripeptidyl peptidase” is able to hydrolyze the peptide bond between the proline and the Yaa residues in a target polypeptide with the general formula  $\text{NH}_2\text{-Xaa-Xaa-Pro-Yaa-(Xaa)}_n$  (SEQ ID NO:25), wherein Xaa is a natural or modified amino acid, Yaa is a natural or modified amino acid except proline, and the  $\alpha$ -amino of the amino terminal residue is not blocked. A “prolyl tripeptidyl-peptidase” does not have to cleave all members of the target peptide. The term “natural amino acid” refers to the 20 amino acids typically produced by a cell. The term “modified amino acid”

refers to, for instance, acetylation, hydroxylation, methylation, amidation, and the attachment of carbohydrate or lipid moieties, cofactors, and the like.

A "target polypeptide" is a polypeptide that is the potential substrate of the amidolytic activity of a prolyl tripeptidyl-peptidase.

5       An active analog, active fragment, or active modification of a polypeptide of the invention is one that has amidolytic activity by hydrolysis of a peptide bond present in the target polypeptide as described herein. Active analogs, fragments, and modifications are described in greater detail herein.

10       "Nucleic acid fragment" as used herein refers to a linear polymeric form of nucleotides of any length, either ribonucleotides or deoxynucleotides, and includes both double- and single-stranded DNA and RNA. A nucleic acid fragment may include both coding and non-coding regions that can be obtained directly from a natural source (e.g., a microorganism), or can be prepared with the aid of recombinant or synthetic techniques. A nucleic acid molecule may be  
15       equivalent to this nucleic acid fragment or it can include this fragment in addition to one or more other nucleotides or polynucleotides. For example, the nucleic acid molecule of the invention can be a vector, such as an expression of cloning vector.

20       "Percentage amino acid identity" refers to a comparison of the amino acids of two polypeptides as described herein.

### BRIEF DESCRIPTION OF THE FIGURES

25       **Fig. 1. Purification of the prolyl tripeptidyl peptidase from the acetone precipitate of the *P. gingivalis* cell extracts. Absorbance at 280 nm (open triangles), amidolytic activity against H-Ala-Phe-Pro-pNA (closed diamonds), and H-Gly-Pro-pNA (closed circles). (a) Separation of PTP-A on hydroxyapatite. (b) Separation of PTP-A on Phenyl-Sepharose HP. (c) Separation of PTP-A on MonoQ FPLC. (d) Chromatofocusing of PTP-A on Mono-P.**

30       **Fig. 2. SDS -PAGE of fractions from purification of PTP-A and the autoradiography of the purified enzyme. Lane a, molecular mass markers (phosphorylase B, 97 kDa; bovine serum albumin, 68 kDa; ovalbumin, 43 kDa; carbonic anhydrase, 30 kDa; soybean trypsin inhibitor, 20 kDa;  $\alpha$ -lactalbumin, 14**

kDa); *lane b*, acetone precipitate from Triton X-100 extract of *P. gingivalis*, *lane c*: hydroxyapatite column eluate; *lane d*, Phenyl-Sepharose column eluate; *lane e*, MonoQ column eluate; *lane f*, purified PTP-A from MonoP column wash; *lane g*, autoradiograph of  $^3\text{H}$ -DFP labeled enzyme exposed for 96 h to X-ray film. All samples were reduced and boiled prior to PAGE analysis.

**Fig. 3. Multiple sequence alignment of *P. gingivalis* PTP-A (PTP-A) and its bacterial and eukaryotic homologues.** Pg-DPP, DPP from *P. gingivalis* (Kiyama, M., et al., (1998) *Bioch. Bioph. Acta* **1396**, 39-46) containing an amino-terminal sequence corrected according to the *P. gingivalis* W83 genome data available from The Institute of Genomic Research at [www.tigr.org](http://www.tigr.org)); Fm-DPP, DPP from *Flavobacterium meningosepticum*; Hs-DPP, human DPP IV; and Mm-FAP, mouse fibroblast activation protein. Peptide sequences obtained from PTP-A analysis described herein are indicated with arrows (note that the sequence of the peptide 81-97 corresponds to the N-terminus of the lower molecular weight form of PTP-A); catalytic triad is marked with asterisks; and the proposed PTP-A membrane-anchoring N-terminal  $\alpha$ -helix is double-underlined. Homologous regions (i.e., regions of identical amino acids and/or conservative substitutions) are highlighted. Identical regions are shown as white letters on a black background.

**Fig. 4. Comparison of *P. gingivalis* PTP-A and DPP active site domains to corresponding sequences of three putative homologues identified within the *P. gingivalis* genome (DPP-H1, DPP-H2 and DPP-H3).** Sequences of *P. gingivalis* PTP-A, DPP, DPP-H1, DPP-H2, and DPP-H3 were obtained from conceptual translation of the following open reading frames retrieved from The Institute for Genomic Research (TIGR) unfinished *P. gingivalis* genome database: gnl | TIGR | *P. gingivalis* contig 126 (positions 13 228 – 15 426), contig 87 (positions 6 424 – 4 399), contig 65 (positions 161 – 1 786), contig 101 (positions 8 895 – 6 845), and contig 9 (positions 4 216 – 2 162), respectively. Residues predicted as catalytic triads are marked with asterisks. Homologous regions (i.e., regions of identical amino acids and/or conservative substitutions) are highlighted.

Identical regions are shown as white letters on a black background. Similar regions (i.e., conservative substitutions) are shown as white letters on a grey background.

5 **Fig. 5. Influence of Pefabloc-serine proteinase inhibitor on *P. gingivalis* growth.**

**Fig. 6. Comparison of *P. gingivalis* PTP-A and DPP to sequences of three putative homologues identified within the *P. gingivalis* genome (DPP-H1, DPP-H2 and DPP-H3).** Sequences of *P. gingivalis* PTP-A (126PP), DPP (87PP),  
10 DPP-H1 (65PP), DPP-H2 (101PP), and DPP-H3 (9PP) were obtained as described in Fig. 4. Homologous regions (i.e., regions of identical amino acids and/or conservative substitutions) are highlighted. Identical regions are shown as white letters on a black background. Similar regions (i.e., conservative substitutions) are shown as white letters on a grey background.

15 **Fig. 7. Nucleotide sequence (SEQ ID NO:38) and amino acid sequence (SEQ ID NO:30) of PTP-A.**

#### DETAILED DESCRIPTION OF THE INVENTION

20 The present invention provides isolated polypeptides, preferably isolated prolyl peptidases, more preferably prolyl dipeptidyl-peptidases and prolyl tripeptidyl-peptidases, most preferably prolyl-tripeptidyl peptidases, that have amidolytic activity by hydrolysis of a peptide bond present in a target polypeptide, where the bond is between a proline and an amino acid residue attached to the  
25 alpha-carboxyl group end of the proline.

When the prolyl peptidase is a prolyl tripeptidyl-peptidase, the peptidase has amidolytic activity by hydrolysis of a peptide bond present in a target polypeptide of the general formula  $\text{NH}_2\text{-Xaa-Xaa-Pro-Yaa-(Xaa)}_n$  (SEQ ID NO:25), wherein Xaa is a natural or modified amino acid, Yaa is a natural or  
30 modified amino acid except proline, and the  $\alpha$ -amino of the amino terminal residue is not blocked, wherein the peptide bond of the target polypeptide that is hydrolyzed is the Pro-Yaa peptide bond. Preferably, isolated polypeptides do not cleave a target peptide having a blocked  $\alpha$ -amino of the amino terminal residue.

Preferably, the only peptide bond of the target peptide that is hydrolyzed is the Pro-Yaa bond. In increasing order of preference, isolated polypeptides can cleave a target peptide that is at least 4 amino acids or at least 300 Da, at least 10 amino acids or at least 750 Da, at least 20 amino acids or at least 1,500 Da, or at least 30 amino acids or at least 3,000 Da. Preferably, the prolyl-tripeptidyl peptidases cleave peptides 1, 2, 7, 8, and 10-15 shown in Table 3, human cystatin C, and interleukin 6.

When the prolyl peptidase is a prolyl dipeptidyl-peptidase, the peptidase has amidolytic activity by hydrolysis of a peptide bond present in a target polypeptide of the general formula  $\text{NH}_2\text{-Xaa-Zaa-Yaa-(Xaa)}_n$  (SEQ ID NO:12), wherein Xaa is a natural or modified amino acid, Zaa is a proline or alanine, Yaa is a natural or modified amino acid except proline or hydroxyproline, and the  $\alpha$ -amino of the amino terminal residue is not blocked, wherein the peptide bond of the target polypeptide that is hydrolyzed is the Zaa-Yaa peptide bond. Preferably, isolated polypeptides does not cleave a target peptide having a blocked  $\alpha$ -amino of the amino terminal residue. Preferably, the only peptide bond of the target peptide that is hydrolyzed is the Pro-Yaa bond.

Due to their cyclic aliphatic character proline residues bestow unique conformational constraints on polypeptide chain structures, significantly affecting the susceptibility of proximal peptide bonds to proteolytic cleavage. Those proline residues, which often appear near the amino-termini of many biologically active peptides, may protect them against proteolytic degradation by peptidases with general specificity. A specialized group of proteolytic enzymes, typically referred to as prolyl peptidases, has evolved to cleave (i.e., hydrolyze) a peptide bond adjacent to a proline residue in a polypeptide. The peptide bond adjacent to a proline residue can be referred to as a prolyl-X bond, where prolyl is the proline residue, and X is an amino acid residue attached to the alpha-carboxyl group end of the proline. The bacterial prolyl peptidases can cleave a polypeptide to liberate a tripeptide or a dipeptide. Prolyl peptidases that do not cleave a target peptide if the  $\alpha$ -amino of the amino terminal residue is blocked can be referred to as exopeptidases. The *in vivo* activity of these specialized proteolytic enzymes may have important physiological significance, because it may lead to inactivation of many biologically active peptides and/or transformation of the activity of other



biologically active peptides. In addition, hydrolysis of prolyl-X bonds in conjunction with general catabolic pathways should allow the complete re-utilization of amino acids by living organisms, including bacteria. However, prolyl peptidases from bacterial pathogens, if released into the host environment, may interfere with the physiological functions of biologically active polypeptides and, therefore, contribute to the pathogenicity of infectious disease.

The external (i.e., cell surface) localization and uncontrolled activity of bacterial peptidases, including prolyl peptidases, likely contributes significantly to run-away inflammation in the human host and the pathological degradation of connective tissue during periodontitis. For instance, working in concert bacterial prolyl peptidases (e.g., prolyl tripeptidyl peptidases and DPP IV) have the ability to completely degrade collagen fragments locally generated by endogenous or bacterial collagenases. Because type I collagen is the major component of periodontal ligament, its enhanced degradation by bacterial prolyl peptidases may contribute to loss of tooth attachment and periodontal pocket formation. Thus, there is a need in the art to characterize bacterial peptidases to facilitate the development of therapies to inhibit the activity of the bacterial peptidases.

The polypeptides of the present invention, preferably prolyl peptidases, can be used as a source of antibodies for inhibiting the peptidase activity and thereby possibly reducing periodontitis, loss of tooth attachment and periodontal pocket formation. Antibodies to prolyl peptidases can also be used to identify and/or isolate additional prolyl peptidases. Knowledge of prolyl peptidases can also be used to make inhibitors of prolyl peptidases and to make immunogenic compositions that could be used to elicit the production of antibodies to prolyl peptidases and thereby possibly reduce gingivitis, periodontitis, loss of tooth attachment, and/or periodontal pocket formation.

An example of a prolyl-tripeptidyl peptidase is prolyl-tripeptidyl peptidase A (SEQ ID NO:30) (also referred to as PTP-A) from *P. gingivalis*. Purified PTP-A has apparent molecular masses of 81.8 and 75.8 kDa. The lower molecular mass peptidase may be due to the proteolytic cleavage of the peptidase from the surface of *P. gingivalis*. PTP-A is a new member of clan SC, family S9 of serine peptidases. Clans of serine peptidases are grouped on the basis of the order of certain amino acids in the polypeptide that make up the "catalytic triad" which

plays a pivotal role peptidase activity. The members of the clan SC are characterized by the catalytic triad in the polypeptide in the order of serine, aspartic acid, and histidine. Members of the clan SC are also characterized by a tertiary structure including  $\beta/\alpha/\beta$  units, and an  $\alpha/\beta$  hydrolase fold. In addition to the catalytic triad order, the amino acid sequence GX $\beta$ XXG (SEQ ID NO:39), where X is any amino acid and S is the active site serine, is a signature of all members of the clan SC with some distinguishing features specific for each family. Family S9 has the consensus sequence GX $\beta$ XXGG (SEQ ID NO:40). Besides this consensus sequence, there is a general similarity of primary structures which classifies peptidases to this family. For instance, peptidases of this family generally have two domains, an amino-terminal domain that contains a membrane binding domain, and a carboxy-terminal domain, also referred to as the catalytic domain. The catalytic domain contains the residues of the catalytic triad. Some members of the S9 family have only the catalytic domain.

The S9 family is diverged and divided in three subfamilies: S9A, cytosolic oligopeptidases from archae and eukaryotes; S9B, eukaryotic acylaminoacylpeptidases; and S9C, dipeptidyl peptidase IV from bacteria and eukaryotes. The catalytic domain of peptidases from family S9 typically begin at about residue 400 of SEQ ID NO:30 and include the remaining carboxy-terminal amino acids (see, e.g., Fulop, et al., (1998) *Cell* 94, 161-170). Despite structural similarities to peptidases from the S9 family, the tripeptidyl-peptidase activity of PTP-A is unusual for this family of enzymes, and no other known similar activity has so far been attributed to any other member of the S9 family. In fact, all strict tripeptidyl-peptidases belong only to the subtilisin family (S8) and S33 family of serine peptidases; however, they neither share a structural relationship with PTP-A nor have activity limited to cleavage after proline residues. In particular, there are no other known prolyl tripeptidyl peptidases with an activity that is increased by iodoacetamide relative to the same prolyl tripeptidyl peptidase in the absence of iodoacetamide under the same conditions. Iodoacetamide is a compound that is traditionally a peptidase inhibitor. Typically, the activity of a prolyl tripeptidyl peptidase is increased about two-fold. Furthermore, unlike oligopeptidases, the prolyl tripeptidyl-peptidases of the present invention can cleave target peptidases having as few as 4 amino acids but also target peptides having at least 30 amino

acids or a molecular weight of at least 3,000 Da. In these respects, the *P. gingivalis* tripeptidyl peptidase is a unique enzyme, and the isolation and characterization of this novel bacterial prolyl peptidase will facilitate the development of therapies to inhibit the activity of the bacterial peptidases.

5           Examples of putative prolyl-dipeptidyl peptidases are DPP-H1 (SEQ ID NO:43), DPP-H2 (SEQ ID NO:44), and DPP-H3 (SEQ ID NO:45). These peptidases have a significant percentage amino acid similarity with DPP IV and PTP-A (see Fig. 6). Each dipeptidyl peptidase is expected to have enzymatic activity, as each has a well preserved catalytic triad (Fig. 4). DPP IV has been  
10 characterized and the gene encoding the peptidase has been cloned, however the substrate specificity has not been well characterized. DPP IV has been found to cleave SEQ ID NOs:6, 20, 23, and 24. DPP IV has been purified in two forms. One of the forms is a full length gene translation product containing a blocked amino-terminal residue. The second form had the amino-terminal amino acid  
15 sequence HSYRAAVYDYDVRRLVKPLSEHVG (SEQ ID NO:48), which corresponds to residues 116-140 of DPP IV (Kiyama, M., et al. (1998) 1396, 39-46), indicating that it was proteolytically truncated on the amino-terminus.

          In *P. gingivalis*, PTP-A and DPP IV activity is cell surface associated. While not intending to be limiting, it is conceivable that the enzyme is membrane  
20 anchored through a putative signal sequence which is not cleaved but remains as a membrane spanning domain similar to other members of the prolyl oligopeptidase family. However, a significant portion of the purified PTP-A has a truncated N-terminus, apparently due to cleavage by Lys-specific peptidase and likely to be an artifact which has occurred during the purification procedure. Nevertheless,  
25 membrane bound PTP-A and DPP IV is proteolytically cleaved and shed during cultivation of the bacteria, as indicated by variable amount of soluble activities found in cell free culture media. The cell surface localization of PTP-A supports a putative physiological function in providing nutrients for growing bacterial cells. The inability of asaccharolytic *P. gingivalis* to utilize free amino acids makes the  
30 bacterium entirely dependant on an external peptide supply. In this regard, PTP-A and DPP IV activities are probably very important, if not indispensable, for bacterial growth, and inhibition of prolyl tripeptidyl-peptidases and dipeptidyl-peptidases may inhibit the *in vivo* growth of organisms, including *P. gingivalis*.

For instance, treatment of *P. gingivalis* cultures in lagphase (i.e., the period after inoculation of a culture and before the organism begins to divide) and early logarithmic growth with the inhibitors PEFABLOCK and 3,4-dichloroisocoumarin inhibits growth of *P. gingivalis*.

5            Preferably, a polypeptide of the invention, preferably a prolyl peptidase, contains the amino acid sequence GXSTXXG (SEQ ID NO:39), most preferably, GXSTXGG (SEQ ID NO:40), where G is glycine, X is any amino acid, and S is the active site serine. The active site serine can be identified by, for instance, labeling with diisopropylfluorophosphate as described herein. Preferably, the catalytic  
10            domain of the prolyl tripeptidyl-peptidases of the invention begins at about residue 400 of SEQ ID NO:30 and includes the remaining carboxy-terminal amino acids and the corresponding amino acids of SEQ ID NOs:43-45 (see Fig. 6), more preferably, at about residue 502 of SEQ ID NO:30 and includes the remaining carboxy-terminal amino acids and the corresponding amino acids of SEQ ID  
15            NOs:43-45 (see Fig. 6), most preferably, at about residue 556 of SEQ ID NO:30 and includes the remaining carboxy-terminal amino acids and the corresponding amino acids of SEQ ID NOs:43-45 (see Fig. 6).

            The invention further includes a polypeptide, preferably a prolyl tripeptidyl-peptidase, that shares a significant level of primary structure with SEQ ID NO:30.  
20            The two amino acid sequences (i.e., the amino acid sequence of the polypeptide and the sequence SEQ ID NO:30) are aligned such that the residues that make up the catalytic triad, i.e., the serine, aspartic acid, and the histidine, are in register, then further aligned to maximize the number of amino acids that they have in common along the lengths of their sequences; gaps in either or both sequences are permitted  
25            in making the alignment in order to place the residues of the catalytic triad in register and to maximize the number of shared amino acids, although the amino acids in each sequence must nonetheless remain in their proper order. The percentage amino acid identity is the higher of the following two numbers: (a) the number of amino acids that the two sequences have in common within the  
30            alignment, divided by the number of amino acids in SEQ ID NO:30, multiplied by 100; or (b) the number of amino acids that the two sequences have in common within the alignment, divided by the number of amino acids in the candidate polypeptide, multiplied by 100. Preferably, a prolyl tripeptidyl peptidase has

greater than 35 % identity, more preferably at least about 40 % identity, most preferably at least about 45 % identity with SEQ ID NO:30. Preferably, amino acids 154-732 of SEQ ID NO:30 are used, more preferably amino acids 400-732 of SEQ ID NO:30 are used. An isolated polypeptide comprising an amino acid  
5 sequence having a percentage amino acid identity of greater than 35 % with SEQ ID NO:30.

In general, the amidolytic activity of the polypeptides of the invention, preferably prolyl peptidases, can be measured by assay of the cleavage of a target polypeptide in the presence of prolyl peptidase and a buffer. Preferably, the lower  
10 ratio of prolyl tripeptidyl-peptidase to target polypeptide is at least about 1:1, more preferably at least about 1:100, even more preferably at least about 1:1,000, most preferably at least about 1:10,000. Preferably, the higher ratio of prolyl peptidase to target polypeptide is no greater than about 1:10,000,000, more preferably no greater than about 1:1,000,000 and most preferably no greater than about  
15 1:100,000. Buffers in which a prolyl peptidase is active are suitable for the assay. Preferably, the buffer is about 200 mM HEPES (N-2-hydroxyethylpiperazine,N'-2-ethansulfonic acid), more preferably about 50 mM HEPES, most preferably about 20 mM HEPES. Preferably, the pH of the buffer is at least about pH 6.0 and no greater than pH 8.0, more preferably about pH 7.5. Preferably, the temperature of  
20 the assay is at about 37°C. The assay can be carried out for at least about 1 minute to no greater than 24 hours. Preferably, the amidolytic activity of the prolyl peptidases are measured at a prolyl peptidase:target polypeptide ratio of at least about 1:100 to no greater than 1:1,000,000 in about 200 mM HEPES, about pH 7.5 at about 37°C for at least about 3 hours. In general, the time of the assay can vary  
25 depending on the substrate and enzyme:substrate ratio. Typically, target peptides are stable under these conditions, and typically it is difficult to detect background levels of hydrolysis in the absence of a prolyl peptidase. Preferably, the assay is allowed to continue until at least 1 % of the target peptide is hydrolyzed.

Prolyl-tripeptidyl peptidases of the present invention preferably are  
30 inhibited by a compound chosen from the group consisting of PEFABLOCK (4-(2-aminoethyl)-benzenesulfonyl-fluoride hydrochloride), diisopropylfluorophosphate, and 3,4-dichloroisocoumarin, more preferably PEFABLOCK and diisopropylfluorophosphate, and most preferably diisopropylfluorophosphate. The

peptidases of the present invention are preferably not inhibited by a compound chosen from the group consisting of leupeptin, antipain, E-64, pepstatin,  $\alpha_1$ -proteinase inhibitor,  $\alpha_1$ -antichymotrypsin and  $\alpha_2$ -macroglobulin, most preferably. Significantly and unexpectedly, the amidolytic activity of a prolyl-tripeptidyl  
5 peptidase of the present invention is increased by iodoacetamide relative to the prolyl-tripeptidyl peptidase in the absence of iodoacetamide under the same conditions. Preferably, the effect of iodoacetamide on amidolytic activity is measured by incubating in 200 mM HEPES, pH 7.6, at least about 0.1 nM of the prolyl tripeptidyl-peptidase with the inhibitor for about 15 minutes, adding about 1  
10 mM of H-Ala-Phe-Pro-pHA, and incubating for at least about 1 minute before assaying for amidolytic activity. Typically, at least about 1 mM to no greater than 100 mM of inhibitor is used.

The polypeptides of the invention include a polypeptide having SEQ ID NO:30, or an active analog, active fragment, or active modification of SEQ ID  
15 NO:30. An active analog, active fragment, or active modification of a polypeptide having SEQ ID NO:30 is one that has amidolytic activity by hydrolysis of the Pro-Yaa peptide bond present in a target polypeptide of the general formula  $\text{NH}_2\text{-Xaa-Xaa-Pro-Yaa-(Xaa)}_n$  (SEQ ID NO:25). Active analogs of a polypeptide having SEQ ID NO:30 include prolyl-tripeptidyl peptidases having amino acid  
20 substitutions that do not eliminate hydrolysis of SEQ ID NO:25 at the Pro-Yaa peptide bond. Substitutes for an amino acid may be selected from other members of the class to which the amino acid belongs. For example, nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and tyrosine. Polar neutral amino acids include glycine, serine,  
25 threonine, cysteine, tyrosine, asparagine and glutamine. The positively charged (basic) amino acids include arginine, lysine and histidine. The negatively charged (acidic) amino acids include aspartic acid and glutamic acid. Examples of preferred conservative substitutions include Lys for Arg and *vice versa* to maintain a positive charge; Glu for Asp and *vice versa* to maintain a negative charge; Ser for  
30 Thr so that a free -OH is maintained; and Gln for Asn to maintain a free  $\text{NH}_2$ .

Active fragments of a prolyl-tripeptidyl peptidase of the invention include prolyl-tripeptidyl peptidases containing deletions or additions of one or more contiguous or noncontiguous amino acids such that the resulting polypeptide will

hydrolyze SEQ ID NO:25 at the Pro-Yaa peptide bond. An example of a fragment of a prolyl-tripeptidyl peptidase is a catalytic domain. Modified prolyl-tripeptidyl peptidases include prolyl-tripeptidyl peptidases that are chemically and enzymatically derivatized at one or more constituent amino acid, including side chain modifications, backbone modifications, and N- and C- terminal modifications including acetylation, hydroxylation, methylation, amidation, and the attachment of carbohydrate or lipid moieties, cofactors, and the like. Modified prolyl-tripeptidyl peptidases will hydrolyze SEQ ID NO:25 at the Pro-Yaa peptide bond.

Prolyl peptidases can be obtained by several methods. Isolation of a prolyl-tripeptidyl peptidase present on the surface of a cell producing the peptidase typically requires lysis of the cell followed by purification methods that are well known in the art. Alternatively, cells can be treated with a detergent, for instance Triton X-100, to remove the peptidase from the cell surface. The following are nonlimiting examples of suitable protein purification procedures: fractionation on immunoaffinity, ion-exchange, hydroxyapatite, Phenyl-Sepharose HP, MonoQ HR 5/5, or MonoP columns; ethanol precipitation; reverse phase HPLC; chromatography on silica or on an ion-exchange resin such as DEAE; chromatofocusing; SDS-PAGE; ammonium sulfate precipitation; gel filtration using, for example, Sephadex G-75. Preferably, isolation of a prolyl-tripeptidyl peptidase from *P. gingivalis* is accomplished using a combination of hydroxyapatite, Phenyl-Sepharose HP, MonoQ HR 5/5 and MonoP column chromatography steps as described herein.

Prolyl peptidases can also be isolated from organisms other than *P. gingivalis*. Other organisms can express a prolyl-tripeptidyl peptidase that is encoded by a coding region having similarity to the PTP-A coding region. A "coding region" is a linear form of nucleotides that encodes a polypeptide, usually via mRNA, when placed under the control of appropriate regulatory sequences. The boundaries of a coding region are generally determined by a translation start codon at its 5' end and a translation stop codon at its 3' end. "Regulatory region" refers to a nucleic acid fragment that regulates expression of a coding region to which a regulatory region is operably linked. Non limiting examples of regulatory regions include promoters, transcription initiation sites, translation start sites, translation

stop sites, and terminators. "Operably linked" refers to a juxtaposition wherein the components so described are in a relationship permitting them to function in their intended manner. A regulatory element is "operably linked" to a coding region when it is joined in such a way that expression of the coding region is achieved under conditions compatible with the regulatory region. Alternatively, other organisms can express a prolyl-tripeptidyl peptidase from a recombinant coding region encoding the peptidase. The identification of similar coding regions in other organisms can be accomplished as described herein. A prolyl-tripeptidyl peptidase can be isolated using purification methods that are well known in the art.

Alternatively, the peptidase can be chemically synthesized using methods that are well known in the art including, for instance, solid phase synthesis. Examples of, for instance, coding and regulatory regions are described herein.

The expression of a prolyl-tripeptidyl peptidase by an organism other than *P. gingivalis* can be detected using specific substrates of the general formula  $\text{NH}_2\text{-Xaa-Xaa-Pro-LG}$  or  $\text{NH}_2\text{-Xaa-Xaa-Pro-Yaa}$  (SEQ ID NO:41), where LG is a leaving group. The leaving group can be a chromogenic or fluorogenic group known to the art. The expression of a prolyl-tripeptidyl peptidase by an organism and subsequent cleavage of a specific substrate results in a free amino acid or a free leaving group, each of which can be assayed using techniques known to those of skill in the art. Other methods can be based on immunogenic properties of PTP-A, for instance immunoassays and histochemistry, the detection of mRNA, and PCR related methods, all of which are known to one of skill in the art.

As described in the Examples, the amino acid sequence of the amino-terminal end of a PTP-A fragment was used to identify the nucleotide sequence of the PTP coding region. The nucleotide sequence was present in a publically available database containing the nucleotide sequence of the partially finished *P. gingivalis* W83 genome. However, even though the nucleotides that encode the *P. gingivalis* PTP-A were known, there was no indication that the nucleotides were in fact transcribed and translated. The data obtained from the database only contained the nucleotide sequence of a genomic clone; there was no disclosure that the nucleotides did or did not contain an open reading frame. Moreover, there is little data known to the art regarding regulatory regions required for either the transcription or the translation of a nucleotide sequence in *P. gingivalis*.



Thus, a person of ordinary skill, having the nucleotide sequence of the genomic clone, would not be able to predict that the open reading frame encoding PTP-A was transcribed or translated. Moreover, even if there was a suggestion that the open reading frame was both transcribed and translated, there is no suggestion that the polypeptide encoded by the open reading frame would have the novel activity of PTP-A.

Accordingly, the present invention is directed to a nucleic acid fragment encoding a polypeptide, particularly a prolyl-tripeptidyl peptidase, active analog, active fragment, or active modification thereof. The nucleic acid fragment can have a nucleotide sequence as shown in SEQ ID NO:38. Alternatively, nucleic acid fragments of the invention include those whose complement hybridize to SEQ ID NO:38 under standard hybridization conditions as described herein. During hybridization the entire nucleotide sequence of the complement can hybridize with SEQ ID NO:38. Preferably, at least about 20 nucleotides of the complement hybridize with SEQ ID NO:38, more preferably at least about 50 nucleotides, most preferably at least about 100 nucleotides.

Alternatively, the nucleic acid fragment can have a nucleotide sequence encoding a polypeptide having the amino acid sequence shown in SEQ ID NO:30. An example of the class of nucleotide sequences encoding such a polypeptide is SEQ ID NO:38. This class of nucleotide sequences is large but finite, and the nucleotide sequence of each member of the class can be readily determined by one skilled in the art by reference to the standard genetic code.

The identification of similar coding regions in other organisms can be accomplished by screening individual wild-type microorganisms for the presence of nucleotide sequences that are similar to the coding region of PTP-A, which is shown in SEQ ID NO:38. Screening methods include, for instance, hybridization of a detectably labeled probe with a nucleic acid fragment.

Standard hybridizing conditions are a modification of the conditions used by Church et al. ((1984) *Proc. Natl. Acad. Sci. USA* 81, 1991): 0.5 M phosphate buffer, pH 7.2, 7 % SDS, 10 mM EDTA, at 68°C, and three washes, each for 20 minutes in 2x SSC, 0.1 % SDS, at 65°C. Preferably, a probe will hybridize to the nucleotide sequence set forth in SEQ ID NO:38 under standard hybridizing conditions. Generally the probe does not have to be complementary to all the

nucleotides of the nucleic acid fragment as long as there is hybridization under the above-stated conditions.

“Complement” and “complementary” refer to the ability of two single stranded nucleic acid fragments to base pair with each other, where an adenine on one nucleic acid fragment will base pair to a thymine on a second nucleic acid fragment and a cytosine on one nucleic acid fragment will base pair to a guanine on a second nucleic acid fragment. Two nucleic acid fragments are complementary to each other when a nucleotide sequence in one nucleic acid fragment can base pair with a nucleotide sequence in a second nucleic acid fragment. For instance, 5'-ATGC and 5'-GCAT are complementary. The term complement and complementary also encompasses two nucleic acid fragments where one nucleic acid fragment contains at least one nucleotide that will not base pair to at least one nucleotide present on a second nucleic acid fragment. For instance the third nucleotide of each of the two nucleic acid fragments 5'-ATTGC and 5'-GCTAT will not base pair, but these two nucleic acid fragments are complementary as defined herein. Typically two nucleic acid fragments are complementary if they hybridize under the standard conditions referred to herein.

Preferred probes are nucleic acid fragments complementary to a coding region or another nucleotide sequence that encodes a prolyl-tripeptidyl peptidase. For instance, a probe can comprise a consecutive series of nucleotides complementary to a portion of SEQ ID NO:38. Preferably a probe is at least about 18 bases, more preferably at least about 21 bases, and most preferably at least about 24 bases in length. Particularly preferred probes are

TTCGATCCGGCAAAGAAATATCCTGTTATTGTCTATGTTTACGGAGGAC  
CT (SEQ ID NO:36,  
GTGGATGCCGATAGAATAGGAGTACATGGCTGGAGCTATGGTGGCTTT  
(SEQ ID NO:37, and SEQ ID NO:38. Methods of detectably labeling a probe are well known to the art.

The nucleic acid fragment that is identified by the probe is further analyzed to determine if it encodes a polypeptide with amidolytic activity of the Pro-Yaa

peptide bond on a target polypeptide of the general formula  $\text{NH}_2\text{-Xaa-Xaa-Pro-Yaa-(Xaa)}_n$  (SEQ ID NO:25). Another method for screening individual microorganisms for the presence of nucleotide sequences that are similar to the coding regions of the present invention is the polymerase chain reaction (PCR).

5 Individual wild-type microorganisms containing nucleic acid fragments encoding a prolyl-tripeptidyl peptidase can also be identified using antibody. Preferably the antibody is directed to PTP-A. The production of antibodies to a particular polypeptide is known to a person of skill in the art, and is further detailed herein.

10 The use of hybridization of a probe to a coding region present in individual wild-type microorganisms can be used as a method to identify a coding region identical or similar to a coding region present in SEQ ID NO:38. The coding region can then be isolated and ligated into a vector as described below. Two nucleic acid sequences are "similar" if the two nucleic acid sequences can be aligned so that the  
15 number of identical amino acids along the lengths of their sequences are optimized. Preferably, two nucleotide acid sequences have, in increasing order of preference, preferably at least about 90 %, at least about 92 %, at least about 94%, at least about 96%, most preferably at least about 98% identity.

As mentioned above, a nucleic acid fragment of the invention can be  
20 inserted in a vector. Construction of vectors containing a nucleic acid fragment of the invention employs standard ligation techniques known in the art. See, e.g., Sambrook et al, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press (1989) or Ausubel, R.M., ed. *Current Protocols in Molecular Biology* (1994). A vector can provide for further cloning (amplification of the  
25 nucleic acid fragment), i.e., a cloning vector, or for expression of the polypeptide encoded by the coding region, i.e., an expression vector. The term vector includes, but is not limited to, plasmid vectors, viral vectors, cosmid vectors, or artificial chromosome vectors. Typically, a vector is capable of replication in a bacterial host, for instance *E. coli*. Preferably the vector is a plasmid.

30 Selection of a vector depends upon a variety of desired characteristics in the resulting construct, such as a selection marker, vector replication rate, and the like. Suitable plasmids for expression in *E. coli*, for example, include pUC(X), pKK223-3, pKK233-2, pTrc99A, and pET-(X) wherein (X) denotes a vector family in which

numerous constructs are available. pUC(X) vectors can be obtained from Pharmacia Biotech (Piscataway, NH) or Sigma Chemical Co. (St. Louis, MO). pKK223-3, pKK233-2 and pTrc99A can be obtained from Pharmacia Biotech. pET-(X) vectors can be obtained from Promega (Madison, WI) Stratagene (La Jolla, CA) and Novagen (Madison, WI). To facilitate replication inside a host cell, the vector preferably includes an origin of replication (known as an "ori") or replicon. For example, ColE1 and P15A replicons are commonly used in plasmids that are to be propagated in *E. coli*.

An expression vector optionally includes regulatory regions operably linked to the coding region. The invention is not limited by the use of any particular promoter, and a wide variety are known. Promoters act as regulatory signals that bind RNA polymerase in a cell to initiate transcription of a downstream (3' direction) coding region. The promoter used in the invention can be a constitutive or an inducible promoter. It can be, but need not be, heterologous with respect to the host cell. Preferred promoters for bacterial transformation include *lac*, *lacUV5*, *tac*, *trc*, T7, SP6 and *ara*.

An expression vector can optionally include a Shine Dalgarno site (e.g., a ribosome binding site), and a start site (e.g., the codon ATG) to initiate translation of the transcribed message to produce the enzyme. It can also include a termination sequence to end translation. A termination sequence is typically a codon for which there exists no corresponding aminoacyl-tRNA, thus ending polypeptide synthesis. The nucleic acid fragment used to transform the host cell can optionally further include a transcription termination sequence. The *rrnB* terminators, which is a stretch of DNA that contains two terminators, T1 and T2, is an often used terminator that is incorporated into bacterial expression systems (J. Brosius et al., (1981) *J. Mol. Biol.* 148 107-127).

The nucleic acid fragment used to transform the host cell optionally includes one or more marker sequences, which typically encode a polypeptide that inactivates or otherwise detects or is detected by a compound in the growth medium. For example, the inclusion of a marker sequence can render the transformed cell resistant to an antibiotic, or it can confer compound-specific metabolism on the transformed cell. Examples of a marker sequence are sequences that confer resistance to kanamycin, ampicillin, chloramphenicol, and tetracycline.

Antibodies can be produced to a polypeptide having the sequence of SEQ ID NOs:30, 43, 44 or 45, or a polypeptide having a percentage amino acid identity as described herein. Alternatively, antibodies can be made to an antigenic analog, antigenic fragment, or antigenic modification of a polypeptide having the sequence of SEQ ID NOs:30, 43, 44 or 45. An antigenic analog, antigenic fragment, or antigenic modification of a polypeptide having SEQ ID NOs:30, 43, 44 or 45 is one that generates an immune response in an animal. Antigenic analogs of a polypeptide having SEQ ID NOs:30, 43, 44 or 45 include prolyl peptidases having amino acid substitutions that do not eliminate peptide antigenicity in an animal. Substitutes for an amino acid may be selected from other members of the class to which the amino acid belongs, as described herein. Fragments of a prolyl peptidase of the invention include prolyl peptidases containing deletions or additions of one or more contiguous or noncontiguous amino acids such that the resulting polypeptide will generate an immune response in an animal. An example of a fragments of a prolylpeptidase is a catalytic domain. Modified prolyl peptidases include prolyl peptidases that are chemically and enzymatically derivatized at one or more constituent amino acids, including side chain modifications, backbone modifications, and N- and C- terminal modifications including acetylation, hydroxylation, methylation, amidation, and the attachment of carbohydrate or lipid moieties, cofactors, and the like.

Accordingly, an aspect of the invention is an immunogenic composition comprising an isolated prolyl peptidase, or an antigenic analog, antigenic fragment, or antigenic modification thereof, preferably a prolyl tripeptidyl-peptidase. The prolyl tripeptidyl-peptidase preferably has amidolytic activity for cleavage of the Pro-Yaa peptide bond present in a target polypeptide with the general formula  $\text{NH}_2\text{-Xaa-Xaa-Pro-Yaa-(Xaa)}_n$  (SEQ ID NO:25), wherein the amidolytic activity is measured at a prolyl tripeptidyl-peptidase:target polypeptide ratio of at least about 1:100 to no greater than about 1:1,000,000 in about 200 mM HEPES, about pH 7.5 at 37°C for at least about 3 hours.

The immunogenic composition can further include excipients or diluents that are pharmaceutically acceptable as carriers and compatible with the immunogenic composition. The term "pharmaceutically acceptable carrier" refers to a carrier(s) that is "acceptable" in the sense of being compatible with the other

ingredients of a composition and not deleterious to the recipient thereof. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol, or the like, and combinations thereof. In addition, if desired, the immunogenic composition may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, and/or adjuvants which enhance the effectiveness of the immune-stimulating composition.

The immunogenic composition can be used in a method for protecting an animal from a disease caused by *P. gingivalis*. This method includes administering the immunogenic composition and eliciting antibodies to a prolyl peptidase, antigenic analog, antigenic fragment, or antigenic modification. The diseases that can be treated in this manner include periodontal diseases, which includes gingivitis and periodontitis. Clinical hallmarks of periodontitis include loss of tooth attachment and periodontal pocket formation.

Alternatively and preferably, periodontal diseases can be treated by the use of inhibitors of a prolyl peptidase. An inhibitor of a prolyl peptidase, preferably a prolyl tripeptidyl-peptidase, can be present in a composition that preferably contains a pharmaceutically acceptable carrier. For instance, inhibitors can be applied systemically, subgingivally (e.g., subgingival irrigation) and/or by controlled release delivery directly into the periodontal pocket using methods well known to the art (see, e.g., Kornman, K., (1993) *J. Periodontol.* 64, 782-791). Preferably, an inhibitor is applied subgingivally or by controlled release delivery.

The prolyl peptidases, active analogs, fragments, and modifications thereof can be used in a method of reducing growth of bacteria *in vitro* or *in vivo*. Preferably, the bacteria is a periodontal pathogen, i.e., a bacterial pathogen that causes periodontal disease, more preferably the bacteria is *P. gingivalis*. The inability of asaccharolytic *P. gingivalis* to utilize free amino acids makes the bacterium entirely dependant on an external peptide supply. The action of the polypeptides of the invention may be required for bacterial growth, and inhibition of the polypeptides of the invention may inhibit the *in vivo* growth of organisms, including *P. gingivalis*. The method includes decreasing the amount of dipeptides and/or tripeptides (e.g., the result of cleavage of SEQ ID NO:25 by a prolyl-tripeptidyl peptidase) and the amount of free amino acids that result from further cleavage of the dipeptides and/or tripeptides present by inhibiting a prolyl

peptidase, active analog, active fragment, or active modification thereof, such that the amount of dipeptides and/or tripeptides generated by the polypeptides is decreased. The amount of dipeptides and/or tripeptides is decreased relative to the amount of dipeptides and/or tripeptides present in the absence of the inhibitor.

- 5 Preferably, the amount of dipeptides and/or tripeptides generated is decreased by an inhibitor, a monoclonal antibody that inhibits the prolyl peptidase, or polyclonal antibodies that inhibit the prolyl peptidase, more preferably, the amount of dipeptides and/or tripeptides generated is decreased by an inhibitor. Preferably, an inhibitor acts to inhibit a polypeptide of the invention, preferably a prolyl peptidase,  
10 by blocking the active site of the polypeptide. The polypeptide can be present on the surface of the bacteria or secreted into the environment, preferably the polypeptide is present in the surface of the bacteria.

- The present invention is also directed to a method of developing an inhibitor of a prolyl peptidase, active analog, active fragment, or active  
15 modification thereof, preferably a prolyl-tripeptidyl peptidase. The method includes identifying a molecule that inhibits the amidolytic activity of the prolyl peptidase. This can be accomplished by, for instance, incubating the prolyl peptidase with a candidate molecule under conditions that promote amidolytic activity of the prolyl peptidase and determining if the amidolytic activity of the  
20 prolyl peptidase is decreased relative to the amidolytic activity in the absence of the molecule. The amidolytic activity can be measured by cleavage of the Pro-Yaa peptide bond present in the target polypeptide SEQ ID NO:25 as described herein. One method of developing an inhibitor includes using the target peptide SEQ ID NO:25 and replacing the Xaa residues with modified amino acids. It is expected  
25 that some modified amino acids will cause the target peptide to act as an inhibitor.

### EXAMPLES

- The present invention is illustrated by the following examples. It is to be understood that the particular examples, materials, amounts, and procedures are to  
30 be interpreted broadly in accordance with the scope and spirit of the invention as set forth herein.

### Example 1

#### Materials

Diisopropylfluorophosphate (DFP), leupeptin and 3,4-dichloroisocoumarin, were purchased from Calbiochem (La Jolla, CA). Antipain, iodoacetamide, substance P, bradykinin and bradykinin related peptides, were obtained from Sigma. Other peptides used in this study were synthesized at the Molecular Genetic Instrumental Facility (University of Georgia, Athens, GA) using Fmoc protocol with an advanced ChemTech MPS350 automated synthesizer. H-Ala-Phe-Pro-pNA, H-Gly-Pro-pNA, Z-Gly-Pro-pNA, Z-Ala-Pro-pNA, and H-Pro-pNA (where pNA is p- Nitroanilide; Z is benzyloxycarbonyl; and H is hydrogen and denotes an unblocked amino-terminal group) were obtained from Bachem (King of Prussia, PA). Prolinal was kindly provided by Dr. James Powers (Georgia Institute of Technology, Atlanta) and cystatin C by Dr. Magnus Abrahamson (University of Lund, Sweden).

#### Methods

*Source and Cultivation of Bacteria*— *P. gingivalis* HG66 was obtained from Dr. Roland Arnold (University of North Carolina, Chapel Hill), while the strains W50 (ATCC 53978) and ATCC 33277 were obtained from the ATCC. All cells were grown as described previously (Chen, Z., et al., (1992) *J. Biol. Chem.* 267, 18896-18901).

*Enzyme Activity Assays*— Routinely, the tripeptidyl peptidase amidolytic activity was measured with H-Ala-Phe-Pro-pNA (1mM) in 0.2 M HEPES (N-2-hydroxyethylpeperazine,N'-2-ethansulfonic acid), pH 7.5 at 37°C. The concentration of enzyme was 0.1 nM to 1 nM. The assay was performed in a total volume of 0.2 ml on microplates, and the initial turnover rate was recorded at 405 nm using a microplate reader (Spectramax Molecular Devices, Sunnyvale, CA). In inhibition studies, the enzyme was first preincubated with inhibitor for 15 min at 37°C, substrate added, and residual activity recorded after 5 minutes to 30 minutes. H-Gly-Pro-pNA, Z-Ala-Pro-pNA, Z-Gly-Pro-pNA and H-Pro-pNA (1 mM final concentration) were assayed in the same manner.



*Protein Determination*—Protein concentration was determined using the BCA reagent kit (Sigma, St. Louis, MO), using bovine serum albumin as a standard.

*Localization of Tripeptidyl-Peptidase Activity*—Cultures of *P. gingivalis* HG66, W50 and ATCC 33277, at different phases of growth, were subjected to the following fractionation procedure. The cells were removed by centrifugation (10,000 x g, 30 minutes), washed twice with 10 mM Tris, 150 mM NaCl, pH 7.4, resuspended in 50 mM Tris, pH 7.6, and disintegrated by ultrasonication in an ice bath at 1500 Hz for 5 cycles (5 minutes sonication/5 minutes brake). Unbroken cells and large debris were removed by centrifugation (10,000 x g, 30 minutes) and the opalescent supernatant subjected to ultracentrifugation (150,000 x g, 120 minutes), yielding a pellet containing bacterial membranes and a supernatant which was considered as membrane-free cell extract. All fractions, as well as the full culture, culture medium, and full culture after sonication, were assayed for amidolytic activity against H-Ala-Phe-Pro-pNA.

*Enzyme Purification*—All purification steps were performed at 4°C except for FPLC separations, which were carried out at room temperature. Cells were harvested by centrifugation (6,000 x g, 30 minutes), washed with 50 mM potassium phosphate buffer, pH 7.4, and resuspended in the same buffer (150 ml per 50 gram of cells wet weight). Triton X-100 (10% volume/volume in H<sub>2</sub>O) was added slowly to the bacterial cell suspension to a final concentration of 0.05%. After 120 minutes of gentle stirring, unbroken cells were removed by centrifugation (28,000 x g, 60 minutes). Proteins in the supernatant were precipitated with cold acetone (-20°C) added to a final concentration of 60% and collected by centrifugation. The pellet was redissolved in 50 mM potassium phosphate buffer, pH 7.0, and extensively dialyzed against 20 mM potassium phosphate, pH 7.0, containing 0.02% sodium azide. The dialyzed fraction was clarified by centrifugation (28,000 x g, 30 min) and applied to a hydroxyapatite column (BioRad, Melville, NY) equilibrated with 20 mM potassium phosphate, pH 7.0, at a flow rate of 20 ml/hour. After equilibration, the column was washed until the A<sub>280</sub> fell to zero. Bound proteins were eluted with a gradient from 20-300 mM potassium phosphate and fractions (7 ml) analyzed for dipeptidyl- and tripeptidyl-peptidase activity using H-Gly-Pro-pNA and H-Ala-Phe-Pro-pNA, respectively. The activity against the latter

substrate was pooled, saturated with 1 M ammonium sulfate, clarified by centrifugation, and directly loaded onto a Phenyl-Sepharose HP (Pharmacia, Piscataway, NJ) column equilibrated with 50 mM potassium phosphate, pH 7.0, containing 1 M ammonium sulfate. The column was washed with two volumes of equilibration buffer, followed by buffer containing 0.5 M ammonium sulfate, and developed with a descending gradient of ammonium sulfate from 0.5 to 0 M. Active fractions were pooled, extensively dialyzed against 20 mM Tris, pH 7.5, and applied to a MonoQ HR 5/5 FPLC column equilibrated with the same buffer. The column was washed with 5 volumes of equilibration buffer at 1.0 ml/minute, following which bound proteins were eluted with a gradient of 0- 300 mM NaCl. The active fractions were pooled, dialyzed against 25 mM Bis-Tris, pH 6.3, and subjected to chromatofocusing on a MonoP FPLC column equilibrated with Bis-Tris buffer, using a pH gradient developed with 50 ml of 10x diluted Polybuffer 74 (Pharmacia), adjusted to a pH of 4.0.

*Electrophoretic Techniques*—The SDS-PAGE system of Schagger and von Jagow (Schagger, H., and von Jagow, G. (1987) *Anal. Biochem.* 166, 368-379), was used to monitor enzyme purification and estimate the enzyme molecular mass. For amino-terminal sequence analysis, proteins resolved in SDS-PAGE were electroblotted to polyvinylidene difluoride membranes using 10 mM CAPS, pH 11, 10% methanol (Matsudaira, P. (1987) *J. Biol. Chem.* 262, 10035-10038). The membrane was washed thoroughly with water and stained with Coomassie Blue G250. The blot was air dried, and protein bands cut out and subjected to NH<sub>2</sub>-terminal sequence analysis with an Applied Biosystems 491 Protein Sequencer using the program designed by the manufacturers.

*Enzyme Fragmentation*—The purified prolyl tripeptidyl peptidase (PTP-A) was partially denatured by incubation in 6 M urea in 0.02 M Tris, pH 7.6, for 60 minutes. Low molecular mass gingipain R (RgpB) (Potempa, J., et al. (1995) *Prospect. Drug Discovery and Design* 2, 445-458) from *P. gingivalis* was then added to make an enzyme:substrate molar ratio of 1:100. The reaction mixture was made in 1 mM cysteine and the sample incubated overnight at 37°C. Generated peptides were separated by reverse-phase HPLC using a  $\mu$ Bondapak C-18 column (3.9 x 300 mm) (Waters, Millford, MA). Peptides were eluted with 0.1% trifluoroacetic acid and acetonitrile containing 0.08% trifluoroacetic acid, using a

gradient from 0 to 80% acetonitrile over 60 minutes. Peptides were monitored at 220 nm and collected manually.

For determination of the active site serine residue and to confirm that the purified enzyme was a serine peptidase, 100 µg of purified PTP-A was first  
5 incubated with 170 µCi of [1,3-<sup>3</sup>H]DFP (Amersham, Arlington Heights, IL) for 30 minutes at 25°C in 20 mM HEPES, pH 7.5. The reaction was quenched by addition of cold DFP to a final concentration of 10 mM and the radiolabelled material analyzed by SDS-PAGE, followed by autoradiographic analysis. The gel was dehydrated, soaked in PPO solution for 2 hours, dried, and the DFP-binding  
10 proteins detected by fluorography after an exposure time of 96 hours on X-ray film (XAR; Kodak, Rochester, NY). The bulk of radiolabelled protein was subjected to proteolytic fragmentation with RgpB and peptides obtained separated by reverse-phase HPLC as described above. Radioactivity in each peptide fraction was measured using a β liquid scintillation counter, and the labeled peptide, as well as  
15 other selected peptides were subjected to sequence analysis.

*Identification of the PTP-A Gene*— The database containing the unfinished *P. gingivalis* W83 genome, available from The Institute for Genomic Research, was searched for the presence of nucleotide sequences corresponding to the NH<sub>2</sub>-terminal and the internal PTP-A amino acid sequences using the TBLASTN  
20 algorithm, BLAST version 2.0.8, and the default values for all parameters (Altschul, S.F., et al., (1997) *Nucleic Acid Res.* 25, 3389-3402). An identified clone gnl | TIGR | *P. gingivalis*\_126 was retrieved from The Institute for Genomic Research data base (<http://www.tigr.org>). The position of the PTP-A gene was localized using the NCBI open reading frame (ORF) finder (available from the  
25 National Center for Biotechnology Information, at <http://www.ncbi.nlm.nih.gov/gorf/gorf.html>). The amino acid sequence, obtained by conceptual translation of the entire ORF, was further used for homology screening by use of the NCBI BLAST search tool.

*Enzyme Specificity*— Peptides were incubated with 1 µg PTP-A at an  
30 enzyme:substrate molar ratio of 1:100 for 3 hours or 24 hours in 50 µl of 200 mM HEPES, pH 7.5, at 37°C, and the reaction stopped by acidification with trifluoroacetic acid. The samples were then subjected to reverse-phase high

pressure liquid chromatography using a  $\mu$ Bondapak C-18 column (3.9 x 300 mm) (Waters, Millford, MA) and an acetonitrile gradient (0-80 % in 0.075% trifluoroacetic acid in 50 min). Each peak, detected at 220 nm, was collected, lyophilized, re-dissolved in 50% (volume/volume) methanol, 0.1% acetic acid and subjected to analysis by mass spectrometry.

*Mass Spectrometry*—A Finnigan MAT 95S, sector mass spectrometer (Finnigan MAT, Bremen, Germany) equipped with an electrospray source (ESI) was used operated essentially as described previously (Stenfors, C., et al., (1997) *J. Biol. Chem.* 272, 5747-5751). Peptides were identified by fitting of the obtained spectra to specific sequences using an Internet application program MsFit available at <http://falcon.ludwig.ucl.ac.uk/msfit.html>.

## Example 2

### Enzyme Localization, Purification and Initial Characterization

Analysis of amidolytic activity against H-Ala-Phe-Pro-pNA in several fractions of *P. gingivalis* HG66, W50 and ATCC 33277 clearly indicated that an enzyme(s) with prolyl tripeptidyl-peptidase activity is localized on the cell surface in all strains tested with less than 5% of the total activity being found in the medium regardless of the growth phase of the bacterial culture. Cell associated enzyme was easily detached from the bacterial surface by treatment with a low concentration (0.05%) of Triton X-100. This procedure released more than 85-90% of activity in a soluble form. Subsequent acetone precipitation of proteins in the Triton X-100 fraction successfully separated the activity from pigment which remained in solution. The redissolved protein fraction, after dialysis, was applied to hydroxyapatite (100 ml) equilibrated with 20 mM potassium phosphate buffer pH 7.0. The elution was carried out with 20 mM potassium phosphate buffer pH 7.0, using a phosphate gradient from 20 mM to 300 mM at flow rate 20 ml/h. At this step substantial separation of the PTP-A activity from both the DPP IV and bulk protein was achieved (Fig. 1a). Further purification performed by subsequent chromatography steps including Phenyl-Sepharose (Fig. 1b), MonoQ (Fig. 1c) and MonoP columns (Fig. 1d), resulted in the isolation of purified enzyme.

Phenyl-Sepharose HP (25 ml) was equilibrated with 50 mM potassium phosphate, 1M ammonium sulfate, pH 7.0, at flow rate 30 ml/h. The column was

washed with two volumes of equilibration buffer and a step gradient of 0.5 M ammonium sulfate was applied, following which a descending gradient of 0.5 to 0 M ammonium sulfate was applied. The PTP-A containing fractions were extensively dialyzed against 20 mM Tris-HCl, pH 7.0, and concentrated by ultrafiltration. The concentrated PTP-A containing fractions were applied to a MonoQ column equilibrated with the same buffer. The column was washed with 5 volumes of equilibration buffer, following which bound protein was eluted with a gradient of 0-300 mM NaCl. The concentrated fraction of PTP-A from the MonoQ column was equilibrated with 25 mM Bis-Tris, pH 6.3, and loaded on a MonoP column equilibrated with the same buffer. A pH gradient was developed using 50 ml of Polybuffer 74, with the pH adjusted to 4.0.

Significantly, the chromatography step on the MonoP column yielded the  $A_{280}$  profile much sharper than the activity peak. Although this imperfect overlap of protein and activity may suggest that the protein component does not represent the active enzyme, the rest of data argues with such a contention. This apparent contradiction may be likely explained by the enzyme inhibition by the reaction product of H-Ala-Phe-Pro-pNA hydrolysis but this possibility has not been explored. The yield of protein and activity recovery in a typical purification procedure is summarized in Table 1.

Table 1. Purification of the PTP- A from *P. gingivalis*

Step	Volume (ml)	Protein (mg)	Total activity*	Specific activity (units/mg)	Purification fold	Yield (%)
5	Triton X-100 extract after centrifugation					
	200	1200	757 673	642	1	100
	Acetone precipitate					
10	50	600	537 622	896	1.4	71
	Hydroxyapatite chromatography					
	50	22	400 039	18 183	28	53
15	Phenyl-Sepharose					
	48	10	312 505	31 250	48	41
	3	1.5	244 828	163 218	254	32
MonoQ						
MonoP						
	4	0.7	188 400	269 142	420	25

\* Based on the enzymatic activity using H-Ala-Phe-Pro-pNA where one unit = mOD/min/1ml

SDS-PAGE analysis of the purified enzyme revealed the presence of two protein bands with apparent molecular masses of 81.8 and 75.8 kDa, respectively (Fig. 2, lane f). Autoradiography of the enzyme sample radiolabeled with [1,3-<sup>3</sup>H]DFP (Fig. 2, lane g) clearly indicated that the bands represented either two distinct serine peptidases or different molecular mass forms of the same enzyme. In an attempt to distinguish between these two options, the electrophoretically resolved proteins were subjected to amino terminal sequence analysis. Unfortunately, it was found that the 81.8 kDa form of PTP-A had a blocked N-terminus. In contrast, the sequence NH<sub>2</sub>-SAQTTRFSAADLNALMP (SEQ ID NO:23) was found at the N-terminus of the lower molecular mass form of the enzyme. This result led us to the possibility that the 75.8 kDa form of PTP-A was derived from the 81.8 kDa form through proteolytic cleavage of a 6 kDa amino-terminal peptide. To confirm this hypothesis and, in addition, to localize the active site residue within *P. gingivalis* PTP-A, the mixture containing both radiolabeled enzymes was proteolytically fragmented and peptides resolved by reverse-phase HPLC. This procedure yielded only one major radioactive peptide peak, and the purified peptide was found to have a single amino acid sequence: IGVHGWXYGGFMTTNL (SEQ ID NO:24), where X apparently represents the active-site serine residue covalently and irreversibly modified by DFP. These data convincingly indicate that the two protein bands of purified PTP-A represents different forms of the same enzyme. The portion of the purified PTP-A having a truncated N-terminus may be due to cleavage by Lys-specific peptidase and is likely to be an artifact which occurred during the purification procedure. Nevertheless, the proteolytic shedding of membrane bound PTP-A also occurs during cultivation of the bacteria, as indicated by variable amount of soluble activities found in cell free culture media.

### Example 3

#### pH Optimum, Stability and Inhibition Profile

Using the amidolytic activity assay with H-Ala-Phe-Pro-pNA it was found that the enzyme has a broad pH optimum from pH 6.0 to 8.0 and in 0.2 M HEPES, pH 7.6 was stable for at least 12 hours at 25°C or 37°C. PTP-A activity was not affected by class specific synthetic inhibitors of cysteine or metalloproteinases

(Table 2). In contrast, preincubation of the enzyme with DFP or PEFABLOCK resulted in total loss of activity, supporting its classification as a serine peptidase. Surprisingly, however, 3,4-dichloroisocoumarin was only a poor inhibitor, and PMSF, leupeptin, antipain and prolinal had no effect at all. Interestingly, preincubation of PTP-A with iodoacetamide, but not with N-ethylmaleimide, stimulated enzyme amidolytic activity about two-fold. Human plasma inhibitors, such as  $\alpha_1$ -proteinase inhibitor,  $\alpha_1$ -antichymotrypsin and  $\alpha_2$ -macroglobulin did not affect the enzyme activity, nor were they cleaved by PTP-A.

The effect of inhibitors on amidolytic activity of DPP IV was also determined using the same conditions as those used for PTP-A, but using H-Gly-Pro-pNA as a substrate.



Table 2. Effect of inhibitors on the amidolytic activity of PTP-A and DPP IV. Results are for a 15-min incubation at 37 C in 0.2 HEPES pH 7.6, with 1 mM H-Ala-Phe-Pro-pNA as substrate.

	Inhibitor	Concentration	Residual activity of PTP-A, %	Residual activity of DPP IV, %
5	Diisopropyl fluorophosphate	10 mM	0	0
		10 mM	96	20
10	Phenylmethanesulfonyl fluoride	1mg/ml	20	15
		10mg/ml	0	0
	PEFABLOC SC	1 mM	56	100
15	3,4-dichloroisocoumarin	5mM	200	100
	Iodoacetamide	5 mM	100	100
	N-Ethylmaleimide	1 mM	98	100
20	1,10- orthophenanthroline	5 mM	93	100
		0.1 mM	100	100
	EDTA	0.1 mM	100	100
25	Leupeptin	0.1 mM	100	20
	Antipain	10 mM	100	0
30	Prolinal	10 mM	100	30
	Val-Pro	10 mM	100	1
	Ala-Pro			
35	Ala-Gly-Pro			

#### Example 4

##### Substrate Specificity

Among several chromogenic substrates tested, including H-Ala-Phe-Pro-pNA, H-Gly-Pro-pNA, Z-Gly-Pro-pNA, Z-Ala-Pro-pNA, H-Pro-pNA, only H-Ala-Phe-Pro-pNA was hydrolyzed by PTP-A indicating a prolyl specific tripeptidyl-peptidase activity. To further confirm this specificity several synthetic peptides composed of 5 to 34 amino acid residues and containing at least one proline residue were tested as substrates for PTP-A. Out of 22 peptides tested only those with a proline residue in the third position from the amino terminal end were cleaved (Table 3), with the significant exception of peptides with adjacent proline residues (peptides 3, 4 and 16). In addition, a free  $\alpha$ -amino group was absolutely required for cleavage after the third proline residue as exemplified by resistance to enzymatic hydrolysis of peptide 9, which differs from the peptide 8 only in acylation of the  $\alpha$ -amino group of the N-terminal valine residue. Except for these two limitations, the peptide bond -Pro-↓-Yaa- was cleaved at the same rate in all peptides with the general formula  $\text{NH}_2\text{-Xaa-Xaa-Pro-Yaa-(Xaa)}_n$  (SEQ ID NO:25), where Xaa represents any amino acid residue while Yaa could be any residue except proline, regardless of the chemical nature of the amino acids and the length of the peptide. In all cases the reaction was completed within 3 hours and prolonged incubation for 24 hours did not affect the pattern of cleavage, confirming the absolute requirement for a proline residue at the third position from the unblocked N-terminus. In addition, these data indicate that the preparation of PTP-A was free of any contamination with either aminopeptidase, dipeptidyl peptidase, or endopeptidase activities.

The cleavage specificity of DPP IV was also determined using the same conditions as those used for PTP-A. The results (Table 3) demonstrate that DPP IV does not cleave between two proline residues.

Table 3. Cleavage specificity of PTP-A and DPP IV on synthetic peptides.

Substrate	Cleavage site	SEQ ID NO:
Peptide 1	H-Arg-Pro-Pro- -Gly-Phe-Ser-Pro-Phe-Arg	1
Peptide 2	H-Arg-Pro-Pro- -Gly-Phe	2
Peptide 3	H-Lys-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg	3
Peptide 4	H-Tyr-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg	4
Peptide 5	H-Arg-Pro-Hyp-Gly-Phe-Ser-Pro-Phe-Arg	5
Peptide 6	H-Arg-Pro- -Lys-Pro- -Gln-Gln-Phe-Phe-Gly-Leu-Met-NH <sub>2</sub>	6
Peptide 7	H-Val-Pro-Pro- -Gly-Glu-Asp-Ser-Lys-Glu-Val-Ala-Ala-Pro-His-Arg-Gln	7
Peptide 8	H-Val-Pro-Pro- -Gly-Glu-Asp-Ser-Lys	8
Peptide 9	Ac-Val-Pro-Pro-Gly-Glu-Asp-Ser-Lys	9
Peptide 10	H-Val-Glu-Pro- -Ile-Pro-Tyr	10
Peptide 11	H-Arg-Gly-Pro- -Phe-Pro-Ile	11
Peptide 12	H-Ala-Arg-Pro- -Ala-D-Lys-amide	12
Peptide 13	H-Pro-Asn-Pro- -Asn-Gln-Gly-Asn-Phe-Ile	13
Peptide 14	H-Arg-His-Pro- -Lys-Tyr-Lys-Thr-Glu-Leu	14
Peptide 15	H-Gly-Val-Pro- -Lys-Thr-His-Leu-Glu-Leu	15
Peptide 16	H-Lys-Gly-Pro-Pro-Ala-Ala-Leu-Thr-Leu	16
Peptide 17	H-Gln-Lys-Gln-Met-Ser-Asp-Arg-Glu-Asn-Asp-Met-Ser-Pro-Ser-Asn-Asn-Val-Val-Pro-Ile-His-Val-Pro-Pro-Thr-Thr-Glu-Asn-Lys-Pro-Lys-Val-Gln	17
Peptide 18	H-Phe-Leu-Arg-Glu-Pro-Val-Ile-Phe-Leu	18
Peptide 19	H-Gly-Ile-Arg-Pro-Tyr-Glu-Ile-Leu-Ala	19
Peptide 20	H-Leu-Pro- -Asp-Leu-Asp-Ser-Ser-Leu-Ala-Ser-Ile-Gln-Glu-Leu-Ser-Pro-Gln-Glu-Pro-Arg-Pro-Pro-Glu-Ala	20
Peptide 21	H-Cys-Leu-Ser-Ser-Gly-Thr-Leu-Pro-Gly-Pro-Gly-Asn-Asp-Ala-Ser-Arg-Glu-Leu-Glu-Ser	21
Peptide 22	H-Lys-Ile-Ala-Gly-Tyr-His-Leu-Glu-Leu	22
Peptide 23	H-Ser-Pro- -Tyr-Ser-Ser-Asp-Thr-Thr	46
Peptide 24	H-Ala-Pro- -Val-Arg-Ser-Leu-Asn-Cys-Thr-Leu-Arg-Asp-Ser-Gln-Gln-Lys	47

| indicates cleavage site mediated by PTP-A

| indicates cleavage site mediated by DPP IV

The lack of cleavage after internal proline residues in the synthetic peptides corresponds well with the absence of any proteolytic activity on several protein substrates including IgA, IgG, albumin, azocasein, carboxymethylated rybonuclease and gelatin. However, the size of substrate, which is a limiting factor in the activity of oligopeptidases (Walter, R., et al., (1980) *Mol. Cell. Biochem.* 30, 111-126), is not restricting in the case of PTP-A, because the enzyme is able to cleave a tripeptide (NH<sub>2</sub>-Xaa-Xaa-Pro) from the N-terminus of both human cystatin C and interleukin 6.

### Example 5

#### PTP-A Sequence Analysis

Partial PTP-A amino acid sequence data allowed us to identify the *P. gingivalis* genomic clone gnl | TIGR | *P. gingivalis*\_126 in the Unfinished Microbial Genomes data base, TIGR. An ORF corresponding to the PTP-A amino acid sequence was found as indicated by the fact that all sequences of the PTP-A derived peptides obtained by the enzyme polypeptide fragmentation with RgpB were present in the protein primary structure inferred from the nucleotide sequence of the ORF. The 732 amino acid polypeptide with a calculated mass of 82, 266 Da was encoded in this ORF. The homology search performed using the NCBI TBLASTN tool against GenBank+EMBL+DDBJ+PDB databases and subsequent multiple sequence alignments using the ClustalW Multiple Sequence Alignment tool (Fig. 3) indicated that PTP-A is a new member of the prolyl oligopeptidase (S9) family of serine peptidases (Rawlings, N.D., et al., (1991) *Biochem. J.* 279, 907-908).

The sequence GX SXGG (SEQ ID NO:40) is a signature feature for the S9 family of serine peptidases. Within this large and diverse S9 family of evolutionary and functionally related enzymes both from prokaryotes and eukaryotes, PTP-A was most closely related to bacterial dipeptidyl peptidase IV (DPP IV) from *Flavobacterium meningosepticum*, *Xantomonas maltophilus*, and *P. gingivalis*, sharing 31.6%, 30.4%, and 28.5% amino acid sequence identity, respectively. Remarkably, the COOH-terminal region of the PTP-A molecule (residues 502 - 732) shows a significant similarity to the eukaryotic prolyl oligopeptidases with 34% and 33% identity to human DPP IV and mouse fibroblast activation protein (FAP), respectively (Fig. 3). This part of the molecule contains the amino acid

residues which encompass the catalytic triad in all characterized prolyl oligopeptidases, and from the multiple alignments with DPP IV of confirmed active site residues (Kabashima, T., et al., (1995) *Arch. Biochem. Biophys.* 320, 123-128) it is apparent that Ser-603, Asp-678 and His-710 represent the catalytic triad of PTP-A (Fig. 3). Such an inference is further supported by the direct labeling of Ser-603 by DFP. In addition, the computer assisted search for sequential motifs characteristic for transmembrane domains revealed the presence of such a putative region within the N-terminal sequences of PTP-A, with residues 5 to 25 most likely folded into a hydrophobic  $\alpha$ -helix responsible for membrane anchoring of this enzyme.

In *P. gingivalis* PTP-A, as well as in DPP IV, all activities are cell surface associated, and it is conceivable that the enzymes are membrane anchored through putative signal sequences which are not cleaved but remain as a membrane spanning domain similar to other members of the prolyl oligopeptidase family. The cell surface localization of di- and tripeptidyl-peptidases suggests a putative physiological function in providing nutrients for growing bacterial cells. Here, the inability of asaccharolytic *P. gingivalis* to utilize free amino acids (Dashper, S.G., et al., *J. Dent Res.* 77, 1133 (Abstract) (1988)) makes the bacterium entirely dependant on an external peptide supply. In this regard, DPP-IV and PTP-A activities are probably very important, if not indispensable, for bacterial growth.

This suggestion is strongly corroborated by the fact that the *P. gingivalis* genome contains three additional genes encoding peptidases homologous with DPP-IV and PTP-A and one related to aminopeptidase B. The peptidases homologous with DPP-IV and PTP-A are referred to as homologs H1 (SEQ ID NO:43), H2 (SEQ ID NO:44), and H3 (SEQ ID NO:45) (Fig. 6). If expressed, each gene product would probably have enzymatic activity because each has a well preserved catalytic triad (Fig. 4). In addition, all of these genes encode a putative signal peptide which may act in providing membrane-anchorage motifs.

**Example 6****Influence of Proteinase Inhibitor on *P. gingivalis* Growth**

To evaluate whether *P. gingivalis* growth was influenced by the presence of a peptidase inhibitor, *P. gingivalis* in logphase growth was diluted 1:5 into liquid media and incubated at 37°C. The cell density was monitored by measuring the optical density at 600 nm (OD<sub>600</sub>). When the optical density began to increase, Pefabloc was added at 0.5 mg/ml or at 2.0 mg/ml. The control culture received no Pefabloc. The cultures receiving Pefabloc exhibited decreased growth (Figure 5). The peptidase inhibitor had to be added before the culture reached an OD<sub>600</sub> of about 0.3 for the peptidase inhibitor to have an effect on growth.

The complete disclosures of all patents, patent applications, publications, and nucleic acid and protein database entries, including for example GenBank accession numbers and EMBL accession numbers, that are cited herein are hereby incorporated by reference as if individually incorporated. Various modifications and alterations of this invention will become apparent to those skilled in the art without departing from the scope and spirit of this invention, and it should be understood that this invention is not to be unduly limited to the illustrative embodiments set forth herein.

20

**Sequence Listing Free Text**

- SEQ ID NOs:1-11: Synthetic peptides
- SEQ ID NO:12: Target peptide
- SEQ ID NOs:13-22: Synthetic peptides
- 25 SEQ ID NO:23: Amino-terminus of the lower molecular mass form of PTP-A.
- SEQ ID NO:24: Amino acid sequence present in PTP-A, where X apparently represents the active-site serine residue covalently and irreversibly modified by DFP.
- 30 SEQ ID NO:25: Target peptide, where Xaa represents a natural or modified amino acid residue, Yaa represents a natural or modified amino acid residue except proline, and N is equal to or greater than 1.
- SEQ ID NO:26: Mouse fibroblast activation protein

- SEQ ID NO:27: Human DPP IV
- SEQ ID NO:28: DPP from *Flavobacterium meningosepticum*
- SEQ ID NO:29: DPP from *P. gingivalis*
- SEQ ID NO:30: *P. gingivalis* PTP-A
- 5 SEQ ID NO:31: Portion of PTP-A
- SEQ ID NO:32: Portion of DPP from *P. gingivalis*
- SEQ ID NO:33: Portion of H1 homolog of *P. gingivalis* DPP
- SEQ ID NO:34: Portion of H2 homolog of *P. gingivalis* DPP
- SEQ ID NO:35: Portion of H3 homolog of *P. gingivalis* DPP
- 10 SEQ ID NOs:36-37: Probes
- SEQ ID NO:38: Nucleotide sequence of coding region encoding PTP-A.
- SEQ ID NO:39: Consensus sequence for clan SC where X is any amino acid and S is the active site serine GXSTXG.
- SEQ ID NO:40: Consensus sequence for family S9 where X is any amino acid and S is the active site serine GXSTGG.
- 15 SEQ ID NO:41: A specific substrate for a prolyl-tripeptidyl peptidase, where Xaa represents a natural or modified amino acid residue, and Yaa represents a natural or modified amino acid residue except proline.
- 20 SEQ ID NO:42: DPP from *P. gingivalis*
- SEQ ID NO:43: H1 homolog of *P. gingivalis* DPP
- SEQ ID NO:44: H2 homolog of *P. gingivalis* DPP
- SEQ ID NO:45: H3 homolog of *P. gingivalis* DPP
- SEQ ID NO:46: Synthetic peptides
- 25 SEQ ID NO:47: Synthetic peptides
- SEQ ID NO:48: Amino terminal sequence of DPP IV

**What is claimed is:**

1. An isolated prolyl tripeptidyl-peptidase, active analog, active fragment, or active modification thereof having amidolytic activity for cleavage of a peptide bond present in a target polypeptide having at least 4 amino acids, wherein the prolyl tripeptidyl-peptidase:target polypeptide ratio is at least about 1:1 to no greater than about 1:10,000,000 in about 200 mM HEPES, about pH 7.5 at 37°C for at least about 3 hours.
2. An isolated prolyl tripeptidyl-peptidase, active analog, active fragment, or active modification thereof having amidolytic activity at a prolyl tripeptidyl-peptidase:target polypeptide ratio of at least about 1:1 to no greater than about 1:10,000,000 in about 200 mM HEPES, about pH 7.5 at 37°C for at least about 3 hours, and wherein the prolyl tripeptidyl-peptidase is isolated from *P. gingivalis*.
3. The isolated prolyl tripeptidyl-peptidase of claim 2 wherein the peptide cleaved by the isolated prolyl tripeptidyl-peptidase comprises the sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:11, H-Ala-Arg-Pro-Ala-D-Lys-amide, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:25, and SEQ ID NO:37.
4. The isolated prolyl tripeptidyl-peptidase of claim 2 wherein the amino acid sequence of the isolated prolyl tripeptidyl-peptidase comprises the amino acid sequence GXSEXG (SEQ ID NO:39).
5. The isolated prolyl tripeptidyl-peptidase of claim 4 wherein the amino acid sequence of the isolated prolyl tripeptidyl-peptidase comprises the amino acid sequence GXSEXG (SEQ ID NO:40).
6. The isolated prolyl tripeptidyl-peptidase of claim 4 wherein the amino acid sequence of the isolated prolyl tripeptidyl-peptidase comprises SEQ ID NO:30.




7. An isolated polypeptide, active analog, active fragment, or active modification thereof having amidolytic activity for cleavage of a peptide bond present in a target polypeptide having at least 4 amino acids, wherein the polypeptide:target polypeptide ratio of at least about 1:1 to no greater than about 1:10,000,000 in about 200 mM HEPES, about pH 7.5 at 37°C for at least about 3 hours.
8. An isolated polypeptide comprising an amino acid sequence having a percentage amino acid identity of greater than 35 % with SEQ ID NO:30.
9. An isolated nucleic acid fragment encoding a prolyl-tripeptidyl peptidase, active analog, active fragment, or active modification thereof, having amidolytic activity for cleavage of a peptide bond present in a target polypeptide having at least 4 amino acids, wherein the prolyl tripeptidyl-peptidase:target polypeptide ratio of at least about 1:1 to no greater than about 1:10,000,000 in about 200 mM HEPES, about pH 7.5 at 37°C for at least about 3 hours.
10. The nucleic acid fragment of claim 9 wherein the nucleic acid fragment has a nucleotide sequence comprising SEQ ID NO:38.
11. The nucleic acid fragment of claim 9 wherein a complement of the nucleic acid fragment hybridizes to SEQ ID NO:38 under hybridization conditions of 0.5 M phosphate buffer, pH 7.2, 7 % SDS, 10 mM EDTA, at 68°C, followed by three for 20 minutes washes in 2x SSC, and 0.1 % SDS, at 65°C, wherein at least about 20 nucleotides of the complement hybridize.
12. An isolated nucleic acid fragment encoding a polypeptide wherein the polypeptide comprises an amino acid sequence having a percentage amino acid identity of greater than 35 % with SEQ ID NO:30.
13. A method of identifying an inhibitor of a prolyl-tripeptidyl peptidase, active analog, active fragment, or active modification thereof, comprising identifying a molecule that inhibits the amidolytic activity of the prolyl-

tripeptidyl peptidase by incubating the prolyl-tripeptidyl peptidase with the molecule under conditions that promote amidolytic activity of the prolyl-tripeptidyl peptidase and determining if the amidolytic activity of the prolyl-tripeptidyl peptidase is inhibited relative to the amidolytic activity in the absence of molecule.


14. A method of reducing growth of a bacterium comprising inhibiting a prolyl tripeptidyl-peptidase, active analog, active fragment, or active modification thereof, by contacting the prolyl tripeptidyl-peptidase with an inhibitor of the prolyl tripeptidyl-peptidase.
15. A method for protecting an animal from a periodontal disease caused by *P. gingivalis* comprising administering to the animal the inhibitor of claim 14 wherein the disease is selected from the group consisting of gingivitis and periodontitis.
16. The method of claim 15 wherein the inhibitor is administered by a method selected from the group consisting of subgingival application and controlled release delivery.
17. A method of reducing growth of a bacterium comprising inhibiting a prolyl dipeptidyl-peptidase, active analog, active fragment, or active modification thereof, by contacting the prolyl dipeptidyl-peptidase with an inhibitor of the prolyl dipeptidyl-peptidase.
18. An immunogenic composition comprising an isolated prolyl tripeptidyl-peptidase, or an antigenic analog, antigenic fragment, or antigenic modification thereof, the prolyl tripeptidyl-peptidase having amidolytic activity for cleavage of a peptide bond present in a target peptide having at least 4 amino acids, wherein the prolyl tripeptidyl-peptidase:target polypeptide ratio is at least about 1:1 to no greater than about 1:10,000,000 in about 200 mM HEPES, about pH 7.5 at 37°C for at least about 3 hours.
19. The immunogenic composition of claim 18 further comprising an adjuvant.

20. A composition comprising an inhibitor of an isolated prolyl tripeptidyl-peptidase and a pharmaceutically acceptable carrier.
21. A dipeptidyl peptidase having an amino acid sequence comprising SEQ ID NO:43.
22. A dipeptidyl peptidase having an amino acid sequence comprising SEQ ID NO:44.
23. A dipeptidyl peptidase having an amino acid sequence comprising SEQ ID NO:45.


Fig 1




c)



d)



a)



b)

Fig. 2




Fig. 3

29 10 No:

26 Mm-FAP  
27 Hs-DPP  
28 Fm-DPP  
29 Pg-DPP  
30 PTP-A

```

1 MKTWLSTEGTTAAAHVVICIVLRPS - YKPEGNT - RALT - - - - - LINGT SYKTYF
1 MKTPWVVLGLLGAAAVTITVPVV LN GTDD TADS - KTYT T YLRNT RLKLYS
1 ---MKKKESLILSHAWAFHGLSAQE TLDK YS Q RA - GISGLASND-----
1 -MKRPVILLIGINTVCAQAQTGNKP DL E TS M YA SAGSGS S PD-----
1 ---MKRTIFQOLFSLCAETALPCSAQSPETSGKE TLEQLMPCG FYN---YPEYVV

Mm-FAP 59 PNWISEQEVYHQS EDDNIEFYNIE RE--SY I SNS MKSVN--ATDYG SPDRQF Y
Hs-DPP 60 LRWISDHEYFYK--ENNIVENAEYGN--S F ENS FDEFGHSINDYS SPDGQFII
Fm-DPP 48 -----GPNYAT--EPTGLAKYSYK SQ--KEKN VDG FQGYT-----SNDESK--HI
Pg-DPP 51 -----GPNYTE NRERTATRYNYASCKAVD FSVERARECPFKQIQNYE SSTGHHII
56 GLQWMC NY YFE---GDDVENKANCKSAQ TRFSAADLNALMEPEGCK QT DAFPSFR

Mm-FAP 114 DESDYSK RYSYATAT YIDLONGEF RGY LPRPIQY C SPVCSKAYVY NNIIYK
Hs-DPP 116 LEYNYVKQ RHSTAS DIDLNRKQ TEERIPNNTQW T SPVGHKAYVWNE IYK
Fm-DPP 92 LQKSSQS RHSELEK EYDOLKSRIV SINNANWIOE PRFSPDCSKVAFLADNNEYQ
Pg-DPP 106 LETDMES RHSYRAAVYDWRNRLVKPLS HVGKVMIPTFSPDGRMVAIVRDNNIEYK
113 TLDAGRG VVLFTQ GLVG D LARKVYLE TNEETAS DESPVGD VAYVR ENYFA

Mm-FAP 174 QRP--G PPFQITYTG NRIENG PDWVYEEEMLATKYALWS EDCRELA VEF SD
Hs-DPP 176 IEP--NLPSYRITWTG IIFYNG TDWVYEEEVFSAYSALWSENGCTFLA AOF EV
Fm-DPP 151 DLN--TGKITQITDCKNEBING GDWVYEEEFHADYYQWN KACDALVEVREDPRKV
166 KFD--F TEVQVITDQINSILNGATDWVYEEEFVTNLMSWS ADNAELAFVRSDES AV
173 RGGKLG GMSRAIAVTI GTETLVYGOAVH REFGIEKGTFS PRGSCLAFYRMOOSAV

Mm-FAP 232 PITAYSYYG DG--QYPRUNPYPKAGAKNPVVR VDTTYP HVG---P E PVEEMI
Hs-DPP 234 PLIEYSEYSDESLOYPKVRPYPKAGAVNPTVKF V TD LS VTNATS TAPASM
Fm-DPP 208 PEIN PIYYQN--LYPKL TYKYPKAGEENSAV A Y S G AQ--FGSSEKY
Pg-DPP 223 BEYR PMYEDK--LYPEDITYKPKAGEKNSTV H Y ADRN KS-----S PIDADG
232 KPTP VDMHP--LEAEKP YYPMAGTPSHHV G YH A G VY----TGEPEK

Mm-FAP 287 ASSDY WLTWVSSER C QWL V NVSV S CDFREDWHAWECPKNQEH EE RT W
Hs-DPP 294 LIGDH LCDVTWATOEK S QWLR I NYSV D CDYDESSGRWNCILVARQH EM TT W
Fm-DPP 262 IPQ Q N--ANDEE VATANR QNKVD K NTK AAVS-----K FTE DN W
Pg-DPP 277 IPR AE D--NADEE AV TLNRLQDFK YY HPK LVPK-----L Q MNKR
285 TN S P--DENI YVAEVNRAONECKVAYDAE GRFVR-----T FVE DKH

Mm-FAP 347 AGGFF TPAFSODATSY KIFS DG HHH IKDTVENAIQITSCWEATY R TQD
Hs-DPP 354 VGRFRP EPHFILDENSEF KIISNEG HIC QIDK DCTFITKGWEVIG E TSD
Fm-DPP 311 TDN --EFLDONS--ELAS DGH HLYYDAAG K QVSKGWEHINY GYNPK
Pg-DPP 326 VSDW QT KEITG G--BAVS DG AHIYLYDNKGVMH RITSGNWVTK G DAS
335 VPLHP--TELPGSNNO SI CSR DG NHLYLYDTTG I QTKGWEVTFNAGFDPK

Mm-FAP 407 SLFYS NE EGYPGRRN YR SIGNSPPSKKCVTC LRKERCQYY ASESYK KYVALVC
Hs-DPP 414 YLYYI NEYKGMPPGGRN YR QLSDYTKVT CLSCELNPERCQYY VSESKE KYVQLRC
Fm-DPP 368 ---TKE YIQ TEKGSIN VSK NINTG--KTOLLSNAEGNN AAFSKTFNYE INTS
Pg-DPP 384 ---GT YIQ ABESPIRAVYA DAKGR--KTSLSLNVGTN DALSGNYAYYINTY
393 ---G YFEFTEASPE RHFYC DIKGG--KTDLTPESGMHRTQLSPD SAIDHIF

Mm-FAP 467 Y PCIPES HDGRTO QVLEENKEL NSL NI PKVE KK K D GLTF YKML
Hs-DPP 473 S PCIPY HSSVNDK QVLEDNSAL KML ONV PSKK DFI I LNETKF YOMI
Fm-DPP 421 S TAK PTKY LKDANGK EL ONDDLLNK SD FIAKEFITIPNA GDOQ NAWMIK
Pg-DPP 435 SS ATPA V FRSGAK TLE INVALRERL AYRYNPKEFTTIKTQSCLE NAWMIK
446 Q SP T PRKVTVTNIG KGS TLL AKNP TGYAMPE RTGT MAAD---QTPF YKMT

Mm-FAP 525 PPFDRSKKYPILLQVYSGECSQS VKSV AVN---WITYLASKEGI LAUVDGRGTAGC
Hs-DPP 531 PPHFDRSKKYPILLQVYAGPCSQKADIV RLN---WATYLASTENI VASFDGRGSGC
Fm-DPP 480 PKNFDPK KYPVLFQYSGPCSQKAVNS DGGNGIWFDM LAQKG YVVCVDGRGTGARG
Pg-DPP 495 PIDFDPSE YPVLFQYSGPNSQOVLDR SFD---WCHYLASKG YVVCVDGRGTGARG
502 PLHFDPK KYPVLFYVYSGPHQOLVTKT RSSVGGNDIYLAQKG YAVFTVDSRG ANRG

```

Fig. 3

Mm-FAP	582	DKELHAYRKIGVYEVEDQITAVRKFIENGEDDERIAIWGWSYGGYVSSALASGIGHF
Hs-DPP	588	DKIMHAINRRLGTEEVEDQIEAARQFSKGEVDNKRIAIWGWSYGGYVTSMLCSGSGVF
Fm-DPP	539	TKYKRVTYKNLGKYETEDQITAAKWEGNQSAVDKSRIGIEGWSYGGYMASLMTKCADVF
Pg-DPP	551	DEMRCTYMOLGVESDDQIAAATAIGOPPVDAAIRIGIWGWSYGGYTTLMSLCRCNGTF
	561	AADEQVHRRILGOTEMADOMCGVDFIKSQSNVDADRIGIEGWSYGGYMTTLMLTHGDVF
		*—————→
Mm-FAP	642	KCGIAPVPVSSWEYYASTYSERFMGLPTKDDNLEHYKNSIVMARAEYFFNVDDLIIHGTA
Hs-DPP	648	KCGIAPVPVRWEYYESVYTERFMGLPTPEDNLEHYKNSIVASRAENFKOVEVLLIHGTA
Fm-DPP	599	KCGIAPVPTNWRREYDSIYTERFLOTPOENK--EGYDLNSPTTYAKLLKG-KELLIHGTA
Pg-DPP	611	KAGIAPVADWRREYDSMYTERFMRTPKENA--SGYKSSAEDVASOLOG-NILLVSCSA
	621	KVGVAAGGPVIDWNRREYDMYGERYFDAPOENP--EGYDAENDEKRAEDLKG-RVLLIHGAI
		*—————*
Mm-FAP	702	DDNVHFQNSAQIAKALVNAQVDFQAMWYSDONHGISSGRSONHLYTHMTHTFKQCFSLSD
Hs-DPP	708	DDNVHFQNSAQISKALVDVGYDFQAMWYDDEHGIASSTAHOHLYTHMSHTFKQCFSLP-
Fm-DPP	656	DDNVHFQNSMEFSEALONKKQDFEMAYPDKNHSIIIGGNIRPOLYKMTNMLLEN----
Pg-DPP	668	DDNVHLONTMLEALVQANTPEDMAIYMDKNHSIIYGCNIRVHLYTRKAKFFFDNL----
	578	DFVVVQHSLELDBACVKARTYPDYYVPSDEHNVMGPD-RVHLYETITRYFTDHL----

Fig. 4


Seq ID No:

PTP-A	556	VDADRIGVHGM	SYGGFMT	...	RLMNHGATDPVV	WQHSHTL	LSACVKARTY	EDYVPSHEH	VACBP-R	717		
DPP	499	VDARIGIWM	SYGGYTT	...	NLLVSGSAD	DNVHLQNT	MLFTTAL	VOANIP	PDMAHYDKNHS	YGGNTR	661	
DPP-H1	350	VDPRIALY	GASHGGYAT	...	PLEVACQ	ANDPRVNI	ESDQIVT	ALRARG	FEVPTAKYNECH	GFHRENS	524	
DPP-H2	640	VNGKKGCE	GASYGGFMT	...	PLLEH	HGSM	DTNVPTAES	NLYNRAKIL	GREVETET	ODHFFTEF	810	
DPP-H3	495	VDGDRIGAV	GASYGGFSV	...	PILLH	HGEHDF	FLASQ	MAAFSA	QILRGVPS	MDHDPDENH	WACBPNA	667



Fig 5

Influence of Pefablock- serine proteinase inhibitor on *P. gingivalis* growth.



Seq 10 No:

Fig. 6

30126PP 1 MKKTI FQQLF---LSVCALTVALPCSAQSPETSGKEETLEQLVPGCKEE--YNFYPEYV  
 4287PP 1 -----VPDGEHY--TEMNRERT  
 4365PP 1 -----VDKGG--NENYHLFA  
 44101PP 1 MKKSLMLLSAATLSSIEAQTIOQMKGGPWPVRAAKTDTVGMNGSKYNPADLLRQAY  
 459PP 1 VNKKIFSMMAAS--IIGSAAMTPSAGTNTGEHLTPELMTLSRVSEMALS--PDGKTAVY

126PP 55 VGLQWMGDNYVF---IEGDDLANKANG-----KSAQTTRESAADLNALMPEGCKEQ  
 87PP 16 AILRY--SYAS---GKAVDTUSVER-----ARECPKQIQ-N-----YE  
 65PP 14 SNIDG---S---NTRDLTPEDGVK---ASILNMLKEQK-D-----YM  
 101PP 61 DATDKDLRNVSAADKDGRIAGRKAGSKAERSEMAVYSFALTAEHAKADIEVFGQGRMSLW  
 9PP 57 AVSFP--DVKT-----NKATRELTVNLD-----GSGRKQITDTESN-----EYAPAW

126PP 104 TTDAPPSFRTLDAGRC--LVVLTQGGLVGFDMLARKVTYL--F--TNEETASLDFSE---  
 87PP 50 VSSTGHHLLFTDMES--IYRHSYRAAVDYDVRRLVKPL--SEHVCKVMIPTFSE---  
 65PP 46 TISMNK---NNPO---IFEPYKLNVTTELTLQLYEN---KDAANPTQGYEFDK---  
 101PP 121 DDQKQIGADSPNSKQDTRFSASISLVPSTHLLKSLLEGGTTATDVRVVLKETA  
 9PP 98 MAGKKS--AFMSNEGG---SMQLWVMNADSTERROLSN-----IEGGITGFLFSE---

126PP 157 -V-----S-DRVAVVNNHN-LYIARG--GKLGEGMSRAIAVTIDGTETLVYQGA--  
 87PP 103 -E-----C-RMVAFVDNN-IFIK---KFDFTDE--VOVTDGQINSILNGATD  
 65PP 90 -D-----S-ELRGSYS-----LVNGIESELYYKD--  
 101PP 181 RSSALYPNYTSEKRLSLKHMMSGTFLSGGSLSPGKYVLTYSYRVSRENKPAVTYNQLRD  
 9PP 144 -E-----E-KOVLFTND-----KFGKRTKDIYPDLDK

126PP 201 -VHQREFGLEKG--TFSPKGSCLAFYEM-----DQS-MVKPTPIVDYH---PI  
 87PP 144 WYEEEFQVTNL--MSASADNAFLAVS-----DES-AVEYRMPMYED---KL  
 65PP 112 -LATGEFRELKK--THDDTFGVIALNYA-----SKN-KDQAYVLTNLD---S  
 101PP 241 AKGNILLNENEALGAMPHEDMIIVIEKEGNAKRLVAFPMGKGKTLVSNLPESQFRM  
 9PP 170 ATGRIITDLMYK--HDEWVETIPHPFI-----AN-ATDGMITTGKD---I

126PP 243 EAEKPLYYPNAGT---PSHHVTVGTYHLA---TG-KTVYLTGTGPEKFLTNLSWSPDE  
 87PP 188 YPDYTYKIKAGE---KNSTVSLHLNVA---ER-NTKSVSLPIDADGYIPRIATDNA  
 65PP 153 DK-TRIVLIDLKQN--K---IREIFANE---DY-DVSGEHLRS-RK---  
 101PP 301 SPARYYLYKQEKGPGRDPLFIRHLDPPDRQSCWRDRSQHYLLNAESGVYGPITGYST  
 9PP 210 ME-GEPEYALMKPW-----S-GIEDFSWSP--DG--QNIAYASRKITG-----

126PP 296 NIDYVAE--VNRAQNECKVNANDAETGRFVRTLFVETDKHYVEP--LH-P---LTFLE-  
 87PP 241 DELAVET--LNRLQNEFKY-YVHPKSLVPKLLQDANKRYVDSWDWIQ-T---LKEFT-  
 65PP 188 -R-----N-YEIDLMA--HEGEKSVVVPVSATYKELHKLME-----KEFK--  
 101PP 361 TYENDIAPDSKALIGTLSTDTRRPFATIMEYNNETGKADTLITRDPSIDAIQYTFD  
 9PP 247 -MAVSLT--TN---SUIYL--YNLASGETHNISEGMMGYDTPK-----FSPD

126PP 346 GSNNQIQQSR-RDGNHLYL-----YDTTGRLIRQVTKGEWEVINFA-----G  
 87PP 292 GGG--FAYVSE-KDGEAHLYL-----YDNKGVVHRRITSGNWDVTKLY-----G  
 65PP 224 GKE--FSVV---E-----YCD-----  
 101PP 421 GKH--LIVGGS-ALAGNIGLNLKSGVTNSYDKQFFLFDLSIRKATALTKNENPSVSAG  
 9PP 287 GKS--IATISMERDGYES-----DLKRLFVADLAIKGRTHVNPTEDYNVDMI

126PP 389 -EPKGIRLYESTASPLERHFCIDINGGKTADLTP-ESGMHRTQLSP--GSAITIDIF  
 87PP 333 -VDASGT-VEYQSAESPERRAVYA--GKGRKTK--LSL-NVGTNDALFSGN--YAYYINTY  
 65PP 235 -EE--I-LLIAVQSDKLYGTYYQFETG--TK-----KFT-----LTYD-L  
 101PP 478 REDRKNN-YTYFRAENG-SRKQYRLKLTLEISOETGEDVVQWFGVAADNGAVWYSGQ  
 9PP 332 QVAPDSKGYELACKEA--ETNLWEITLKTGNIROITQGHQHDYADFSVRND---VMLAKR

Fig. 6

```

126PP 446 QSPVIRKVTITNIGKESHTLLEAKNPDTGYAMPETPTG-----TLMADGQTPLYKLT
87PP 388 SSAATPAVSVFRSGAKELRTLEDNVALRERKAYFYNPKFTTTKTQSS-LELNAAWIV
65PP 269 -----HQLK-----EEF-----MAEVRPI-----KFKSRDG-LTIHGFTT
101PP 536 SENNADRLYRFDGTSGKLVDLSAEKLANIDFTPAROWN-----YTAPOG-TVVEGYY
9PP 387 HSFELEDDLYRVNLKNGAAQAVTAENKVILRLTPTTCEKR---WKTTDG-GNMLTAVV

126PP 501 MELHFDPAKKYEVIVVYGG---EHALVTKTWRSSVGGWDIYMAOKGYAVFTVDSRGSAN
87PP 447 KPIDFDPSRHYFVLNVQYSG---PNSDOVLD--RYSFD-WEHYLASKGYVAVCDGRGTGA
65PP 299 LKAALEGKKNVFLVNFHGG---E---GIRD--SWGPNPETQLFASRGYATLOVNFRISSG
101PP 589 LPPQFDESKKYFMLVYYGGTSEINRTLEG--HYSLA---MYAACSYVVYTLNPSSTTG
9PP 443 LPPNFDKNKKYFALLYCQGG---E---NTVS-QFWSFRWNLRLMAEQSYIVIAPNRHGVPS

126PP 559 RGAAEQVIHRRIGQTEPAALOMCEVD-FLKSQSNVLAADRICVHWSYGGFMTNMLLTHG
87PP 502 RGEWRKCTYMQGVFESDSOLAAAT-ALGQLPYVLAARICIGWSYGGYTFLMSLCRGN
65PP 353 YGKEFLRAGFKQIGRKAMDEVEDGVR-VAISQGNVLEDRITAIYGASISGYATLMGLVKTTP
101PP 643 YGQELYAARHVNAWSDRTADEITIGATKEFIRTHSEVNGKAVCFGASVGGFMTQYLTQNT-
9PP 498 FGQKNEQISGDYEGQNNRDYLTAVD-EMKKEPVLDGRICAVGASVGGFSVYWLAGHHD

126PP 618 DVEKVGAVAGGPVI-----D-----EN--RYEIMYGERYFDA--EOENPEGYD-AANLLK
87PP 561 GTEKAGLAVAPVA-----C-----WR--FYDSVYTERFMRT--EKENASGYK-MSSALD
65PP 412 DLYACGVVDYVGVSNITYTFFSFPEYK--PFKEVKEIMYLDNPEAAIAKE-VSHFFQ
101PP 702 EIFAAAVSHAGISS--S---N---YNGSGYNGMGSTVASTDSYPWNPPDLHAGHSFLFR
9PP 557 KRFAAFLAHAGIFN-EMQYATTEEMFA-NNDIGGFWEKEN---VVAQRTYA-TSPHKF

126PP 662 RAGDEKGRKLLHGAIEPVVWVHSLFLDACVKARTYPDYVYPSHEENVMGPE--VHL
87PP 605 VASQLQGNELIVSISADNDHLENTMLFTEALVQANIPFDMALYMDKNHSIYGGNTSYHL
65PP 469 ID-KINKPLEVVQSANPRNINIESDQIVTALRARSFEVPMVKYNEGGFHRENSMEL
101PP 755 AD-KIHTPLLLHGSVETNVPATAESVNLNNAIKILGREVEGLEETEQDHFILPEPRIRW
9PP 612 VQ-NWDTIIMIHGELEFRILASQAMAAFDAAQLRGVPSMLIYPDENWVLOEQNALLF

126PP 721 YETITRYFTDHI-----
87PP 665 YTRKAKELFDNI-----
65PP 528 YRAELSEFAKHKK-----
101PP 814 TNSICAEASWQDDPTWWNELYPVNL
9PP 671 HRTFFGWLDRWKK-----

```

Fig 7

## P. gingivalis W 83 PTP sequence

13228 atgaagaagacaatcttccaacaactatctgtctgtttgtgcc  
 M K K T I F Q Q L F L S V C A  
 13273 cttacagtggccttgccctgttcggctcagtcctcctgaaacgagt  
 L T V A L P C S A Q S P E T S  
 13318 ggtaaggagtttactcttgagcaactgatgcccgaggagaaaagag  
 G K E F T L E Q L M P G G K E  
 13363 ttttataacttttaccgccgaatacgtggcgtttgcaatggatg  
 F Y N F Y P E Y V V G L Q W M  
 13408 ggagacaattatgtctttatcgaggggtgatgatttagttttaat  
 G D N Y V F I E G D D L V F N  
 13453 aaggcgaatggcaaatcggtcagacgaccagattttctgctgcc  
 K A N G K S A Q T T R F S A A  
 13498 gatctcaatgcactcatgccggagggatgcaaatttcagacgact  
 D L N A L M P E G C K F Q T T  
 13543 gatgctttcccttcattccgcacactcgatgccggacggggactg  
 D A F P S F R T L D A G R G L  
 13588 gtcgttctatttacccaaggaggattagtcggattcgatatgctt  
 V V L F T Q G G L V G F D M L  
 13633 gctcgaaaggtgacttatcttttcgataccaatgaggagacggct  
 A R K V T Y L F D T N E E T A  
 13678 tctttggatttttctcctgtgggagaccgtgttgccatgtcaga  
 S L D F S P V G D R V A Y V R  
 13723 aaccataacctttacattgctcgtggagggtaaattgggagaagggt  
 N H N L Y I A R G G K L G E G  
 13768 atgtcacgagctatcgctgtgactatcgatggaactgagactctc  
 M S R A I A V T I D G T E T L  
 13813 gtatatggccaggccgtacaccagcgtgaattcggtatcgaaaaa  
 V Y G Q A V H Q R E F G I E K  
 13858 ggtacattctggtctccaaaaggagctgccttgctttctatcga  
 G T F W S P K G S C L A F Y R  
 13903 atggatcagagtatggtgaagcctaccccgatagtggtattatcat  
 M D Q S M V K P T P I V D Y H  
 13948 ccgctcgaagccgagtcctaaacgcgtttattaccccatggcagggt  
 P L E A E S K P L Y Y P M A G  
 13993 actccgtcacaccacgttacggttgggatctatcatctggccaca  
 T P S H H V T V G I Y H L A T  
 14038 ggtaagaccgtctatctacaaacgggtgaacccaaggaaaaattt  
 G K T V Y L Q T G E P K E K F  
 14083 ctgacgaatttgagttggagtccggacgaaaatatcttgatgta  
 L T N L S W S P D E N I L Y V  
 14128 gctgaggtgaatcgctcctcaaaacgaatgtaaggtaaatgcctat  
 A E V N R A Q N E C K V N A Y  
 14173 gacgctgagaccggtagattcgctccgtacgctttttgttgaaacc  
 D A E T G R F V R T L F V E T

Fig. 7

14218 gataaacattatgtagagccgttacatcccctgacattccttcog  
D K H Y V E P L H P L T F L P  
14263 ggaagtaacaatcagttcatttggcagagccgtcgcgacggatgg  
G S N N Q F I W Q S R R D G W  
14308 aaccatctctatctgtatgatactacaggtcgtctgatccgtcag  
N H L Y L Y D T T G R L I R Q  
14353 gtgacaaaaggggagtgagggttacaaactttgcaggcttcgat  
V T K G E W E V T N F A G F D  
14398 cccaaggaacacggctctatttcgaaagtaccgaagccagccct  
P K G T R L Y F E S T E A S P  
14443 ctggaacgccatttttactgtattgatataaaggaggaaagaca  
L E R H F Y C I D I K G G K T  
14488 aaagatctgactccggagtcgggaatgcaccgcactcagctatct  
K D L T P E S G M H R T Q L S  
14533 cctgatgggtctgccataatcgatatttttcagtcacctactgtc  
P D G S A I I D I F Q S P T V  
14578 ccgcgtaaggttacagtgacaaatatcggaaggggtctcacaca  
P R K V T V T N I G K G S H T  
14623 ctcttgagggttaagaaccccgatacgggctatgccatgccggag  
L L E A K N P D T G Y A M P E  
14668 atcagaacgggtaccatcatggcgccgatgggcagacacctctt  
I R T G T I M A A D G Q T P L  
14713 tattacaagctcacgatgccgcttcatttcgatccggcaaagaaa  
Y Y K L T M P L H F D P A K K  
14758 tatcctgttattgtctatgtttacggaggacctcatgcccaactc  
Y P V I V Y V Y G G P H A Q L  
14803 gtaaccaagacatggcgagctctgtcgggtggatgggatattctat  
V T K T W R S S V G G W D I Y  
14848 atggcacagaaaggctatgccgtctttacgggtggatagtcgcgga  
M A Q K G Y A V F T V D S R G  
14893 tctgccaatagaggggctgctttcgagcagggttattcatcgtcgt  
S A N R G A A F E Q V I H R R  
14938 ttggggcagaccgagatggccgatcagatgtgcggtgtggatttc  
L G Q T E M A D Q M C G V D F  
14983 ctcaagagccaatcatgggtggatgccgatagaataggagtagat  
L K S Q S W V D A D R I G V H  
15028 ggctggagctatgggtgctttatgactacgaatctgatgcttacg  
G W S Y G G F M T T N L M L T  
15073 cacggcgatgtcttcaaagtcggagtagccggcgggcctgtcata  
H G D V F K V G V A G G P V I  
15118 gactggaatcgatatgagattatgtacggtgagcgttatttcgat  
D W N R Y E I M Y G E R Y F D  
15163 gcgccacaggaaaatcccgaaggatacgtgctgccaacctgctc  
A P Q E N P E G Y D A A N L L  
15208 aaacgagccggtgatctgaaaggacgacttatgctgattcatgga  
K R A G D L K G R L M L I H G  
15253 gcgatcgatccggtcgtggtatggcagcattcactccttttcctt

Fig 7

A I D P V V V W Q H S L L F L  
 15298 gatgcttgctgaaggcacgcacctatcctgactattacgtctat  
 D A C V K A R T Y P D Y Y V Y  
 15343 ccgagccacgaacataatgtgatggggccggacagagtacatttg  
 P S H E H N V M G P D R V H L  
 15388 tatgaaacaataacccgttatttcacagatcacttatga 15426  
 Y E T I T R Y F T D H L \*

SEQ ID NO: 38  
 TCAGTCTCCTGAAACGAGTGGTAAGGAGTTTACTCTTGAGCAACTGATGCCCGAGGAAAAGAGTTTATA  
 ACTTTTACCCGAATACGTGGTTCGGTTTGCAATGGATGGGAGACAATTATGTCTTTATCGAGGGTGATGAT  
 TTAGTTTTTAATAAGGCGAATGGCAATCGGCTCAGACGACCAGATTTCTGCTGCCGATCTCAATGCACT  
 CATGCCGGAGGGATGCAATTTTCAGACGACTGATGCTTTCCCTTCATTCCGCACACTCGATGCCGGACGGG  
 GACTGGTTCGTTCTATTTACCCAAGGAGGATTAGTCGGATTCGATATGCTTGCTCGAAAGGTGACTTATCTT  
 TTCGATACCAATGAGGAGACGGCTTCTTTGGATTTTCTCCTGTGGGAGACCGTGTGCCTATGTCAGAAA  
 CCATAACCTTTACATTGCTCGTGGAGGTAAATTTGGGAGAAGGTATGTCACGAGCTATCGCTGTGACTATCG  
 ATGGAACGTGAGACTCTCGTATATGGCCAGGCCGTACACCAGCGTGAATTCGGTATCGAAAAAGGTACATTCT  
 TGGTCTCCAAAAGGGAGCTGCCTTGCTTTCTATCGAATGGATCAGAGTATGGTGAAAGCTACCCCGATAGT  
 GGATTATCATCCGCTCGAAGCCGAGTCCAAACCGCTTATTACCCCATGGCAGGTACTCCGTCACACCACG  
 TTACGGTTGGGATCTATCATCTGGCCACAGGTAAGACCGTCTATCTACAAACGGGTGAACCCAAAGGAAAA  
 TTTCTGACGAATTTGAGTTGGAGTCCGGACGAAATATCTTGATGTAGCTGAGGTGAATCGTGCTCAAAA  
 CGAATGTAAGGTAAATGCCTATGACGCTGAGACCGGTAGATTGCTCCGTACGCTTTTGTGTAACCGATA  
 AACATTATGTAGAGCCGTACATCCCTGACATTCTTCCGGGAAGTAACAATCAGTTCATTGTGGCAGAGC  
 CGTCGCGACGGATGGAACCATCTCTATCTGTATGATACTACAGGTCTGCTGATCCGTCAGGTGACAAAAGG  
 GGAGTGGGAGGTTACAACTTTGCAGGCTTCGATCCCAAGGGAACACGGCTCTATTTCGAAAGTACCGAAG  
 CCAGCCCTCTCGAAGCCCATTTTACTGTATTGATATCAAAGGAGGAAAGACAAAAGATCTGACTCCGGAG  
 TCGGGAATGCACCGCACTCAGCTATCTCCTGATGGTTCTGCCATAATCGATATTTTTCAGTCACCTACTGT  
 CCCGCGTAAGGTTACAGTGACAAATATCGGCAAAGGCTCTCACACACTCTTGGAGGCTAAGAACCCTGATA  
 CGGGCTATGCCATGCCGAGATCAGAACGGGTACCATCATGGCGGCCGATGGGCAGACACCTCTTTATTAC  
 AAGCTCACGATGCCGCTTCATTTCGATCCGGCAAAGAAATATCCTGTTATTGTCTATGTTTACGGAGGACC  
 TCATGCCCAACTCGTAACCAAGACATGGCGCAGCTCTGTCCGTGGATGGGATATCTATATGGCACAGAAAG  
 GCTATGCCGCTCTTACGGTGGATAGTCCGGATCTGCCAATAGAGGGGCTGCTTTCGAGCAGGTATTTCAT  
 CGTCGTTTGGGGCAGACCGAGATGGCCGATCAGATGTGCGGTGTGGATTTCCTCAGAGCCAATCATGGGT  
 GGATGCCGATAGAATAGGAGTACATGGCTGGAGCTATGGTGGCTTTATGACTACGAATCTGATGCTTACGC  
 ACGGCGATGCTTCAAAGTCGGAGTAGCCGCGGGCTGTATAGACTGGAATCGATATGAGATTATGTAC  
 GGTGAGCGTTATTTTCGATGCCCCACAGGAAATCCCGAAGGATACGATGCTGCCAACCTGCTCAAACGAGC  
 CGGTGATCTGAAAGGACGACTTATGCTGATTCATGGAGCGATCGATCCGGTCTGGTATGGCAGCATTCAC  
 TCCTTTTCTTGTATGCTTGCGTGAAGGCACGCACCTATCTGACTATTACGTCTATCCGAGCCACGAACAT  
 AATGTGATGGGGCCGACAGAGTACATTTGTATGAAACAATAACCCGTATTTTCACAGATCATTATGA

CORRECTED VERSION

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
8 September 2000 (08.09.2000)

PCT

(10) International Publication Number  
WO 00/52147 A3

- (51) International Patent Classification<sup>7</sup>: C12N 15/57, (71) Applicants and  
9/48, A61K 39/02 (72) Inventors: TRAVIS, James [US/US]; 825 Riverbend  
Parkway, Athens, GA 30605 (US). POTEPA, Jan  
[US/US]; Apt. #102, 170 Barrington Drive, Athens, GA  
30605 (US). BANBULA, Agnieszka [US/US]; Apt. #E13,  
280 Picadilly Square, Athens, GA 30605 (US).
- (21) International Application Number: PCT/US00/05551
- (22) International Filing Date: 3 March 2000 (03.03.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/123,148 5 March 1999 (05.03.1999) US (81) Designated States (national): AE, AL, AM, AT, AU, AZ,  
BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK,  
DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,  
IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,  
LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT,
- (71) Applicant: UNIVERSITY OF GEORGIA RESEARCH  
FOUNDATION, INC. [US/US]; 632 Boyd Graduate Stud-  
ies, Athens, GA 30602-7411 (US).

[Continued on next page]

(54) Title: BACTERIAL PROLYL PEPTIDASES AND METHODS OF USE

SEQ ID NO:  
a  
21 No-FAP 1  
22 No-FAP 1  
23 No-FAP 1  
24 No-FAP 1  
25 No-FAP 1  
26 No-FAP 1  
27 No-FAP 1  
28 No-FAP 1  
29 No-FAP 1  
30 No-FAP 1  
31 No-FAP 1  
32 No-FAP 1  
33 No-FAP 1  
34 No-FAP 1  
35 No-FAP 1  
36 No-FAP 1  
37 No-FAP 1  
38 No-FAP 1  
39 No-FAP 1  
40 No-FAP 1  
41 No-FAP 1  
42 No-FAP 1  
43 No-FAP 1  
44 No-FAP 1  
45 No-FAP 1  
46 No-FAP 1  
47 No-FAP 1  
48 No-FAP 1  
49 No-FAP 1  
50 No-FAP 1  
51 No-FAP 1  
52 No-FAP 1  
53 No-FAP 1  
54 No-FAP 1  
55 No-FAP 1  
56 No-FAP 1  
57 No-FAP 1  
58 No-FAP 1  
59 No-FAP 1  
60 No-FAP 1  
61 No-FAP 1  
62 No-FAP 1  
63 No-FAP 1  
64 No-FAP 1  
65 No-FAP 1  
66 No-FAP 1  
67 No-FAP 1  
68 No-FAP 1  
69 No-FAP 1  
70 No-FAP 1  
71 No-FAP 1  
72 No-FAP 1  
73 No-FAP 1  
74 No-FAP 1  
75 No-FAP 1  
76 No-FAP 1  
77 No-FAP 1  
78 No-FAP 1  
79 No-FAP 1  
80 No-FAP 1  
81 No-FAP 1  
82 No-FAP 1  
83 No-FAP 1  
84 No-FAP 1  
85 No-FAP 1  
86 No-FAP 1  
87 No-FAP 1  
88 No-FAP 1  
89 No-FAP 1  
90 No-FAP 1  
91 No-FAP 1  
92 No-FAP 1  
93 No-FAP 1  
94 No-FAP 1  
95 No-FAP 1  
96 No-FAP 1  
97 No-FAP 1  
98 No-FAP 1  
99 No-FAP 1  
100 No-FAP 1  
101 No-FAP 1  
102 No-FAP 1  
103 No-FAP 1  
104 No-FAP 1  
105 No-FAP 1  
106 No-FAP 1  
107 No-FAP 1  
108 No-FAP 1  
109 No-FAP 1  
110 No-FAP 1  
111 No-FAP 1  
112 No-FAP 1  
113 No-FAP 1  
114 No-FAP 1  
115 No-FAP 1  
116 No-FAP 1  
117 No-FAP 1  
118 No-FAP 1  
119 No-FAP 1  
120 No-FAP 1  
121 No-FAP 1  
122 No-FAP 1  
123 No-FAP 1  
124 No-FAP 1  
125 No-FAP 1  
126 No-FAP 1  
127 No-FAP 1  
128 No-FAP 1  
129 No-FAP 1  
130 No-FAP 1  
131 No-FAP 1  
132 No-FAP 1  
133 No-FAP 1  
134 No-FAP 1  
135 No-FAP 1  
136 No-FAP 1  
137 No-FAP 1  
138 No-FAP 1  
139 No-FAP 1  
140 No-FAP 1  
141 No-FAP 1  
142 No-FAP 1  
143 No-FAP 1  
144 No-FAP 1  
145 No-FAP 1  
146 No-FAP 1  
147 No-FAP 1  
148 No-FAP 1  
149 No-FAP 1  
150 No-FAP 1  
151 No-FAP 1  
152 No-FAP 1  
153 No-FAP 1  
154 No-FAP 1  
155 No-FAP 1  
156 No-FAP 1  
157 No-FAP 1  
158 No-FAP 1  
159 No-FAP 1  
160 No-FAP 1  
161 No-FAP 1  
162 No-FAP 1  
163 No-FAP 1  
164 No-FAP 1  
165 No-FAP 1  
166 No-FAP 1  
167 No-FAP 1  
168 No-FAP 1  
169 No-FAP 1  
170 No-FAP 1  
171 No-FAP 1  
172 No-FAP 1  
173 No-FAP 1  
174 No-FAP 1  
175 No-FAP 1  
176 No-FAP 1  
177 No-FAP 1  
178 No-FAP 1  
179 No-FAP 1  
180 No-FAP 1  
181 No-FAP 1  
182 No-FAP 1  
183 No-FAP 1  
184 No-FAP 1  
185 No-FAP 1  
186 No-FAP 1  
187 No-FAP 1  
188 No-FAP 1  
189 No-FAP 1  
190 No-FAP 1  
191 No-FAP 1  
192 No-FAP 1  
193 No-FAP 1  
194 No-FAP 1  
195 No-FAP 1  
196 No-FAP 1  
197 No-FAP 1  
198 No-FAP 1  
199 No-FAP 1  
200 No-FAP 1  
201 No-FAP 1  
202 No-FAP 1  
203 No-FAP 1  
204 No-FAP 1  
205 No-FAP 1  
206 No-FAP 1  
207 No-FAP 1  
208 No-FAP 1  
209 No-FAP 1  
210 No-FAP 1  
211 No-FAP 1  
212 No-FAP 1  
213 No-FAP 1  
214 No-FAP 1  
215 No-FAP 1  
216 No-FAP 1  
217 No-FAP 1  
218 No-FAP 1  
219 No-FAP 1  
220 No-FAP 1  
221 No-FAP 1  
222 No-FAP 1  
223 No-FAP 1  
224 No-FAP 1  
225 No-FAP 1  
226 No-FAP 1  
227 No-FAP 1  
228 No-FAP 1  
229 No-FAP 1  
230 No-FAP 1  
231 No-FAP 1  
232 No-FAP 1  
233 No-FAP 1  
234 No-FAP 1  
235 No-FAP 1  
236 No-FAP 1  
237 No-FAP 1  
238 No-FAP 1  
239 No-FAP 1  
240 No-FAP 1  
241 No-FAP 1  
242 No-FAP 1  
243 No-FAP 1  
244 No-FAP 1  
245 No-FAP 1  
246 No-FAP 1  
247 No-FAP 1  
248 No-FAP 1  
249 No-FAP 1  
250 No-FAP 1  
251 No-FAP 1  
252 No-FAP 1  
253 No-FAP 1  
254 No-FAP 1  
255 No-FAP 1  
256 No-FAP 1  
257 No-FAP 1  
258 No-FAP 1  
259 No-FAP 1  
260 No-FAP 1  
261 No-FAP 1  
262 No-FAP 1  
263 No-FAP 1  
264 No-FAP 1  
265 No-FAP 1  
266 No-FAP 1  
267 No-FAP 1  
268 No-FAP 1  
269 No-FAP 1  
270 No-FAP 1  
271 No-FAP 1  
272 No-FAP 1  
273 No-FAP 1  
274 No-FAP 1  
275 No-FAP 1  
276 No-FAP 1  
277 No-FAP 1  
278 No-FAP 1  
279 No-FAP 1  
280 No-FAP 1  
281 No-FAP 1  
282 No-FAP 1  
283 No-FAP 1  
284 No-FAP 1  
285 No-FAP 1  
286 No-FAP 1  
287 No-FAP 1  
288 No-FAP 1  
289 No-FAP 1  
290 No-FAP 1  
291 No-FAP 1  
292 No-FAP 1  
293 No-FAP 1  
294 No-FAP 1  
295 No-FAP 1  
296 No-FAP 1  
297 No-FAP 1  
298 No-FAP 1  
299 No-FAP 1  
300 No-FAP 1  
301 No-FAP 1  
302 No-FAP 1  
303 No-FAP 1  
304 No-FAP 1  
305 No-FAP 1  
306 No-FAP 1  
307 No-FAP 1  
308 No-FAP 1  
309 No-FAP 1  
310 No-FAP 1  
311 No-FAP 1  
312 No-FAP 1  
313 No-FAP 1  
314 No-FAP 1  
315 No-FAP 1  
316 No-FAP 1  
317 No-FAP 1  
318 No-FAP 1  
319 No-FAP 1  
320 No-FAP 1  
321 No-FAP 1  
322 No-FAP 1  
323 No-FAP 1  
324 No-FAP 1  
325 No-FAP 1  
326 No-FAP 1  
327 No-FAP 1  
328 No-FAP 1  
329 No-FAP 1  
330 No-FAP 1  
331 No-FAP 1  
332 No-FAP 1  
333 No-FAP 1  
334 No-FAP 1  
335 No-FAP 1  
336 No-FAP 1  
337 No-FAP 1  
338 No-FAP 1  
339 No-FAP 1  
340 No-FAP 1  
341 No-FAP 1  
342 No-FAP 1  
343 No-FAP 1  
344 No-FAP 1  
345 No-FAP 1  
346 No-FAP 1  
347 No-FAP 1  
348 No-FAP 1  
349 No-FAP 1  
350 No-FAP 1  
351 No-FAP 1  
352 No-FAP 1  
353 No-FAP 1  
354 No-FAP 1  
355 No-FAP 1  
356 No-FAP 1  
357 No-FAP 1  
358 No-FAP 1  
359 No-FAP 1  
360 No-FAP 1  
361 No-FAP 1  
362 No-FAP 1  
363 No-FAP 1  
364 No-FAP 1  
365 No-FAP 1  
366 No-FAP 1  
367 No-FAP 1  
368 No-FAP 1  
369 No-FAP 1  
370 No-FAP 1  
371 No-FAP 1  
372 No-FAP 1  
373 No-FAP 1  
374 No-FAP 1  
375 No-FAP 1  
376 No-FAP 1  
377 No-FAP 1  
378 No-FAP 1  
379 No-FAP 1  
380 No-FAP 1  
381 No-FAP 1  
382 No-FAP 1  
383 No-FAP 1  
384 No-FAP 1  
385 No-FAP 1  
386 No-FAP 1  
387 No-FAP 1  
388 No-FAP 1  
389 No-FAP 1  
390 No-FAP 1  
391 No-FAP 1  
392 No-FAP 1  
393 No-FAP 1  
394 No-FAP 1  
395 No-FAP 1  
396 No-FAP 1  
397 No-FAP 1  
398 No-FAP 1  
399 No-FAP 1  
400 No-FAP 1  
401 No-FAP 1  
402 No-FAP 1  
403 No-FAP 1  
404 No-FAP 1  
405 No-FAP 1  
406 No-FAP 1  
407 No-FAP 1  
408 No-FAP 1  
409 No-FAP 1  
410 No-FAP 1  
411 No-FAP 1  
412 No-FAP 1  
413 No-FAP 1  
414 No-FAP 1  
415 No-FAP 1  
416 No-FAP 1  
417 No-FAP 1  
418 No-FAP 1  
419 No-FAP 1  
420 No-FAP 1  
421 No-FAP 1  
422 No-FAP 1  
423 No-FAP 1  
424 No-FAP 1  
425 No-FAP 1  
426 No-FAP 1  
427 No-FAP 1  
428 No-FAP 1  
429 No-FAP 1  
430 No-FAP 1  
431 No-FAP 1  
432 No-FAP 1  
433 No-FAP 1  
434 No-FAP 1  
435 No-FAP 1  
436 No-FAP 1  
437 No-FAP 1  
438 No-FAP 1  
439 No-FAP 1  
440 No-FAP 1  
441 No-FAP 1  
442 No-FAP 1  
443 No-FAP 1  
444 No-FAP 1  
445 No-FAP 1  
446 No-FAP 1  
447 No-FAP 1  
448 No-FAP 1  
449 No-FAP 1  
450 No-FAP 1  
451 No-FAP 1  
452 No-FAP 1  
453 No-FAP 1  
454 No-FAP 1  
455 No-FAP 1  
456 No-FAP 1  
457 No-FAP 1  
458 No-FAP 1  
459 No-FAP 1  
460 No-FAP 1  
461 No-FAP 1  
462 No-FAP 1  
463 No-FAP 1  
464 No-FAP 1  
465 No-FAP 1  
466 No-FAP 1  
467 No-FAP 1  
468 No-FAP 1  
469 No-FAP 1  
470 No-FAP 1  
471 No-FAP 1  
472 No-FAP 1  
473 No-FAP 1  
474 No-FAP 1  
475 No-FAP 1  
476 No-FAP 1  
477 No-FAP 1  
478 No-FAP 1  
479 No-FAP 1  
480 No-FAP 1  
481 No-FAP 1  
482 No-FAP 1  
483 No-FAP 1  
484 No-FAP 1  
485 No-FAP 1  
486 No-FAP 1  
487 No-FAP 1  
488 No-FAP 1  
489 No-FAP 1  
490 No-FAP 1  
491 No-FAP 1  
492 No-FAP 1  
493 No-FAP 1  
494 No-FAP 1  
495 No-FAP 1  
496 No-FAP 1  
497 No-FAP 1  
498 No-FAP 1  
499 No-FAP 1  
500 No-FAP 1  
501 No-FAP 1  
502 No-FAP 1  
503 No-FAP 1  
504 No-FAP 1  
505 No-FAP 1  
506 No-FAP 1  
507 No-FAP 1  
508 No-FAP 1  
509 No-FAP 1  
510 No-FAP 1  
511 No-FAP 1  
512 No-FAP 1  
513 No-FAP 1  
514 No-FAP 1  
515 No-FAP 1  
516 No-FAP 1  
517 No-FAP 1  
518 No-FAP 1  
519 No-FAP 1  
520 No-FAP 1  
521 No-FAP 1  
522 No-FAP 1  
523 No-FAP 1  
524 No-FAP 1  
525 No-FAP 1  
526 No-FAP 1  
527 No-FAP 1  
528 No-FAP 1  
529 No-FAP 1  
530 No-FAP 1  
531 No-FAP 1  
532 No-FAP 1  
533 No-FAP 1  
534 No-FAP 1  
535 No-FAP 1  
536 No-FAP 1  
537 No-FAP 1  
538 No-FAP 1  
539 No-FAP 1  
540 No-FAP 1  
541 No-FAP 1  
542 No-FAP 1  
543 No-FAP 1  
544 No-FAP 1  
545 No-FAP 1  
546 No-FAP 1  
547 No-FAP 1  
548 No-FAP 1  
549 No-FAP 1  
550 No-FAP 1  
551 No-FAP 1  
552 No-FAP 1  
553 No-FAP 1  
554 No-FAP 1  
555 No-FAP 1  
556 No-FAP 1  
557 No-FAP 1  
558 No-FAP 1  
559 No-FAP 1  
560 No-FAP 1  
561 No-FAP 1  
562 No-FAP 1  
563 No-FAP 1  
564 No-FAP 1  
565 No-FAP 1  
566 No-FAP 1  
567 No-FAP 1  
568 No-FAP 1  
569 No-FAP 1  
570 No-FAP 1  
571 No-FAP 1  
572 No-FAP 1  
573 No-FAP 1  
574 No-FAP 1  
575 No-FAP 1  
576 No-FAP 1  
577 No-FAP 1  
578 No-FAP 1  
579 No-FAP 1  
580 No-FAP 1  
581 No-FAP 1  
582 No-FAP 1  
583 No-FAP 1  
584 No-FAP 1  
585 No-FAP 1  
586 No-FAP 1  
587 No-FAP 1  
588 No-FAP 1  
589 No-FAP 1  
590 No-FAP 1  
591 No-FAP 1  
592 No-FAP 1  
593 No-FAP 1  
594 No-FAP 1  
595 No-FAP 1  
596 No-FAP 1  
597 No-FAP 1  
598 No-FAP 1  
599 No-FAP 1  
600 No-FAP 1  
601 No-FAP 1  
602 No-FAP 1  
603 No-FAP 1  
604 No-FAP 1  
605 No-FAP 1  
606 No-FAP 1  
607 No-FAP 1  
608 No-FAP 1  
609 No-FAP 1  
610 No-FAP 1  
611 No-FAP 1  
612 No-FAP 1  
613 No-FAP 1  
614 No-FAP 1  
615 No-FAP 1  
616 No-FAP 1  
617 No-FAP 1  
618 No-FAP 1  
619 No-FAP 1  
620 No-FAP 1  
621 No-FAP 1  
622 No-FAP 1  
623 No-FAP 1  
624 No-FAP 1  
625 No-FAP 1  
626 No-FAP 1  
627 No-FAP 1  
628 No-FAP 1  
629 No-FAP 1  
630 No-FAP 1  
631 No-FAP 1  
632 No-FAP 1  
633 No-FAP 1  
634 No-FAP 1  
635 No-FAP 1  
636 No-FAP 1  
637 No-FAP 1  
638 No-FAP 1  
639 No-FAP 1  
640 No-FAP 1  
641 No-FAP 1  
642 No-FAP 1  
643 No-FAP 1  
644 No-FAP 1  
645 No-FAP 1  
646 No-FAP 1  
647 No-FAP 1  
648 No-FAP 1  
649 No-FAP 1  
650 No-FAP 1  
651 No-FAP 1  
652 No-FAP 1  
653 No-FAP 1  
654 No-FAP 1  
655 No-FAP 1  
656 No-FAP 1  
657 No-FAP 1  
658 No-FAP 1  
659 No-FAP 1  
660 No-FAP 1  
661 No-FAP 1  
662 No-FAP 1  
663 No-FAP 1  
664 No-FAP 1  
665 No-FAP 1  
666 No-FAP 1  
667 No-FAP 1  
668 No-FAP 1  
669 No-FAP 1  
670 No-FAP 1  
671 No-FAP 1  
672 No-FAP 1  
673 No-FAP 1  
674 No-FAP 1  
675 No-FAP 1  
676 No-FAP 1  
677 No-FAP 1  
678 No-FAP 1  
679 No-FAP 1  
680 No-FAP 1  
681 No-FAP 1  
682 No-FAP 1  
683 No-FAP 1  
684 No-FAP 1  
685 No-FAP 1  
686 No-FAP 1  
687 No-FAP 1  
688 No-FAP 1  
689 No-FAP 1  
690 No-FAP 1  
691 No-FAP 1  
692 No-FAP 1  
693 No-FAP 1  
694 No-FAP 1  
695 No-FAP 1  
696 No-FAP 1  
697 No-FAP 1  
698 No-FAP 1  
699 No-FAP 1  
700 No-FAP 1  
701 No-FAP 1  
702 No-FAP 1  
703 No-FAP 1  
704 No-FAP 1  
705 No-FAP 1  
706 No-FAP 1  
707 No-FAP 1  
708 No-FAP 1  
709 No-FAP 1  
710 No-FAP 1  
711 No-FAP 1  
712 No-FAP 1  
713 No-FAP 1  
714 No-FAP 1  
715 No-FAP 1  
716 No-FAP 1  
717 No-FAP 1  
718 No-FAP 1  
719 No-FAP 1  
720 No-FAP 1  
721 No-FAP 1  
722 No-FAP 1  
723 No-FAP 1  
724 No-FAP 1  
725 No-FAP 1  
726 No-FAP 1  
727 No-FAP 1  
728 No-FAP 1  
729 No-FAP 1  
730 No-FAP 1  
731 No-FAP 1  
732 No-FAP 1  
733 No-FAP 1  
734 No-FAP 1  
735 No-FAP 1  
736 No-FAP 1  
737 No-FAP 1  
738 No-FAP 1  
739 No-FAP 1  
740 No-FAP 1  
741 No-FAP 1  
742 No-FAP 1  
743 No-FAP 1  
744 No-FAP 1  
745 No-FAP 1  
746 No-FAP 1  
747 No-FAP 1  
748 No-FAP 1  
749 No-FAP 1  
750 No-FAP 1  
751 No-FAP 1  
752 No-FAP 1  
753 No-FAP 1  
754 No-FAP 1  
755 No-FAP 1  
756 No-FAP 1  
757 No-FAP 1  
758 No-FAP 1  
759 No-FAP 1  
760 No-FAP 1  
761 No-FAP 1  
762 No-FAP 1  
763 No-FAP 1  
764 No-FAP 1  
765 No-FAP 1  
766 No-FAP 1  
767 No-FAP 1  
768 No-FAP 1  
769 No-FAP 1  
770 No-FAP 1  
771 No-FAP 1  
772 No-FAP 1  
773 No-FAP 1  
774 No-FAP 1  
775 No-FAP 1  
776 No-FAP 1  
777 No-FAP 1  
778 No-FAP 1  
779 No-FAP 1  
780 No-FAP 1  
781 No-FAP 1  
782 No-FAP 1  
783 No-FAP 1  
784 No-FAP 1  
785 No-FAP 1  
786 No-FAP 1  
787 No-FAP 1  
788 No-FAP 1  
789 No-FAP 1  
790 No-FAP 1  
791 No-FAP 1  
792 No-FAP 1  
793 No-FAP 1  
794 No-FAP 1  
795 No-FAP 1  
796 No-FAP 1  
797 No-FAP 1  
798 No-FAP 1  
799 No-FAP 1  
800 No-FAP 1  
801 No-FAP 1  
802 No-FAP 1  
803 No-FAP 1  
804 No-FAP 1  
805 No-FAP 1  
806 No-FAP 1  
807 No-FAP 1  
808 No-FAP 1  
809 No-FAP 1  
810 No-FAP 1  
811 No-FAP 1  
812 No-FAP 1  
813 No-FAP 1  
814 No-FAP 1  
815 No-FAP 1  
816 No-FAP 1  
817 No-FAP 1  
818 No-FAP 1  
819 No-FAP 1  
820 No-FAP 1  
821 No-FAP 1  
822 No-FAP 1  
823 No-FAP 1  
824 No-FAP 1  
825 No-FAP 1  
826 No-FAP 1  
827 No-FAP 1  
828 No-FAP 1  
829 No-FAP 1  
830 No-FAP 1  
831 No-FAP 1  
832 No-FAP 1  
833 No-FAP 1  
834 No-FAP 1  
835 No-FAP 1  
836 No-FAP 1  
837 No-FAP 1  
838 No-FAP 1  
839 No-FAP 1  
840 No-FAP 1  
841 No-FAP 1  
842 No-FAP 1  
843 No-FAP 1  
844 No-FAP 1  
845 No-FAP 1  
846 No-FAP 1  
847 No-FAP 1  
848 No-FAP 1  
849 No-FAP 1  
850 No-FAP 1  
851 No-FAP 1  
852 No-FAP 1  
853 No-FAP 1  
854 No-FAP 1  
855 No-FAP 1  
856 No-FAP 1  
857 No-FAP 1  
858 No-FAP 1  
859 No-FAP 1  
860 No-FAP 1  
861 No-FAP 1  
862 No-FAP 1  
863 No-FAP 1  
864 No-FAP 1  
865 No-FAP 1  
866 No-FAP 1  
867 No-FAP 1  
868 No-FAP 1  
869 No-FAP 1  
870 No-FAP 1  
871 No-FAP 1  
872 No-FAP 1  
873 No-FAP 1  
874 No-FAP 1  
875 No-FAP 1  
876 No-FAP 1  
877 No-FAP 1  
878 No-FAP 1  
879 No-FAP 1  
880 No-FAP 1  
881 No-FAP 1  
882 No-FAP 1  
883 No-FAP 1  
884 No-FAP 1  
885 No-FAP 1  
886 No-FAP 1  
887 No-FAP 1  
888 No-FAP 1  
889 No-FAP 1  
890 No-FAP 1  
891 No-FAP 1  
892 No-FAP 1  
893 No-FAP 1  
894 No-FAP 1  
895 No-FAP 1  
896 No-FAP 1  
897 No-FAP 1  
898 No-FAP 1  
899 No-FAP 1  
900 No-FAP 1  
901 No-FAP 1  
902 No-FAP 1  
903 No-FAP 1  
904 No-FAP 1  
905 No-FAP 1  
906 No-FAP 1  
907 No-FAP 1  
908 No-FAP 1  
909 No-FAP 1  
910 No-FAP 1  
911 No-FAP 1  
912 No-FAP 1  
913 No-FAP 1  
914 No-FAP 1  
915 No-FAP 1  
916 No-FAP 1  
917 No-FAP 1  
918 No-FAP 1  
919 No-FAP 1  
920 No-FAP 1  
921 No-FAP 1  
922 No-FAP 1  
923 No-FAP 1  
924 No-FAP 1  
925 No-FAP 1  
926 No-FAP 1  
927 No-FAP 1  
928 No-FAP 1  
929 No-FAP 1  
930 No-FAP 1  
931 No-FAP 1  
932 No-FAP 1  
933 No-FAP 1  
934 No-FAP 1  
935 No-FAP 1  
936 No-FAP 1  
937 No-FAP 1  
938 No-FAP 1  
939 No-FAP 1  
940 No-FAP 1  
941 No-FAP 1  
942 No-FAP 1  
943 No-FAP 1  
944 No-FAP 1  
945 No-FAP 1  
946 No-FAP 1  
947 No-FAP 1  
948 No-FAP 1  
949 No-FAP 1  
950 No-FAP 1  
951 No-FAP 1  
952 No-FAP 1  
953 No-FAP 1  
954 No-FAP 1  
955 No-FAP 1  
956 No-FAP 1  
957 No-FAP 1  
958 No-FAP 1  
959 No-FAP 1  
960 No-FAP 1  
961 No-FAP 1  
962 No-FAP 1  
963 No-FAP 1  
964 No-FAP 1  
965 No-FAP 1  
966 No-FAP 1  
967 No-FAP 1  
968 No-FAP 1  
969 No-FAP 1  
970 No-FAP 1  
971 No-FAP 1  
972 No-FAP 1  
973 No-FAP 1  
974 No-FAP 1  
975 No-FAP 1  
976 No-FAP 1  
977 No-FAP 1  
978 No-FAP 1  
979 No-FAP 1  
980 No-FAP 1  
981 No-FAP 1  
982 No-FAP 1  
983 No-FAP 1  
984 No-FAP 1  
985 No-FAP 1  
986 No-FAP 1  
987 No-FAP 1  
988 No-FAP 1  
989 No-FAP 1  
990 No-FAP 1  
991 No-FAP 1  
992 No-FAP 1  
993 No-FAP 1  
994 No-FAP 1  
995 No-FAP 1  
996 No-FAP 1  
997 No-FAP 1  
998 No-FAP 1  
999 No-FAP 1  
1000 No-FAP 1

(57) Abstract: The present invention provides isolated polypeptides, prolyl tripeptidyl-peptidases, and active analogs, active fragments or active modifications thereof, having amidolytic activity for cleavage of a peptide bond present in a target peptide having at least 30 amino acids. Isolated nucleic acid fragments encoding isolated prolyl tripeptidyl-peptidases are also provided, as are methods of reducing growth of a bacterium by inhibiting a prolyl tripeptidyl-peptidase.

WO 00/52147 A3



RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA,  
UG, UZ, VN, YU, ZA, ZW.

(88) Date of publication of the international search report:  
12 April 2001

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent  
(AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent  
(AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU,  
MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GW, ML, MR, NE, SN, TD, TG).

(48) Date of publication of this corrected version:  
1 November 2001

(15) Information about Correction:  
see PCT Gazette No. 44/2001 of 1 November 2001, Section  
II

**Published:**

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



## BACTERIAL PROLYL PEPTIDASES AND METHODS OF USE

5

## CONTINUING APPLICATION DATA

This patent application claims the benefit of U.S. provisional patent application No. 60/123,148, filed March 5, 1999, which is incorporated by reference herein.

10

## GOVERNMENT FUNDING

The present invention was made with government support under Grant No. DE 09761, awarded by the National Institutes of Health. The Government may have certain rights in this invention.

15

## BACKGROUND OF THE INVENTION

*Porphyromonas gingivalis* (formerly *Bacteroides gingivalis*) is an obligately anaerobic bacterium which is implicated in periodontal disease. *P. gingivalis* produces several distinct proteolytic enzymes, many of which are recognized as important virulence factors. A number of physiologically significant proteins, including collagen, fibronectin, immunoglobulins, complement factors C3, C4, C5, and B, lysozyme, iron-binding proteins, plasma proteinase inhibitors, fibrin and fibrinogen, and factors of the plasma coagulation cascade system, are hydrolyzed by *P. gingivalis* proteases. Broad proteolytic activity plays a role in the evasion of host defense mechanisms and the destruction of gingival connective tissue in progressive periodontitis.

20

25

Progressive periodontitis is characterized by acute tissue degradation promoted by collagen digestion and a vigorous inflammatory response characterized by excessive neutrophil infiltration. Gingival crevicular fluid accumulates in periodontitis as periodontal tissue erosion progresses at the foci of the infection, and numerous plasma proteins are exposed to proteinases expressed by the bacteria at the injury site. Neutrophils are recruited to the gingiva, in part, by the humoral chemotactic factor C5a. The complement components C3 and C5 are activated by complex plasma proteases with "trypsin-like" specificities called convertases. The human plasma convertases

30

35

cleave the  $\alpha$ -chains of C3 and C5 at a specific site generating biologically active factors known as anaphylatoxins (i.e. C3a and C5a). The anaphylatoxins are potent proinflammatory factors exhibiting chemotactic and/or spasmogenic activities as well as promoting increased vascular permeability. The larger products from C3 and C5 cleavage (i.e. C3b and C5b) participate in functions including complement cascade activation, opsonization, and lytic complex formation.

Recent studies have indicated that this periodontopathogen produces at least seven different enzymes belonging to the cysteine and serine catalytic classes of peptidases, among which three cysteine proteinases (gingipains) are predominant (Potempa, J., et al. (1995) *Prospect. Drug Discovery and Design* 2, 445-458). The gingipains are the best characterized group of *P. gingivalis* enzymes as their structure, function, enzymatic properties and pathological significance are known. From *in vitro* studies it is apparent that two gingipains R (also referred to generally as "Arg-gingipains" and more specifically as RgpA and RgpB), enzymes specific for cleavage at Arg-Xaa peptide bonds, have a significant potential to contribute to the development and/or maintenance of a pathological inflammatory state in infected periodontal pockets through: (i) activation of the kallikrein-kinin cascade, (ii) the release of neutrophil chemotactic activity from native and oxidized C5 of the complement pathway, and (iii) activation of factor X. In addition, gingipain K (also referred to as "Lys-gingipain"), an enzyme which cleaves Lys-Xaa peptide bonds, degrades fibrinogen. This may add to a bleeding on probing tendency associated with periodontitis. Finally, the presence of a hemagglutinin/adhesion domain in the non covalent multiprotein complexes of RgpA and gingipain K suggests participation of these enzymes in the binding of *P. gingivalis* to extracellular matrix proteins which may facilitate tissue invasion by this pathogen.

In comparison to the gingipains, relatively little is known about other cysteine proteinases produced by *P. gingivalis*. Two genes, referred to as *tp* and *prtT* have been cloned and sequenced and although they encode a putative papain-like and streptopain-like cysteine proteinases, respectively, neither has been purified and characterized.

The presence of serine proteinase activity in cultures of *P. gingivalis* has been known for several years; however, only limited information is available about such enzymes. Indeed, a serine endopeptidase has been isolated from culture media, although it was only superficially characterized (Hinode D., et al.,  
5 (1993) *Infect. Immun.* 59, 3060-3068). On the other hand, an enzyme referred to as glycylprolyl peptidase (DPP IV) was found to be associated with bacterial surfaces and two molecular mass forms of this peptidase have been described. This enzyme has also been shown to possess the ability to hydrolyze partially degraded type I collagen, releasing the Gly-Pro dipeptide, and it was suggested  
10 that, in collaboration with collagenase, glycylprolyl peptidase may contribute to the destruction of the periodontal ligament (Abiko, Y., et al. (1985) *J.Dent. Res.* 64, 106-111). In addition to this potential pathological function, glycylprolyl peptidase may also play a vital role in providing *P. gingivalis* with dipeptides which can be transported inside the cell and serve as a source of carbon,  
15 nitrogen, and energy for this asaccharolytic organism. Recently, a gene encoding glycylprolyl peptidase in *P. gingivalis* has been cloned and sequenced, and it is now apparent that this enzyme is homologous to dipeptidyl-peptidase IV (DPP-IV) from other organisms (Kiyama, M., et al. (1998) 1396, 39-46). The nucleotide sequence of the genome of this bacterium is currently being  
20 determined by The Institute for Genomic Research, and is available at [www.tigr.org](http://www.tigr.org).

### SUMMARY OF THE INVENTION

The present invention is directed to an isolated prolyl tripeptidyl-  
25 peptidase, active analog, active fragment, or active modification thereof having amidolytic activity for cleavage of a peptide bond present in a target polypeptide having at least 4 amino acids. Alternatively, the isolated prolyl tripeptidyl-peptidase, active analog, active fragment, or active modification thereof is isolated from *P. gingivalis*. Typically, amidolytic activity is determined with a  
30 prolyl tripeptidyl-peptidase:target polypeptide ratio of at least about 1:1 to no greater than about 1:10,000,000 in about 200 mM HEPES, about pH 7.5 at 37°C for at least about 3 hours. The peptide cleaved by the isolated prolyl tripeptidyl-peptidase can include the sequence of SEQ ID NO:1, SEQ ID NO:2, SEQ ID

NO:7, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:11, H-Ala-Arg-Pro-Ala-D-Lys-amide, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:25, or SEQ ID NO:37. The amino acid sequence of the isolated prolyl tripeptidyl-peptidase can include the amino acid sequence GXSXXG (SEQ ID NO:39), the amino acid sequence GXSXGG (SEQ ID NO:40), or the amino acid sequence of SEQ ID NO:30.

Another aspect of the invention is an isolated polypeptide, active analog, active fragment, or active modification thereof having amidolytic activity for cleavage of a peptide bond present in a target polypeptide having at least 4 amino acids. Typically, the polypeptide:target polypeptide ratio of at least about 1:1 to no greater than about 1:10,000,000 in about 200 mM HEPES, about pH 7.5 at 37°C for at least about 3 hours.

The invention is also directed to an isolated polypeptide comprising an amino acid sequence having a percentage amino acid identity of greater than 35 % with SEQ ID NO:30.

An alternative aspect of the invention is an isolated nucleic acid fragment encoding a prolyl-tripeptidyl peptidase, active analog, active fragment, or active modification thereof, having amidolytic activity for cleavage of a peptide bond present in a target polypeptide having at least 4 amino acids. Typically, the prolyl tripeptidyl-peptidase:target polypeptide ratio of at least about 1:1 to no greater than about 1:10,000,000 in about 200 mM HEPES, about pH 7.5 at 37°C for at least about 3 hours. The nucleic acid fragment can have a nucleotide sequence comprising SEQ ID NO:38. A complement of the nucleic acid fragment can hybridize to SEQ ID NO:38 under hybridization conditions of 0.5 M phosphate buffer, pH 7.2, 7 % SDS, 10 mM EDTA, at 68°C, followed by three for 20 minutes washes in 2x SSC, and 0.1 % SDS, at 65°C, wherein at least about 20 nucleotides of the complement hybridize.

Another aspect of the invention is an isolated nucleic acid fragment encoding a polypeptide that includes an amino acid sequence having a percentage amino acid identity of greater than 35 % with SEQ ID NO:30.

The invention is also directed at a method of identifying an inhibitor of a prolyl-tripeptidyl peptidase, active analog, active fragment, or active modification thereof, including identifying a molecule that inhibits the

amidolytic activity of the prolyl-tripeptidyl peptidase. The inhibitor is identified by incubating the prolyl-tripeptidyl peptidase with the molecule under conditions that promote amidolytic activity of the prolyl-tripeptidyl peptidase and determining if the amidolytic activity of the prolyl-tripeptidyl peptidase is inhibited relative to the amidolytic activity in the absence of molecule.

An aspect of the invention is a method of reducing growth of a bacterium. This method includes inhibiting a prolyl tripeptidyl-peptidase, active analog, active fragment, or active modification thereof, or a prolyl dipeptidyl-peptidase, active analog, active fragment, or active modification thereof. The method includes contacting the prolyl tripeptidyl-peptidase with an inhibitor of the prolyl tripeptidyl-peptidase. The method can be used to protect an animal from a periodontal disease caused by *P. gingivalis* including administering to the animal the inhibitor. The disease can be selected from the group consisting of gingivitis and periodontitis. The inhibitor can be administered by a method selected from the group consisting of subgingival application and controlled release delivery.

Another aspect of the invention is an immunogenic composition including an isolated prolyl tripeptidyl-peptidase, or an antigenic analog, antigenic fragment, or antigenic modification thereof, the prolyl tripeptidyl-peptidase having amidolytic activity for cleavage of a peptide bond present in a target peptide having at least 4 amino acids. Typically, the prolyl tripeptidyl-peptidase:target polypeptide ratio is at least about 1:1 to no greater than about 1:10,000,000 in about 200 mM HEPES, about pH 7.5 at 37°C for at least about 3 hours. The immunogenic composition can include an adjuvant.

The invention is also directed to a composition including an inhibitor of an isolated prolyl tripeptidyl-peptidase and a pharmaceutically acceptable carrier.

Additional aspects of the invention include a dipeptidyl peptidase having an amino acid sequence including SEQ ID NO:43, SEQ ID NO:44, or SEQ ID NO:45.

### Definitions

“Polypeptide” as used herein refers to a polymer of amino acids and does not refer to a specific length of a polymer of amino acids. Thus, for example, the terms peptide, oligopeptide, protein, and enzyme are included within the definition of polypeptide. This term also includes post-expression modifications of the polypeptide, for example, glycosylations, acetylations, phosphorylations, and the like. A polypeptide can be produced by an organism, or produced using recombinant techniques, or chemically or enzymatically synthesized.

“Peptidase,” “proteinase,” and “protease” all refer to enzymes that catalyze the hydrolysis of peptide bonds in a polypeptide. A “peptide bond” or “amide bond” is a covalent bond between the alpha-amino group of one amino acid and the alpha-carboxyl group of another amino acid. “Peptidase inhibitor,” “proteinase inhibitor,” “protease inhibitor,” and “inhibitor” all refer to molecules that inhibit a peptidase that catalyzes the hydrolysis of peptide bonds in a polypeptide.

As used herein, the term “isolated” means that a polypeptide or a nucleic acid fragment has been either removed from its natural environment, produced using recombinant techniques, or chemically or enzymatically synthesized. Preferably, the polypeptide or nucleic acid fragment is purified, i.e., essentially free from any other polypeptides or nucleic acid fragments and associated cellular products or other impurities.

“Amidolytic activity” refers to the ability of a polypeptide to catalyze the hydrolysis of at least one peptide bond in a polypeptide. The term “cleavage” can also be used to refer to the hydrolysis of a peptide bond in a polypeptide.

“Prolyl-tripeptidyl peptidase” and “PTP” refer to a polypeptide having a particular “amidolytic activity”. A “prolyl-tripeptidyl peptidase” is able to hydrolyze the peptide bond between the proline and the Yaa residues in a target polypeptide with the general formula  $\text{NH}_2\text{-Xaa-Xaa-Pro-Yaa-(Xaa)}_n$  (SEQ ID NO:25), wherein Xaa is a natural or modified amino acid, Yaa is a natural or modified amino acid except proline, and the  $\alpha$ -amino of the amino terminal residue is not blocked. A “prolyl tripeptidyl-peptidase” does not have to cleave all members of the target peptide. The term “natural amino acid” refers to the 20 amino acids typically produced by a cell. The term “modified amino acid”

refers to, for instance, acetylation, hydroxylation, methylation, amidation, and the attachment of carbohydrate or lipid moieties, cofactors, and the like.

A “target polypeptide” is a polypeptide that is the potential substrate of the amidolytic activity of a prolyl tripeptidyl-peptidase.

5       An active analog, active fragment, or active modification of a polypeptide of the invention is one that has amidolytic activity by hydrolysis of a peptide bond present in the target polypeptide as described herein. Active analogs, fragments, and modifications are described in greater detail herein.

10       “Nucleic acid fragment” as used herein refers to a linear polymeric form of nucleotides of any length, either ribonucleotides or deoxynucleotides, and includes both double- and single-stranded DNA and RNA. A nucleic acid fragment may include both coding and non-coding regions that can be obtained directly from a natural source (e.g., a microorganism), or can be prepared with the aid of recombinant or synthetic techniques. A nucleic acid molecule may be  
15       equivalent to this nucleic acid fragment or it can include this fragment in addition to one or more other nucleotides or polynucleotides. For example, the nucleic acid molecule of the invention can be a vector, such as an expression of cloning vector.

20       “Percentage amino acid identity” refers to a comparison of the amino acids of two polypeptides as described herein.

### BRIEF DESCRIPTION OF THE FIGURES

25       **Fig. 1. Purification of the prolyl tripeptidyl peptidase from the acetone precipitate of the *P. gingivalis* cell extracts. Absorbance at 280 nm (open triangles), amidolytic activity against H-Ala-Phe-Pro-pNA (closed diamonds), and H-Gly-Pro-pNA (closed circles). (a) Separation of PTP-A on hydroxyapatite. (b) Separation of PTP-A on Phenyl-Sepharose HP. (c) Separation of PTP-A on MonoQ FPLC. (d) Chromatofocusing of PTP-A on Mono-P.**

30       **Fig. 2. SDS -PAGE of fractions from purification of PTP-A and the autoradiography of the purified enzyme. Lane a, molecular mass markers (phosphorylase B, 97 kDa; bovine serum albumin, 68 kDa; ovalbumin, 43 kDa; carbonic anhydrase, 30 kDa; soybean trypsin inhibitor, 20 kDa;  $\alpha$ -lactalbumin, 14**

kDa); *lane b*, acetone precipitate from Triton X-100 extract of *P. gingivalis*, *lane c*: hydroxyapatite column eluate; *lane d*, Phenyl-Sepharose column eluate; *lane e*, MonoQ column eluate; *lane f*, purified PTP-A from MonoP column wash; *lane g*, autoradiograph of  $^3\text{H}$ -DFP labeled enzyme exposed for 96 h to X-ray film. All samples were reduced and boiled prior to PAGE analysis.

**Fig. 3. Multiple sequence alignment of *P. gingivalis* PTP-A (PTP-A) and its bacterial and eukaryotic homologues.** Pg-DPP, DPP from *P. gingivalis* (Kiyama, M., et al., (1998) *Bioch. Bioph. Acta* 1396, 39-46) containing an amino-terminal sequence corrected according to the *P. gingivalis* W83 genome data available from The Institute of Genomic Research at [www.tigr.org](http://www.tigr.org)); Fm-DPP, DPP from *Flavobacterium meningosepticum*; Hs-DPP, human DPP IV; and Mm-FAP, mouse fibroblast activation protein. Peptide sequences obtained from PTP-A analysis described herein are indicated with arrows (note that the sequence of the peptide 81-97 corresponds to the N-terminus of the lower molecular weight form of PTP-A); catalytic triad is marked with asterisks; and the proposed PTP-A membrane-anchoring N-terminal  $\alpha$ -helix is double-underlined. Homologous regions (i.e., regions of identical amino acids and/or conservative substitutions) are highlighted. Identical regions are shown as white letters on a black background.

**Fig. 4. Comparison of *P. gingivalis* PTP-A and DPP active site domains to corresponding sequences of three putative homologues identified within the *P. gingivalis* genome (DPP-H1, DPP-H2 and DPP-H3).** Sequences of *P. gingivalis* PTP-A, DPP, DPP-H1, DPP-H2, and DPP-H3 were obtained from conceptual translation of the following open reading frames retrieved from The Institute for Genomic Research (TIGR) unfinished *P. gingivalis* genome database: gnl | TIGR | *P. gingivalis* contig 126 (positions 13 228 – 15 426), contig 87 (positions 6 424 – 4 399), contig 65 (positions 161 – 1 786), contig 101 (positions 8 895 – 6 845), and contig 9 (positions 4 216 – 2 162), respectively. Residues predicted as catalytic triads are marked with asterisks. Homologous regions (i.e., regions of identical amino acids and/or conservative substitutions) are highlighted.



Identical regions are shown as white letters on a black background. Similar regions (i.e., conservative substitutions) are shown as white letters on a grey background.

5 **Fig. 5. Influence of Pefabloc-serine proteinase inhibitor on *P. gingivalis* growth.**

**Fig. 6. Comparison of *P. gingivalis* PTP-A and DPP to sequences of three putative homologues identified within the *P. gingivalis* genome (DPP-H1, DPP-H2 and DPP-H3).** Sequences of *P. gingivalis* PTP-A (126PP), DPP (87PP),  
10 DPP-H1 (65PP), DPP-H2 (101PP), and DPP-H3 (9PP) were obtained as described in Fig. 4. Homologous regions (i.e., regions of identical amino acids and/or conservative substitutions) are highlighted. Identical regions are shown as white letters on a black background. Similar regions (i.e., conservative substitutions) are shown as white letters on a grey background.

15 **Fig. 7. Nucleotide sequence (SEQ ID NO:38) and amino acid sequence (SEQ ID NO:30) of PTP-A.**

#### DETAILED DESCRIPTION OF THE INVENTION

20 The present invention provides isolated polypeptides, preferably isolated prolyl peptidases, more preferably prolyl dipeptidyl-peptidases and prolyl tripeptidyl-peptidases, most preferably prolyl-tripeptidyl peptidases, that have amidolytic activity by hydrolysis of a peptide bond present in a target polypeptide, where the bond is between a proline and an amino acid residue attached to the  
25 alpha-carboxyl group end of the proline.

When the prolyl peptidase is a prolyl tripeptidyl-peptidase, the peptidase has amidolytic activity by hydrolysis of a peptide bond present in a target polypeptide of the general formula  $\text{NH}_2\text{-Xaa-Xaa-Pro-Yaa-(Xaa)}_n$  (SEQ ID NO:25), wherein Xaa is a natural or modified amino acid, Yaa is a natural or  
30 modified amino acid except proline, and the  $\alpha$ -amino of the amino terminal residue is not blocked, wherein the peptide bond of the target polypeptide that is hydrolyzed is the Pro-Yaa peptide bond. Preferably, isolated polypeptides do not cleave a target peptide having a blocked  $\alpha$ -amino of the amino terminal residue.

Preferably, the only peptide bond of the target peptide that is hydrolyzed is the Pro-Yaa bond. In increasing order of preference, isolated polypeptides can cleave a target peptide that is at least 4 amino acids or at least 300 Da, at least 10 amino acids or at least 750 Da, at least 20 amino acids or at least 1,500 Da, or at least 30 amino acids or at least 3,000 Da. Preferably, the prolyl-tripeptidyl peptidases cleave peptides 1, 2, 7, 8, and 10-15 shown in Table 3, human cystatin C, and interleukin 6.

When the prolyl peptidase is a prolyl dipeptidyl-peptidase, the peptidase has amidolytic activity by hydrolysis of a peptide bond present in a target polypeptide of the general formula  $\text{NH}_2\text{-Xaa-Zaa-Yaa-(Xaa)}_n$  (SEQ ID NO:12), wherein Xaa is a natural or modified amino acid, Zaa is a proline or alanine, Yaa is a natural or modified amino acid except proline or hydroxyproline, and the  $\alpha$ -amino of the amino terminal residue is not blocked, wherein the peptide bond of the target polypeptide that is hydrolyzed is the Zaa-Yaa peptide bond. Preferably, isolated polypeptides does not cleave a target peptide having a blocked  $\alpha$ -amino of the amino terminal residue. Preferably, the only peptide bond of the target peptide that is hydrolyzed is the Pro-Yaa bond.

Due to their cyclic aliphatic character proline residues bestow unique conformational constraints on polypeptide chain structures, significantly affecting the susceptibility of proximal peptide bonds to proteolytic cleavage. Those proline residues, which often appear near the amino-termini of many biologically active peptides, may protect them against proteolytic degradation by peptidases with general specificity. A specialized group of proteolytic enzymes, typically referred to as prolyl peptidases, has evolved to cleave (i.e., hydrolyze) a peptide bond adjacent to a proline residue in a polypeptide. The peptide bond adjacent to a proline residue can be referred to as a prolyl-X bond, where prolyl is the proline residue, and X is an amino acid residue attached to the alpha-carboxyl group end of the proline. The bacterial prolyl peptidases can cleave a polypeptide to liberate a tripeptide or a dipeptide. Prolyl peptidases that do not cleave a target peptide if the  $\alpha$ -amino of the amino terminal residue is blocked can be referred to as exopeptidases. The *in vivo* activity of these specialized proteolytic enzymes may have important physiological significance, because it may lead to inactivation of many biologically active peptides and/or transformation of the activity of other

biologically active peptides. In addition, hydrolysis of prolyl-X bonds in conjunction with general catabolic pathways should allow the complete re-utilization of amino acids by living organisms, including bacteria. However, prolyl peptidases from bacterial pathogens, if released into the host environment, may interfere with the physiological functions of biologically active polypeptides and, therefore, contribute to the pathogenicity of infectious disease.

The external (i.e., cell surface) localization and uncontrolled activity of bacterial peptidases, including prolyl peptidases, likely contributes significantly to run-away inflammation in the human host and the pathological degradation of connective tissue during periodontitis. For instance, working in concert bacterial prolyl peptidases (e.g., prolyl tripeptidyl peptidases and DPP IV) have the ability to completely degrade collagen fragments locally generated by endogenous or bacterial collagenases. Because type I collagen is the major component of periodontal ligament, its enhanced degradation by bacterial prolyl peptidases may contribute to loss of tooth attachment and periodontal pocket formation. Thus, there is a need in the art to characterize bacterial peptidases to facilitate the development of therapies to inhibit the activity of the bacterial peptidases.

The polypeptides of the present invention, preferably prolyl peptidases, can be used as a source of antibodies for inhibiting the peptidase activity and thereby possibly reducing periodontitis, loss of tooth attachment and periodontal pocket formation. Antibodies to prolyl peptidases can also be used to identify and/or isolate additional prolyl peptidases. Knowledge of prolyl peptidases can also be used to make inhibitors of prolyl peptidases and to make immunogenic compositions that could be used to elicit the production of antibodies to prolyl peptidases and thereby possibly reduce gingivitis, periodontitis, loss of tooth attachment, and/or periodontal pocket formation.

An example of a prolyl-tripeptidyl peptidase is prolyl-tripeptidyl peptidase A (SEQ ID NO:30) (also referred to as PTP-A) from *P. gingivalis*. Purified PTP-A has apparent molecular masses of 81.8 and 75.8 kDa. The lower molecular mass peptidase may be due to the proteolytic cleavage of the peptidase from the surface of *P. gingivalis*. PTP-A is a new member of clan SC, family S9 of serine peptidases. Clans of serine peptidases are grouped on the basis of the order of certain amino acids in the polypeptide that make up the "catalytic triad" which

plays a pivotal role peptidase activity. The members of the clan SC are characterized by the catalytic triad in the polypeptide in the order of serine, aspartic acid, and histidine. Members of the clan SC are also characterized by a tertiary structure including  $\beta/\alpha/\beta$  units, and an  $\alpha/\beta$  hydrolase fold. In addition to the catalytic triad order, the amino acid sequence GX $\beta$ XXG (SEQ ID NO:39), where X is any amino acid and S is the active site serine, is a signature of all members of the clan SC with some distinguishing features specific for each family. Family S9 has the consensus sequence GX $\beta$ XXGG (SEQ ID NO:40). Besides this consensus sequence, there is a general similarity of primary structures which classifies peptidases to this family. For instance, peptidases of this family generally have two domains, an amino-terminal domain that contains a membrane binding domain, and a carboxy-terminal domain, also referred to as the catalytic domain. The catalytic domain contains the residues of the catalytic triad. Some members of the S9 family have only the catalytic domain.

The S9 family is diverged and divided in three subfamilies: S9A, cytosolic oligopeptidases from archae and eukaryotes; S9B, eukaryotic acylaminoacylpeptidases; and S9C, dipeptidyl peptidase IV from bacteria and eukaryotes. The catalytic domain of peptidases from family S9 typically begin at about residue 400 of SEQ ID NO:30 and include the remaining carboxy-terminal amino acids (see, e.g., Fulop, et al., (1998) *Cell* 94, 161-170). Despite structural similarities to peptidases from the S9 family, the tripeptidyl-peptidase activity of PTP-A is unusual for this family of enzymes, and no other known similar activity has so far been attributed to any other member of the S9 family. In fact, all strict tripeptidyl-peptidases belong only to the subtilisin family (S8) and S33 family of serine peptidases; however, they neither share a structural relationship with PTP-A nor have activity limited to cleavage after proline residues. In particular, there are no other known prolyl tripeptidyl peptidases with an activity that is increased by iodoacetamide relative to the same prolyl tripeptidyl peptidase in the absence of iodoacetamide under the same conditions. Iodoacetamide is a compound that is traditionally a peptidase inhibitor. Typically, the activity of a prolyl tripeptidyl peptidase is increased about two-fold. Furthermore, unlike oligopeptidases, the prolyl tripeptidyl-peptidases of the present invention can cleave target peptides having as few as 4 amino acids but also target peptides having at least 30 amino

acids or a molecular weight of at least 3,000 Da. In these respects, the *P. gingivalis* tripeptidyl peptidase is a unique enzyme, and the isolation and characterization of this novel bacterial prolyl peptidase will facilitate the development of therapies to inhibit the activity of the bacterial peptidases.

5           Examples of putative prolyl-dipeptidyl peptidases are DPP-H1 (SEQ ID NO:43), DPP-H2 (SEQ ID NO:44), and DPP-H3 (SEQ ID NO:45). These peptidases have a significant percentage amino acid similarity with DPP IV and PTP-A (see Fig. 6). Each dipeptidyl peptidase is expected to have enzymatic activity, as each has a well preserved catalytic triad (Fig. 4). DPP IV has been  
10 characterized and the gene encoding the peptidase has been cloned, however the substrate specificity has not been well characterized. DPP IV has been found to cleave SEQ ID NOs:6, 20, 23, and 24. DPP IV has been purified in two forms. One of the forms is a full length gene translation product containing a blocked amino-terminal residue. The second form had the amino-terminal amino acid  
15 sequence HSYRAAVYDYDVRRLVKPLSEHVG (SEQ ID NO:48), which corresponds to residues 116-140 of DPP IV (Kiyama, M., et al. (1998) 1396, 39-46), indicating that it was proteolytically truncated on the amino-terminus.

          In *P. gingivalis*, PTP-A and DPP IV activity is cell surface associated. While not intending to be limiting, it is conceivable that the enzyme is membrane  
20 anchored through a putative signal sequence which is not cleaved but remains as a membrane spanning domain similar to other members of the prolyl oligopeptidase family. However, a significant portion of the purified PTP-A has a truncated N-terminus, apparently due to cleavage by Lys-specific peptidase and likely to be an artifact which has occurred during the purification procedure. Nevertheless,  
25 membrane bound PTP-A and DPP IV is proteolytically cleaved and shed during cultivation of the bacteria, as indicated by variable amount of soluble activities found in cell free culture media. The cell surface localization of PTP-A supports a putative physiological function in providing nutrients for growing bacterial cells. The inability of asaccharolytic *P. gingivalis* to utilize free amino acids makes the  
30 bacterium entirely dependant on an external peptide supply. In this regard, PTP-A and DPP IV activities are probably very important, if not indispensable, for bacterial growth, and inhibition of prolyl tripeptidyl-peptidases and dipeptidyl-peptidases may inhibit the *in vivo* growth of organisms, including *P. gingivalis*.

For instance, treatment of *P. gingivalis* cultures in lagphase (i.e., the period after inoculation of a culture and before the organism begins to divide) and early logarithmic growth with the inhibitors PEFABLOCK and 3,4-dichloroisocoumarin inhibits growth of *P. gingivalis*.

5            Preferably, a polypeptide of the invention, preferably a prolyl peptidase, contains the amino acid sequence GXSEXG (SEQ ID NO:39), most preferably, GXSEXGG (SEQ ID NO:40), where G is glycine, X is any amino acid, and S is the active site serine. The active site serine can be identified by, for instance, labeling with diisopropylfluorophosphate as described herein. Preferably, the catalytic  
10            domain of the prolyl tripeptidyl-peptidases of the invention begins at about residue 400 of SEQ ID NO:30 and includes the remaining carboxy-terminal amino acids and the corresponding amino acids of SEQ ID NOs:43-45 (see Fig. 6), more preferably, at about residue 502 of SEQ ID NO:30 and includes the remaining carboxy-terminal amino acids and the corresponding amino acids of SEQ ID  
15            NOs:43-45 (see Fig. 6), most preferably, at about residue 556 of SEQ ID NO:30 and includes the remaining carboxy-terminal amino acids and the corresponding amino acids of SEQ ID NOs:43-45 (see Fig. 6).

            The invention further includes a polypeptide, preferably a prolyl tripeptidyl-peptidase, that shares a significant level of primary structure with SEQ ID NO:30.  
20            The two amino acid sequences (i.e., the amino acid sequence of the polypeptide and the sequence SEQ ID NO:30) are aligned such that the residues that make up the catalytic triad, i.e., the serine, aspartic acid, and the histidine, are in register, then further aligned to maximize the number of amino acids that they have in common along the lengths of their sequences; gaps in either or both sequences are permitted  
25            in making the alignment in order to place the residues of the catalytic triad in register and to maximize the number of shared amino acids, although the amino acids in each sequence must nonetheless remain in their proper order. The percentage amino acid identity is the higher of the following two numbers: (a) the number of amino acids that the two sequences have in common within the  
30            alignment, divided by the number of amino acids in SEQ ID NO:30, multiplied by 100; or (b) the number of amino acids that the two sequences have in common within the alignment, divided by the number of amino acids in the candidate polypeptide, multiplied by 100. Preferably, a prolyl tripeptidyl peptidase has

greater than 35 % identity, more preferably at least about 40 % identity, most preferably at least about 45 % identity with SEQ ID NO:30. Preferably, amino acids 154-732 of SEQ ID NO:30 are used, more preferably amino acids 400-732 of SEQ ID NO:30 are used. An isolated polypeptide comprising an amino acid  
5 sequence having a percentage amino acid identity of greater than 35 % with SEQ ID NO:30.

In general, the amidolytic activity of the polypeptides of the invention, preferably prolyl peptidases, can be measured by assay of the cleavage of a target polypeptide in the presence of prolyl peptidase and a buffer. Preferably, the lower  
10 ratio of prolyl tripeptidyl-peptidase to target polypeptide is at least about 1:1, more preferably at least about 1:100, even more preferably at least about 1:1,000, most preferably at least about 1:10,000. Preferably, the higher ratio of prolyl peptidase to target polypeptide is no greater than about 1:10,000,000, more preferably no greater than about 1:1,000,000 and most preferably no greater than about  
15 1:100,000. Buffers in which a prolyl peptidase is active are suitable for the assay. Preferably, the buffer is about 200 mM HEPES (N-2-hydroxyethylpiperazine,N'-2-ethansulfonic acid), more preferably about 50 mM HEPES, most preferably about 20 mM HEPES. Preferably, the pH of the buffer is at least about pH 6.0 and no greater than pH 8.0, more preferably about pH 7.5. Preferably, the temperature of  
20 the assay is at about 37°C. The assay can be carried out for at least about 1 minute to no greater than 24 hours. Preferably, the amidolytic activity of the prolyl peptidases are measured at a prolyl peptidase:target polypeptide ratio of at least about 1:100 to no greater than 1:1,000,000 in about 200 mM HEPES, about pH 7.5 at about 37°C for at least about 3 hours. In general, the time of the assay can vary  
25 depending on the substrate and enzyme:substrate ratio. Typically, target peptides are stable under these conditions, and typically it is difficult to detect background levels of hydrolysis in the absence of a prolyl peptidase. Preferably, the assay is allowed to continue until at least 1 % of the target peptide is hydrolyzed.

Prolyl-tripeptidyl peptidases of the present invention preferably are  
30 inhibited by a compound chosen from the group consisting of PEFABLOCK (4-(2-aminoethyl)-benzenesulfonyl-fluoride hydrochloride), diisopropylfluorophosphate, and 3,4-dichloroisocoumarin, more preferably PEFABLOCK and diisopropylfluorophosphate, and most preferably diisopropylfluorophosphate. The

peptidases of the present invention are preferably not inhibited by a compound chosen from the group consisting of leupeptin, antipain, E-64, pepstatin,  $\alpha_1$ -proteinase inhibitor,  $\alpha_1$ -antichymotrypsin and  $\alpha_2$ -macroglobulin, most preferably. Significantly and unexpectedly, the amidolytic activity of a prolyl-tripeptidyl peptidase of the present invention is increased by iodoacetamide relative to the prolyl-tripeptidyl peptidase in the absence of iodoacetamide under the same conditions. Preferably, the effect of iodoacetamide on amidolytic activity is measured by incubating in 200 mM HEPES, pH 7.6, at least about 0.1 nM of the prolyl tripeptidyl-peptidase with the inhibitor for about 15 minutes, adding about 1 mM of H-Ala-Phe-Pro-pHA, and incubating for at least about 1 minute before assaying for amidolytic activity. Typically, at least about 1 mM to no greater than 100 mM of inhibitor is used.

The polypeptides of the invention include a polypeptide having SEQ ID NO:30, or an active analog, active fragment, or active modification of SEQ ID NO:30. An active analog, active fragment, or active modification of a polypeptide having SEQ ID NO:30 is one that has amidolytic activity by hydrolysis of the Pro-Yaa peptide bond present in a target polypeptide of the general formula  $\text{NH}_2\text{-Xaa-Xaa-Pro-Yaa-(Xaa)}_n$  (SEQ ID NO:25). Active analogs of a polypeptide having SEQ ID NO:30 include prolyl-tripeptidyl peptidases having amino acid substitutions that do not eliminate hydrolysis of SEQ ID NO:25 at the Pro-Yaa peptide bond. Substitutes for an amino acid may be selected from other members of the class to which the amino acid belongs. For example, nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and tyrosine. Polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine and glutamine. The positively charged (basic) amino acids include arginine, lysine and histidine. The negatively charged (acidic) amino acids include aspartic acid and glutamic acid. Examples of preferred conservative substitutions include Lys for Arg and *vice versa* to maintain a positive charge; Glu for Asp and *vice versa* to maintain a negative charge; Ser for Thr so that a free -OH is maintained; and Gln for Asn to maintain a free  $\text{NH}_2$ .

Active fragments of a prolyl-tripeptidyl peptidase of the invention include prolyl-tripeptidyl peptidases containing deletions or additions of one or more contiguous or noncontiguous amino acids such that the resulting polypeptide will



hydrolyze SEQ ID NO:25 at the Pro-Yaa peptide bond. An example of a fragment of a prolyl-tripeptidyl peptidase is a catalytic domain. Modified prolyl-tripeptidyl peptidases include prolyl-tripeptidyl peptidases that are chemically and enzymatically derivatized at one or more constituent amino acid, including side chain modifications, backbone modifications, and N- and C- terminal modifications including acetylation, hydroxylation, methylation, amidation, and the attachment of carbohydrate or lipid moieties, cofactors, and the like. Modified prolyl-tripeptidyl peptidases will hydrolyze SEQ ID NO:25 at the Pro-Yaa peptide bond.

Prolyl peptidases can be obtained by several methods. Isolation of a prolyl-tripeptidyl peptidase present on the surface of a cell producing the peptidase typically requires lysis of the cell followed by purification methods that are well known in the art. Alternatively, cells can be treated with a detergent, for instance Triton X-100, to remove the peptidase from the cell surface. The following are nonlimiting examples of suitable protein purification procedures: fractionation on immunoaffinity, ion-exchange, hydroxyapatite, Phenyl-Sepharose HP, MonoQ HR 5/5, or MonoP columns; ethanol precipitation; reverse phase HPLC; chromatography on silica or on an ion-exchange resin such as DEAE; chromatofocusing; SDS-PAGE; ammonium sulfate precipitation; gel filtration using, for example, Sephadex G-75. Preferably, isolation of a prolyl-tripeptidyl peptidase from *P. gingivalis* is accomplished using a combination of hydroxyapatite, Phenyl-Sepharose HP, MonoQ HR 5/5 and MonoP column chromatography steps as described herein.

Prolyl peptidases can also be isolated from organisms other than *P. gingivalis*. Other organisms can express a prolyl-tripeptidyl peptidase that is encoded by a coding region having similarity to the PTP-A coding region. A "coding region" is a linear form of nucleotides that encodes a polypeptide, usually via mRNA, when placed under the control of appropriate regulatory sequences. The boundaries of a coding region are generally determined by a translation start codon at its 5' end and a translation stop codon at its 3' end. "Regulatory region" refers to a nucleic acid fragment that regulates expression of a coding region to which a regulatory region is operably linked. Non limiting examples of regulatory regions include promoters, transcription initiation sites, translation start sites, translation

stop sites, and terminators. "Operably linked" refers to a juxtaposition wherein the components so described are in a relationship permitting them to function in their intended manner. A regulatory element is "operably linked" to a coding region when it is joined in such a way that expression of the coding region is achieved under conditions compatible with the regulatory region. Alternatively, other organisms can express a prolyl-tripeptidyl peptidase from a recombinant coding region encoding the peptidase. The identification of similar coding regions in other organisms can be accomplished as described herein. A prolyl-tripeptidyl peptidase can be isolated using purification methods that are well known in the art.

Alternatively, the peptidase can be chemically synthesized using methods that are well known in the art including, for instance, solid phase synthesis. Examples of, for instance, coding and regulatory regions are described herein.

The expression of a prolyl-tripeptidyl peptidase by an organism other than *P. gingivalis* can be detected using specific substrates of the general formula  $\text{NH}_2\text{-Xaa-Xaa-Pro-LG}$  or  $\text{NH}_2\text{-Xaa-Xaa-Pro-Yaa}$  (SEQ ID NO:41), where LG is a leaving group. The leaving group can be a chromogenic or fluorogenic group known to the art. The expression of a prolyl-tripeptidyl peptidase by an organism and subsequent cleavage of a specific substrate results in a free amino acid or a free leaving group, each of which can be assayed using techniques known to those of skill in the art. Other methods can be based on immunogenic properties of PTP-A, for instance immunoassays and histochemistry, the detection of mRNA, and PCR related methods, all of which are known to one of skill in the art.

As described in the Examples, the amino acid sequence of the amino-terminal end of a PTP-A fragment was used to identify the nucleotide sequence of the PTP coding region. The nucleotide sequence was present in a publically available database containing the nucleotide sequence of the partially finished *P. gingivalis* W83 genome. However, even though the nucleotides that encode the *P. gingivalis* PTP-A were known, there was no indication that the nucleotides were in fact transcribed and translated. The data obtained from the database only contained the nucleotide sequence of a genomic clone; there was no disclosure that the nucleotides did or did not contain an open reading frame. Moreover, there is little data known to the art regarding regulatory regions required for either the transcription or the translation of a nucleotide sequence in *P. gingivalis*.

Thus, a person of ordinary skill, having the nucleotide sequence of the genomic clone, would not be able to predict that the open reading frame encoding PTP-A was transcribed or translated. Moreover, even if there was a suggestion that the open reading frame was both transcribed and translated, there is no suggestion  
5 that the polypeptide encoded by the open reading frame would have the novel activity of PTP-A.

Accordingly, the present invention is directed to a nucleic acid fragment encoding a polypeptide, particularly a prolyl-tripeptidyl peptidase, active analog, active fragment, or active modification thereof. The nucleic acid fragment can  
10 have a nucleotide sequence as shown in SEQ ID NO:38. Alternatively, nucleic acid fragments of the invention include those whose complement hybridize to SEQ ID NO:38 under standard hybridization conditions as described herein. During hybridization the entire nucleotide sequence of the complement can hybridize with SEQ ID NO:38. Preferably, at least about 20 nucleotides of the complement  
15 hybridize with SEQ ID NO:38, more preferably at least about 50 nucleotides, most preferably at least about 100 nucleotides.

Alternatively, the nucleic acid fragment can have a nucleotide sequence encoding a polypeptide having the amino acid sequence shown in SEQ ID NO:30. An example of the class of nucleotide sequences encoding such a polypeptide is  
20 SEQ ID NO:38. This class of nucleotide sequences is large but finite, and the nucleotide sequence of each member of the class can be readily determined by one skilled in the art by reference to the standard genetic code.

The identification of similar coding regions in other organisms can be accomplished by screening individual wild-type microorganisms for the presence  
25 of nucleotide sequences that are similar to the coding region of PTP-A, which is shown in SEQ ID NO:38. Screening methods include, for instance, hybridization of a detectably labeled probe with a nucleic acid fragment.

Standard hybridizing conditions are a modification of the conditions used by Church et al. ((1984) *Proc. Natl. Acad. Sci. USA* 81, 1991): 0.5 M phosphate  
30 buffer, pH 7.2, 7 % SDS, 10 mM EDTA, at 68°C, and three washes, each for 20 minutes in 2x SSC, 0.1 % SDS, at 65°C. Preferably, a probe will hybridize to the nucleotide sequence set forth in SEQ ID NO:38 under standard hybridizing conditions. Generally the probe does not have to be complementary to all the

nucleotides of the nucleic acid fragment as long as there is hybridization under the above-stated conditions.

“Complement” and “complementary” refer to the ability of two single stranded nucleic acid fragments to base pair with each other, where an adenine on one nucleic acid fragment will base pair to a thymine on a second nucleic acid fragment and a cytosine on one nucleic acid fragment will base pair to a guanine on a second nucleic acid fragment. Two nucleic acid fragments are complementary to each other when a nucleotide sequence in one nucleic acid fragment can base pair with a nucleotide sequence in a second nucleic acid fragment. For instance, 5'-ATGC and 5'-GCAT are complementary. The term complement and complementary also encompasses two nucleic acid fragments where one nucleic acid fragment contains at least one nucleotide that will not base pair to at least one nucleotide present on a second nucleic acid fragment. For instance the third nucleotide of each of the two nucleic acid fragments 5'-ATTGC and 5'-GCTAT will not base pair, but these two nucleic acid fragments are complementary as defined herein. Typically two nucleic acid fragments are complementary if they hybridize under the standard conditions referred to herein.

Preferred probes are nucleic acid fragments complementary to a coding region or another nucleotide sequence that encodes a prolyl-tripeptidyl peptidase. For instance, a probe can comprise a consecutive series of nucleotides complementary to a portion of SEQ ID NO:38. Preferably a probe is at least about 18 bases, more preferably at least about 21 bases, and most preferably at least about 24 bases in length. Particularly preferred probes are

TTCGATCCGGCAAAGAAATATCCTGTTATTGTCTATGTTTACGGAGGAC  
CT (SEQ ID NO:36,  
GTGGATGCCGATAGAATAGGAGTACATGGCTGGAGCTATGGTGGCTTT  
(SEQ ID NO:37, and SEQ ID NO:38. Methods of detectably labeling a probe are well known to the art.

The nucleic acid fragment that is identified by the probe is further analyzed to determine if it encodes a polypeptide with amidolytic activity of the Pro-Yaa

peptide bond on a target polypeptide of the general formula  $\text{NH}_2\text{-Xaa-Xaa-Pro-Yaa-(Xaa)}_n$  (SEQ ID NO:25). Another method for screening individual microorganisms for the presence of nucleotide sequences that are similar to the coding regions of the present invention is the polymerase chain reaction (PCR).

5 Individual wild-type microorganisms containing nucleic acid fragments encoding a prolyl-tripeptidyl peptidase can also be identified using antibody. Preferably the antibody is directed to PTP-A. The production of antibodies to a particular polypeptide is known to a person of skill in the art, and is further detailed herein.

10 The use of hybridization of a probe to a coding region present in individual wild-type microorganisms can be used as a method to identify a coding region identical or similar to a coding region present in SEQ ID NO:38. The coding region can then be isolated and ligated into a vector as described below. Two nucleic acid sequences are "similar" if the two nucleic acid sequences can be aligned so that the number of identical amino acids along the lengths of their sequences are optimized. 15 Preferably, two nucleotide acid sequences have, in increasing order of preference, preferably at least about 90 %, at least about 92 %, at least about 94%, at least about 96%, most preferably at least about 98% identity.

As mentioned above, a nucleic acid fragment of the invention can be 20 inserted in a vector. Construction of vectors containing a nucleic acid fragment of the invention employs standard ligation techniques known in the art. See, e.g., Sambrook et al, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press (1989) or Ausubel, R.M., ed. *Current Protocols in Molecular Biology* (1994). A vector can provide for further cloning (amplification of the 25 nucleic acid fragment), i.e., a cloning vector, or for expression of the polypeptide encoded by the coding region, i.e., an expression vector. The term vector includes, but is not limited to, plasmid vectors, viral vectors, cosmid vectors, or artificial chromosome vectors. Typically, a vector is capable of replication in a bacterial host, for instance *E. coli*. Preferably the vector is a plasmid.

30 Selection of a vector depends upon a variety of desired characteristics in the resulting construct, such as a selection marker, vector replication rate, and the like. Suitable plasmids for expression in *E. coli*, for example, include pUC(X), pKK223-3, pKK223-2, pTrc99A, and pET-(X) wherein (X) denotes a vector family in which

numerous constructs are available. pUC(X) vectors can be obtained from Pharmacia Biotech (Piscataway, NH) or Sigma Chemical Co. (St. Louis, MO). pKK223-3, pKK233-2 and pTrc99A can be obtained from Pharmacia Biotech. pET-(X) vectors can be obtained from Promega (Madison, WI) Stratagene (La Jolla, CA) and Novagen (Madison, WI). To facilitate replication inside a host cell, the vector preferably includes an origin of replication (known as an "ori") or replicon. For example, ColE1 and P15A replicons are commonly used in plasmids that are to be propagated in *E. coli*.

5 An expression vector optionally includes regulatory regions operably linked to the coding region. The invention is not limited by the use of any particular promoter, and a wide variety are known. Promoters act as regulatory signals that bind RNA polymerase in a cell to initiate transcription of a downstream (3' direction) coding region. The promoter used in the invention can be a constitutive or an inducible promoter. It can be, but need not be, heterologous with respect to the host cell. Preferred promoters for bacterial transformation include *lac*, *lacUV5*, *tac*, *trc*, T7, SP6 and *ara*.

10 An expression vector can optionally include a Shine Dalgarno site (e.g., a ribosome binding site), and a start site (e.g., the codon ATG) to initiate translation of the transcribed message to produce the enzyme. It can also include a termination sequence to end translation. A termination sequence is typically a codon for which there exists no corresponding aminoacyl-tRNA, thus ending polypeptide synthesis. The nucleic acid fragment used to transform the host cell can optionally further include a transcription termination sequence. The *rrnB* terminators, which is a stretch of DNA that contains two terminators, T1 and T2, is an often used terminator that is incorporated into bacterial expression systems (J. Brosius et al., (1981) *J. Mol. Biol.* 148 107-127).

20 The nucleic acid fragment used to transform the host cell optionally includes one or more marker sequences, which typically encode a polypeptide that inactivates or otherwise detects or is detected by a compound in the growth medium. For example, the inclusion of a marker sequence can render the transformed cell resistant to an antibiotic, or it can confer compound-specific metabolism on the transformed cell. Examples of a marker sequence are sequences that confer resistance to kanamycin, ampicillin, chloramphenicol, and tetracycline.

Antibodies can be produced to a polypeptide having the sequence of SEQ ID NOs:30, 43, 44 or 45, or a polypeptide having a percentage amino acid identity as described herein. Alternatively, antibodies can be made to an antigenic analog, antigenic fragment, or antigenic modification of a polypeptide having the sequence of SEQ ID NOs:30, 43, 44 or 45. An antigenic analog, antigenic fragment, or antigenic modification of a polypeptide having SEQ ID NOs:30, 43, 44 or 45 is one that generates an immune response in an animal. Antigenic analogs of a polypeptide having SEQ ID NOs:30, 43, 44 or 45 include prolyl peptidases having amino acid substitutions that do not eliminate peptide antigenicity in an animal. Substitutes for an amino acid may be selected from other members of the class to which the amino acid belongs, as described herein. Fragments of a prolyl peptidase of the invention include prolyl peptidases containing deletions or additions of one or more contiguous or noncontiguous amino acids such that the resulting polypeptide will generate an immune response in an animal. An example of a fragments of a prolylpeptidase is a catalytic domain. Modified prolyl peptidases include prolyl peptidases that are chemically and enzymatically derivatized at one or more constituent amino acids, including side chain modifications, backbone modifications, and N- and C- terminal modifications including acetylation, hydroxylation, methylation, amidation, and the attachment of carbohydrate or lipid moieties, cofactors, and the like.

Accordingly, an aspect of the invention is an immunogenic composition comprising an isolated prolyl peptidase, or an antigenic analog, antigenic fragment, or antigenic modification thereof, preferably a prolyl tripeptidyl-peptidase. The prolyl tripeptidyl-peptidase preferably has amidolytic activity for cleavage of the Pro-Yaa peptide bond present in a target polypeptide with the general formula  $\text{NH}_2\text{-Xaa-Xaa-Pro-Yaa-(Xaa)}_n$  (SEQ ID NO:25), wherein the amidolytic activity is measured at a prolyl tripeptidyl-peptidase:target polypeptide ratio of at least about 1:100 to no greater than about 1:1,000,000 in about 200 mM HEPES, about pH 7.5 at 37°C for at least about 3 hours.

The immunogenic composition can further include excipients or diluents that are pharmaceutically acceptable as carriers and compatible with the immunogenic composition. The term “pharmaceutically acceptable carrier” refers to a carrier(s) that is “acceptable” in the sense of being compatible with the other

ingredients of a composition and not deleterious to the recipient thereof. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol, or the like, and combinations thereof. In addition, if desired, the immunogenic composition may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, and/or adjuvants which enhance the effectiveness of the immune-stimulating composition.

The immunogenic composition can be used in a method for protecting an animal from a disease caused by *P. gingivalis*. This method includes administering the immunogenic composition and eliciting antibodies to a prolyl peptidase, antigenic analog, antigenic fragment, or antigenic modification. The diseases that can be treated in this manner include periodontal diseases, which includes gingivitis and periodontitis. Clinical hallmarks of periodontitis include loss of tooth attachment and periodontal pocket formation.

Alternatively and preferably, periodontal diseases can be treated by the use of inhibitors of a prolyl peptidase. An inhibitor of a prolyl peptidase, preferably a prolyl tripeptidyl-peptidase, can be present in a composition that preferably contains a pharmaceutically acceptable carrier. For instance, inhibitors can be applied systemically, subgingivally (e.g., subgingival irrigation) and/or by controlled release delivery directly into the periodontal pocket using methods well known to the art (see, e.g., Kornman, K., (1993) *J. Periodontol.* 64, 782-791). Preferably, an inhibitor is applied subgingivally or by controlled release delivery.

The prolyl peptidases, active analogs, fragments, and modifications thereof can be used in a method of reducing growth of bacteria *in vitro* or *in vivo*. Preferably, the bacteria is a periodontal pathogen, i.e., a bacterial pathogen that causes periodontal disease, more preferably the bacteria is *P. gingivalis*. The inability of asaccharolytic *P. gingivalis* to utilize free amino acids makes the bacterium entirely dependant on an external peptide supply. The action of the polypeptides of the invention may be required for bacterial growth, and inhibition of the polypeptides of the invention may inhibit the *in vivo* growth of organisms, including *P. gingivalis*. The method includes decreasing the amount of dipeptides and/or tripeptides (e.g., the result of cleavage of SEQ ID NO:25 by a prolyl-tripeptidyl peptidase) and the amount of free amino acids that result from further cleavage of the dipeptides and/or tripeptides present by inhibiting a prolyl



peptidase, active analog, active fragment, or active modification thereof, such that the amount of dipeptides and/or tripeptides generated by the polypeptides is decreased. The amount of dipeptides and/or tripeptides is decreased relative to the amount of dipeptides and/or tripeptides present in the absence of the inhibitor.

5 Preferably, the amount of dipeptides and/or tripeptides generated is decreased by an inhibitor, a monoclonal antibody that inhibits the prolyl peptidase, or polyclonal antibodies that inhibit the prolyl peptidase, more preferably, the amount of dipeptides and/or tripeptides generated is decreased by an inhibitor. Preferably, an inhibitor acts to inhibit a polypeptide of the invention, preferably a prolyl peptidase,  
10 by blocking the active site of the polypeptide. The polypeptide can be present on the surface of the bacteria or secreted into the environment, preferably the polypeptide is present in the surface of the bacteria.

The present invention is also directed to a method of developing an inhibitor of a prolyl peptidase, active analog, active fragment, or active  
15 modification thereof, preferably a prolyl-tripeptidyl peptidase. The method includes identifying a molecule that inhibits the amidolytic activity of the prolyl peptidase. This can be accomplished by, for instance, incubating the prolyl peptidase with a candidate molecule under conditions that promote amidolytic activity of the prolyl peptidase and determining if the amidolytic activity of the  
20 prolyl peptidase is decreased relative to the amidolytic activity in the absence of the molecule. The amidolytic activity can be measured by cleavage of the Pro-Yaa peptide bond present in the target polypeptide SEQ ID NO:25 as described herein. One method of developing an inhibitor includes using the target peptide SEQ ID NO:25 and replacing the Xaa residues with modified amino acids. It is expected  
25 that some modified amino acids will cause the target peptide to act as an inhibitor.

### EXAMPLES

The present invention is illustrated by the following examples. It is to be understood that the particular examples, materials, amounts, and procedures are to  
30 be interpreted broadly in accordance with the scope and spirit of the invention as set forth herein.

### Example 1

#### Materials

Diisopropylfluorophosphate (DFP), leupeptin and 3,4-dichloroisocoumarin, were purchased from Calbiochem (La Jolla, CA). Antipain, iodoacetamide, substance P, bradykinin and bradykinin related peptides, were obtained from Sigma. Other peptides used in this study were synthesized at the Molecular Genetic Instrumental Facility (University of Georgia, Athens, GA) using Fmoc protocol with an advanced ChemTech MPS350 automated synthesizer. H-Ala-Phe-Pro-pNA, H-Gly-Pro-pNA, Z-Gly-Pro-pNA, Z-Ala-Pro-pNA, and H-Pro-pNA (where pNA is p- Nitroanilide; Z is benzyloxycarbonyl; and H is hydrogen and denotes an unblocked amino-terminal group) were obtained from Bachem (King of Prussia, PA). Prolinal was kindly provided by Dr. James Powers (Georgia Institute of Technology, Atlanta) and cystatin C by Dr. Magnus Abrahamson (University of Lund, Sweden).

#### Methods

*Source and Cultivation of Bacteria*— *P. gingivalis* HG66 was obtained from Dr. Roland Arnold (University of North Carolina, Chapel Hill), while the strains W50 (ATCC 53978) and ATCC 33277 were obtained from the ATCC. All cells were grown as described previously (Chen, Z., et al., (1992) *J. Biol. Chem.* 267, 18896-18901).

*Enzyme Activity Assays*— Routinely, the tripeptidyl peptidase amidolytic activity was measured with H-Ala-Phe-Pro-pNA (1 mM) in 0.2 M HEPES (N-2-hydroxyethylpiperazine,N'-2-ethansulfonic acid), pH 7.5 at 37°C. The concentration of enzyme was 0.1 nM to 1 nM. The assay was performed in a total volume of 0.2 ml on microplates, and the initial turnover rate was recorded at 405 nm using a microplate reader (Spectramax Molecular Devices, Sunnyvale, CA). In inhibition studies, the enzyme was first preincubated with inhibitor for 15 min at 37°C, substrate added, and residual activity recorded after 5 minutes to 30 minutes. H-Gly-Pro-pNA, Z-Ala-Pro-pNA, Z-Gly-Pro-pNA and H-Pro-pNA (1 mM final concentration) were assayed in the same manner.

*Protein Determination*—Protein concentration was determined using the BCA reagent kit (Sigma, St. Louis, MO), using bovine serum albumin as a standard.

*Localization of Tripeptidyl-Peptidase Activity*—Cultures of *P. gingivalis* HG66, W50 and ATCC 33277, at different phases of growth, were subjected to the following fractionation procedure. The cells were removed by centrifugation (10,000 x g, 30 minutes), washed twice with 10 mM Tris, 150 mM NaCl, pH 7.4, resuspended in 50 mM Tris, pH 7.6, and disintegrated by ultrasonication in an ice bath at 1500 Hz for 5 cycles (5 minutes sonication/5 minutes brake). Unbroken cells and large debris were removed by centrifugation (10,000 x g, 30 minutes) and the opalescent supernatant subjected to ultracentrifugation (150,000 x g, 120 minutes), yielding a pellet containing bacterial membranes and a supernatant which was considered as membrane-free cell extract. All fractions, as well as the full culture, culture medium, and full culture after sonication, were assayed for amidolytic activity against H-Ala-Phe-Pro-pNA.

*Enzyme Purification*—All purification steps were performed at 4°C except for FPLC separations, which were carried out at room temperature. Cells were harvested by centrifugation (6,000 x g, 30 minutes), washed with 50 mM potassium phosphate buffer, pH 7.4, and resuspended in the same buffer (150 ml per 50 gram of cells wet weight). Triton X-100 (10% volume/volume in H<sub>2</sub>O) was added slowly to the bacterial cell suspension to a final concentration of 0.05%. After 120 minutes of gentle stirring, unbroken cells were removed by centrifugation (28,000 x g, 60 minutes). Proteins in the supernatant were precipitated with cold acetone (-20°C) added to a final concentration of 60% and collected by centrifugation. The pellet was redissolved in 50 mM potassium phosphate buffer, pH 7.0, and extensively dialyzed against 20 mM potassium phosphate, pH 7.0, containing 0.02% sodium azide. The dialyzed fraction was clarified by centrifugation (28,000 x g, 30 min) and applied to a hydroxyapatite column (BioRad, Melville, NY) equilibrated with 20 mM potassium phosphate, pH 7.0, at a flow rate of 20 ml/hour. After equilibration, the column was washed until the A<sub>280</sub> fell to zero. Bound proteins were eluted with a gradient from 20-300 mM potassium phosphate and fractions (7 ml) analyzed for dipeptidyl- and tripeptidyl-peptidase activity using H-Gly-Pro-pNA and H-Ala-Phe-Pro-pNA, respectively. The activity against the latter

substrate was pooled, saturated with 1 M ammonium sulfate, clarified by centrifugation, and directly loaded onto a Phenyl-Sepharose HP (Pharmacia, Piscataway, NJ) column equilibrated with 50 mM potassium phosphate, pH 7.0, containing 1 M ammonium sulfate. The column was washed with two volumes of equilibration buffer, followed by buffer containing 0.5 M ammonium sulfate, and developed with a descending gradient of ammonium sulfate from 0.5 to 0 M. Active fractions were pooled, extensively dialyzed against 20 mM Tris, pH 7.5, and applied to a MonoQ HR 5/5 FPLC column equilibrated with the same buffer. The column was washed with 5 volumes of equilibration buffer at 1.0 ml/minute, following which bound proteins were eluted with a gradient of 0- 300 mM NaCl. The active fractions were pooled, dialyzed against 25 mM Bis-Tris, pH 6.3, and subjected to chromatofocusing on a MonoP FPLC column equilibrated with Bis-Tris buffer, using a pH gradient developed with 50 ml of 10x diluted Polybuffer 74 (Pharmacia), adjusted to a pH of 4.0.

*Electrophoretic Techniques*— The SDS-PAGE system of Schagger and von Jagow (Schagger, H., and von Jagow, G. (1987) *Anal. Biochem.* 166, 368-379), was used to monitor enzyme purification and estimate the enzyme molecular mass. For amino-terminal sequence analysis, proteins resolved in SDS-PAGE were electroblotted to polyvinylidene difluoride membranes using 10 mM CAPS, pH 11, 10% methanol (Matsudaira, P. (1987) *J. Biol. Chem.* 262, 10035-10038). The membrane was washed thoroughly with water and stained with Coomassie Blue G250. The blot was air dried, and protein bands cut out and subjected to NH<sub>2</sub>-terminal sequence analysis with an Applied Biosystems 491 Protein Sequencer using the program designed by the manufacturers.

*Enzyme Fragmentation* —The purified prolyl tripeptidyl peptidase (PTP-A) was partially denatured by incubation in 6 M urea in 0.02 M Tris, pH 7.6, for 60 minutes. Low molecular mass gingipain R (RgpB) (Potempa, J., et al. (1995) *Prospect. Drug Discovery and Design* 2, 445-458) from *P. gingivalis* was then added to make an enzyme:substrate molar ratio of 1:100. The reaction mixture was made in 1 mM cysteine and the sample incubated overnight at 37°C. Generated peptides were separated by reverse-phase HPLC using a  $\mu$ Bondapak C-18 column (3.9 x 300 mm) (Waters, Millford, MA). Peptides were eluted with 0.1% trifluoroacetic acid and acetonitrile containing 0.08% trifluoroacetic acid, using a

gradient from 0 to 80% acetonitrile over 60 minutes. Peptides were monitored at 220 nm and collected manually.

For determination of the active site serine residue and to confirm that the purified enzyme was a serine peptidase, 100 µg of purified PTP-A was first  
5 : incubated with 170 µCi of [1,3-<sup>3</sup>H]DFP (Amersham, Arlington Heights, IL) for 30 minutes at 25°C in 20 mM HEPES, pH 7.5. The reaction was quenched by addition of cold DFP to a final concentration of 10 mM and the radiolabelled material analyzed by SDS-PAGE, followed by autoradiographic analysis. The gel was dehydrated, soaked in PPO solution for 2 hours, dried, and the DFP-binding  
10 proteins detected by fluorography after an exposure time of 96 hours on X-ray film (XAR; Kodak, Rochester, NY). The bulk of radiolabelled protein was subjected to proteolytic fragmentation with RgpB and peptides obtained separated by reverse-phase HPLC as described above. Radioactivity in each peptide fraction was measured using a β liquid scintillation counter, and the labeled peptide, as well as  
15 other selected peptides were subjected to sequence analysis.

*Identification of the PTP-A Gene*— The database containing the unfinished *P. gingivalis* W83 genome, available from The Institute for Genomic Research, was searched for the presence of nucleotide sequences corresponding to the NH<sub>2</sub>-terminal and the internal PTP-A amino acid sequences using the TBLASTN  
20 algorithm, BLAST version 2.0.8, and the default values for all parameters (Altschul, S.F., et al.,(1997) *Nucleic Acid Res.* 25, 3389-3402). An identified clone gnl | TIGR | *P. gingivalis*\_126 was retrieved from The Institute for Genomic Research data base (<http://www.tigr.org>). The position of the PTP-A gene was localized using the NCBI open reading frame (ORF) finder (available from the  
25 National Center for Biotechnology Information, at <http://www.ncbi.nlm.nih.gov/gorf/gorf.html>). The amino acid sequence, obtained by conceptual translation of the entire ORF, was further used for homology screening by use of the NCBI BLAST search tool.

*Enzyme Specificity*— Peptides were incubated with 1 µg PTP-A at an  
30 enzyme:substrate molar ratio of 1:100 for 3 hours or 24 hours in 50 µl of 200 mM HEPES, pH 7.5, at 37°C, and the reaction stopped by acidification with trifluoroacetic acid. The samples were then subjected to reverse-phase high

pressure liquid chromatography using a  $\mu$ Bondapak C-18 column (3.9 x 300 mm) (Waters, Millford, MA) and an acetonitrile gradient (0-80 % in 0.075% trifluoroacetic acid in 50 min). Each peak, detected at 220 nm, was collected, lyophilized, re-dissolved in 50% (volume/volume) methanol, 0.1% acetic acid and subjected to analysis by mass spectrometry.

*Mass Spectrometry*—A Finnigan MAT 95S, sector mass spectrometer (Finnigan MAT, Bremen, Germany) equipped with an electrospray source (ESI) was used operated essentially as described previously (Stenfors, C., et al., (1997) *J. Biol. Chem.* 272, 5747-5751). Peptides were identified by fitting of the obtained spectra to specific sequences using an Internet application program MsFit available at <http://falcon.ludwig.ucl.ac.uk/msfit.html>.

## Example 2

### Enzyme Localization, Purification and Initial Characterization

Analysis of amidolytic activity against H-Ala-Phe-Pro-pNA in several fractions of *P. gingivalis* HG66, W50 and ATCC 33277 clearly indicated that an enzyme(s) with prolyl tripeptidyl-peptidase activity is localized on the cell surface in all strains tested with less than 5% of the total activity being found in the medium regardless of the growth phase of the bacterial culture. Cell associated enzyme was easily detached from the bacterial surface by treatment with a low concentration (0.05%) of Triton X-100. This procedure released more than 85-90% of activity in a soluble form. Subsequent acetone precipitation of proteins in the Triton X-100 fraction successfully separated the activity from pigment which remained in solution. The redissolved protein fraction, after dialysis, was applied to hydroxyapatite (100 ml) equilibrated with 20 mM potassium phosphate buffer pH 7.0. The elution was carried out with 20 mM potassium phosphate buffer pH 7.0, using a phosphate gradient from 20 mM to 300 mM at flow rate 20 ml/h. At this step substantial separation of the PTP-A activity from both the DPP IV and bulk protein was achieved (Fig. 1a). Further purification performed by subsequent chromatography steps including Phenyl-Sepharose (Fig. 1b), MonoQ (Fig. 1c) and MonoP columns (Fig. 1d), resulted in the isolation of purified enzyme.

Phenyl-Sepharose HP (25 ml) was equilibrated with 50 mM potassium phosphate, 1M ammonium sulfate, pH 7.0, at flow rate 30 ml/h. The column was

washed with two volumes of equilibration buffer and a step gradient of 0.5 M ammonium sulfate was applied, following which a descending gradient of 0.5 to 0 M ammonium sulfate was applied. The PTP-A containing fractions were extensively dialyzed against 20 mM Tris-HCl, pH 7.0, and concentrated by ultrafiltration. The concentrated PTP-A containing fractions were applied to a MonoQ column equilibrated with the same buffer. The column was washed with 5 volumes of equilibration buffer, following which bound protein was eluted with a gradient of 0-300 mM NaCl. The concentrated fraction of PTP-A from the MonoQ column was equilibrated with 25 mM Bis-Tris, pH 6.3, and loaded on a MonoP column equilibrated with the same buffer. A pH gradient was developed using 50 ml of Polybuffer 74, with the pH adjusted to 4.0.

Significantly, the chromatography step on the MonoP column yielded the  $A_{280}$  profile much sharper than the activity peak. Although this imperfect overlap of protein and activity may suggest that the protein component does not represent the active enzyme, the rest of data argues with such a contention. This apparent contradiction may be likely explained by the enzyme inhibition by the reaction product of H-Ala-Phe-Pro-pNA hydrolysis but this possibility has not been explored. The yield of protein and activity recovery in a typical purification procedure is summarized in Table 1.

Table 1. Purification of the PTP- A from *P. gingivalis*

Step	Volume (ml)	Protein (mg)	Total activity*	Specific activity (units/mg)	Purification fold	Yield (%)
Triton X-100 extract after centrifugation	200	1200	757 673	642	1	100
Acetone precipitate	50	600	537 622	896	1.4	71
Hydroxyapatite chromatography	50	22	400 039	18 183	28	53
Phenyl-Sepharose	48	10	312 505	31 250	48	41
MonoQ	3	1.5	244 828	163 218	254	32
MonoP	4	0.7	188 400	269 142	420	25

\* Based on the enzymatic activity using H-Ala-Phe-Pro-pNA where one unit = mOD/min/1ml



SDS-PAGE analysis of the purified enzyme revealed the presence of two protein bands with apparent molecular masses of 81.8 and 75.8 kDa, respectively (Fig. 2, lane f). Autoradiography of the enzyme sample radiolabeled with [1,3-<sup>3</sup>H]DFP (Fig. 2, lane g) clearly indicated that the bands represented either two distinct serine peptidases or different molecular mass forms of the same enzyme. In an attempt to distinguish between these two options, the electrophoretically resolved proteins were subjected to amino terminal sequence analysis. Unfortunately, it was found that the 81.8 kDa form of PTP-A had a blocked N-terminus. In contrast, the sequence NH<sub>2</sub>-SAQTTRFSAADLNALMP (SEQ ID NO:23) was found at the N-terminus of the lower molecular mass form of the enzyme. This result led us to the possibility that the 75.8 kDa form of PTP-A was derived from the 81.8 kDa form through proteolytic cleavage of a 6 kDa amino-terminal peptide. To confirm this hypothesis and, in addition, to localize the active site residue within *P. gingivalis* PTP-A, the mixture containing both radiolabeled enzymes was proteolytically fragmented and peptides resolved by reverse-phase HPLC. This procedure yielded only one major radioactive peptide peak, and the purified peptide was found to have a single amino acid sequence: IGVHGWXYGGFMTTNL (SEQ ID NO:24), where X apparently represents the active-site serine residue covalently and irreversibly modified by DFP. These data convincingly indicate that the two protein bands of purified PTP-A represents different forms of the same enzyme. The portion of the purified PTP-A having a truncated N-terminus may be due to cleavage by Lys-specific peptidase and is likely to be an artifact which occurred during the purification procedure. Nevertheless, the proteolytic shedding of membrane bound PTP-A also occurs during cultivation of the bacteria, as indicated by variable amount of soluble activities found in cell free culture media.

### Example 3

#### pH Optimum, Stability and Inhibition Profile

Using the amidolytic activity assay with H-Ala-Phe-Pro-pNA it was found that the enzyme has a broad pH optimum from pH 6.0 to 8.0 and in 0.2 M HEPES, pH 7.6 was stable for at least 12 hours at 25°C or 37°C. PTP-A activity was not affected by class specific synthetic inhibitors of cysteine or metalloproteinases

(Table 2). In contrast, preincubation of the enzyme with DFP or PEFABLOCK resulted in total loss of activity, supporting its classification as a serine peptidase. Surprisingly, however, 3,4-dichloroisocoumarin was only a poor inhibitor, and PMSF, leupeptin, antipain and prolinal had no effect at all. Interestingly, preincubation of PTP-A with iodoacetamide, but not with N-ethylmaleimide, stimulated enzyme amidolytic activity about two-fold. Human plasma inhibitors, such as  $\alpha_1$ -proteinase inhibitor,  $\alpha_1$ -antichymotrypsin and  $\alpha_2$ -macroglobulin did not affect the enzyme activity, nor were they cleaved by PTP-A.

The effect of inhibitors on amidolytic activity of DPP IV was also determined using the same conditions as those used for PTP-A, but using H-Gly-Pro-pNA as a substrate.

Table 2. Effect of inhibitors on the amidolytic activity of PTP-A and DPP IV.  
Results are for a 15-min incubation at 37 C in 0.2 HEPES pH 7.6,  
with 1 mM H-Ala-Phe-Pro-pNA as substrate.

	Inhibitor	Concentration	Residual activity of PTP-A, %	Residual activity of DPP IV, %
5	Diisopropyl fluorophosphate	10 mM	0	0
		10 mM	96	20
10	Phenylmethanesulfonyl fluoride	1mg/ml	20	15
		10mg/ml	0	0
	PEFABLOC SC	1 mM	56	100
15	3,4-dichloroisocoumarin	5mM	200	100
	Iodoacetamide	5 mM	100	100
	N-Ethylmaleimide	1 mM	98	100
20	1,10- orthophenanthroline	5 mM	93	100
		0.1 mM	100	100
	EDTA	0.1 mM	100	100
25	Leupeptin	0.1 mM	100	20
	Antipain	10 mM	100	0
30	Prolinal	10 mM	100	30
	Val-Pro	10 mM	100	1
35	Ala-Pro			
	Ala-Gly-Pro			

### Example 4

#### Substrate Specificity

Among several chromogenic substrates tested, including H-Ala-Phe-Pro-pNA, H-Gly-Pro-pNA, Z-Gly-Pro-pNA, Z-Ala-Pro-pNA, H-Pro-pNA, only H-Ala-Phe-Pro-pNA was hydrolyzed by PTP-A indicating a prolyl specific tripeptidyl-peptidase activity. To further confirm this specificity several synthetic peptides composed of 5 to 34 amino acid residues and containing at least one proline residue were tested as substrates for PTP-A. Out of 22 peptides tested only those with a proline residue in the third position from the amino terminal end were cleaved (Table 3), with the significant exception of peptides with adjacent proline residues (peptides 3, 4 and 16). In addition, a free  $\alpha$ -amino group was absolutely required for cleavage after the third proline residue as exemplified by resistance to enzymatic hydrolysis of peptide 9, which differs from the peptide 8 only in acylation of the  $\alpha$ -amino group of the N-terminal valine residue. Except for these two limitations, the peptide bond -Pro-↓-Yaa- was cleaved at the same rate in all peptides with the general formula  $\text{NH}_2\text{-Xaa-Xaa-Pro-Yaa-(Xaa)}_n$  (SEQ ID NO:25), where Xaa represents any amino acid residue while Yaa could be any residue except proline, regardless of the chemical nature of the amino acids and the length of the peptide. In all cases the reaction was completed within 3 hours and prolonged incubation for 24 hours did not affect the pattern of cleavage, confirming the absolute requirement for a proline residue at the third position from the unblocked N-terminus. In addition, these data indicate that the preparation of PTP-A was free of any contamination with either aminopeptidase, dipeptidyl peptidase, or endopeptidase activities.

The cleavage specificity of DPP IV was also determined using the same conditions as those used for PTP-A. The results (Table 3) demonstrate that DPP IV does not cleave between two proline residues.

Table 3. Cleavage specificity of PTP-A and DPP IV on synthetic peptides.

Substrate	Cleavage site	SEQ ID NO:
Peptide 1	H-Arg- <b>Pro</b> -Pro-I-Gly-Phe-Ser- <b>Pro</b> -Phe-Arg	1
Peptide 2	H-Arg- <b>Pro</b> -Pro-I-Gly-Phe	2
Peptide 3	H-Lys-Arg- <b>Pro</b> -Pro-Gly-Phe-Ser- <b>Pro</b> -Phe-Arg	3
Peptide 4	H-Tyr-Arg- <b>Pro</b> -Pro-Gly-Phe-Ser- <b>Pro</b> -Phe-Arg	4
Peptide 5	H-Arg- <b>Pro</b> -Hyp-Gly-Phe-Ser- <b>Pro</b> -Phe-Arg	5
Peptide 6	H-Arg- <b>Pro</b> -I-Lys- <b>Pro</b> -I-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH <sub>2</sub>	6
Peptide 7	H-Val- <b>Pro</b> -Pro-I-Gly-Glu-Asp-Ser-Lys-Glu-Val-Ala-Ala- <b>Pro</b> -His-Arg-Gln	7
Peptide 8	H-Val- <b>Pro</b> -Pro-I-Gly-Glu-Asp-Ser-Lys	8
Peptide 9	Ac-Val- <b>Pro</b> -Pro-Gly-Glu-Asp-Ser-Lys	9
Peptide 10	H-Val-Glu- <b>Pro</b> -I-Ile- <b>Pro</b> -Tyr	10
Peptide 11	H-Arg-Gly- <b>Pro</b> -I-Phe- <b>Pro</b> -Ile	11
Peptide 12	H-Ala-Arg- <b>Pro</b> -I-Ala-D-Lys-amide	12
Peptide 13	H- <b>Pro</b> -Asn- <b>Pro</b> -I-Asn-Gln-Gly-Asn-Phe-Ile	13
Peptide 14	H-Arg-His- <b>Pro</b> -I-Lys-Tyr-Lys-Thr-Glu-Leu	14
Peptide 15	H-Gly-Val- <b>Pro</b> -I-Lys-Thr-His-Leu-Glu-Leu	15
Peptide 16	H-Lys-Gly- <b>Pro</b> - <b>Pro</b> -Ala-Ala-Leu-Thr-Leu	16
Peptide 17	H-Gln-Lys-Gln-Met-Ser-Asp-Arg-Glu-Asn-Asp-Met-Ser- <b>Pro</b> -Ser-Asn-Val-Val- <b>Pro</b> -Ile-His-Val- <b>Pro</b> - <b>Pro</b> -Thr-Thr-Glu-Asn-Lys- <b>Pro</b> -Lys-Val-Gln	17
Peptide 18	H-Phe-Leu-Arg-Glu- <b>Pro</b> -Val-Ile-Phe-Leu	18
Peptide 19	H-Gly-Ile-Arg- <b>Pro</b> -Tyr-Glu-Ile-Leu-Ala	19
Peptide 20	H-Leu- <b>Pro</b> -I-Asp-Leu-Asp-Ser-Ser-Leu-Ala-Ser-Ile-Gln-Glu-Leu-Ser- <b>Pro</b> -Gln-Glu- <b>Pro</b> -Arg- <b>Pro</b> - <b>Pro</b> -Glu-Ala	20
Peptide 21	H-Cys-Leu-Ser-Ser-Gly-Thr-Leu- <b>Pro</b> -Gly- <b>Pro</b> -Gly-Asn-Asp-Ala-Ser-Arg-Glu-Leu-Glu-Ser	21
Peptide 22	H-Lys-Ile-Ala-Gly-Tyr-His-Leu-Glu-Leu	22
Peptide 23	H-Ser- <b>Pro</b> -I-Tyr-Ser-Ser-Asp-Thr-Thr	46
Peptide 24	H-Ala- <b>Pro</b> -I-Val-Arg-Ser-Leu-Asn-Cys-Thr-Leu-Arg-Asp-Ser-Gln-Gln-Lys	47
! indicates cleavage site mediated by PTP-A		
! indicates cleavage site mediated by DPP IV		

The lack of cleavage after internal proline residues in the synthetic peptides corresponds well with the absence of any proteolytic activity on several protein substrates including IgA, IgG, albumin, azocasein, carboxymethylated ribonuclease and gelatin. However, the size of substrate, which is a limiting factor in the activity of oligopeptidases (Walter, R., et al., (1980) *Mol. Cell. Biochem.* 30, 111-126), is not restricting in the case of PTP-A, because the enzyme is able to cleave a tripeptide (NH<sub>2</sub>-Xaa-Xaa-Pro) from the N-terminus of both human cystatin C and interleukin 6.

### Example 5

#### PTP-A Sequence Analysis

Partial PTP-A amino acid sequence data allowed us to identify the *P. gingivalis* genomic clone gnl | TIGR | *P. gingivalis*\_126 in the Unfinished Microbial Genomes data base, TIGR. An ORF corresponding to the PTP-A amino acid sequence was found as indicated by the fact that all sequences of the PTP-A derived peptides obtained by the enzyme polypeptide fragmentation with RgpB were present in the protein primary structure inferred from the nucleotide sequence of the ORF. The 732 amino acid polypeptide with a calculated mass of 82, 266 Da was encoded in this ORF. The homology search performed using the NCBI TBLASTN tool against GenBank+EMBL+DDBJ+PDB databases and subsequent multiple sequence alignments using the ClustalW Multiple Sequence Alignment tool (Fig. 3) indicated that PTP-A is a new member of the prolyl oligopeptidase (S9) family of serine peptidases (Rawlings, N.D., et al., (1991) *Biochem. J.* 279, 907-908).

The sequence GX SXGG (SEQ ID NO:40) is a signature feature for the S9 family of serine peptidases. Within this large and diverse S9 family of evolutionary and functionally related enzymes both from prokaryotes and eukaryotes, PTP-A was most closely related to bacterial dipeptidyl peptidase IV (DPP IV) from *Flavobacterium meningosepticum*, *Xantomonas maltophilus*, and *P. gingivalis*, sharing 31.6%, 30.4%, and 28.5% amino acid sequence identity, respectively. Remarkably, the COOH-terminal region of the PTP-A molecule (residues 502 - 732) shows a significant similarity to the eukaryotic prolyl oligopeptidases with 34% and 33% identity to human DPP IV and mouse fibroblast activation protein (FAP), respectively (Fig. 3). This part of the molecule contains the amino acid

residues which encompass the catalytic triad in all characterized prolyl oligopeptidases, and from the multiple alignments with DPP IV of confirmed active site residues (Kabashima, T., et al., (1995) *Arch. Biochem. Biophys.* 320, 123-128) it is apparent that Ser-603, Asp-678 and His-710 represent the catalytic triad of PTP-A (Fig. 3). Such an inference is further supported by the direct labeling of Ser-603 by DFP. In addition, the computer assisted search for sequential motifs characteristic for transmembrane domains revealed the presence of such a putative region within the N-terminal sequences of PTP-A, with residues 5 to 25 most likely folded into a hydrophobic  $\alpha$ -helix responsible for membrane anchoring of this enzyme.

In *P. gingivalis* PTP-A, as well as in DPP IV, all activities are cell surface associated, and it is conceivable that the enzymes are membrane anchored through putative signal sequences which are not cleaved but remain as a membrane spanning domain similar to other members of the prolyl oligopeptidase family. The cell surface localization of di- and tripeptidyl-peptidases suggests a putative physiological function in providing nutrients for growing bacterial cells. Here, the inability of asaccharolytic *P. gingivalis* to utilize free amino acids (Dashper, S.G., et al., *J. Dent Res.* 77, 1133 (Abstract) (1988)) makes the bacterium entirely dependant on an external peptide supply. In this regard, DPP-IV and PTP-A activities are probably very important, if not indispensable, for bacterial growth.

This suggestion is strongly corroborated by the fact that the *P. gingivalis* genome contains three additional genes encoding peptidases homologous with DPP-IV and PTP-A and one related to aminopeptidase B. The peptidases homologous with DPP-IV and PTP-A are referred to as homologs H1 (SEQ ID NO:43), H2 (SEQ ID NO:44), and H3 (SEQ ID NO:45) (Fig. 6). If expressed, each gene product would probably have enzymatic activity because each has a well preserved catalytic triad (Fig. 4). In addition, all of these genes encode a putative signal peptide which may act in providing membrane-anchorage motifs.

**Example 6****Influence of Proteinase Inhibitor on *P. gingivalis* Growth**

To evaluate whether *P. gingivalis* growth was influenced by the presence of a peptidase inhibitor, *P. gingivalis* in logphase growth was diluted 1:5 into liquid media and incubated at 37°C. The cell density was monitored by measuring the optical density at 600 nm (OD<sub>600</sub>). When the optical density began to increase, Pefabloc was added at 0.5 mg/ml or at 2.0 mg/ml. The control culture received no Pefabloc. The cultures receiving Pefabloc exhibited decreased growth (Figure 5). The peptidase inhibitor had to be added before the culture reached an OD<sub>600</sub> of about 0.3 for the peptidase inhibitor to have an effect on growth.

The complete disclosures of all patents, patent applications, publications, and nucleic acid and protein database entries, including for example GenBank accession numbers and EMBL accession numbers, that are cited herein are hereby incorporated by reference as if individually incorporated. Various modifications and alterations of this invention will become apparent to those skilled in the art without departing from the scope and spirit of this invention, and it should be understood that this invention is not to be unduly limited to the illustrative embodiments set forth herein.

20

**Sequence Listing Free Text**

- SEQ ID NOs:1-11: Synthetic peptides
- SEQ ID NO:12: Target peptide
- SEQ ID NOs:13-22: Synthetic peptides
- 25 SEQ ID NO:23: Amino-terminus of the lower molecular mass form of PTP-A.
- SEQ ID NO:24: Amino acid sequence present in PTP-A, where X apparently represents the active-site serine residue covalently and irreversibly modified by DFP.
- 30 SEQ ID NO:25: Target peptide, where Xaa represents a natural or modified amino acid residue, Yaa represents a natural or modified amino acid residue except proline, and N is equal to or greater than 1.
- SEQ ID NO:26: Mouse fibroblast activation protein



- SEQ ID NO:27: Human DPP IV
- SEQ ID NO:28: DPP from *Flavobacterium meningosepticum*
- SEQ ID NO:29: DPP from *P. gingivalis*
- SEQ ID NO:30: *P. gingivalis* PTP-A
- 5 SEQ ID NO:31: Portion of PTP-A
- SEQ ID NO:32: Portion of DPP from *P. gingivalis*
- SEQ ID NO:33: Portion of H1 homolog of *P. gingivalis* DPP
- SEQ ID NO:34: Portion of H2 homolog of *P. gingivalis* DPP
- SEQ ID NO:35: Portion of H3 homolog of *P. gingivalis* DPP
- 10 SEQ ID NOs:36-37: Probes
- SEQ ID NO:38: Nucleotide sequence of coding region encoding PTP-A.
- SEQ ID NO:39: Consensus sequence for clan SC where X is any amino acid and S is the active site serine GXSTXXG.
- SEQ ID NO:40: Consensus sequence for family S9 where X is any amino acid and S is the active site serine GXSTXGG.
- 15 SEQ ID NO:41: A specific substrate for a prolyl-tripeptidyl peptidase, where Xaa represents a natural or modified amino acid residue, and Yaa represents a natural or modified amino acid residue except proline.
- 20 SEQ ID NO:42: DPP from *P. gingivalis*
- SEQ ID NO:43: H1 homolog of *P. gingivalis* DPP
- SEQ ID NO:44: H2 homolog of *P. gingivalis* DPP
- SEQ ID NO:45: H3 homolog of *P. gingivalis* DPP
- SEQ ID NO:46: Synthetic peptides
- 25 SEQ ID NO:47: Synthetic peptides
- SEQ ID NO:48: Amino terminal sequence of DPP IV

**What is claimed is:**

1. An isolated prolyl tripeptidyl-peptidase, active analog, active fragment, or active modification thereof having amidolytic activity for cleavage of a peptide bond present in a target polypeptide having at least 4 amino acids, wherein the prolyl tripeptidyl-peptidase:target polypeptide ratio is at least about 1:1 to no greater than about 1:10,000,000 in about 200 mM HEPES, about pH 7.5 at 37°C for at least about 3 hours.
2. An isolated prolyl tripeptidyl-peptidase, active analog, active fragment, or active modification thereof having amidolytic activity at a prolyl tripeptidyl-peptidase:target polypeptide ratio of at least about 1:1 to no greater than about 1:10,000,000 in about 200 mM HEPES, about pH 7.5 at 37°C for at least about 3 hours, and wherein the prolyl tripeptidyl-peptidase is isolated from *P. gingivalis*.
3. The isolated prolyl tripeptidyl-peptidase of claim 2 wherein the peptide cleaved by the isolated prolyl tripeptidyl-peptidase comprises the sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:11, H-Ala-Arg-Pro-Ala-D-Lys-amide, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:25, and SEQ ID NO:37.
4. The isolated prolyl tripeptidyl-peptidase of claim 2 wherein the amino acid sequence of the isolated prolyl tripeptidyl-peptidase comprises the amino acid sequence GXSEXG (SEQ ID NO:39).
5. The isolated prolyl tripeptidyl-peptidase of claim 4 wherein the amino acid sequence of the isolated prolyl tripeptidyl-peptidase comprises the amino acid sequence GXSEXG (SEQ ID NO:40).
6. The isolated prolyl tripeptidyl-peptidase of claim 4 wherein the amino acid sequence of the isolated prolyl tripeptidyl-peptidase comprises SEQ ID NO:30.

7. An isolated polypeptide, active analog, active fragment, or active modification thereof having amidolytic activity for cleavage of a peptide bond present in a target polypeptide having at least 4 amino acids, wherein the polypeptide:target polypeptide ratio of at least about 1:1 to no greater than about 1:10,000,000 in about 200 mM HEPES, about pH 7.5 at 37°C for at least about 3 hours.
8. An isolated polypeptide comprising an amino acid sequence having a percentage amino acid identity of greater than 35 % with SEQ ID NO:30.
9. An isolated nucleic acid fragment encoding a prolyl-tripeptidyl peptidase, active analog, active fragment, or active modification thereof, having amidolytic activity for cleavage of a peptide bond present in a target polypeptide having at least 4 amino acids, wherein the prolyl tripeptidyl-peptidase:target polypeptide ratio of at least about 1:1 to no greater than about 1:10,000,000 in about 200 mM HEPES, about pH 7.5 at 37°C for at least about 3 hours.
10. The nucleic acid fragment of claim 9 wherein the nucleic acid fragment has a nucleotide sequence comprising SEQ ID NO:38.
11. The nucleic acid fragment of claim 9 wherein a complement of the nucleic acid fragment hybridizes to SEQ ID NO:38 under hybridization conditions of 0.5 M phosphate buffer, pH 7.2, 7 % SDS, 10 mM EDTA, at 68°C, followed by three for 20 minutes washes in 2x SSC, and 0.1 % SDS, at 65°C, wherein at least about 20 nucleotides of the complement hybridize.
12. An isolated nucleic acid fragment encoding a polypeptide wherein the polypeptide comprises an amino acid sequence having a percentage amino acid identity of greater than 35 % with SEQ ID NO:30.
13. A method of identifying an inhibitor of a prolyl-tripeptidyl peptidase, active analog, active fragment, or active modification thereof, comprising identifying a molecule that inhibits the amidolytic activity of the prolyl-

tripeptidyl peptidase by incubating the prolyl-tripeptidyl peptidase with the molecule under conditions that promote amidolytic activity of the prolyl-tripeptidyl peptidase and determining if the amidolytic activity of the prolyl-tripeptidyl peptidase is inhibited relative to the amidolytic activity in the absence of molecule.

14. A method of reducing growth of a bacterium comprising inhibiting a prolyl tripeptidyl-peptidase, active analog, active fragment, or active modification thereof, by contacting the prolyl tripeptidyl-peptidase with an inhibitor of the prolyl tripeptidyl-peptidase.
15. A method for protecting an animal from a periodontal disease caused by *P. gingivalis* comprising administering to the animal the inhibitor of claim 14 wherein the disease is selected from the group consisting of gingivitis and periodontitis.
16. The method of claim 15 wherein the inhibitor is administered by a method selected from the group consisting of subgingival application and controlled release delivery.
17. A method of reducing growth of a bacterium comprising inhibiting a prolyl dipeptidyl-peptidase, active analog, active fragment, or active modification thereof, by contacting the prolyl dipeptidyl-peptidase with an inhibitor of the prolyl dipeptidyl-peptidase.
18. An immunogenic composition comprising an isolated prolyl tripeptidyl-peptidase, or an antigenic analog, antigenic fragment, or antigenic modification thereof, the prolyl tripeptidyl-peptidase having amidolytic activity for cleavage of a peptide bond present in a target peptide having at least 4 amino acids, wherein the prolyl tripeptidyl-peptidase:target polypeptide ratio is at least about 1:1 to no greater than about 1:10,000,000 in about 200 mM HEPES, about pH 7.5 at 37°C for at least about 3 hours.
19. The immunogenic composition of claim 18 further comprising an adjuvant.

20. A composition comprising an inhibitor of an isolated prolyl tripeptidyl-peptidase and a pharmaceutically acceptable carrier.
21. A dipeptidyl peptidase having an amino acid sequence comprising SEQ ID NO:43.
22. A dipeptidyl peptidase having an amino acid sequence comprising SEQ ID NO:44.
23. A dipeptidyl peptidase having an amino acid sequence comprising SEQ ID NO:45.

1/19




Fig. 1a




Fig. 1b

2/19




Fig. 1c




Fig. 1d

3/19




Fig. 2






Fig. 3

SEQ ID NO:	
26 Mm-FAP	1 MKTWLAVTVEGVTTLAALALVVICIVLRPSR-VYKPEGNTK-RALT LKDI L NGTFSYKTYF
27 Hs-DPP	1 MKTPWRVLLGLGAAALVTITVVPVVLNKGDDATADSR-KTYTLTDYLNKNTYRLKLYS
28 Fm-DPP	1 ---MKKKIFSLISIAVAVAFHGLSAQEHTLDKITYSGQYRAK-GISGIIASLND---
29 Pg-DPP	1 -MKRPVTHLLIGIVIMCAMAQTGNKPFVDLKEITSGMFYARSAGSGIRSMPD---
30 PTP-A	1 ---MKKTHLFOQLFLSVCAITVALPCSAQSPETSGKEFTLEQLMPGCKEFYN-FYPEYVV
Mm-FAP	59 PNWISSEQEYLHQSEDDNIVFVNIETRE--SYTHLSNSTMKS VN--ATDYGISPDQRFVY
Hs-DPP	60 LRWISDHEYLYK--QENNILVFNAEYEN--SSVFLNSTFDEFGHSINDYSSISPDGQFTL
Fm-DPP	48 -----GENYATH--EPTGIAKNSYKITSQ--KEKNIVDGSFQGYT-----FSNDESK--ITL
Pg-DPP	51 -----GENYTEMNRERTALIRKNYASGKAVDITLFSVERARECPFKQIQNIYEVSSSTGHHTL
	56 GLQWMCNDNYVFIE---GDDLIVENKANKESAQITRFSAADLNALMPEGCKFOTIDAFPSFR
Mm-FAP	114 LESDYSKLRMSYTAIVYIYVDLONGEFVRGYELPRPIQYTLQSPVCGSKLAVYVYNNIYTLK
Hs-DPP	116 LEYNYVKQWRHSYTAISYDIYDLNKRQLITEERIPNNTQWVTSIPVGHKLA YVWNNILYVK
Fm-DPP	92 LQKSSQSIYRHSFLGKEFEVKDLKSEITVSTNNANWIOE-PKFSPDGSKVAFIADNNLFYQ
Pg-DPP	106 LFTDMESIYRHSYRAAVYDYVRRNLVKPLSEHVGVKVMIPTESPDGRMVAEVRDNNITIK
	113 TLDAGRCGLVVLFTQGGVLVGFEDMLARKVTYTLFDTNEETASLDFSPVGD RVAYVRNHNLYIA
Mm-FAP	174 QRP--GPPFQITVYTGRENRIIFNGITPDWVYEEEMLATKYALWSPDCKFLAMVEFNDSDI
Hs-DPP	176 IEP--NLPSYRLTWTGKEDIHYNGIHDWVYEEEFVSAYSALWSPENETELAMAOQFNDTEV
Fm-DPP	151 DLN--TGKITITITDGKKNFIIINGLGDWVYEEEFCHADYYQNN-KACDALVFVREDEKVV
Pg-DPP	166 KFD--FQTEVQVITDGOINSILNGATDWYEEEFQVTNLMSSS-ADNAFLAVRSDESAY
	173 RGGKLGEGMSRAIAVTIDGTETLVYGOAVHQREFGIEKGTFWIS-PKESCLAFVYRMDQSMV
Mm-FAP	232 PLITAYSYYGCG--QYFRTINIPYKAGAKNPVVRVFTVDDTYPHVG---PMEMPVVPEMI
Hs-DPP	234 PLIEYSFYSDESLOVPKTVRVPYKAGAVNPTVKFFVNTDLSSTVNTATSIQITAPASM
Fm-DPP	208 PEHNPPIYYQN--LYPKLMTYKYPKAGEENSATVAYLYQLSSKSAQ---LNFGSSEKY
Pg-DPP	223 PEYRMPMVEK--LYHEDYTKYPKAGEKNTVSLHLYNVADRNTKS---VSLPIDADG
	232 KPTPLVDYHP---LEAESKPLVYEMAGTPSHHVTVGIVYHLAKKIVY---LQTGEKKEK

Fig. 3a

6/19

Mm-FAP	287	ASSDYVFSWLTWVSSERVCIQWLKRVQNVSMISICDFREDHWAWECPKNQEHVEESRTGM
Hs-DPP	294	LFGDHYLCDVTWATQERISLQWLRIQNYSMDCDYDESSGRWNCCLVARQHIEMSTTGM
Fm-DPP	262	YIIPQLFQTN---ANDEIVATARRHQNKVVDLKNTKFAVS-----K-LFTEITDNFAM
Pg-DPP	277	YIIPRTAFID---NADEIAVMTINRLQNDFFKMYVYHPKSLVPK-----LILQDMNKRY
	285	ELTNLSWSP---DENILYMAEVNRAQNECKVNAYDAETGRFVR-----TLFVEITDKHY
Mm-FAP	347	AGGFFVSTPAPFSQDATSVMKIFISDKDGVKHHVILKDTVENAIOITSGKWEATYIFRMTQD
Hs-DPP	354	VGRFRPSEPHFILLDENSFYKIIISNEGGYRHICYFIQIDKDCFTFKGTWEVIGIEPALTSD
Fm-DPP	311	LETDMLT-MEELDDNS--FLWASERDGHRLVWYDAAAGKLKKQVSKGCDWEHINYYGYNPK
Pg-DPP	326	MDSDWLTQTLKEFITGEG--FAYVSEKDCFAHLYLYDNKGVMMHRRITSGNMIVTKLYGVNAS
	335	MEPLHP--LTFLPGSNNOFIWQSRRDGMNHLVLYDYITGRLIRQVITKGEWEVTNFAGFDPK
Mm-FAP	407	SLFYSSNEFEGYPGRRNIIYRITISIGNSPPSKKCVTCILRKERCQYYTASIFS YKAKVYALVC
Hs-DPP	414	YLYYISNEYKGMPPGRNLKYLQLSDYTKVT-CLSCENPERCQYYSVSF SKEAKVYQLRC
Fm-DPP	368	---TKEVVIQIIEKGSINKVSKLNINTG---KTQLLSNAEGNNSAF S KTFNVEINTS
Pg-DPP	384	-----GTVEYQSADESPIRAVYDAIDAKGR---KIKLSLVGTN-DALESGNYAYYINTY
	393	-----GTRLYFESIEASPLERHFYCIDIKGG---KIKDLTPESGMHRTQLSPDCSAIIDIF
Mm-FAP	467	Y-GPGIPITSLHDGRTDQETQVLEENKELENSIRNIQIPKVEIKKIK-DGGLTFWYKMITL
Hs-DPP	473	S-GPGIPLYTLHSSVNDKGLRVLIEDNSALDKMLONVQMPSKLLDFHIL-LNETKFWYQMITL
Fm-DPP	421	S-TAKVPTKYTLKDKANGKDVKEIQNNDLLNKLKSDNFIAKEFIITIPNAAQCDQMNAWMIK
Pg-DPP	435	SSAATPAMVSVFRSKGAKELRTLEDNVALRERELKAYRYNPKFETTKTQSSCLELNAWIVK
	446	Q-SPTVERKVTVTNIG-KGSHITLLEAKNPDTGYAMPEIRTGTMMAAD--GQTPLYKILTM
Mm-FAP	525	PPQFDRSKKKYPLILIQVYGGPCSQSKSVFAVN---WITYLASKEGIVIALVDGRGTAFQGG
Hs-DPP	531	PPHFDSKSKKYPILLDQVYAGPCSQKADIVFRLN---MATYLASTENIIVASFDGRGSGYQGG
Fm-DPP	480	PKNFDPKAKKYPVEMFYQSGPGSQQVANSWDGGNGIMFDMLAQKG-YLVVQVVDGRGTGFRG
Pg-DPP	495	PIDFDP SRHYPLVMQVSGNSQQLDRYSFD---MEHYLASKG-YVVAQVVDGRGTGARG
	502	PLHEDPAKKYPVIMVYVGGHQAQIMTKTMRSSVSGGDIYMAQKG-MAVFTVDSRGSAIRFG

Fig. 3b

7/19

Mm-FAP	582	DKELHAYVRKLGVEVEDQITAVRKFIEMGFIDEERITAIWWSYGGYVSSIALASGIGLF
Hs-DPP	588	DKIMHAINRRLGTFEVEDQTEARQFSKMGFVDNKRITAIWWSYGGYVTSMTLGSQSGVF
Fm-DPP	539	TKYKKVTVKRNLCGYELEDQITAAKMGNOQSYVDKSRIGIFGWSYGGYMASIAMTKGADV
Pg-DPP	551	SEWRKCTVMQLGVFEESDDQITAAATAIIGQLPVVDAARIGIWSYGGYITLMSLCRGNELF
	561	AAFEQVIHRRLGQTEMADQMCCEVDFLKSQSWVDADFIQVHEWSYGGFMTHNIMLTHGADV
		* →
Mm-FAP	642	KCGIAPVSSWENYASIVSERFMGLPTKDDNLEHYKNSITVMARAERYFRNVDYELLIHGTA
Hs-DPP	648	KCGIAPVSRWENYESVYTERFMGLPTPEDNLDHYRNSITVMSRAENFKQVEYELLIHGTA
Fm-DPP	599	KMGIAVAPVTVNRFYDSIYTERFLQTPQENK--DGYDLNSPTTYAKLLKG-KFLLLIHGTA
Pg-DPP	611	KAGIAPVADWRFYDSVYTERFMRTPKENA--SGYKMSSSADVASQLQG-NLLITVSSSA
	621	KVGMAGGPVIDNRYEITMYGERYFDAPQENP--EGYDAANLLKRGDLKG-RIMLIHGAI
		* →
Mm-FAP	702	DDNVHFQNSAQIAKALVNAQVDFQAMVYSDQNHGTSSEFSONHLYITHTHFLKQCFSLSD
Hs-DPP	708	DDNVHFQNSAQISKALVDVGVDFQAMVYIDEDHGCIASSTAHQHIYTHMSHFIKQCFSLP-
Fm-DPP	656	DDNVHFQNSMEFSEALIQNKKQDFDMMAPDKNHSIIIGCNTFRPQLYEKMTNYILEN----
Pg-DPP	668	DDNVHQNITMLFTEALVQANLPEEDMAIYMDKNHSIIYGCNTFRNHLVTRKAKFLFDNL----
	678	DPVVMQHSLSLFLDACMKARTYPDYVYVYPSHEINVMGPD-RVHLYETIIRYFTDHL----

Fig. 3c

	SEQ ID NO:
PTP-A	556
DPP	499
DPP-H1	350
DPP-H2	640
DPP-H3	495
	717
	661
	524
	810
	667

Fig. 4

9/19

Influence of Pefablock-serine proteinase inhibitor on *P. gingivalis* growth.




Fig. 5

10/19




Fig. 6

11/19

[illegible]

Fig. 6a



12/19

```

126PP 201 -VHQREFGTEKG--TFMSPKGSLAFVFM-----DQS-MVKPTHTVDYH---PI
87PP 144 WYEEEFVGNL--MSASADNAFLAFVS-----DES-AVPEYRMPMYED---KL
65PP 112 -LATGEFRLLK--THDDTFGVAFNYA-----SKN-KDEAYVLTNLD---S
101PP 241 ARGNILLNNEKEALGMPHEDMIMVIRKEGNAKRLVAFPMGKGEKTLVSNLPESQFRM
9PP 170 ATGRIITDLMYK--HWDEWVETPHPI-----AN-ATDGMITGKD---II

126PP 243 EAESKPLVYPMAGT---PSHHVTVGYHHLA---TG-KTVYLOTGEPEKEKFLTNISMSPDE
87PP 188 YPEDYTKYPKAGE---KNSITVSLHYNVA---DR-NTKSVSPIDADGYIPRLAETDNA
65PP 153 DK-TRIVLYDLKQN---K--IIRREIFANE--DY-DVSGIHLS-RK--
101PP 301 SPAPRYLLEYKQEKGPCKDPLFIRHLPDDDRQSDWRDRSQIYLLNAESGVYGPTEFGYST
9PP 210 ME-GEPEAEPMKPW-----S-GIEDFSWSP--DG--QNIAYASRKKTG---

126PP 296 NIIIVAE--VNRAQNECKVNAQDAETGEFVRTLFEVETDKHVEP--LH-P---LHLEP
87PP 241 DELAVMT--LNRLQNDFKM--YVHPKSLVPKLILODKNKRIVDSDWIQ-T---LKEFTT-
65PP 188 -R-----N-YEIDLMA--VEGEKSVVVHVVSATYKELLLKLE---KEFK--
101PP 361 TYHMDIAPDSKRRLIGTLSTDWTRRPFRFATIMEYNMETGKADTLITRDPSIDALQYTPD
9PP 247 -MAYSLS--TN---SDIYII--YNLASGRTHNISEGMMGYDTYPK-----FSPD

126PP 346 CSNNQFIHWQSR-RDGMNHILYI-----YDITGRLLIRQVTKGEWETNFA---G
87PP 292 CGG--FAYVSE-KDGFATHTY-----YDNKGVMHRRITSGNWDVTKLI---G
65PP 224 GRE--FSVM--D-----YDD-----
101PP 421 GRH--LIVMGS-ADAFNGNIGNLKSGVTPNSYEDKQFFLFDLSIRKATADIKNPNPSVSAG
9PP 287 GKS--IAWISMERDGYES-----DLKRLFVADLAFGKRTHVNPTEFDYNNVDMI

```

Fig. 6b

```

126PP 389 -EDPKGTRILYFESTEASPLERHFVCIIDIKGCKTKDITP-ESGMHRTQLSPD-GSAILIDIF
87PP 333 -VDA SCH-VFYQSAEESPIRRANVALDAKGRKTK-LSL-NVGTNDALFSGN-YAYYINTY
65PP 235 --DE--E-ILLIAVQSDKLYGTYYQFDIR--TK--KFI--LLYD-L
101PP 478 RFDKNN-YMIFRAENG-SRKLQYRLEKTKLEISQITGTEDVVQWFGVAADNGAVWYSGQ
9PP 332 QMAPDSKGYFLACKEA--ETNLWEHFLKTKIRQLTQGQHDYADFVRND--VMLAKR

126PP 446 QSPTVPRKVMVTNIGKGSHTLLEAKNPDTGYAMPETITG----TIMAADGQOTPLVYKLT
87PP 388 SSAATEPAVVSFRSKAKELRTLEDVVALRERLKAYYNPKFTTITKQSC-LELNAVITV
65PP 269 ----MPQLK-----EED-----MAEVRPI-----KFKSRDG-LTIHGFT
101PP 536 SANNADRLVRDGTGKGLVWDSAEKLANIDFTPADWN-----YTAPDG-TTVVEGWY
9PP 387 HSFEEDDDLYRVNLKNGAAQAVTAENKVIIDRITPTITCEKR---WNKIIDG-GNMLTWNV

126PP 501 MELHFDPAKKYPMLVVMYGG--PHAOIVTKTWSSVGGWDIYMAOKGYAVFTVDSRGSAN
87PP 447 KPIDEDPSRHYPVLVMVQVSG--PNSQVLD--RYSFD-WEHYLASKGVMAVACVDCRGTGA
65PP 299 LEKAALLEGKKVPLIYNPHGG--P--QGIRD--SWGENPETQLFASRGVATLQVNFRISSG
101PP 589 LPPOFDSSKKYPMLVVMYGGTSPINRTLEG--HYSLA---MYAAQGYVYTLNPSGHTG
9PP 443 LIPNFDKKNKYPALIMCOEG--P--QNTVS-QFMSFRWNLRMLAEQGYLVIAPRPHGVPG

126PP 559 RGAAPFEOVIHRRIGQTEADQMCQVD-FLKSQSWVDADRIGVHGSYGGFMITNMLTHG
87PP 502 RGEEMRKCTYMQLVFESDDQIAAAT-ALIGQLPYVDAARIGIWCWSYGGYITLMSLCRGN
65PP 353 YGKEFLRAGFKQIGRKAMDDVEDGVR-VAISQGWDPDRITAIYCASHEGYAILMGLVKTP
101PP 643 YGOEYAAARHVNAWDRTADDEILGATKEFIRTHSFVNGKKVGCFCGASVGGFMIOYLOTKT-
9PP 498 EQKANEQISGDYGGQNPVRYLITAVD-EMKKEPVDSDRIGAVGASVGGFSVYWLACHHD

```

Fig. 6c

14/19

```

126PP 618 DVEKVGVAAGPMI-----D-----MN--RYEIMYGERYFDA--PQENPEGYD--AANLLK
87PP 561 GTEKAGTAVAPVA-----D-----MR--FYDSVYTERFMRT--PKENASGYK--MSSALD
65PP 412 DLYACGVYGVSNITYTFDSFPEYMK--PFKEMVKEILWYDLDNPEFAAIAKE--VSPFFQ
101PP 702 DIFAAAMSHAGISSIS--N-----YMGSGYWGMYSTVASTDSYPMNNPDLVAGHSHLFR
9PP 557 KFEAAFIHAGIFNLEMQYATTEEMFA--NWDIGGPFWEKEN--VVAQRTYA--TSHKF

126PP 662 RAGDLKGRIMLIHGADDPVVMVQHSILFLDQCVKARTYPDYVYPSHEHNMVGED--RVHEL
87PP 605 VASQLQGNLIIVSGSADDNVHLQNTMLFTALVQANIPFDMAIYMDKNHSIYGGNTRYHL
65PP 469 ID-KINKPLFVVQGANDPRVNNINESDQIVTALRARGFEVPMVKYNEGCHGFHRENSMEL
101PP 755 AD-KIHUPLLILLHGSVDINVPТАESVNLVYNAKILGREVEFIEFTQDHFILPEPERIRW
9PP 612 MQ-NWDTPPILMIHGELDFRILLASQMAAFDAQLRGVPSMLIYDENHNVLOEQNALLF

126PP 721 YETITRYETDHL-----
87PP 665 YTRKAKFLFDNL-----
65PP 528 YRAMLGFFAKHLKK-----
101PP 814 TNSICAWFAFWLQDDPTWNNELYPPVNL
9PP 671 HRIFFGWLDRWLKK-----

```

Fig. 6d




Fig. 7

16/19

P. gingivalis W 83 PTP sequence

SEQ ID NO: 38 13228 atgaagaagacaatcttccaacaactatctgtctgtttgtgcc  
 SEQ ID NO: 30 M K K T I F Q Q L F L S V C A  
 13273 cttacagtggccttgcccttggtcggctcagtcctcctgaaacgagt  
 L T V A L P C S A Q S P E T S  
 13318 ggtaaggagtttactccttgagcaactgatgcccggaggaaaagag  
 G K E F T L E Q L M P G G K E  
 13363 ttttataacttttaccgccgaatacgtggtcggtttgcaatggatg  
 F Y N F Y P E Y V V G L Q W M  
 13408 ggagacaattatgtctttatcgagggtgatgatttagtttttaat  
 G D N Y V F I E G D D L V F N  
 13453 aaggcgaatggcaaatacggctcagacgaccagattttctgctgcc  
 K A N G K S A Q T T R F S A A  
 13498 gatctcaatgcactcatgccggagggatgcaaatctcagacgact  
 D L N A L M P E G C K F Q T T  
 13543 gatgctttcccttcattccgcacactcgatgccggacggggactg  
 D A F P S F R T L D A G R G L  
 13588 gtcgttctatcttaccgaaggaggattagtcggattcgatatgctt  
 V V L F T Q G G L V G F D M L  
 13633 gctcgaagggtgacttatcttttcgataccaatgaggagacggct  
 A R K V T Y L F D T N E E T A  
 13678 tctttggattttttctcctgtgggagaccgtggtgcctatgtcaga  
 S L D F S P V G D R V A Y V R  
 13723 aaccataacctttacattgctcgtggaggtaaattgggagaagg  
 N H N L Y I A R G G K L G E G  
 13768 atgtcacgagctatcgctgtgactatcgatggaactgagactctc  
 M S R A I A V T I D G T E T L  
 13813 gtatatggccaggccgtacaccagcgtgaattcggtatcgaaaaa  
 V Y G Q A V H Q R E F G I E K  
 13858 ggtacattctggtctccaaaaggagctgccttgctttctatcga  
 G T F W S P K G S C L A F Y R  
 13903 atggatcagagtatggtgaagcctaccccgatagtggattatcat  
 M D Q S M V K P T P I V D Y H  
 13948 ccgctcgaagccgagtcctcaaacgctttattaccccatggcagg  
 P L E A E S K P L Y Y P M A G  
 13993 actccgtcacaccacgttacgggtgggatctatcatctggccaca  
 T P S H H V T V G I Y H L A T  
 14038 ggtaagaccgtctatctacaaacgggtgaacccaaggaaaaat  
 G K T V Y L Q T G E P K E K F  
 14083 ctgacgaatttgagttggagtcgggacgaaaatatcttgatgta  
 L T N L S W S P D E N I L Y V  
 14128 gctgaggtgaatcgctgctcaaacgaatgtaaggtaaagtgcctat  
 A E V N R A Q N E C K V N A Y  
 14173 gacgctgagaccggttagattcgctccgtacgctttttgttgaaac  
 D A E T G R F V R T L F V E T  
 14218 gataaacattatgtagagccgttacatccctgacattccttccg  
 D K H Y V E P L H P L T F L P

Fig. 7a

17/19

-----

14263 ggaagtaacaatcagttcatttggcagagccgtcgcgacggatgg  
G S N N Q F I W Q S R R D G W

14308 aaccatctctatctgtatgatactacaggtcgtctgatccgtcag  
N H L Y L Y D T T G R L I R Q

14353 gtgacaaaaggggagtgagggttacaaactttgcaggcttcgat  
V T K G E W E V T N F A G F D

14398 cccaaggggaacacggctctatttcgaaagtaccgaagccagccct  
P K G T R L Y F E S T E A S P

14443 ctcgaacgccatttttactgtattgatatacaaaggaggaaagaca  
L E R H F Y C I D I K G G K T

14488 aaagatctgactccggagtcgggaatgcaccgcactcagctatct  
K D L T P E S G M H R T Q L S

14533 cctgatggttctgccataatcgataatttttcagtcacctactgtc  
P D G S A I I D I F Q S P T V

14578 ccgcgtaagggttacagtgacaaatatcggcaaaggggtctcacaca  
P R K V T V T N I G K G S H T

14623 ctcttgagggctaagaaccccgatacgggctatgccatgccggag  
L L E A K N P D T G Y A M P E

14668 atcagaacgggtaccatcatggcgccgatgggcagacacctctt  
I R T G T I M A A D G Q T P L

14713 tattacaagctcacgatgccgcttcatttcgatccggcaaagaaa  
Y Y K L T M P L H F D P A K K

14758 tatcctgttattgtctatgtttacggaggacctcatgccaactc  
Y P V I V Y V Y G G P H A Q L

14803 gtaaccaagacatggcgcagctctgtcgggtggatgggatatctat  
V T K T W R S S V G G W D I Y

14848 atggcacagaaaggctatgccgtctttacgggtggatagtcgcgga  
M A Q K G Y A V F T V D S R G

14893 tctgccaatagaggggctgctttcgagcaggttattcatcgctcg  
S A N R G A A F E Q V I H R R

14938 ttggggcagaccgagatggccgatcagatgtgcggtgtggatttc  
L G Q T E M A D Q M C G V D F

14983 ctcaagagccaatcatgggtggatgccgatagaataggagtacat  
L K S Q S W V D A D R I G V H

15028 ggctggagctatggtggctttatgactacgaatctgatgcttacg  
G W S Y G G F M T T N L M L T

15073 cacggcgatgtcttcaaagtcggagtagccggcgggcctgtcata  
H G D V F K V G V A G G P V I

15118 gactggaatcgatatgagattatgtacggtgagcggttatttcgat  
D W N R Y E I M Y G E R Y F D

15163 gcgccacaggaaaatcccgaaggatacgatgctgccaacctgctc  
A P Q E N P E G Y D A A N L L

15208 aaacgagccggtgatctgaaaggacgacttatgctgattcatgga  
K R A G D L K G R L M L I H G

15253 gcgatcgatccggtcgtggtatggcagcattcactccttttcctt

Fig. 7b

18/19

-----  
A I D P V V V W Q H S L L F L  
15298 gatgcttgcggtgaaggcacgcacctatcctgactattacgtctat  
D A C V K A R T Y P D Y Y V Y  
15343 ccgagccacgaacataatgtgatggggccggacagagtacatttg  
P S H E H N V M G P D R V H L  
15388 tatgaaacaataacccggtattttcacagatcacttatga 15426  
Y E T I T R Y F T D H L \*

Fig. 7c  
-----

SEQ ID NO:38 ATGAAGAAGACAAATCTTCCAACAACATATTTCTGTCTGTGTTGTGCCCTTACAGTGGCCCTTGCCCTTGTTCGGC  
TCAGTCTCCTGAAACGAGTGGTAAGGAGTTTACTCTTGAGCAACTGATGCCCGGAGGAAAGAGTTTATATA  
ACTTTTACCCCGAAATACGTGGTCGGTTTGCAATGGATGGGAGACAAATATATGTCTTTATCGAGGGTGATGAT  
TTAGTTTAAATGAAGCGGAATGGCAAAATCGGCTCAGACGACCAGATTTTCTGTCTGCCGATCTCAATGCACT  
CATGCCGGAGGGATGCAAAATTTTCAGACGACTGATGCTTTCCCTTCAATCCGCACACTCGATGCCGGACGGG  
GACTGGTCGTTCTATTTACCCCAAGGAGGATTAGTCGGATTCGATATGCTTGTCTGAAAGGTGACTTATCTTT  
TTCGATACCAATGAGGAGACGGCTTCTTTGGATTTTCTCCTGTGGGAGACCGTGTGCTATGTCAGAAA  
CCATAACCTTTACATTGCTCGTGGAGGTAAATTTGGAGAAAGGTATGTCACGAGCTATCGCTGTGACTATCG  
ATGGAACGTGAGACTCTCGTATATGGCCAGGCCGTACACCGTGAATTCGGTATCGAAATAGGTACATTC  
TGGTCTCCAAAAGGGAGCTGCCCTTGTCTTATCGAATGGATCAGAGTATGTTGAAGCCTTACCCCGATAGT  
GGATATCATCCGCTCGAAGCCGAGTCCAAACCGCTTTATTAACCCCATGGCAGGTACTCCGTACACCCACG  
TTACGGTTGGGATCTATCATCTGGCCACAGGTAAAGCCGTCTATCTACAAACGGGTGAACCCAAAGGAAAAA  
TTTCTGACGAAATTGAGTTGGAGTCCGGACGAAATATCTTGTATGTAGCTGAGGTGAATCGTGTCTCAAAA  
CGAATGTAAGGTAAATGCCCTATGACGCTGAGACCGGTAGATTCGTCCGTACCGCTTTTGTGTGAAACCGGATA  
AACATTATGTAGAGCCGTTACATCCCTGACATTCCTTCCGGGAAGTAACAATCAGTTCATTTTGGCAGAGC  
CGTCGGACGGATGGAACCATCTCTATCTGTATGATACATACAGGTCTGTGATCCGTACAGGTGACAAAAAGG  
GGAGTGGGAGGTTACAAACTTTGACGGCTTCGATCCCAAGGGAACACGGCTCTATTTCGAAAGTACCCGAG  
CCAGCCCTCTCGAACGCCATTTTACTGTATTTGATATCAAGGGAAGGAGGTAAGATCTGACTCCGGAG  
TCGGGAATGCACCCGACTCAGCTATCTCCTGTATCGGCAAGGTTCTCACACTCTTGGAGGCTAAGAACCCCGATA  
CCCGCTAAGGTTACAGTGACAAATATCGGCAAGGTTCTCACACTCTTGGAGGCTAAGAACCCCGATA  
CGGCTATGCCATGCCGGAGATCAGAACGGGTACCATCATGGCGGCCGATGGGAGGCTAAGAACCCCGATA  
AAGCTACGATGCCGCTTCAATTTTCGATCCGGCAAGGATATCCTGTTATTTGTCTATGTTTACGGAGGACC  
TCATGCCCAACTCGTAACCAAGACATGGCGCAGCTCTGTCTGGATGGGATATCTATATGGCACAGAAAG  
GCTATGCCGCTCTTACGGTGGATAGTCGCGGATCTGCCAATAGAGGGCTGTCTTCGAGCAGGTTATTCAT  
CGTCGTTTGGGGCAGACCGAGATGGCCGATCAGATGTCCGTTGTGATTTCCCTCAAGAGCCCAATCATGGGT  
GGATGCCGATAGAAATAGGAGTACATGGCTGGAGCTATGGTGGCTTTATGACTACGAATCTGATGCTTACGC  
ACGGCGATGCTCTCAAAGTCGGAGTAGCCCGGGGCCCTGTCTATAGACTGGAATCGATATGAGATTATGTAC  
GGTGAGCGTTATTTTCGATGCCCCACAGGAAAAATCCCGAAGGATACGATGCTGCCAACCTGTCTCAAAACGAGC  
CGGTGATCTGAAAGGACGACTTATGCTGATTTCATGGAGCGATCGATCCGGTCTGTGGTATGGCAGCATTCAC  
TCCCTTTCTCTTGATGCTTGCGTGAAGGCACGACCTATCTCTGACTATTCGTCATCTATCCGAGCCACGAAACAT  
AATGTGATGGGGCCGGACAGAGTACATTTGTGATGAAACAATAACCCGTTATTTTCACAGATCACTTATGA

Fig. 7d



# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/05551

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/57 C12N9/48 A61K39/02

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	KIYAMA, M. ET AL.: "Sequence analysis of the Porphyromonas gingivalis dipeptidyl peptidase IV gene" BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1396, no. 1, 4 March 1998 (1998-03-04), pages 39-46, XP000925951 cited in the application the whole document	7
A	---	1-6, 8-16, 18-20
	-/--	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

### \* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

5 October 2000

Date of mailing of the international search report

10.01.01

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentaan 2  
NL - 2280 HV Rijswijk  
Tel (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Fuchs, U

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/05551

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE WPI Section Ch, Derwent Publications Ltd., London, GB; Class B04, AN 1990-053917 XP002149298 & JP 02 005880 A (SUNSTAR KK), 10 January 1990 (1990-01-10)	7
A	abstract	1-6, 8-16, 18-20
P,X	--- BANBULA, A. ET AL.: "Prolyl Tripetidyl Peptidase from Porphyromonas gingivalis" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 14, April 1999 (1999-04), pages 9246-9252, XP002149297 the whole document	1-16, 18-20
A	--- KABASHIMA, T. ET AL.: "Cloning, Sequencing, and Expression of the Dipeptidyl Peptidase IV Gene from Flavobacterium meningosepticum in Escherichia coli" ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, vol. 320, no. 1, 20 June 1995 (1995-06-20), pages 123-128, XP000925965 the whole document	1-16, 18-20
A	--- KURAMITSU, H.K.: "Proteases of Porphyromonas gingivalis: what don't they do?" ORAL MICROBIOLOGY AND IMMUNOLOGY, vol. 13, no. 5, October 1998 (1998-10), pages 263-270, XP000925947 abstract page 267, column 2, line 34 -page 268, column 1, line 58 -----	1-16, 18-20

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 00/05551

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
  
Although claims 15 and 16 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-16 AND 18-20 COMPLETELY

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

## 1. Claims: 1-16 and 18-20 completely

An isolated prolyl tripeptidyl peptidase, active analog, active fragment, or active modification thereof having amidolytic activity for cleavage of a peptide bond present in a target polypeptide having at least 4 amino acids; an isolated prolyl tripeptidyl peptidase, active analog, active fragment, or active modification thereof being isolated from *Porphyromonas gingivalis*; an isolated polypeptide, active analog, active fragment, or active modification thereof having amidolytic activity for cleavage of a peptide bond present in a target polypeptide having at least 4 amino acids; an isolated polypeptide comprising an amino acid sequence having a percentage amino acid identity of greater than 35% with SEQ ID NO: 30; an isolated nucleic acid fragment encoding a prolyl tripeptidyl peptidase, active analog, active fragment, or active modification thereof having amidolytic activity for cleavage of a peptide bond present in a target polypeptide having at least 4 amino acids, an isolated nucleic acid fragment encoding a polypeptide comprising an amino acid sequence having a percentage amino acid identity of greater than 35% with SEQ ID NO: 30; a method of identifying an inhibitor of a prolyl tripeptidyl peptidase, active analog, active fragment, or active modification thereof; a method of reducing growth of a bacterium comprising inhibiting a prolyl tripeptidyl peptidase, active analog, active fragment, or active modification thereof; an immunogenic composition comprising an isolated prolyl tripeptidyl peptidase, or an antigenic analog, antigenic fragment, or antigenic modification thereof, the prolyl tripeptidyl peptidase having amidolytic activity for cleavage of a peptide bond present in a target peptide having at least 4 amino acids; a composition comprising an inhibitor of an isolated prolyl tripeptidyl peptidase;

## 2. Claim : 17 partially and 21 completely

A method of reducing growth of a bacterium comprising inhibiting a prolyl dipeptidyl peptidase, active analog, active fragment, or active modification thereof; a dipeptidyl peptidase having an amino acid sequence comprising SEQ ID NO: 43;

## 3. Claim : 17 partially and 22 completely

A method of reducing growth of a bacterium comprising inhibiting a prolyl dipeptidyl peptidase, active analog, active fragment, or active modification thereof; a dipeptidyl peptidase having an amino acid sequence comprising SEQ ID NO: 44;

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

4. Claim : 17 partially and 23 completely

A method of reducing growth of a bacterium comprising inhibiting a prolyl dipeptidyl peptidase, active analog, active fragment, or active modification thereof; a dipeptidyl peptidase having an amino acid sequence comprising SEQ ID NO: 45.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/05551

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
JP 2005880 A	10-01-1990	NONE	

CORRECTED VERSION

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
8 September 2000 (08.09.2000)

PCT

(10) International Publication Number  
WO 00/52147 A3

- (51) International Patent Classification<sup>7</sup>: C12N 15/57, (71) Applicants and  
9/48, A61K 39/02 (72) Inventors: TRAVIS, James [US/US]; 825 Riverbend  
Parkway, Athens, GA 30605 (US). POTEPA, Jan  
[US/US]; Apt. #102, 170 Barrington Drive, Athens, GA  
30605 (US). BANBULA, Agnieszka [US/US]; Apt. #E13,  
280 Picadilly Square, Athens, GA 30605 (US).
- (21) International Application Number: PCT/US00/05551
- (22) International Filing Date: 3 March 2000 (03.03.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/123,148 5 March 1999 (05.03.1999) US (81) Designated States (*national*): AE, AL, AM, AT, AU, AZ,  
BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK,  
DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,  
IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,  
LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT,
- (71) Applicant: UNIVERSITY OF GEORGIA RESEARCH  
FOUNDATION, INC. [US/US]; 632 Boyd Graduate Stud-  
ies, Athens, GA 30602-7411 (US).

*[Continued on next page]*

(54) Title: BACTERIAL PROLYL PEPTIDASES AND METHODS OF USE

SEQ ID NO: 1

a

26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657 658 659 660 661 662 663 664 665 666 667 668 669 670 671 672 673 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 762 763 764 765 766 767 768 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 790 791 792 793 794 795 796 797 798 799 800 801 802 803 804 805 806 807 808 809 810 811 812 813 814 815 816 817 818 819 820 821 822 823 824 825 826 827 828 829 830 831 832 833 834 835 836 837 838 839 840 841 842 843 844 845 846 847 848 849 850 851 852 853 854 855 856 857 858 859 860 861 862 863 864 865 866 867 868 869 870 871 872 873 874 875 876 877 878 879 880 881 882 883 884 885 886 887 888 889 890 891 892 893 894 895 896 897 898 899 900 901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 916 917 918 919 920 921 922 923 924 925 926 927 928 929 930 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 947 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 970 971 972 973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000 1001 1002 1003 1004 1005 1006 1007 1008 1009 1010 1011 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025 1026 1027 1028 1029 1030 1031 1032 1033 1034 1035 1036 1037 1038 1039 1040 1041 1042 1043 1044 1045 1046 1047 1048 1049 1050 1051 1052 1053 1054 1055 1056 1057 1058 1059 1060 1061 1062 1063 1064 1065 1066 1067 1068 1069 1070 1071 1072 1073 1074 1075 1076 1077 1078 1079 1080 1081 1082 1083 1084 1085 1086 1087 1088 1089 1090 1091 1092 1093 1094 1095 1096 1097 1098 1099 1100 1101 1102 1103 1104 1105 1106 1107 1108 1109 1110 1111 1112 1113 1114 1115 1116 1117 1118 1119 1120 1121 1122 1123 1124 1125 1126 1127 1128 1129 1130 1131 1132 1133 1134 1135 1136 1137 1138 1139 1140 1141 1142 1143 1144 1145 1146 1147 1148 1149 1150 1151 1152 1153 1154 1155 1156 1157 1158 1159 1160 1161 1162 1163 1164 1165 1166 1167 1168 1169 1170 1171 1172 1173 1174 1175 1176 1177 1178 1179 1180 1181 1182 1183 1184 1185 1186 1187 1188 1189 1190 1191 1192 1193 1194 1195 1196 1197 1198 1199 1200 1201 1202 1203 1204 1205 1206 1207 1208 1209 1210 1211 1212 1213 1214 1215 1216 1217 1218 1219 1220 1221 1222 1223 1224 1225 1226 1227 1228 1229 1230 1231 1232 1233 1234 1235 1236 1237 1238 1239 1240 1241 1242 1243 1244 1245 1246 1247 1248 1249 1250 1251 1252 1253 1254 1255 1256 1257 1258 1259 1260 1261 1262 1263 1264 1265 1266 1267 1268 1269 1270 1271 1272 1273 1274 1275 1276 1277 1278 1279 1280 1281 1282 1283 1284 1285 1286 1287 1288 1289 1290 1291 1292 1293 1294 1295 1296 1297 1298 1299 1300 1301 1302 1303 1304 1305 1306 1307 1308 1309 1310 1311 1312 1313 1314 1315 1316 1317 1318 1319 1320 1321 1322 1323 1324 1325 1326 1327 1328 1329 1330 1331 1332 1333 1334 1335 1336 1337 1338 1339 1340 1341 1342 1343 1344 1345 1346 1347 1348 1349 1350 1351 1352 1353 1354 1355 1356 1357 1358 1359 1360 1361 1362 1363 1364 1365 1366 1367 1368 1369 1370 1371 1372 1373 1374 1375 1376 1377 1378 1379 1380 1381 1382 1383 1384 1385 1386 1387 1388 1389 1390 1391 1392 1393 1394 1395 1396 1397 1398 1399 1400 1401 1402 1403 1404 1405 1406 1407 1408 1409 1410 1411 1412 1413 1414 1415 1416 1417 1418 1419 1420 1421 1422 1423 1424 1425 1426 1427 1428 1429 1430 1431 1432 1433 1434 1435 1436 1437 1438 1439 1440 1441 1442 1443 1444 1445 1446 1447 1448 1449 1450 1451 1452 1453 1454 1455 1456 1457 1458 1459 1460 1461 1462 1463 1464 1465 1466 1467 1468 1469 1470 1471 1472 1473 1474 1475 1476 1477 1478 1479 1480 1481 1482 1483 1484 1485 1486 1487 1488 1489 1490 1491 1492 1493 1494 1495 1496 1497 1498 1499 1500 1501 1502 1503 1504 1505 1506 1507 1508 1509 1510 1511 1512 1513 1514 1515 1516 1517 1518 1519 1520 1521 1522 1523 1524 1525 1526 1527 1528 1529 1530 1531 1532 1533 1534 1535 1536 1537 1538 1539 1540 1541 1542 1543 1544 1545 1546 1547 1548 1549 1550 1551 1552 1553 1554 1555 1556 1557 1558 1559 1560 1561 1562 1563 1564 1565 1566 1567 1568 1569 1570 1571 1572 1573 1574 1575 1576 1577 1578 1579 1580 1581 1582 1583 1584 1585 1586 1587 1588 1589 1590 1591 1592 1593 1594 1595 1596 1597 1598 1599 1600 1601 1602 1603 1604 1605 1606 1607 1608 1609 1610 1611 1612 1613 1614 1615 1616 1617 1618 1619 1620 1621 1622 1623 1624 1625 1626 1627 1628 1629 1630 1631 1632 1633 1634 1635 1636 1637 1638 1639 1640 1641 1642 1643 1644 1645 1646 1647 1648 1649 1650 1651 1652 1653 1654 1655 1656 1657 1658 1659 1660 1661 1662 1663 1664 1665 1666 1667 1668 1669 1670 1671 1672 1673 1674 1675 1676 1677 1678 1679 1680 1681 1682 1683 1684 1685 1686 1687 1688 1689 1690 1691 1692 1693 1694 1695 1696 1697 1698 1699 1700 1701 1702 1703 1704 1705 1706 1707 1708 1709 1710 1711 1712 1713 1714 1715 1716 1717 1718 1719 1720 1721 1722 1723 1724 1725 1726 1727 1728 1729 1730 1731 1732 1733 1734 1735 1736 1737 1738 1739 1740 1741 1742 1743 1744 1745 1746 1747 1748 1749 1750 1751 1752 1753 1754 1755 1756 1757 1758 1759 1760 1761 1762 1763 1764 1765 1766 1767 1768 1769 1770 1771 1772 1773 1774 1775 1776 1777 1778 1779 1780 1781 1782 1783 1784 1785 1786 1787 1788 1789 1790 1791 1792 1793 1794 1795 1796 1797 1798 1799 1800 1801 1802 1803 1804 1805 1806 1807 1808 1809 1810 1811 1812 1813 1814 1815 1816 1817 1818 1819 1820 1821 1822 1823 1824 1825 1826 1827 1828 1829 1830 1831 1832 1833 1834 1835 1836 1837 1838 1839 1840 1841 1842 1843 1844 1845 1846 1847 1848 1849 1850 1851 1852 1853 1854 1855 1856 1857 1858 1859 1860 1861 1862 1863 1864 1865 1866 1867 1868 1869 1870 1871 1872 1873 1874 1875 1876 1877 1878 1879 1880 1881 1882 1883 1884 1885 1886 1887 1888 1889 1890 1891 1892 1893 1894 1895 1896 1897 1898 1899 1900 1901 1902 1903 1904 1905 1906 1907 1908 1909 1910 1911 1912 1913 1914 1915 1916 1917 1918 1919 1920 1921 1922 1923 1924 1925 1926 1927 1928 1929 1930 1931 1932 1933 1934 1935 1936 1937 1938 1939 1940 1941 1942 1943 1944 1945 1946 1947 1948 1949 1950 1951 1952 1953 1954 1955 1956 1957 1958 1959 1960 1961 1962 1963 1964 1965 1966 1967 1968 1969 1970 1971 1972 1973 1974 1975 1976 1977 1978 1979 1980 1981 1982 1983 1984 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 2036 2037 2038 2039 2040 2041 2042 2043 2044 2045 2046 2047 2048 2049 2050 2051 2052 2053 2054 2055 2056 2057 2058 2059 2060 2061 2062 2063 2064 2065 2066 2067 2068 2069 2070 2071 2072 2073 2074 2075 2076 2077 2078 2079 2080 2081 2082 2083 2084 2085 2086 2087 2088 2089 2090 2091 2092 2093 2094 2095 2096 2097 2098 2099 2100 2101 2102 2103 2104 2105 2106 2107 2108 2109 2110 2111 2112 2113 2114 2115 2116 2117 2118 2119 2120 2121 2122 2123 2124 2125 2126 2127 2128 2129 2130 2131 2132 2133 2134 2135 2136 2137 2138 2139 2140 2141 2142 2143 2144 2145 2146 2147 2148 2149 2150 2151 2152 2153 2154 2155 2156 2157 2158 2159 2160 2161 2162 2163 2164 2165 2166 2167 2168 2169 2170 2171 2172 2173 2174 2175 2176 2177 2178 2179 2180 2181 2182 2183 2184 2185 2186 2187 2188 2189 2190 2191 2192 2193 2194 2195 2196 2197 2198 2199 2200 2201 2202 2203 2204 2205 2206 2207 2208 2209 2210 2211 2212 2213 2214 2215 2216 2217 2218 2219 2220 2221 2222 2223 2224 2225 2226 2227 2228 2229 2230 2231 2232 2233 2234 2235 2236 2237 2238 2239 2240 2241 2242 2243 2244 2245 2246 2247 2248 2249 2250 2251 2252 2253 2254 2255 2256 2257 2258 2259 2260 2261 2262 2263 2264 2265 2266 2267 2268 2269 2270 2271 2272 2273 2274 2275 2276 2277 2278 2279 2280 2281 2282 2283 2284 2285 2286 2287 2288 2289 2290 2291 2292 2293 2294 2295 2296 2297 2298 2299 2300 2301 2302 2303 2304 2305 2306 2307 2308 2309 2310 2311 2312 2313 2314 2315 2316 2317 2318 2319 2320 2321 2322 2323 2324 2325 2326 2327 2328 2329 2330 2331 2332 2333 2334 2335 2336 2337 2338 2339 2340 2341 2342 2343 2344 2345 2346 2347 2348 2349 2350 2351 2352 2353 2354 2355 2356 2357 2358 2359 2360 2361 2362 2363 2364 2365 2366 2367 2368 2369 2370 2371 2372 2373 2374 2375 2376 2377 2378 2379 2380 2381 2382 2383 2384 2385 2386 2387 2388 2389 2390 2391 2392 2393 2394 2395 2396 2397 2398 2399 2400 2401 2402 2403 2404 2405 2406 2407 2408 2409 2410 2411 2412 2413 2414 2415 2416 2417 2418 2419 2420 2421 2422 2423 2424 2425 2426 2427 2428 2429 2430 2431 2432 2433 2434 2435 2436 2437 2438 2439 2440 2441 2442 2443 2444 2445 2446 2447 2448 2449 2450 2451 2452 2453 2454 2455 2456 2457 2458 2459 2460 2461 2462 2463 2464 2465 2466 2467 2468 2469 2470 2471 2472 2473 2474 2475 2476 2477 2478 2479 2480 2481 2482 2483 2484 2485 2486 2487 2488 2489 2490 2491 2492 2493 2494 2495 2496 2497 2498 2499 2500 2501 2502 2503 2504 2505 2506 2507 2508 2509 2510 2



RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA,  
UG, UZ, VN, YU, ZA, ZW.

(88) Date of publication of the international search report:  
12 April 2001

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent  
(AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent  
(AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU,  
MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GW, ML, MR, NE, SN, TD, TG).

(48) Date of publication of this corrected version:  
1 November 2001

(15) Information about Correction:  
see PCT Gazette No. 44/2001 of 1 November 2001, Section  
II

**Published:**

— with international search report

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



## BACTERIAL PROLYL PEPTIDASES AND METHODS OF USE

5

**CONTINUING APPLICATION DATA**

This patent application claims the benefit of U.S. provisional patent application No. 60/123,148, filed March 5, 1999, which is incorporated by reference herein.

10

**GOVERNMENT FUNDING**

The present invention was made with government support under Grant No. DE 09761, awarded by the National Institutes of Health. The Government may have certain rights in this invention.

15

**BACKGROUND OF THE INVENTION**

*Porphyromonas gingivalis* (formerly *Bacteroides gingivalis*) is an obligately anaerobic bacterium which is implicated in periodontal disease. *P. gingivalis* produces several distinct proteolytic enzymes, many of which are recognized as important virulence factors. A number of physiologically significant proteins, including collagen, fibronectin, immunoglobulins, complement factors C3, C4, C5, and B, lysozyme, iron-binding proteins, plasma proteinase inhibitors, fibrin and fibrinogen, and factors of the plasma coagulation cascade system, are hydrolyzed by *P. gingivalis* proteases. Broad proteolytic activity plays a role in the evasion of host defense mechanisms and the destruction of gingival connective tissue in progressive periodontitis.

Progressive periodontitis is characterized by acute tissue degradation promoted by collagen digestion and a vigorous inflammatory response characterized by excessive neutrophil infiltration. Gingival crevicular fluid accumulates in periodontitis as periodontal tissue erosion progresses at the foci of the infection, and numerous plasma proteins are exposed to proteinases expressed by the bacteria at the injury site. Neutrophils are recruited to the gingiva, in part, by the humoral chemotactic factor C5a. The complement components C3 and C5 are activated by complex plasma proteases with "trypsin-like" specificities called convertases. The human plasma convertases

35

cleave the  $\alpha$ -chains of C3 and C5 at a specific site generating biologically active factors known as anaphylatoxins (i.e. C3a and C5a). The anaphylatoxins are potent proinflammatory factors exhibiting chemotactic and/or spasmogenic activities as well as promoting increased vascular permeability. The larger products from C3 and C5 cleavage (i.e. C3b and C5b) participate in functions including complement cascade activation, opsonization, and lytic complex formation.

Recent studies have indicated that this periodontopathogen produces at least seven different enzymes belonging to the cysteine and serine catalytic classes of peptidases, among which three cysteine proteinases (gingipains) are predominant (Potempa, J., et al. (1995) *Prospect. Drug Discovery and Design* 2, 445-458). The gingipains are the best characterized group of *P. gingivalis* enzymes as their structure, function, enzymatic properties and pathological significance are known. From *in vitro* studies it is apparent that two gingipains R (also referred to generally as "Arg-gingipains" and more specifically as RgpA and RgpB), enzymes specific for cleavage at Arg-Xaa peptide bonds, have a significant potential to contribute to the development and/or maintenance of a pathological inflammatory state in infected periodontal pockets through: (i) activation of the kallikrein-kinin cascade, (ii) the release of neutrophil chemotactic activity from native and oxidized C5 of the complement pathway, and (iii) activation of factor X. In addition, gingipain K (also referred to as "Lys-gingipain"), an enzyme which cleaves Lys-Xaa peptide bonds, degrades fibrinogen. This may add to a bleeding on probing tendency associated with periodontitis. Finally, the presence of a hemagglutinin/adhesion domain in the non covalent multiprotein complexes of RgpA and gingipain K suggests participation of these enzymes in the binding of *P. gingivalis* to extracellular matrix proteins which may facilitate tissue invasion by this pathogen.

In comparison to the gingipains, relatively little is known about other cysteine proteinases produced by *P. gingivalis*. Two genes, referred to as *tp* and *prtT* have been cloned and sequenced and although they encode a putative papain-like and streptopain-like cysteine proteinases, respectively, neither has been purified and characterized.

The presence of serine proteinase activity in cultures of *P. gingivalis* has been known for several years; however, only limited information is available about such enzymes. Indeed, a serine endopeptidase has been isolated from culture media, although it was only superficially characterized (Hinode D., et al.,  
5 (1993) *Infect. Immun.* 59, 3060-3068). On the other hand, an enzyme referred to as glycylprolyl peptidase (DPP IV) was found to be associated with bacterial surfaces and two molecular mass forms of this peptidase have been described. This enzyme has also been shown to possess the ability to hydrolyze partially degraded type I collagen, releasing the Gly-Pro dipeptide, and it was suggested  
10 that, in collaboration with collagenase, glycylprolyl peptidase may contribute to the destruction of the periodontal ligament (Abiko, Y., et al. (1985) *J.Dent. Res.* 64, 106-111). In addition to this potential pathological function, glycylprolyl peptidase may also play a vital role in providing *P. gingivalis* with dipeptides which can be transported inside the cell and serve as a source of carbon,  
15 nitrogen, and energy for this asaccharolytic organism. Recently, a gene encoding glycylprolyl peptidase in *P. gingivalis* has been cloned and sequenced, and it is now apparent that this enzyme is homologous to dipeptidyl-peptidase IV (DPP-IV) from other organisms (Kiyama, M., et al. (1998) 1396, 39-46). The nucleotide sequence of the genome of this bacterium is currently being  
20 determined by The Institute for Genomic Research, and is available at [www.tigr.org](http://www.tigr.org).

### SUMMARY OF THE INVENTION

The present invention is directed to an isolated prolyl tripeptidyl-  
25 peptidase, active analog, active fragment, or active modification thereof having amidolytic activity for cleavage of a peptide bond present in a target polypeptide having at least 4 amino acids. Alternatively, the isolated prolyl tripeptidyl-peptidase, active analog, active fragment, or active modification thereof is isolated from *P. gingivalis*. Typically, amidolytic activity is determined with a  
30 prolyl tripeptidyl-peptidase:target polypeptide ratio of at least about 1:1 to no greater than about 1:10,000,000 in about 200 mM HEPES, about pH 7.5 at 37°C for at least about 3 hours. The peptide cleaved by the isolated prolyl tripeptidyl-peptidase can include the sequence of SEQ ID NO:1, SEQ ID NO:2, SEQ ID

NO:7, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:11, H-Ala-Arg-Pro-Ala-D-Lys-amide, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:25, or SEQ ID NO:37. The amino acid sequence of the isolated prolyl tripeptidyl-peptidase can include the amino acid sequence GXSTXXG (SEQ ID NO:39), the amino acid sequence GXSTXGG (SEQ ID NO:40), or the amino acid sequence of SEQ ID NO:30.

Another aspect of the invention is an isolated polypeptide, active analog, active fragment, or active modification thereof having amidolytic activity for cleavage of a peptide bond present in a target polypeptide having at least 4 amino acids. Typically, the polypeptide:target polypeptide ratio of at least about 1:1 to no greater than about 1:10,000,000 in about 200 mM HEPES, about pH 7.5 at 37°C for at least about 3 hours.

The invention is also directed to an isolated polypeptide comprising an amino acid sequence having a percentage amino acid identity of greater than 35 % with SEQ ID NO:30.

An alternative aspect of the invention is an isolated nucleic acid fragment encoding a prolyl-tripeptidyl peptidase, active analog, active fragment, or active modification thereof, having amidolytic activity for cleavage of a peptide bond present in a target polypeptide having at least 4 amino acids. Typically, the prolyl tripeptidyl-peptidase:target polypeptide ratio of at least about 1:1 to no greater than about 1:10,000,000 in about 200 mM HEPES, about pH 7.5 at 37°C for at least about 3 hours. The nucleic acid fragment can have a nucleotide sequence comprising SEQ ID NO:38. A complement of the nucleic acid fragment can hybridize to SEQ ID NO:38 under hybridization conditions of 0.5 M phosphate buffer, pH 7.2, 7 % SDS, 10 mM EDTA, at 68°C, followed by three for 20 minutes washes in 2x SSC, and 0.1 % SDS, at 65°C, wherein at least about 20 nucleotides of the complement hybridize.

Another aspect of the invention is an isolated nucleic acid fragment encoding a polypeptide that includes an amino acid sequence having a percentage amino acid identity of greater than 35 % with SEQ ID NO:30.

The invention is also directed at a method of identifying an inhibitor of a prolyl-tripeptidyl peptidase, active analog, active fragment, or active modification thereof, including identifying a molecule that inhibits the

amidolytic activity of the prolyl-tripeptidyl peptidase. The inhibitor is identified by incubating the prolyl-tripeptidyl peptidase with the molecule under conditions that promote amidolytic activity of the prolyl-tripeptidyl peptidase and determining if the amidolytic activity of the prolyl-tripeptidyl peptidase is inhibited relative to the amidolytic activity in the absence of molecule.

An aspect of the invention is a method of reducing growth of a bacterium. This method includes inhibiting a prolyl tripeptidyl-peptidase, active analog, active fragment, or active modification thereof, or a prolyl dipeptidyl-peptidase, active analog, active fragment, or active modification thereof. The method includes contacting the prolyl tripeptidyl-peptidase with an inhibitor of the prolyl tripeptidyl-peptidase. The method can be used to protect an animal from a periodontal disease caused by *P. gingivalis* including administering to the animal the inhibitor. The disease can be selected from the group consisting of gingivitis and periodontitis. The inhibitor can be administered by a method selected from the group consisting of subgingival application and controlled release delivery.

Another aspect of the invention is an immunogenic composition including an isolated prolyl tripeptidyl-peptidase, or an antigenic analog, antigenic fragment, or antigenic modification thereof, the prolyl tripeptidyl-peptidase having amidolytic activity for cleavage of a peptide bond present in a target peptide having at least 4 amino acids. Typically, the prolyl tripeptidyl-peptidase:target polypeptide ratio is at least about 1:1 to no greater than about 1:10,000,000 in about 200 mM HEPES, about pH 7.5 at 37°C for at least about 3 hours. The immunogenic composition can include an adjuvant.

The invention is also directed to a composition including an inhibitor of an isolated prolyl tripeptidyl-peptidase and a pharmaceutically acceptable carrier.

Additional aspects of the invention include a dipeptidyl peptidase having an amino acid sequence including SEQ ID NO:43, SEQ ID NO:44, or SEQ ID NO:45.

### Definitions

“Polypeptide” as used herein refers to a polymer of amino acids and does not refer to a specific length of a polymer of amino acids. Thus, for example, the terms peptide, oligopeptide, protein, and enzyme are included within the definition of polypeptide. This term also includes post-expression modifications of the polypeptide, for example, glycosylations, acetylations, phosphorylations, and the like. A polypeptide can be produced by an organism, or produced using recombinant techniques, or chemically or enzymatically synthesized.

“Peptidase,” “proteinase,” and “protease” all refer to enzymes that catalyze the hydrolysis of peptide bonds in a polypeptide. A “peptide bond” or “amide bond” is a covalent bond between the alpha-amino group of one amino acid and the alpha-carboxyl group of another amino acid. “Peptidase inhibitor,” “proteinase inhibitor,” “protease inhibitor,” and “inhibitor” all refer to molecules that inhibit a peptidase that catalyzes the hydrolysis of peptide bonds in a polypeptide.

As used herein, the term “isolated” means that a polypeptide or a nucleic acid fragment has been either removed from its natural environment, produced using recombinant techniques, or chemically or enzymatically synthesized. Preferably, the polypeptide or nucleic acid fragment is purified, i.e., essentially free from any other polypeptides or nucleic acid fragments and associated cellular products or other impurities.

“Amidolytic activity” refers to the ability of a polypeptide to catalyze the hydrolysis of at least one peptide bond in a polypeptide. The term “cleavage” can also be used to refer to the hydrolysis of a peptide bond in a polypeptide. “Prolyl-tripeptidyl peptidase” and “PTP” refer to a polypeptide having a particular “amidolytic activity”. A “prolyl-tripeptidyl peptidase” is able to hydrolyze the peptide bond between the proline and the Yaa residues in a target polypeptide with the general formula  $\text{NH}_2\text{-Xaa-Xaa-Pro-Yaa-(Xaa)}_n$  (SEQ ID NO:25), wherein Xaa is a natural or modified amino acid, Yaa is a natural or modified amino acid except proline, and the  $\alpha$ -amino of the amino terminal residue is not blocked. A “prolyl tripeptidyl-peptidase” does not have to cleave all members of the target peptide. The term “natural amino acid” refers to the 20 amino acids typically produced by a cell. The term “modified amino acid”

refers to, for instance, acetylation, hydroxylation, methylation, amidation, and the attachment of carbohydrate or lipid moieties, cofactors, and the like.

A “target polypeptide” is a polypeptide that is the potential substrate of the amidolytic activity of a prolyl tripeptidyl-peptidase.

5       An active analog, active fragment, or active modification of a polypeptide of the invention is one that has amidolytic activity by hydrolysis of a peptide bond present in the target polypeptide as described herein. Active analogs, fragments, and modifications are described in greater detail herein.

10       “Nucleic acid fragment” as used herein refers to a linear polymeric form of nucleotides of any length, either ribonucleotides or deoxynucleotides, and includes both double- and single-stranded DNA and RNA. A nucleic acid fragment may include both coding and non-coding regions that can be obtained directly from a natural source (e.g., a microorganism), or can be prepared with the aid of recombinant or synthetic techniques. A nucleic acid molecule may be

15       equivalent to this nucleic acid fragment or it can include this fragment in addition to one or more other nucleotides or polynucleotides. For example, the nucleic acid molecule of the invention can be a vector, such as an expression of cloning vector.

20       “Percentage amino acid identity” refers to a comparison of the amino acids of two polypeptides as described herein.

## BRIEF DESCRIPTION OF THE FIGURES

25       **Fig. 1. Purification of the prolyl tripeptidyl peptidase from the acetone precipitate of the *P. gingivalis* cell extracts. Absorbance at 280 nm (open triangles), amidolytic activity against H-Ala-Phe-Pro-pNA (closed diamonds), and H-Gly-Pro-pNA (closed circles). (a) Separation of PTP-A on hydroxyapatite. (b) Separation of PTP-A on Phenyl-Sepharose HP. (c) Separation of PTP-A on MonoQ FPLC. (d) Chromatofocusing of PTP-A on Mono-P.**

30       **Fig. 2. SDS -PAGE of fractions from purification of PTP-A and the autoradiography of the purified enzyme. Lane a, molecular mass markers (phosphorylase B, 97 kDa; bovine serum albumin, 68 kDa; ovalbumin, 43 kDa; carbonic anhydrase, 30 kDa; soybean trypsin inhibitor, 20 kDa;  $\alpha$ -lactalbumin, 14**

kDa); *lane b*, acetone precipitate from Triton X-100 extract of *P. gingivalis*, *lane c*: hydroxyapatite column eluate; *lane d*, Phenyl-Sepharose column eluate; *lane e*, MonoQ column eluate; *lane f*, purified PTP-A from MonoP column wash; *lane g*, autoradiograph of  $^3\text{H}$ -DFP labeled enzyme exposed for 96 h to X-ray film. All  
 5 samples were reduced and boiled prior to PAGE analysis.

**Fig. 3. Multiple sequence alignment of *P. gingivalis* PTP-A (PTP-A) and its bacterial and eukaryotic homologues.** Pg-DPP, DPP from *P. gingivalis* (Kiyama, M., et al., (1998) *Bioch. Bioph. Acta* 1396, 39-46) containing an  
 10 amino-terminal sequence corrected according to the *P. gingivalis* W83 genome data available from The Institute of Genomic Research at [www.tigr.org](http://www.tigr.org)); Fm-DPP, DPP from *Flavobacterium meningosepticum*; Hs-DPP, human DPP IV; and Mm-FAP, mouse fibroblast activation protein. Peptide sequences obtained from PTP-A analysis described herein are indicated with arrows (note that the  
 15 sequence of the peptide 81-97 corresponds to the N-terminus of the lower molecular weight form of PTP-A); catalytic triad is marked with asterisks; and the proposed PTP-A membrane-anchoring N-terminal  $\alpha$ -helix is double-underlined. Homologous regions (i.e., regions of identical amino acids and/or conservative substitutions) are highlighted. Identical regions are shown as white  
 20 letters on a black background.

**Fig. 4. Comparison of *P. gingivalis* PTP-A and DPP active site domains to corresponding sequences of three putative homologues identified within the *P. gingivalis* genome (DPP-H1, DPP-H2 and DPP-H3).** Sequences of *P.*  
 25 *gingivalis* PTP-A, DPP, DPP-H1, DPP-H2, and DPP-H3 were obtained from conceptual translation of the following open reading frames retrieved from The Institute for Genomic Research (TIGR) unfinished *P. gingivalis* genome database:  
 gnl | TIGR | *P. gingivalis* contig 126 (positions 13 228 – 15 426), contig 87 (positions 6 424 – 4 399), contig 65 (positions 161 – 1 786), contig 101 (positions  
 30 8 895 – 6 845), and contig 9 (positions 4 216 – 2 162), respectively. Residues predicted as catalytic triads are marked with asterisks. Homologous regions (i.e., regions of identical amino acids and/or conservative substitutions) are highlighted.



Identical regions are shown as white letters on a black background. Similar regions (i.e., conservative substitutions) are shown as white letters on a grey background.

**Fig. 5. Influence of Pefabloc-serine proteinase inhibitor on *P. gingivalis* growth.**

**Fig. 6. Comparison of *P. gingivalis* PTP-A and DPP to sequences of three putative homologues identified within the *P. gingivalis* genome (DPP-H1, DPP-H2 and DPP-H3). Sequences of *P. gingivalis* PTP-A (126PP), DPP (87PP), DPP-H1 (65PP), DPP-H2 (101PP), and DPP-H3 (9PP) were obtained as described in Fig. 4. Homologous regions (i.e., regions of identical amino acids and/or conservative substitutions) are highlighted. Identical regions are shown as white letters on a black background. Similar regions (i.e., conservative substitutions) are shown as white letters on a grey background.**

**Fig. 7. Nucleotide sequence (SEQ ID NO:38) and amino acid sequence (SEQ ID NO:30) of PTP-A.**

#### DETAILED DESCRIPTION OF THE INVENTION

The present invention provides isolated polypeptides, preferably isolated prolyl peptidases, more preferably prolyl dipeptidyl-peptidases and prolyl tripeptidyl-peptidases, most preferably prolyl-tripeptidyl peptidases, that have amidolytic activity by hydrolysis of a peptide bond present in a target polypeptide, where the bond is between a proline and an amino acid residue attached to the alpha-carboxyl group end of the proline.

When the prolyl peptidase is a prolyl tripeptidyl-peptidase, the peptidase has amidolytic activity by hydrolysis of a peptide bond present in a target polypeptide of the general formula  $\text{NH}_2\text{-Xaa-Xaa-Pro-Yaa-(Xaa)}_n$  (SEQ ID NO:25), wherein Xaa is a natural or modified amino acid, Yaa is a natural or modified amino acid except proline, and the  $\alpha$ -amino of the amino terminal residue is not blocked, wherein the peptide bond of the target polypeptide that is hydrolyzed is the Pro-Yaa peptide bond. Preferably, isolated polypeptides do not cleave a target peptide having a blocked  $\alpha$ -amino of the amino terminal residue.

Preferably, the only peptide bond of the target peptide that is hydrolyzed is the Pro-Yaa bond. In increasing order of preference, isolated polypeptides can cleave a target peptide that is at least 4 amino acids or at least 300 Da, at least 10 amino acids or at least 750 Da, at least 20 amino acids or at least 1,500 Da, or at least 30 amino acids or at least 3,000 Da. Preferably, the prolyl-tripeptidyl peptidases cleave peptides 1, 2, 7, 8, and 10-15 shown in Table 3, human cystatin C, and interleukin 6.

When the prolyl peptidase is a prolyl dipeptidyl-peptidase, the peptidase has amidolytic activity by hydrolysis of a peptide bond present in a target polypeptide of the general formula  $\text{NH}_2\text{-Xaa-Zaa-Yaa-(Xaa)}_n$  (SEQ ID NO:12), wherein Xaa is a natural or modified amino acid, Zaa is a proline or alanine, Yaa is a natural or modified amino acid except proline or hydroxyproline, and the  $\alpha$ -amino of the amino terminal residue is not blocked, wherein the peptide bond of the target polypeptide that is hydrolyzed is the Zaa-Yaa peptide bond. Preferably, isolated polypeptides does not cleave a target peptide having a blocked  $\alpha$ -amino of the amino terminal residue. Preferably, the only peptide bond of the target peptide that is hydrolyzed is the Pro-Yaa bond.

Due to their cyclic aliphatic character proline residues bestow unique conformational constraints on polypeptide chain structures, significantly affecting the susceptibility of proximal peptide bonds to proteolytic cleavage. Those proline residues, which often appear near the amino-termini of many biologically active peptides, may protect them against proteolytic degradation by peptidases with general specificity. A specialized group of proteolytic enzymes, typically referred to as prolyl peptidases, has evolved to cleave (i.e., hydrolyze) a peptide bond adjacent to a proline residue in a polypeptide. The peptide bond adjacent to a proline residue can be referred to as a prolyl-X bond, where prolyl is the proline residue, and X is an amino acid residue attached to the alpha-carboxyl group end of the proline. The bacterial prolyl peptidases can cleave a polypeptide to liberate a tripeptide or a dipeptide. Prolyl peptidases that do not cleave a target peptide if the  $\alpha$ -amino of the amino terminal residue is blocked can be referred to as exopeptidases. The *in vivo* activity of these specialized proteolytic enzymes may have important physiological significance, because it may lead to inactivation of many biologically active peptides and/or transformation of the activity of other

biologically active peptides. In addition, hydrolysis of prolyl-X bonds in conjunction with general catabolic pathways should allow the complete re-utilization of amino acids by living organisms, including bacteria. However, prolyl peptidases from bacterial pathogens, if released into the host environment, may interfere with the physiological functions of biologically active polypeptides and, therefore, contribute to the pathogenicity of infectious disease.

The external (i.e., cell surface) localization and uncontrolled activity of bacterial peptidases, including prolyl peptidases, likely contributes significantly to run-away inflammation in the human host and the pathological degradation of connective tissue during periodontitis. For instance, working in concert bacterial prolyl peptidases (e.g., prolyl tripeptidyl peptidases and DPP IV) have the ability to completely degrade collagen fragments locally generated by endogenous or bacterial collagenases. Because type I collagen is the major component of periodontal ligament, its enhanced degradation by bacterial prolyl peptidases may contribute to loss of tooth attachment and periodontal pocket formation. Thus, there is a need in the art to characterize bacterial peptidases to facilitate the development of therapies to inhibit the activity of the bacterial peptidases.

The polypeptides of the present invention, preferably prolyl peptidases, can be used as a source of antibodies for inhibiting the peptidase activity and thereby possibly reducing periodontitis, loss of tooth attachment and periodontal pocket formation. Antibodies to prolyl peptidases can also be used to identify and/or isolate additional prolyl peptidases. Knowledge of prolyl peptidases can also be used to make inhibitors of prolyl peptidases and to make immunogenic compositions that could be used to elicit the production of antibodies to prolyl peptidases and thereby possibly reduce gingivitis, periodontitis, loss of tooth attachment, and/or periodontal pocket formation.

An example of a prolyl-tripeptidyl peptidase is prolyl-tripeptidyl peptidase A (SEQ ID NO:30) (also referred to as PTP-A) from *P. gingivalis*. Purified PTP-A has apparent molecular masses of 81.8 and 75.8 kDa. The lower molecular mass peptidase may be due to the proteolytic cleavage of the peptidase from the surface of *P. gingivalis*. PTP-A is a new member of clan SC, family S9 of serine peptidases. Clans of serine peptidases are grouped on the basis of the order of certain amino acids in the polypeptide that make up the "catalytic triad" which

plays a pivotal role peptidase activity. The members of the clan SC are characterized by the catalytic triad in the polypeptide in the order of serine, aspartic acid, and histidine. Members of the clan SC are also characterized by a tertiary structure including  $\beta/\alpha/\beta$  units, and an  $\alpha/\beta$  hydrolase fold. In addition to the catalytic triad order, the amino acid sequence GXSEXG (SEQ ID NO:39), where X is any amino acid and S is the active site serine, is a signature of all members of the clan SC with some distinguishing features specific for each family. Family S9 has the consensus sequence GXSEXG (SEQ ID NO:40). Besides this consensus sequence, there is a general similarity of primary structures which classifies peptidases to this family. For instance, peptidases of this family generally have two domains, an amino-terminal domain that contains a membrane binding domain, and a carboxy-terminal domain, also referred to as the catalytic domain. The catalytic domain contains the residues of the catalytic triad. Some members of the S9 family have only the catalytic domain.

The S9 family is diverged and divided in three subfamilies: S9A, cytosolic oligopeptidases from archae and eukaryotes; S9B, eukaryotic acylaminoacylpeptidases; and S9C, dipeptidyl peptidase IV from bacteria and eukaryotes. The catalytic domain of peptidases from family S9 typically begin at about residue 400 of SEQ ID NO:30 and include the remaining carboxy-terminal amino acids (see, e.g., Fulop, et al., (1998) *Cell* 94, 161-170). Despite structural similarities to peptidases from the S9 family, the tripeptidyl-peptidase activity of PTP-A is unusual for this family of enzymes, and no other known similar activity has so far been attributed to any other member of the S9 family. In fact, all strict tripeptidyl-peptidases belong only to the subtilisin family (S8) and S33 family of serine peptidases; however, they neither share a structural relationship with PTP-A nor have activity limited to cleavage after proline residues. In particular, there are no other known prolyl tripeptidyl peptidases with an activity that is increased by iodoacetamide relative to the same prolyl tripeptidyl peptidase in the absence of iodoacetamide under the same conditions. Iodoacetamide is a compound that is traditionally a peptidase inhibitor. Typically, the activity of a prolyl tripeptidyl peptidase is increased about two-fold. Furthermore, unlike oligopeptidases, the prolyl tripeptidyl-peptidases of the present invention can cleave target peptides having as few as 4 amino acids but also target peptides having at least 30 amino

acids or a molecular weight of at least 3,000 Da. In these respects, the *P. gingivalis* tripeptidyl peptidase is a unique enzyme, and the isolation and characterization of this novel bacterial prolyl peptidase will facilitate the development of therapies to inhibit the activity of the bacterial peptidases.

5           Examples of putative prolyl-dipeptidyl peptidases are DPP-H1 (SEQ ID NO:43), DPP-H2 (SEQ ID NO:44), and DPP-H3 (SEQ ID NO:45). These peptidases have a significant percentage amino acid similarity with DPP IV and PTP-A (see Fig. 6). Each dipeptidyl peptidase is expected to have enzymatic activity, as each has a well preserved catalytic triad (Fig. 4). DPP IV has been  
10 characterized and the gene encoding the peptidase has been cloned, however the substrate specificity has not been well characterized. DPP IV has been found to cleave SEQ ID NOs:6, 20, 23, and 24. DPP IV has been purified in two forms. One of the forms is a full length gene translation product containing a blocked amino-terminal residue. The second form had the amino-terminal amino acid  
15 sequence HSYRAAVYDYDVRRLVKPLSEHVG (SEQ ID NO:48), which corresponds to residues 116-140 of DPP IV (Kiyama, M., et al. (1998) 1396, 39-46), indicating that it was proteolytically truncated on the amino-terminus.

          In *P. gingivalis*, PTP-A and DPP IV activity is cell surface associated. While not intending to be limiting, it is conceivable that the enzyme is membrane  
20 anchored through a putative signal sequence which is not cleaved but remains as a membrane spanning domain similar to other members of the prolyl oligopeptidase family. However, a significant portion of the purified PTP-A has a truncated N-terminus, apparently due to cleavage by Lys-specific peptidase and likely to be an artifact which has occurred during the purification procedure. Nevertheless,  
25 membrane bound PTP-A and DPP IV is proteolytically cleaved and shed during cultivation of the bacteria, as indicated by variable amount of soluble activities found in cell free culture media. The cell surface localization of PTP-A supports a putative physiological function in providing nutrients for growing bacterial cells. The inability of asaccharolytic *P. gingivalis* to utilize free amino acids makes the  
30 bacterium entirely dependant on an external peptide supply. In this regard, PTP-A and DPP IV activities are probably very important, if not indispensable, for bacterial growth, and inhibition of prolyl tripeptidyl-peptidases and dipeptidyl-peptidases may inhibit the *in vivo* growth of organisms, including *P. gingivalis*.

For instance, treatment of *P. gingivalis* cultures in lagphase (i.e., the period after inoculation of a culture and before the organism begins to divide) and early logarithmic growth with the inhibitors PEFABLOCK and 3,4-dichloroisocoumarin inhibits growth of *P. gingivalis*.

5            Preferably, a polypeptide of the invention, preferably a prolyl peptidase, contains the amino acid sequence GXSEXG (SEQ ID NO:39), most preferably, GXSEXGG (SEQ ID NO:40), where G is glycine, X is any amino acid, and S is the active site serine. The active site serine can be identified by, for instance, labeling with diisopropylfluorophosphate as described herein. Preferably, the catalytic  
10           domain of the prolyl tripeptidyl-peptidases of the invention begins at about residue 400 of SEQ ID NO:30 and includes the remaining carboxy-terminal amino acids and the corresponding amino acids of SEQ ID NOs:43-45 (see Fig. 6), more preferably, at about residue 502 of SEQ ID NO:30 and includes the remaining carboxy-terminal amino acids and the corresponding amino acids of SEQ ID  
15           NOs:43-45 (see Fig. 6), most preferably, at about residue 556 of SEQ ID NO:30 and includes the remaining carboxy-terminal amino acids and the corresponding amino acids of SEQ ID NOs:43-45 (see Fig. 6).

            The invention further includes a polypeptide, preferably a prolyl tripeptidyl-peptidase, that shares a significant level of primary structure with SEQ ID NO:30.  
20           The two amino acid sequences (i.e., the amino acid sequence of the polypeptide and the sequence SEQ ID NO:30) are aligned such that the residues that make up the catalytic triad, i.e., the serine, aspartic acid, and the histidine, are in register, then further aligned to maximize the number of amino acids that they have in common along the lengths of their sequences; gaps in either or both sequences are permitted  
25           in making the alignment in order to place the residues of the catalytic triad in register and to maximize the number of shared amino acids, although the amino acids in each sequence must nonetheless remain in their proper order. The percentage amino acid identity is the higher of the following two numbers: (a) the number of amino acids that the two sequences have in common within the  
30           alignment, divided by the number of amino acids in SEQ ID NO:30, multiplied by 100; or (b) the number of amino acids that the two sequences have in common within the alignment, divided by the number of amino acids in the candidate polypeptide, multiplied by 100. Preferably, a prolyl tripeptidyl peptidase has

greater than 35 % identity, more preferably at least about 40 % identity, most preferably at least about 45 % identity with SEQ ID NO:30. Preferably, amino acids 154-732 of SEQ ID NO:30 are used, more preferably amino acids 400-732 of SEQ ID NO:30 are used. An isolated polypeptide comprising an amino acid  
5 sequence having a percentage amino acid identity of greater than 35 % with SEQ ID NO:30.

In general, the amidolytic activity of the polypeptides of the invention, preferably prolyl peptidases, can be measured by assay of the cleavage of a target polypeptide in the presence of prolyl peptidase and a buffer. Preferably, the lower  
10 ratio of prolyl tripeptidyl-peptidase to target polypeptide is at least about 1:1, more preferably at least about 1:100, even more preferably at least about 1:1,000, most preferably at least about 1:10,000. Preferably, the higher ratio of prolyl peptidase to target polypeptide is no greater than about 1:10,000,000, more preferably no greater than about 1:1,000,000 and most preferably no greater than about  
15 1:100,000. Buffers in which a prolyl peptidase is active are suitable for the assay. Preferably, the buffer is about 200 mM HEPES (N-2-hydroxyethylpiperazine,N'-2-ethansulfonic acid), more preferably about 50 mM HEPES, most preferably about 20 mM HEPES. Preferably, the pH of the buffer is at least about pH 6.0 and no greater than pH 8.0, more preferably about pH 7.5. Preferably, the temperature of  
20 the assay is at about 37°C. The assay can be carried out for at least about 1 minute to no greater than 24 hours. Preferably, the amidolytic activity of the prolyl peptidases are measured at a prolyl peptidase:target polypeptide ratio of at least about 1:100 to no greater than 1:1,000,000 in about 200 mM HEPES, about pH 7.5 at about 37°C for at least about 3 hours. In general, the time of the assay can vary  
25 depending on the substrate and enzyme:substrate ratio. Typically, target peptides are stable under these conditions, and typically it is difficult to detect background levels of hydrolysis in the absence of a prolyl peptidase. Preferably, the assay is allowed to continue until at least 1 % of the target peptide is hydrolyzed.

Prolyl-tripeptidyl peptidases of the present invention preferably are  
30 inhibited by a compound chosen from the group consisting of PEFABLOCK (4-(2-aminoethyl)-benzenesulfonyl-fluoride hydrochloride), diisopropylfluorophosphate, and 3,4-dichloroisocoumarin, more preferably PEFABLOCK and diisopropylfluorophosphate, and most preferably diisopropylfluorophosphate. The

peptidases of the present invention are preferably not inhibited by a compound chosen from the group consisting of leupeptin, antipain, E-64, pepstatin,  $\alpha_1$ -proteinase inhibitor,  $\alpha_1$ -antichymotrypsin and  $\alpha_2$ -macroglobulin, most preferably. Significantly and unexpectedly, the amidolytic activity of a prolyl-tripeptidyl  
5 peptidase of the present invention is increased by iodoacetamide relative to the prolyl-tripeptidyl peptidase in the absence of iodoacetamide under the same conditions. Preferably, the effect of iodoacetamide on amidolytic activity is measured by incubating in 200 mM HEPES, pH 7.6, at least about 0.1 nM of the prolyl tripeptidyl-peptidase with the inhibitor for about 15 minutes, adding about 1  
10 mM of H-Ala-Phe-Pro-pHA, and incubating for at least about 1 minute before assaying for amidolytic activity. Typically, at least about 1 mM to no greater than 100 mM of inhibitor is used.

The polypeptides of the invention include a polypeptide having SEQ ID NO:30, or an active analog, active fragment, or active modification of SEQ ID  
15 NO:30. An active analog, active fragment, or active modification of a polypeptide having SEQ ID NO:30 is one that has amidolytic activity by hydrolysis of the Pro-Yaa peptide bond present in a target polypeptide of the general formula  $\text{NH}_2\text{-Xaa-Xaa-Pro-Yaa-(Xaa)}_n$  (SEQ ID NO:25). Active analogs of a polypeptide having SEQ ID NO:30 include prolyl-tripeptidyl peptidases having amino acid  
20 substitutions that do not eliminate hydrolysis of SEQ ID NO:25 at the Pro-Yaa peptide bond. Substitutes for an amino acid may be selected from other members of the class to which the amino acid belongs. For example, nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and tyrosine. Polar neutral amino acids include glycine, serine,  
25 threonine, cysteine, tyrosine, asparagine and glutamine. The positively charged (basic) amino acids include arginine, lysine and histidine. The negatively charged (acidic) amino acids include aspartic acid and glutamic acid. Examples of preferred conservative substitutions include Lys for Arg and *vice versa* to maintain a positive charge; Glu for Asp and *vice versa* to maintain a negative charge; Ser for  
30 Thr so that a free -OH is maintained; and Gln for Asn to maintain a free  $\text{NH}_2$ .

Active fragments of a prolyl-tripeptidyl peptidase of the invention include prolyl-tripeptidyl peptidases containing deletions or additions of one or more contiguous or noncontiguous amino acids such that the resulting polypeptide will



hydrolyze SEQ ID NO:25 at the Pro-Yaa peptide bond. An example of a fragment of a prolyl-tripeptidyl peptidase is a catalytic domain. Modified prolyl-tripeptidyl peptidases include prolyl-tripeptidyl peptidases that are chemically and enzymatically derivatized at one or more constituent amino acid, including side chain modifications, backbone modifications, and N- and C- terminal modifications including acetylation, hydroxylation, methylation, amidation, and the attachment of carbohydrate or lipid moieties, cofactors, and the like. Modified prolyl-tripeptidyl peptidases will hydrolyze SEQ ID NO:25 at the Pro-Yaa peptide bond.

Prolyl peptidases can be obtained by several methods. Isolation of a prolyl-tripeptidyl peptidase present on the surface of a cell producing the peptidase typically requires lysis of the cell followed by purification methods that are well known in the art. Alternatively, cells can be treated with a detergent, for instance Triton X-100, to remove the peptidase from the cell surface. The following are nonlimiting examples of suitable protein purification procedures: fractionation on immunoaffinity, ion-exchange, hydroxyapatite, Phenyl-Sepharose HP, MonoQ HR 5/5, or MonoP columns; ethanol precipitation; reverse phase HPLC; chromatography on silica or on an ion-exchange resin such as DEAE; chromatofocusing; SDS-PAGE; ammonium sulfate precipitation; gel filtration using, for example, Sephadex G-75. Preferably, isolation of a prolyl-tripeptidyl peptidase from *P. gingivalis* is accomplished using a combination of hydroxyapatite, Phenyl-Sepharose HP, MonoQ HR 5/5 and MonoP column chromatography steps as described herein.

Prolyl peptidases can also be isolated from organisms other than *P. gingivalis*. Other organisms can express a prolyl-tripeptidyl peptidase that is encoded by a coding region having similarity to the PTP-A coding region. A "coding region" is a linear form of nucleotides that encodes a polypeptide, usually via mRNA, when placed under the control of appropriate regulatory sequences. The boundaries of a coding region are generally determined by a translation start codon at its 5' end and a translation stop codon at its 3' end. "Regulatory region" refers to a nucleic acid fragment that regulates expression of a coding region to which a regulatory region is operably linked. Non limiting examples of regulatory regions include promoters, transcription initiation sites, translation start sites, translation

stop sites, and terminators. "Operably linked" refers to a juxtaposition wherein the components so described are in a relationship permitting them to function in their intended manner. A regulatory element is "operably linked" to a coding region when it is joined in such a way that expression of the coding region is achieved under conditions compatible with the regulatory region. Alternatively, other organisms can express a prolyl-tripeptidyl peptidase from a recombinant coding region encoding the peptidase. The identification of similar coding regions in other organisms can be accomplished as described herein. A prolyl-tripeptidyl peptidase can be isolated using purification methods that are well known in the art.

Alternatively, the peptidase can be chemically synthesized using methods that are well known in the art including, for instance, solid phase synthesis. Examples of, for instance, coding and regulatory regions are described herein.

The expression of a prolyl-tripeptidyl peptidase by an organism other than *P. gingivalis* can be detected using specific substrates of the general formula  $\text{NH}_2\text{-Xaa-Xaa-Pro-LG}$  or  $\text{NH}_2\text{-Xaa-Xaa-Pro-Yaa}$  (SEQ ID NO:41), where LG is a leaving group. The leaving group can be a chromogenic or fluorogenic group known to the art. The expression of a prolyl-tripeptidyl peptidase by an organism and subsequent cleavage of a specific substrate results in a free amino acid or a free leaving group, each of which can be assayed using techniques known to those of skill in the art. Other methods can be based on immunogenic properties of PTP-A, for instance immunoassays and histochemistry, the detection of mRNA, and PCR related methods, all of which are known to one of skill in the art.

As described in the Examples, the amino acid sequence of the amino-terminal end of a PTP-A fragment was used to identify the nucleotide sequence of the PTP coding region. The nucleotide sequence was present in a publically available database containing the nucleotide sequence of the partially finished *P. gingivalis* W83 genome. However, even though the nucleotides that encode the *P. gingivalis* PTP-A were known, there was no indication that the nucleotides were in fact transcribed and translated. The data obtained from the database only contained the nucleotide sequence of a genomic clone; there was no disclosure that the nucleotides did or did not contain an open reading frame. Moreover, there is little data known to the art regarding regulatory regions required for either the transcription or the translation of a nucleotide sequence in *P. gingivalis*.

Thus, a person of ordinary skill, having the nucleotide sequence of the genomic clone, would not be able to predict that the open reading frame encoding PTP-A was transcribed or translated. Moreover, even if there was a suggestion that the open reading frame was both transcribed and translated, there is no suggestion  
5 that the polypeptide encoded by the open reading frame would have the novel activity of PTP-A.

Accordingly, the present invention is directed to a nucleic acid fragment encoding a polypeptide, particularly a prolyl-tripeptidyl peptidase, active analog, active fragment, or active modification thereof. The nucleic acid fragment can  
10 have a nucleotide sequence as shown in SEQ ID NO:38. Alternatively, nucleic acid fragments of the invention include those whose complement hybridize to SEQ ID NO:38 under standard hybridization conditions as described herein. During hybridization the entire nucleotide sequence of the complement can hybridize with SEQ ID NO:38. Preferably, at least about 20 nucleotides of the complement  
15 hybridize with SEQ ID NO:38, more preferably at least about 50 nucleotides, most preferably at least about 100 nucleotides.

Alternatively, the nucleic acid fragment can have a nucleotide sequence encoding a polypeptide having the amino acid sequence shown in SEQ ID NO:30. An example of the class of nucleotide sequences encoding such a polypeptide is  
20 SEQ ID NO:38. This class of nucleotide sequences is large but finite, and the nucleotide sequence of each member of the class can be readily determined by one skilled in the art by reference to the standard genetic code.

The identification of similar coding regions in other organisms can be accomplished by screening individual wild-type microorganisms for the presence  
25 of nucleotide sequences that are similar to the coding region of PTP-A, which is shown in SEQ ID NO:38. Screening methods include, for instance, hybridization of a detectably labeled probe with a nucleic acid fragment.

Standard hybridizing conditions are a modification of the conditions used by Church et al. ((1984) *Proc. Natl. Acad. Sci. USA* 81, 1991): 0.5 M phosphate  
30 buffer, pH 7.2, 7 % SDS, 10 mM EDTA, at 68°C, and three washes, each for 20 minutes in 2x SSC, 0.1 % SDS, at 65°C. Preferably, a probe will hybridize to the nucleotide sequence set forth in SEQ ID NO:38 under standard hybridizing conditions. Generally the probe does not have to be complementary to all the

nucleotides of the nucleic acid fragment as long as there is hybridization under the above-stated conditions.

“Complement” and “complementary” refer to the ability of two single stranded nucleic acid fragments to base pair with each other, where an adenine on one nucleic acid fragment will base pair to a thymine on a second nucleic acid fragment and a cytosine on one nucleic acid fragment will base pair to a guanine on a second nucleic acid fragment. Two nucleic acid fragments are complementary to each other when a nucleotide sequence in one nucleic acid fragment can base pair with a nucleotide sequence in a second nucleic acid fragment. For instance, 5'-ATGC and 5'-GCAT are complementary. The term complement and complementary also encompasses two nucleic acid fragments where one nucleic acid fragment contains at least one nucleotide that will not base pair to at least one nucleotide present on a second nucleic acid fragment. For instance the third nucleotide of each of the two nucleic acid fragments 5'-ATTGC and 5'-GCTAT will not base pair, but these two nucleic acid fragments are complementary as defined herein. Typically two nucleic acid fragments are complementary if they hybridize under the standard conditions referred to herein.

Preferred probes are nucleic acid fragments complementary to a coding region or another nucleotide sequence that encodes a prolyl-tripeptidyl peptidase. For instance, a probe can comprise a consecutive series of nucleotides complementary to a portion of SEQ ID NO:38. Preferably a probe is at least about 18 bases, more preferably at least about 21 bases, and most preferably at least about 24 bases in length. Particularly preferred probes are TTCGATCCGGCAAAGAAATATCCTGTTATTGTCTATGTTTACGGAGGAC CT (SEQ ID NO:36, GTGGATGCCGATAGAATAGGAGTACATGGCTGGAGCTATGGTGGCTTT (SEQ ID NO:37, and SEQ ID NO:38. Methods of detectably labeling a probe are well known to the art.

The nucleic acid fragment that is identified by the probe is further analyzed to determine if it encodes a polypeptide with amidolytic activity of the Pro-Yaa

peptide bond on a target polypeptide of the general formula  $\text{NH}_2\text{-Xaa-Xaa-Pro-Yaa-(Xaa)}_n$  (SEQ ID NO:25). Another method for screening individual microorganisms for the presence of nucleotide sequences that are similar to the coding regions of the present invention is the polymerase chain reaction (PCR).

5 Individual wild-type microorganisms containing nucleic acid fragments encoding a prolyl-tripeptidyl peptidase can also be identified using antibody. Preferably the antibody is directed to PTP-A. The production of antibodies to a particular polypeptide is known to a person of skill in the art, and is further detailed herein.

10 The use of hybridization of a probe to a coding region present in individual wild-type microorganisms can be used as a method to identify a coding region identical or similar to a coding region present in SEQ ID NO:38. The coding region can then be isolated and ligated into a vector as described below. Two nucleic acid sequences are "similar" if the two nucleic acid sequences can be aligned so that the number of identical amino acids along the lengths of their sequences are optimized. 15 Preferably, two nucleotide acid sequences have, in increasing order of preference, preferably at least about 90 %, at least about 92 %, at least about 94%, at least about 96%, most preferably at least about 98% identity.

As mentioned above, a nucleic acid fragment of the invention can be 20 inserted in a vector. Construction of vectors containing a nucleic acid fragment of the invention employs standard ligation techniques known in the art. See, e.g., Sambrook et al, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press (1989) or Ausubel, R.M., ed. *Current Protocols in Molecular Biology* (1994). A vector can provide for further cloning (amplification of the 25 nucleic acid fragment), i.e., a cloning vector, or for expression of the polypeptide encoded by the coding region, i.e., an expression vector. The term vector includes, but is not limited to, plasmid vectors, viral vectors, cosmid vectors, or artificial chromosome vectors. Typically, a vector is capable of replication in a bacterial host, for instance *E. coli*. Preferably the vector is a plasmid.

30 Selection of a vector depends upon a variety of desired characteristics in the resulting construct, such as a selection marker, vector replication rate, and the like. Suitable plasmids for expression in *E. coli*, for example, include pUC(X), pKK223-3, pKK223-2, pTrc99A, and pET-(X) wherein (X) denotes a vector family in which

numerous constructs are available. pUC(X) vectors can be obtained from Pharmacia Biotech (Piscataway, NH) or Sigma Chemical Co. (St. Louis, MO). pKK223-3, pKK233-2 and pTrc99A can be obtained from Pharmacia Biotech. pET-(X) vectors can be obtained from Promega (Madison, WI) Stratagene (La Jolla, CA) and Novagen (Madison, WI). To facilitate replication inside a host cell, the vector preferably includes an origin of replication (known as an "ori") or replicon. For example, ColE1 and P15A replicons are commonly used in plasmids that are to be propagated in *E. coli*.

An expression vector optionally includes regulatory regions operably linked to the coding region. The invention is not limited by the use of any particular promoter, and a wide variety are known. Promoters act as regulatory signals that bind RNA polymerase in a cell to initiate transcription of a downstream (3' direction) coding region. The promoter used in the invention can be a constitutive or an inducible promoter. It can be, but need not be, heterologous with respect to the host cell. Preferred promoters for bacterial transformation include *lac*, *lacUV5*, *tac*, *trc*, T7, SP6 and *ara*.

An expression vector can optionally include a Shine Dalgarno site (e.g., a ribosome binding site), and a start site (e.g., the codon ATG) to initiate translation of the transcribed message to produce the enzyme. It can also include a termination sequence to end translation. A termination sequence is typically a codon for which there exists no corresponding aminoacyl-tRNA, thus ending polypeptide synthesis. The nucleic acid fragment used to transform the host cell can optionally further include a transcription termination sequence. The *rrnB* terminators, which is a stretch of DNA that contains two terminators, T1 and T2, is an often used terminator that is incorporated into bacterial expression systems (J. Brosius et al., (1981) *J. Mol. Biol.* 148 107-127).

The nucleic acid fragment used to transform the host cell optionally includes one or more marker sequences, which typically encode a polypeptide that inactivates or otherwise detects or is detected by a compound in the growth medium. For example, the inclusion of a marker sequence can render the transformed cell resistant to an antibiotic, or it can confer compound-specific metabolism on the transformed cell. Examples of a marker sequence are sequences that confer resistance to kanamycin, ampicillin, chloramphenicol, and tetracycline.

Antibodies can be produced to a polypeptide having the sequence of SEQ ID NOs:30, 43, 44 or 45, or a polypeptide having a percentage amino acid identity as described herein. Alternatively, antibodies can be made to an antigenic analog, antigenic fragment, or antigenic modification of a polypeptide having the sequence of SEQ ID NOs:30, 43, 44 or 45. An antigenic analog, antigenic fragment, or antigenic modification of a polypeptide having SEQ ID NOs:30, 43, 44 or 45 is one that generates an immune response in an animal. Antigenic analogs of a polypeptide having SEQ ID NOs:30, 43, 44 or 45 include prolyl peptidases having amino acid substitutions that do not eliminate peptide antigenicity in an animal. Substitutes for an amino acid may be selected from other members of the class to which the amino acid belongs, as described herein. Fragments of a prolyl peptidase of the invention include prolyl peptidases containing deletions or additions of one or more contiguous or noncontiguous amino acids such that the resulting polypeptide will generate an immune response in an animal. An example of a fragments of a prolylpeptidase is a catalytic domain. Modified prolyl peptidases include prolyl peptidases that are chemically and enzymatically derivatized at one or more constituent amino acids, including side chain modifications, backbone modifications, and N- and C- terminal modifications including acetylation, hydroxylation, methylation, amidation, and the attachment of carbohydrate or lipid moieties, cofactors, and the like.

Accordingly, an aspect of the invention is an immunogenic composition comprising an isolated prolyl peptidase, or an antigenic analog, antigenic fragment, or antigenic modification thereof, preferably a prolyl tripeptidyl-peptidase. The prolyl tripeptidyl-peptidase preferably has amidolytic activity for cleavage of the Pro-Yaa peptide bond present in a target polypeptide with the general formula  $\text{NH}_2\text{-Xaa-Xaa-Pro-Yaa-(Xaa)}_n$  (SEQ ID NO:25), wherein the amidolytic activity is measured at a prolyl tripeptidyl-peptidase:target polypeptide ratio of at least about 1:100 to no greater than about 1:1,000,000 in about 200 mM HEPES, about pH 7.5 at 37°C for at least about 3 hours.

The immunogenic composition can further include excipients or diluents that are pharmaceutically acceptable as carriers and compatible with the immunogenic composition. The term "pharmaceutically acceptable carrier" refers to a carrier(s) that is "acceptable" in the sense of being compatible with the other

ingredients of a composition and not deleterious to the recipient thereof. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol, or the like, and combinations thereof. In addition, if desired, the immunogenic composition may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, and/or adjuvants which enhance the effectiveness of the immune-stimulating composition.

The immunogenic composition can be used in a method for protecting an animal from a disease caused by *P. gingivalis*. This method includes administering the immunogenic composition and eliciting antibodies to a prolyl peptidase, antigenic analog, antigenic fragment, or antigenic modification. The diseases that can be treated in this manner include periodontal diseases, which includes gingivitis and periodontitis. Clinical hallmarks of periodontitis include loss of tooth attachment and periodontal pocket formation.

Alternatively and preferably, periodontal diseases can be treated by the use of inhibitors of a prolyl peptidase. An inhibitor of a prolyl peptidase, preferably a prolyl tripeptidyl-peptidase, can be present in a composition that preferably contains a pharmaceutically acceptable carrier. For instance, inhibitors can be applied systemically, subgingivally (e.g., subgingival irrigation) and/or by controlled release delivery directly into the periodontal pocket using methods well known to the art (see, e.g., Kornman, K., (1993) *J. Periodontol.* 64, 782-791). Preferably, an inhibitor is applied subgingivally or by controlled release delivery.

The prolyl peptidases, active analogs, fragments, and modifications thereof can be used in a method of reducing growth of bacteria *in vitro* or *in vivo*. Preferably, the bacteria is a periodontal pathogen, i.e., a bacterial pathogen that causes periodontal disease, more preferably the bacteria is *P. gingivalis*. The inability of asaccharolytic *P. gingivalis* to utilize free amino acids makes the bacterium entirely dependant on an external peptide supply. The action of the polypeptides of the invention may be required for bacterial growth, and inhibition of the polypeptides of the invention may inhibit the *in vivo* growth of organisms, including *P. gingivalis*. The method includes decreasing the amount of dipeptides and/or tripeptides (e.g., the result of cleavage of SEQ ID NO:25 by a prolyl-tripeptidyl peptidase) and the amount of free amino acids that result from further cleavage of the dipeptides and/or tripeptides present by inhibiting a prolyl



peptidase, active analog, active fragment, or active modification thereof, such that the amount of dipeptides and/or tripeptides generated by the polypeptides is decreased. The amount of dipeptides and/or tripeptides is decreased relative to the amount of dipeptides and/or tripeptides present in the absence of the inhibitor.

5 Preferably, the amount of dipeptides and/or tripeptides generated is decreased by an inhibitor, a monoclonal antibody that inhibits the prolyl peptidase, or polyclonal antibodies that inhibit the prolyl peptidase, more preferably, the amount of dipeptides and/or tripeptides generated is decreased by an inhibitor. Preferably, an inhibitor acts to inhibit a polypeptide of the invention, preferably a prolyl peptidase,

10 by blocking the active site of the polypeptide. The polypeptide can be present on the surface of the bacteria or secreted into the environment, preferably the polypeptide is present in the surface of the bacteria.

The present invention is also directed to a method of developing an inhibitor of a prolyl peptidase, active analog, active fragment, or active

15 modification thereof, preferably a prolyl-tripeptidyl peptidase. The method includes identifying a molecule that inhibits the amidolytic activity of the prolyl peptidase. This can be accomplished by, for instance, incubating the prolyl peptidase with a candidate molecule under conditions that promote amidolytic activity of the prolyl peptidase and determining if the amidolytic activity of the

20 prolyl peptidase is decreased relative to the amidolytic activity in the absence of the molecule. The amidolytic activity can be measured by cleavage of the Pro-Yaa peptide bond present in the target polypeptide SEQ ID NO:25 as described herein. One method of developing an inhibitor includes using the target peptide SEQ ID NO:25 and replacing the Xaa residues with modified amino acids. It is expected

25 that some modified amino acids will cause the target peptide to act as an inhibitor.

### EXAMPLES

The present invention is illustrated by the following examples. It is to be understood that the particular examples, materials, amounts, and procedures are to

30 be interpreted broadly in accordance with the scope and spirit of the invention as set forth herein.

### Example 1

#### Materials

Diisopropylfluorophosphate (DFP), leupeptin and 3,4-dichloroisocoumarin, were purchased from Calbiochem (La Jolla, CA). Antipain, iodoacetamide, substance P, bradykinin and bradykinin related peptides, were obtained from Sigma. Other peptides used in this study were synthesized at the Molecular Genetic Instrumental Facility (University of Georgia, Athens, GA) using Fmoc protocol with an advanced ChemTech MPS350 automated synthesizer. H-Ala-Phe-Pro-pNA, H-Gly-Pro-pNA, Z-Gly-Pro-pNA, Z-Ala-Pro-pNA, and H-Pro-pNA (where pNA is p- Nitroanilide; Z is benzyloxycarbonyl; and H is hydrogen and denotes an unblocked amino-terminal group) were obtained from Bachem (King of Prussia, PA). Prolinal was kindly provided by Dr. James Powers (Georgia Institute of Technology, Atlanta) and cystatin C by Dr. Magnus Abrahamson (University of Lund, Sweden).

#### Methods

*Source and Cultivation of Bacteria*— *P. gingivalis* HG66 was obtained from Dr. Roland Arnold (University of North Carolina, Chapel Hill), while the strains W50 (ATCC 53978) and ATCC 33277 were obtained from the ATCC. All cells were grown as described previously (Chen, Z., et al., (1992) *J. Biol. Chem.* 267, 18896-18901).

*Enzyme Activity Assays*— Routinely, the tripeptidyl peptidase amidolytic activity was measured with H-Ala-Phe-Pro-pNA (1mM) in 0.2 M HEPES (N-2-hydroxyethylpeperazine,N'-2-ethansulfonic acid), pH 7.5 at 37°C. The concentration of enzyme was 0.1 nM to 1 nM. The assay was performed in a total volume of 0.2 ml on microplates, and the initial turnover rate was recorded at 405 nm using a microplate reader (Spectramax Molecular Devices, Sunnyvale, CA). In inhibition studies, the enzyme was first preincubated with inhibitor for 15 min at 37°C, substrate added, and residual activity recorded after 5 minutes to 30 minutes. H-Gly-Pro-pNA, Z-Ala-Pro-pNA, Z-Gly-Pro-pNA and H-Pro-pNA (1 mM final concentration) were assayed in the same manner.

*Protein Determination*—Protein concentration was determined using the BCA reagent kit (Sigma, St. Louis, MO), using bovine serum albumin as a standard.

*Localization of Tripeptidyl-Peptidase Activity*—Cultures of *P. gingivalis* HG66, W50 and ATCC 33277, at different phases of growth, were subjected to the following fractionation procedure. The cells were removed by centrifugation (10,000 x g, 30 minutes), washed twice with 10 mM Tris, 150 mM NaCl, pH 7.4, resuspended in 50 mM Tris, pH 7.6, and disintegrated by ultrasonication in an ice bath at 1500 Hz for 5 cycles (5 minutes sonication/5 minutes brake). Unbroken cells and large debris were removed by centrifugation (10,000 x g, 30 minutes) and the opalescent supernatant subjected to ultracentrifugation (150,000 x g, 120 minutes), yielding a pellet containing bacterial membranes and a supernatant which was considered as membrane-free cell extract. All fractions, as well as the full culture, culture medium, and full culture after sonication, were assayed for amidolytic activity against H-Ala-Phe-Pro-pNA.

*Enzyme Purification*—All purification steps were performed at 4°C except for FPLC separations, which were carried out at room temperature. Cells were harvested by centrifugation (6,000 x g, 30 minutes), washed with 50 mM potassium phosphate buffer, pH 7.4, and resuspended in the same buffer (150 ml per 50 gram of cells wet weight). Triton X-100 (10% volume/volume in H<sub>2</sub>O) was added slowly to the bacterial cell suspension to a final concentration of 0.05%. After 120 minutes of gentle stirring, unbroken cells were removed by centrifugation (28,000 x g, 60 minutes). Proteins in the supernatant were precipitated with cold acetone (-20°C) added to a final concentration of 60% and collected by centrifugation. The pellet was redissolved in 50 mM potassium phosphate buffer, pH 7.0, and extensively dialyzed against 20 mM potassium phosphate, pH 7.0, containing 0.02% sodium azide. The dialyzed fraction was clarified by centrifugation (28,000 x g, 30 min) and applied to a hydroxyapatite column (BioRad, Melville, NY) equilibrated with 20 mM potassium phosphate, pH 7.0, at a flow rate of 20 ml/hour. After equilibration, the column was washed until the A<sub>280</sub> fell to zero. Bound proteins were eluted with a gradient from 20-300 mM potassium phosphate and fractions (7 ml) analyzed for dipeptidyl- and tripeptidyl-peptidase activity using H-Gly-Pro-pNA and H-Ala-Phe-Pro-pNA, respectively. The activity against the latter

substrate was pooled, saturated with 1 M ammonium sulfate, clarified by centrifugation, and directly loaded onto a Phenyl-Sepharose HP (Pharmacia, Piscataway, NJ) column equilibrated with 50 mM potassium phosphate, pH 7.0, containing 1 M ammonium sulfate. The column was washed with two volumes of equilibration buffer, followed by buffer containing 0.5 M ammonium sulfate, and developed with a descending gradient of ammonium sulfate from 0.5 to 0 M. Active fractions were pooled, extensively dialyzed against 20 mM Tris, pH 7.5, and applied to a MonoQ HR 5/5 FPLC column equilibrated with the same buffer. The column was washed with 5 volumes of equilibration buffer at 1.0 ml/minute, following which bound proteins were eluted with a gradient of 0- 300 mM NaCl. The active fractions were pooled, dialyzed against 25 mM Bis-Tris, pH 6.3, and subjected to chromatofocusing on a MonoP FPLC column equilibrated with Bis-Tris buffer, using a pH gradient developed with 50 ml of 10x diluted Polybuffer 74 (Pharmacia), adjusted to a pH of 4.0.

*Electrophoretic Techniques*—The SDS-PAGE system of Schagger and von Jagow (Schagger, H., and von Jagow, G. (1987) *Anal. Biochem.* 166, 368-379), was used to monitor enzyme purification and estimate the enzyme molecular mass. For amino-terminal sequence analysis, proteins resolved in SDS-PAGE were electroblotted to polyvinylidene difluoride membranes using 10 mM CAPS, pH 11, 10% methanol (Matsudaira, P. (1987) *J. Biol. Chem.* 262, 10035-10038). The membrane was washed thoroughly with water and stained with Coomassie Blue G250. The blot was air dried, and protein bands cut out and subjected to NH<sub>2</sub>-terminal sequence analysis with an Applied Biosystems 491 Protein Sequencer using the program designed by the manufacturers.

*Enzyme Fragmentation*—The purified prolyl tripeptidyl peptidase (PTP-A) was partially denatured by incubation in 6 M urea in 0.02 M Tris, pH 7.6, for 60 minutes. Low molecular mass gingipain R (RgpB) (Potempa, J., et al. (1995) *Prospect. Drug Discovery and Design* 2, 445-458) from *P. gingivalis* was then added to make an enzyme:substrate molar ratio of 1:100. The reaction mixture was made in 1 mM cysteine and the sample incubated overnight at 37°C. Generated peptides were separated by reverse-phase HPLC using a  $\mu$ Bondapak C-18 column (3.9 x 300 mm) (Waters, Millford, MA). Peptides were eluted with 0.1% trifluoroacetic acid and acetonitrile containing 0.08% trifluoroacetic acid, using a

gradient from 0 to 80% acetonitrile over 60 minutes. Peptides were monitored at 220 nm and collected manually.

For determination of the active site serine residue and to confirm that the purified enzyme was a serine peptidase, 100 µg of purified PTP-A was first  
5 incubated with 170 µCi of [1,3-<sup>3</sup>H]DFP (Amersham, Arlington Heights, IL) for 30 minutes at 25°C in 20 mM HEPES, pH 7.5. The reaction was quenched by addition of cold DFP to a final concentration of 10 mM and the radiolabelled material analyzed by SDS-PAGE, followed by autoradiographic analysis. The gel was dehydrated, soaked in PPO solution for 2 hours, dried, and the DFP-binding  
10 proteins detected by fluorography after an exposure time of 96 hours on X-ray film (XAR; Kodak, Rochester, NY). The bulk of radiolabelled protein was subjected to proteolytic fragmentation with RgpB and peptides obtained separated by reverse-phase HPLC as described above. Radioactivity in each peptide fraction was measured using a β liquid scintillation counter, and the labeled peptide, as well as  
15 other selected peptides were subjected to sequence analysis.

*Identification of the PTP-A Gene*— The database containing the unfinished *P. gingivalis* W83 genome, available from The Institute for Genomic Research, was searched for the presence of nucleotide sequences corresponding to the NH<sub>2</sub>-terminal and the internal PTP-A amino acid sequences using the TBLASTN  
20 algorithm, BLAST version 2.0.8, and the default values for all parameters (Altschul, S.F., et al., (1997) *Nucleic Acid Res.* 25, 3389-3402). An identified clone gnl | TIGR | *P. gingivalis*\_126 was retrieved from The Institute for Genomic Research data base (<http://www.tigr.org>). The position of the PTP-A gene was localized using the NCBI open reading frame (ORF) finder (available from the  
25 National Center for Biotechnology Information, at <http://www.ncbi.nlm.nih.gov/gorf/gorf.html>). The amino acid sequence, obtained by conceptual translation of the entire ORF, was further used for homology screening by use of the NCBI BLAST search tool.

*Enzyme Specificity*— Peptides were incubated with 1 µg PTP-A at an  
30 enzyme:substrate molar ratio of 1:100 for 3 hours or 24 hours in 50 µl of 200 mM HEPES, pH 7.5, at 37°C, and the reaction stopped by acidification with trifluoroacetic acid. The samples were then subjected to reverse-phase high

pressure liquid chromatography using a  $\mu$ Bondapak C-18 column (3.9 x 300 mm) (Waters, Millford, MA) and an acetonitrile gradient (0-80 % in 0.075% trifluoroacetic acid in 50 min). Each peak, detected at 220 nm, was collected, lyophilized, re-dissolved in 50% (volume/volume) methanol, 0.1% acetic acid and subjected to analysis by mass spectrometry.

*Mass Spectrometry*—A Finnigan MAT 95S, sector mass spectrometer (Finnigan MAT, Bremen, Germany) equipped with an electrospray source (ESI) was used operated essentially as described previously (Stenfors, C., et al., (1997) *J. Biol. Chem.* 272, 5747-5751). Peptides were identified by fitting of the obtained spectra to specific sequences using an Internet application program MsFit available at <http://falcon.ludwig.ucl.ac.uk/msfit.html>.

## Example 2

### Enzyme Localization, Purification and Initial Characterization

Analysis of amidolytic activity against H-Ala-Phe-Pro-pNA in several fractions of *P. gingivalis* HG66, W50 and ATCC 33277 clearly indicated that an enzyme(s) with prolyl tripeptidyl-peptidase activity is localized on the cell surface in all strains tested with less than 5% of the total activity being found in the medium regardless of the growth phase of the bacterial culture. Cell associated enzyme was easily detached from the bacterial surface by treatment with a low concentration (0.05%) of Triton X-100. This procedure released more than 85-90% of activity in a soluble form. Subsequent acetone precipitation of proteins in the Triton X-100 fraction successfully separated the activity from pigment which remained in solution. The redissolved protein fraction, after dialysis, was applied to hydroxyapatite (100 ml) equilibrated with 20 mM potassium phosphate buffer pH 7.0. The elution was carried out with 20 mM potassium phosphate buffer pH 7.0, using a phosphate gradient from 20 mM to 300 mM at flow rate 20 ml/h. At this step substantial separation of the PTP-A activity from both the DPP IV and bulk protein was achieved (Fig. 1a). Further purification performed by subsequent chromatography steps including Phenyl-Sepharose (Fig. 1b), MonoQ (Fig. 1c) and MonoP columns (Fig. 1d), resulted in the isolation of purified enzyme.

Phenyl-Sepharose HP (25 ml) was equilibrated with 50 mM potassium phosphate, 1M ammonium sulfate, pH 7.0, at flow rate 30 ml/h. The column was

washed with two volumes of equilibration buffer and a step gradient of 0.5 M ammonium sulfate was applied, following which a descending gradient of 0.5 to 0 M ammonium sulfate was applied. The PTP-A containing fractions were extensively dialyzed against 20 mM Tris-HCl, pH 7.0, and concentrated by  
5 ultrafiltration. The concentrated PTP-A containing fractions were applied to a MonoQ column equilibrated with the same buffer. The column was washed with 5 volumes of equilibration buffer, following which bound protein was eluted with a gradient of 0-300 mM NaCl. The concentrated fraction of PTP-A from the MonoQ column was equilibrated with 25 mM Bis-Tris, pH 6.3, and loaded on a MonoP  
10 column equilibrated with the same buffer. A pH gradient was developed using 50 ml of Polybuffer 74, with the pH adjusted to 4.0.

Significantly, the chromatography step on the MonoP column yielded the  $A_{280}$  profile much sharper than the activity peak. Although this imperfect overlap of protein and activity may suggest that the protein component does not represent  
15 the active enzyme, the rest of data argues with such a contention. This apparent contradiction may be likely explained by the enzyme inhibition by the reaction product of H-Ala-Phe-Pro-pNA hydrolysis but this possibility has not been explored. The yield of protein and activity recovery in a typical purification procedure is summarized in Table 1.

Table 1. Purification of the PTP- A from *P. gingivalis*

Step	Volume (ml)	Protein (mg)	Total activity*	Specific activity (units/mg)	Purification fold	Yield (%)
5	Triton X-100 extract after centrifugation					
	200	1200	757 673	642	1	100
	Acetone precipitate					
10	50	600	537 622	896	1.4	71
	Hydroxyapatite chromatography					
	50	22	400 039	18 183	28	53
15	Phenyl-Sepharose					
	48	10	312 505	31 250	48	41
	3	1.5	244 828	163 218	254	32
MonoQ						
MonoP						
	4	0.7	188 400	269 142	420	25

\* Based on the enzymatic activity using H-Ala-Phe-Pro-pNA where one unit = mOD/min/1ml



SDS-PAGE analysis of the purified enzyme revealed the presence of two protein bands with apparent molecular masses of 81.8 and 75.8 kDa, respectively (Fig. 2, lane f). Autoradiography of the enzyme sample radiolabeled with [1,3-<sup>3</sup>H]DFP (Fig. 2, lane g) clearly indicated that the bands represented either two distinct serine peptidases or different molecular mass forms of the same enzyme. In an attempt to distinguish between these two options, the electrophoretically resolved proteins were subjected to amino terminal sequence analysis. Unfortunately, it was found that the 81.8 kDa form of PTP-A had a blocked N-terminus. In contrast, the sequence NH<sub>2</sub>-SAQTTRFSAADLNALMP (SEQ ID NO:23) was found at the N-terminus of the lower molecular mass form of the enzyme. This result led us to the possibility that the 75.8 kDa form of PTP-A was derived from the 81.8 kDa form through proteolytic cleavage of a 6 kDa amino-terminal peptide. To confirm this hypothesis and, in addition, to localize the active site residue within *P. gingivalis* PTP-A, the mixture containing both radiolabeled enzymes was proteolytically fragmented and peptides resolved by reverse-phase HPLC. This procedure yielded only one major radioactive peptide peak, and the purified peptide was found to have a single amino acid sequence: IGVHGWXYGGFMTTNL (SEQ ID NO:24), where X apparently represents the active-site serine residue covalently and irreversibly modified by DFP. These data convincingly indicate that the two protein bands of purified PTP-A represents different forms of the same enzyme. The portion of the purified PTP-A having a truncated N-terminus may be due to cleavage by Lys-specific peptidase and is likely to be an artifact which occurred during the purification procedure. Nevertheless, the proteolytic shedding of membrane bound PTP-A also occurs during cultivation of the bacteria, as indicated by variable amount of soluble activities found in cell free culture media.

### Example 3

#### pH Optimum, Stability and Inhibition Profile

Using the amidolytic activity assay with H-Ala-Phe-Pro-pNA it was found that the enzyme has a broad pH optimum from pH 6.0 to 8.0 and in 0.2 M HEPES, pH 7.6 was stable for at least 12 hours at 25°C or 37°C. PTP-A activity was not affected by class specific synthetic inhibitors of cysteine or metalloproteinases

(Table 2). In contrast, preincubation of the enzyme with DFP or PEFABLOCK resulted in total loss of activity, supporting its classification as a serine peptidase. Surprisingly, however, 3,4-dichloroisocoumarin was only a poor inhibitor, and PMSF, leupeptin, antipain and prolinal had no effect at all. Interestingly, preincubation of PTP-A with iodoacetamide, but not with N-ethylmaleimide, stimulated enzyme amidolytic activity about two-fold. Human plasma inhibitors, such as  $\alpha_1$ -proteinase inhibitor,  $\alpha_1$ -antichymotrypsin and  $\alpha_2$ -macroglobulin did not affect the enzyme activity, nor were they cleaved by PTP-A.

The effect of inhibitors on amidolytic activity of DPP IV was also determined using the same conditions as those used for PTP-A, but using H-Gly-Pro-pNA as a substrate.

Table 2. Effect of inhibitors on the amidolytic activity of PTP-A and DPP IV.  
Results are for a 15-min incubation at 37 C in 0.2 HEPES pH 7.6,  
with 1 mM H-Ala-Phe-Pro-pNA as substrate.

	Inhibitor	Concentration	Residual activity of PTP-A, %	Residual activity of DPP IV, %
5	Diisopropyl fluorophosphate	10 mM	0	0
		10 mM	96	20
10	Phenylmethanesulfonyl fluoride	1mg/ml	20	15
		10mg/ml	0	0
	PEFABLOC SC	1 mM	56	100
15	3,4-dichloroisocoumarin	5mM	200	100
	Iodoacetamide	5 mM	100	100
	N-Ethylmaleimide	1 mM	98	100
20	1,10- orthophenanthroline	5 mM	93	100
		0.1 mM	100	100
	EDTA	0.1 mM	100	100
25	Leupeptin	0.1 mM	100	20
	Antipain	10 mM	100	0
30	Prolinal	10 mM	100	30
	Val-Pro	10 mM	100	1
	Ala-Pro			
35	Ala-Gly-Pro			

### Example 4

#### Substrate Specificity

Among several chromogenic substrates tested, including H-Ala-Phe-Pro-pNA, H-Gly-Pro-pNA, Z-Gly-Pro-pNA, Z-Ala-Pro-pNA, H-Pro-pNA, only H-Ala-Phe-Pro-pNA was hydrolyzed by PTP-A indicating a prolyl specific tripeptidyl-peptidase activity. To further confirm this specificity several synthetic peptides composed of 5 to 34 amino acid residues and containing at least one proline residue were tested as substrates for PTP-A. Out of 22 peptides tested only those with a proline residue in the third position from the amino terminal end were cleaved (Table 3), with the significant exception of peptides with adjacent proline residues (peptides 3, 4 and 16). In addition, a free  $\alpha$ -amino group was absolutely required for cleavage after the third proline residue as exemplified by resistance to enzymatic hydrolysis of peptide 9, which differs from the peptide 8 only in acylation of the  $\alpha$ -amino group of the N-terminal valine residue. Except for these two limitations, the peptide bond -Pro-↓-Yaa- was cleaved at the same rate in all peptides with the general formula  $\text{NH}_2\text{-Xaa-Xaa-Pro-Yaa-(Xaa)}_n$  (SEQ ID NO:25), where Xaa represents any amino acid residue while Yaa could be any residue except proline, regardless of the chemical nature of the amino acids and the length of the peptide. In all cases the reaction was completed within 3 hours and prolonged incubation for 24 hours did not affect the pattern of cleavage, confirming the absolute requirement for a proline residue at the third position from the unblocked N-terminus. In addition, these data indicate that the preparation of PTP-A was free of any contamination with either aminopeptidase, dipeptidyl peptidase, or endopeptidase activities.

The cleavage specificity of DPP IV was also determined using the same conditions as those used for PTP-A. The results (Table 3) demonstrate that DPP IV does not cleave between two proline residues.

Table 3. Cleavage specificity of PTP-A and DPP IV on synthetic peptides.

Substrate	Cleavage site	SEQ ID NO:
Peptide 1	H-Arg-Pro-Pro- -Gly-Phe-Ser-Pro-Phe-Arg	1
Peptide 2	H-Arg-Pro-Pro- -Gly-Phe	2
Peptide 3	H-Lys-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg	3
Peptide 4	H-Tyr-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg	4
Peptide 5	H-Arg-Pro-Hyp-Gly-Phe-Ser-Pro-Phe-Arg	5
Peptide 6	H-Arg-Pro- -Lys-Pro- -Gln-Gln-Phe-Phe-Gly-Leu-Met-NH <sub>2</sub>	6
Peptide 7	H-Val-Pro-Pro- -Gly-Glu-Asp-Ser-Lys-Glu-Val-Ala-Ala-Pro-His-Arg-Gln	7
Peptide 8	H-Val-Pro-Pro- -Gly-Glu-Asp-Ser-Lys	8
Peptide 9	Ac-Val-Pro-Pro-Gly-Glu-Asp-Ser-Lys	9
Peptide 10	H-Val-Glu-Pro- -Ile-Pro-Tyr	10
Peptide 11	H-Arg-Gly-Pro- -Phe-Pro-Ile	11
Peptide 12	H-Ala-Arg-Pro- -Ala-D-Lys-amide	13
Peptide 13	H-Pro-Asn-Pro- -Asn-Gln-Gly-Asn-Phe-Ile	14
Peptide 14	H-Arg-His-Pro- -Lys-Tyr-Lys-Thr-Glu-Leu	15
Peptide 15	H-Gly-Val-Pro- -Lys-Thr-His-Leu-Glu-Leu	16
Peptide 16	H-Lys-Gly-Pro-Pro-Ala-Ala-Leu-Thr-Leu	17
Peptide 17	H-Gln-Lys-Gln-Met-Ser-Asp-Arg-Glu-Asn-Asp-Met-Ser-Pro-Ser-Asn-Val-Val-Pro-Ile-His-Val-Pro-Pro-Thr-Thr-Glu-Asn-Lys-Pro-Lys-Val-Gln	18
Peptide 18	H-Phe-Leu-Arg-Glu-Pro-Val-Ile-Phe-Leu	19
Peptide 19	H-Gly-Ile-Arg-Pro-Tyr-Glu-Ile-Leu-Ala	20
Peptide 20	H-Leu-Pro- -Asp-Leu-Asp-Ser-Ser-Leu-Ala-Ser-Ile-Gln-Glu-Leu-Ser-Pro-Gln-Glu-Pro-Arg-Pro-Pro-Glu-Ala	21
Peptide 21	H-Cys-Leu-Ser-Ser-Gly-Thr-Leu-Pro-Gly-Pro-Gly-Asn-Asp-Ala-Ser-Arg-Glu-Leu-Glu-Ser	22
Peptide 22	H-Lys-Ile-Ala-Gly-Tyr-His-Leu-Glu-Leu	46
Peptide 23	H-Ser-Pro- -Tyr-Ser-Ser-Asp-Thr-Thr	47
Peptide 24	H-Ala-Pro- -Val-Arg-Ser-Leu-Asn-Cys-Thr-Leu-Arg-Asp-Ser-Gln-Gln-Lys	

| indicates cleavage site mediated by PTP-A

† indicates cleavage site mediated by DPP IV

The lack of cleavage after internal proline residues in the synthetic peptides corresponds well with the absence of any proteolytic activity on several protein substrates including IgA, IgG, albumin, azocasein, carboxymethylated ribonuclease and gelatin. However, the size of substrate, which is a limiting factor in the activity of oligopeptidases (Walter, R., et al., (1980) *Mol. Cell. Biochem.* 30, 111-126), is not restricting in the case of PTP-A, because the enzyme is able to cleave a tripeptide (NH<sub>2</sub>-Xaa-Xaa-Pro) from the N-terminus of both human cystatin C and interleukin 6.

### Example 5

#### PTP-A Sequence Analysis

Partial PTP-A amino acid sequence data allowed us to identify the *P. gingivalis* genomic clone gnl | TIGR | *P. gingivalis*\_126 in the Unfinished Microbial Genomes data base, TIGR. An ORF corresponding to the PTP-A amino acid sequence was found as indicated by the fact that all sequences of the PTP-A derived peptides obtained by the enzyme polypeptide fragmentation with RgpB were present in the protein primary structure inferred from the nucleotide sequence of the ORF. The 732 amino acid polypeptide with a calculated mass of 82, 266 Da was encoded in this ORF. The homology search performed using the NCBI TBLASTN tool against GenBank+EMBL+DDBJ+PDB databases and subsequent multiple sequence alignments using the ClustalW Multiple Sequence Alignment tool (Fig. 3) indicated that PTP-A is a new member of the prolyl oligopeptidase (S9) family of serine peptidases (Rawlings, N.D., et al., (1991) *Biochem. J.* 279, 907-908).

The sequence GX SXGG (SEQ ID NO:40) is a signature feature for the S9 family of serine peptidases. Within this large and diverse S9 family of evolutionary and functionally related enzymes both from prokaryotes and eukaryotes, PTP-A was most closely related to bacterial dipeptidyl peptidase IV (DPP IV) from *Flavobacterium meningosepticum*, *Xantomonas maltophilus*, and *P. gingivalis*, sharing 31.6%, 30.4%, and 28.5% amino acid sequence identity, respectively. Remarkably, the COOH-terminal region of the PTP-A molecule (residues 502 - 732) shows a significant similarity to the eukaryotic prolyl oligopeptidases with 34% and 33% identity to human DPP IV and mouse fibroblast activation protein (FAP), respectively (Fig. 3). This part of the molecule contains the amino acid

residues which encompass the catalytic triad in all characterized prolyl oligopeptidases, and from the multiple alignments with DPP IV of confirmed active site residues (Kabashima, T., et al., (1995) *Arch. Biochem. Biophys.* 320, 123-128) it is apparent that Ser-603, Asp-678 and His-710 represent the catalytic triad of PTP-A (Fig. 3). Such an inference is further supported by the direct labeling of Ser-603 by DFP. In addition, the computer assisted search for sequential motifs characteristic for transmembrane domains revealed the presence of such a putative region within the N-terminal sequences of PTP-A, with residues 5 to 25 most likely folded into a hydrophobic  $\alpha$ -helix responsible for membrane anchoring of this enzyme.

In *P. gingivalis* PTP-A, as well as in DPP IV, all activities are cell surface associated, and it is conceivable that the enzymes are membrane anchored through putative signal sequences which are not cleaved but remain as a membrane spanning domain similar to other members of the prolyl oligopeptidase family. The cell surface localization of di- and tripeptidyl-peptidases suggests a putative physiological function in providing nutrients for growing bacterial cells. Here, the inability of asaccharolytic *P. gingivalis* to utilize free amino acids (Dashper, S.G., et al., *J. Dent Res.* 77, 1133 (Abstract) (1988)) makes the bacterium entirely dependant on an external peptide supply. In this regard, DPP-IV and PTP-A activities are probably very important, if not indispensable, for bacterial growth.

This suggestion is strongly corroborated by the fact that the *P. gingivalis* genome contains three additional genes encoding peptidases homologous with DPP-IV and PTP-A and one related to aminopeptidase B. The peptidases homologous with DPP-IV and PTP-A are referred to as homologs H1 (SEQ ID NO:43), H2 (SEQ ID NO:44), and H3 (SEQ ID NO:45) (Fig. 6). If expressed, each gene product would probably have enzymatic activity because each has a well preserved catalytic triad (Fig. 4). In addition, all of these genes encode a putative signal peptide which may act in providing membrane-anchorage motifs.

**Example 6****Influence of Proteinase Inhibitor on *P. gingivalis* Growth**

To evaluate whether *P. gingivalis* growth was influenced by the presence of a peptidase inhibitor, *P. gingivalis* in logphase growth was diluted 1:5 into liquid media and incubated at 37°C. The cell density was monitored by measuring the optical density at 600 nm (OD<sub>600</sub>). When the optical density began to increase, Pefabloc was added at 0.5 mg/ml or at 2.0 mg/ml. The control culture received no Pefabloc. The cultures receiving Pefabloc exhibited decreased growth (Figure 5). The peptidase inhibitor had to be added before the culture reached an OD<sub>600</sub> of about 0.3 for the peptidase inhibitor to have an effect on growth.

The complete disclosures of all patents, patent applications, publications, and nucleic acid and protein database entries, including for example GenBank accession numbers and EMBL accession numbers, that are cited herein are hereby incorporated by reference as if individually incorporated. Various modifications and alterations of this invention will become apparent to those skilled in the art without departing from the scope and spirit of this invention, and it should be understood that this invention is not to be unduly limited to the illustrative embodiments set forth herein.

**Sequence Listing Free Text**

- SEQ ID NOs:1-11: Synthetic peptides
- SEQ ID NO:12: Target peptide
- SEQ ID NOs:13-22: Synthetic peptides
- SEQ ID NO:23: Amino-terminus of the lower molecular mass form of PTP-A.
- SEQ ID NO:24: Amino acid sequence present in PTP-A, where X apparently represents the active-site serine residue covalently and irreversibly modified by DFP.
- SEQ ID NO:25: Target peptide, where Xaa represents a natural or modified amino acid residue, Yaa represents a natural or modified amino acid residue except proline, and N is equal to or greater than 1.
- SEQ ID NO:26: Mouse fibroblast activation protein



	SEQ ID NO:27:	Human DPP IV
	SEQ ID NO:28:	DPP from <i>Flavobacterium meningosepticum</i>
	SEQ ID NO:29:	DPP from <i>P. gingivalis</i>
	SEQ ID NO:30:	<i>P. gingivalis</i> PTP-A
5	SEQ ID NO:31:	Portion of PTP-A
	SEQ ID NO:32:	Portion of DPP from <i>P. gingivalis</i>
	SEQ ID NO:33:	Portion of H1 homolog of <i>P. gingivalis</i> DPP
	SEQ ID NO:34:	Portion of H2 homolog of <i>P. gingivalis</i> DPP
	SEQ ID NO:35:	Portion of H3 homolog of <i>P. gingivalis</i> DPP
10	SEQ ID NOs:36-37:	Probes
	SEQ ID NO:38:	Nucleotide sequence of coding region encoding PTP-A.
	SEQ ID NO:39:	Consensus sequence for clan SC where X is any amino acid and S is the active site serine GXSTXXG.
	SEQ ID NO:40:	Consensus sequence for family S9 where X is any amino acid and S is the active site serine GXSTXGG.
15	SEQ ID NO:41:	A specific substrate for a prolyl-tripeptidyl peptidase, where Xaa represents a natural or modified amino acid residue, and Yaa represents a natural or modified amino acid residue except proline.
20	SEQ ID NO:42:	DPP from <i>P. gingivalis</i>
	SEQ ID NO:43:	H1 homolog of <i>P. gingivalis</i> DPP
	SEQ ID NO:44:	H2 homolog of <i>P. gingivalis</i> DPP
	SEQ ID NO:45:	H3 homolog of <i>P. gingivalis</i> DPP
	SEQ ID NO:46:	Synthetic peptides
25	SEQ ID NO:47:	Synthetic peptides
	SEQ ID NO:48:	Amino terminal sequence of DPP IV

**What is claimed is:**

1. An isolated prolyl tripeptidyl-peptidase, active analog, active fragment, or active modification thereof having amidolytic activity for cleavage of a peptide bond present in a target polypeptide having at least 4 amino acids, wherein the prolyl tripeptidyl-peptidase:target polypeptide ratio is at least about 1:1 to no greater than about 1:10,000,000 in about 200 mM HEPES, about pH 7.5 at 37°C for at least about 3 hours.
2. An isolated prolyl tripeptidyl-peptidase, active analog, active fragment, or active modification thereof having amidolytic activity at a prolyl tripeptidyl-peptidase:target polypeptide ratio of at least about 1:1 to no greater than about 1:10,000,000 in about 200 mM HEPES, about pH 7.5 at 37°C for at least about 3 hours, and wherein the prolyl tripeptidyl-peptidase is isolated from *P. gingivalis*.
3. The isolated prolyl tripeptidyl-peptidase of claim 2 wherein the peptide cleaved by the isolated prolyl tripeptidyl-peptidase comprises the sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:11, H-Ala-Arg-Pro-Ala-D-Lys-amide, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:25, and SEQ ID NO:37.
4. The isolated prolyl tripeptidyl-peptidase of claim 2 wherein the amino acid sequence of the isolated prolyl tripeptidyl-peptidase comprises the amino acid sequence GXSEXG (SEQ ID NO:39).
5. The isolated prolyl tripeptidyl-peptidase of claim 4 wherein the amino acid sequence of the isolated prolyl tripeptidyl-peptidase comprises the amino acid sequence GXSEXG (SEQ ID NO:40).
6. The isolated prolyl tripeptidyl-peptidase of claim 4 wherein the amino acid sequence of the isolated prolyl tripeptidyl-peptidase comprises SEQ ID NO:30.

7. An isolated polypeptide, active analog, active fragment, or active modification thereof having amidolytic activity for cleavage of a peptide bond present in a target polypeptide having at least 4 amino acids, wherein the polypeptide:target polypeptide ratio of at least about 1:1 to no greater than about 1:10,000,000 in about 200 mM HEPES, about pH 7.5 at 37°C for at least about 3 hours.
8. An isolated polypeptide comprising an amino acid sequence having a percentage amino acid identity of greater than 35 % with SEQ ID NO:30.
9. An isolated nucleic acid fragment encoding a prolyl-tripeptidyl peptidase, active analog, active fragment, or active modification thereof, having amidolytic activity for cleavage of a peptide bond present in a target polypeptide having at least 4 amino acids, wherein the prolyl tripeptidyl-peptidase:target polypeptide ratio of at least about 1:1 to no greater than about 1:10,000,000 in about 200 mM HEPES, about pH 7.5 at 37°C for at least about 3 hours.
10. The nucleic acid fragment of claim 9 wherein the nucleic acid fragment has a nucleotide sequence comprising SEQ ID NO:38.
11. The nucleic acid fragment of claim 9 wherein a complement of the nucleic acid fragment hybridizes to SEQ ID NO:38 under hybridization conditions of 0.5 M phosphate buffer, pH 7.2, 7 % SDS, 10 mM EDTA, at 68°C, followed by three for 20 minutes washes in 2x SSC, and 0.1 % SDS, at 65°C, wherein at least about 20 nucleotides of the complement hybridize.
12. An isolated nucleic acid fragment encoding a polypeptide wherein the polypeptide comprises an amino acid sequence having a percentage amino acid identity of greater than 35 % with SEQ ID NO:30.
13. A method of identifying an inhibitor of a prolyl-tripeptidyl peptidase, active analog, active fragment, or active modification thereof, comprising identifying a molecule that inhibits the amidolytic activity of the prolyl-

tripeptidyl peptidase by incubating the prolyl-tripeptidyl peptidase with the molecule under conditions that promote amidolytic activity of the prolyl-tripeptidyl peptidase and determining if the amidolytic activity of the prolyl-tripeptidyl peptidase is inhibited relative to the amidolytic activity in the absence of molecule.

14. A method of reducing growth of a bacterium comprising inhibiting a prolyl tripeptidyl-peptidase, active analog, active fragment, or active modification thereof, by contacting the prolyl tripeptidyl-peptidase with an inhibitor of the prolyl tripeptidyl-peptidase.
15. A method for protecting an animal from a periodontal disease caused by *P. gingivalis* comprising administering to the animal the inhibitor of claim 14 wherein the disease is selected from the group consisting of gingivitis and periodontitis.
16. The method of claim 15 wherein the inhibitor is administered by a method selected from the group consisting of subgingival application and controlled release delivery.
17. A method of reducing growth of a bacterium comprising inhibiting a prolyl dipeptidyl-peptidase, active analog, active fragment, or active modification thereof, by contacting the prolyl dipeptidyl-peptidase with an inhibitor of the prolyl dipeptidyl-peptidase.
18. An immunogenic composition comprising an isolated prolyl tripeptidyl-peptidase, or an antigenic analog, antigenic fragment, or antigenic modification thereof, the prolyl tripeptidyl-peptidase having amidolytic activity for cleavage of a peptide bond present in a target peptide having at least 4 amino acids, wherein the prolyl tripeptidyl-peptidase:target polypeptide ratio is at least about 1:1 to no greater than about 1:10,000,000 in about 200 mM HEPES, about pH 7.5 at 37°C for at least about 3 hours.
19. The immunogenic composition of claim 18 further comprising an adjuvant.

20. A composition comprising an inhibitor of an isolated prolyl tripeptidyl-peptidase and a pharmaceutically acceptable carrier.
21. A dipeptidyl peptidase having an amino acid sequence comprising SEQ ID NO:43.
22. A dipeptidyl peptidase having an amino acid sequence comprising SEQ ID NO:44.
23. A dipeptidyl peptidase having an amino acid sequence comprising SEQ ID NO:45.

1/19




Fig. 1a




Fig. 1b

2/19




Fig. 1c




Fig. 1d

3/19




Fig. 2






Fig. 3

SEQ ID NO:	
26	Mm-FAP
27	Hs-DPP
28	Fm-DPP
29	Pg-DPP
30	PTP-A
1	MKTWLTGTEGCTTAAALAVICIVLRPSR-VYKPEGNTK-RALTCLKDILNGTFSYKTYF
1	MKTPWRVLLCLIGAAALVTITVPVVLNKGTDITADSR-KTYTLDYLNKNTYRLKLYS
1	---MKKKITSLISAVAFHGLSAQEITLDKYSQYRAK-GISGHASLND-----
1	-MKRPVITLLIGIVTMCMAQTGNKRPVDLEITSCMFYARSAGSIRSMPD-----
1	---MKKTIIFQQIFLSVCAITVALPCSAQSPETSGKEETLEQLMPGCKEFYN-FYPEYVV
59	PNWISQEQYTHQS-EDDNTVFYNIETRE--SYIILSNSINMKSUN--ATDYGLISPDQRFV
60	LRWISDHEYLYK--QENNILVENAEYEN--SVFLENSTFDEFGHSINDYSLSPDGQFEL
48	-----CENYATII--EPTGIAKNSYKITSQ--KEKNIIVDGSFQGYT-----FSNDESK--IL
51	-----CEHYTEMNRERTAITIRVNVASEKAVDTLFSVERARECPFKQIQNIYEVSSSTGHHEL
56	GLQWMECDNYVFIE---GDDLIVENKANCKSAQITRFSAADLNALMPEGCKEFTIDAFPSFR
114	ESDYSKLRMSYITATYYINDLQNGEFVRGYELPRPIQYIQMSPVGSKIAAYVYNNIYLYK
116	LEYNYVKQWRHSYITASYDIYDLNKRQLITEERIPNNTQWYVSPVGHKLAAYVNNIDLYVK
92	LQKSSQSIYRHSFELGKFEVKDLKSRITVSTNNANWIOE-PKFSPDGSKVAFIADNNILFYQ
106	LFTDMESIYRHSYRAAVYDIDVRRNLVKPLSEHVGVKVMIPITFSPDGRMVAEVRDNNITFK
113	TLDAGRGLVVLFTQGGVLGCFDMLARKVITYLFDITNEETASLDFSPVGDVRVAYVRNHNLYDA
174	QRP--GPPPFQITVTGRENRIIFNGIPDWVYEEEMLATKYVALMWSPDCKFLAYVIEFNDSDI
176	IEP--NLPSYRIITWTCKEDITHVNGITIDWVYEEEFVSAYSALMWSENGTELAYAQFNDIEV
151	DLN--TGKITQITTDCKKNEIINGICDWVYEEEFCHADYYQAN-KAGDALFVRFDERKV
166	KFD--FDTEVQVITDQINSHINGATDWVYEEEFVTLNLSMS-ADNAELAFVRSDESAN
173	RGGKLGEGMSRAIAVTIDGTETLVYQAVHQREFGIEKGTFS-PKGSCLAFYRMDOSMV
232	PIIAYSYVGDG--QVERTINIPYKAGAKNPVVRVFIIDTTYPHHG---PMEVPVPEMI
234	PLHEYSFYSDLSLOPKTVTRMPYPKAGAVNPTVKFFVNVNTDLSSTVNTATSIQITAPASM
208	PEINPIIYQON--LYPMITKYKPKAGEENSANVAVLYQLSSCKSAQ---LNFGSSEKY
223	PEYRMPMYEK--LYFEDYTYKPKAGEKNSTVSLILVAVADRNITKS---VSLPIDADG
232	KPTPIVDYHP---LEAESKPIYVPMAGTPSHHVTVGIVHILATCKTIVY---LQIGEBKEK

Fig. 3a

6/19

Mm-FAP	287	ASSDYFSLTWVSSERVCLQWLKRVQNVSMLSICDFFREDWHAWCPKQEHVBSRTG
Hs-DPP	294	LHGHDYLCDVWTWATQERISLQWLRRIQNYSMDDICDYDESSGRWNCCLVARQHHEMSTTG
Fm-DPP	262	YHPLFQTN--ANDEIVVATNRHONKVDLLKVNTRKAAVS-----K-LFTEEDNAN
Pg-DPP	277	YHPRFAFD--NADEIVVATNRLONDFKMYVHPKSLVPK-----LILQDMNKRY
	285	ELTNLSNSP--DENILVAEVRNRAONECKNAYDAEIGRFVR-----TLFVEIDKH
Mm-FAP	347	AGGFVSTPAFSDATSVYKIFSDKDGKHHYTKDVTVENAIOITSGKWEAIVIFRVTQD
Hs-DPP	354	VGRFRPSEPHFILLDGNSTFYKIIISNEEGYRHICYFQIDKRDCTFITKGTWEVIGTEALTS
Fm-DPP	311	LETDLT-MEFLDDNS--FLWASERDGHRLHYWYDAACKLKQVSKGDWEIINNYGYNPK
Pg-DPP	326	YDSDWIOTLKFTTGG--FAYVSEKDGFAHLYLDNKGVMHRRITSGNWDVTKLYGVDS
	335	MEPLHP--LTELPGSNNOETIWOSSRRDGNHLYLDYDITGERLIRQVTKGEWEVTFNFAFDPK
Mm-FAP	407	SLFYSSNEFEGYPGRNIVYISIGNSPPSKKCVTCIIRKERCQYITASFYKAKKVALVC
Hs-DPP	414	YLYIISNEYKMGPGGRNLYKIQLSDYTKVT-CLSCENPERCQYYSVSFSKEAKYQLR
Fm-DPP	368	-----TKEVYIQTTEKGSINKVSKNINTG---KTQLLSNAEGNNSAFSKTFNFIN
Pg-DPP	384	-----GTVFYQSAAESPTRRAVYDAIDAKGR---KITKLSLVNVTN-DALFSGNYAYYINTY
	393	-----GIRLYFESIEASPLERHFYCIDIKGG---KITKDLTPESGMHRTQLSPDGSATIDIF
Mm-FAP	467	Y-CPGLPISTLHDGRTDQETQVLEENKELENSELRNIQLPKVETKKLK-DGGLTFWYKMIT
Hs-DPP	473	S-CPGLPIYTLHSSVNDKGLRVLEENSAIDKMLQNVOMPSSKLDFTII-LNETKFWYOMIL
Fm-DPP	421	S-TAKVETKYHLKDANGKDVKELONNDDLLNKLKSDNFIAKEFITIPNAEGDQMNAMWIK
Pg-DPP	435	SSAATPANVSVFRSKGAKELRLTEDNVALREELKAYRYNPKFTTUKTQSSLELNAWIVK
	446	Q-SETVPERKVTVTNIG-KGSHTLLEAKNPDTGYAMPEIRTGTMMAAD--GQTPLYKLT
Mm-FAP	525	PPQFDRSKKVPILLIQVYGGPCSSVKSVAVN---WITYLASKEGIVIALVDGRGTAFQG
Hs-DPP	531	PPHFDKSKKVPILLIYVAGPCSKOKADIVFRLN---WATYLASTENIIVASFDRGRSGYQG
Fm-DPP	480	PKNEFDPKAKKVPVFMFQYSGPCSQQVANSMDGGNGIMFDMLAQKG-YLVVQVDGRGTGFRG
Pg-DPP	495	PIDFDPSEHVPVLMVQVSCNSQVLDVMSFD---MEHYLASKG-YVVAQVDGRGTGARG
	502	ELHEDPAKKYEVIVIVYGGGPHQVTKTIRSSVSGGMDIMMAQKG-YAVFTVDSRGSANRG

Fig. 3b

7/19

Mm-FAP	582	DKELHAYVRKLGMEVEDQITAPRKFIEMGFIDEERTAIWGSYGGYVSSIALASGIGLF
Hs-DPP	588	DKITMHAIRRLCTFEVEDQIEAPQFQSKMGFVINKRTAIWGSYGGYVTSMTLCSGSGVF
Fm-DPP	539	TKMKKVTYKKNLCKMEIEDQITPAKMTGNQSYVDKSRIGIFGWSYGGYMASLMTKQADVF
Pg-DPP	551	EEWRKCTYMQCLGVFEESDDQIAAATAIGQLPYVDAARIGIWGSYGGYTHLMSLCRGNELF
	561	AAFEQVTHRRILGQIEMADQMCQGVDFLKQSQWVDADRIGVHGWSYGGFMIIINLMLTHGDVF
		*
Mm-FAP	642	KCGIAPVSSMEYVASITVSEIFMGLPTKDDNLEPHVKNSITVMARAEIFRNVDVLLIHGTA
Hs-DPP	648	KCGIAPVSSMEYVESVYTERVMGLPTPEDNLDHVRNSITVMSRAENFKQVENLLIHGTA
Fm-DPP	599	KMGIAVAPVNNRRFYDSITVTERFLOTPOENK--DEYDLNSPTTYAKLLKG-KFLLIHGTA
Pg-DPP	611	KAGIAPVADMPEDYDSVYTERFMTPKENA--SGYKMSAIDVASQIQG-NLLIVSSSA
	621	KVGAGGGEVILDMNRYEIMIGERYFDAPQENP--EGYDAANLLIKRAGDLKG-RLLMIHCAI
		*
Mm-FAP	702	DDNVHFQNSAQIAKALVNAQVDFQAMVYSDQNHGHSGRSQNHLYTHMTHTLKQCFSLSD
Hs-DPP	708	DDNVHFCQSAQISKALVDVGVDFOAMVYIDEDHGHTASSTAHOHTYTHMSHETLKQCFSLP-
Fm-DPP	656	DDNVHFQNSMEFESEALIQNKQDFEFMAYEDKKNHSIIIGCNTIRPQLYEKMTNVILEN----
Pg-DPP	668	DDNVHLQNTMLETEALVQANIPEDMAIYMDKKNHSIIYGCNIRMHLYTRKAKELFDNL----
	678	EPVVMQCHSLLELDACVAKARTYPLYYVYPSHEENVMCPD-BMHLYETIIRYFIDHL----
		*

Fig. 3c

8/19

SEQ ID NO:

PTP-A	556	VDADRI	GVH	GSYGGF	MT	...	RLMLTH	GAID	DPV	WV	QHS	LL	FL	DA	CVK	ARTYP	QY	VY	TP	SHET	VM	GED	-R	717										
DPP	499	VDAA	RIGI	WGSYGG	YIT	...	NLLIV	SGS	AD	DN	VHL	QNT	ML	FT	DA	LV	QAN	IP	DA	IM	KN	HS	LYGG	NT	661									
DPP-H1	350	VDP	DR	IAI	YGAS	HGGY	AT	...	PLF	VV	QG	AND	PR	WNI	NE	SQ	IV	TAL	RA	RG	FE	VY	MY	KY	NE	CH	GF	HRE	NS	524				
DPP-H2	640	VNG	KV	CG	QF	GAS	YGGF	MT	...	PL	LL	HG	SV	DT	NV	PT	AE	SN	LY	NAL	KIL	GR	EV	ET	IE	FT	EQ	DH	FI	LE	PER	810		
DPP-H3	495	VDE	DR	IC	AV	CA	SYGG	FSV	...	PL	MI	HG	EL	DF	RI	LA	SQ	AA	AF	DA	AQ	LR	GV	PS	EM	LI	YP	DE	NH	WV	LQ	EQ	NA	667

Fig. 4

Influence of Pefablock-serine proteinase inhibitor on *P. gingivalis* growth.




Fig. 5




Fig. 6

11/19

SEQ ID NO:

30 126PP 1 MKKIIIFQQLF---LSVCALTVALPCSAQSPETSGKEFTLEQLMPGCKEF--YNFYPEYV  
 42 87PP 1 ---VPDGEHY--TEMNERT  
 43 65PP 1 ---VDKGG---NENYHLFA  
 44 101PP 1 MKKSLMLILLSAATLSSIEAQTIQOMKAGGWPVRAAFKTDVTGMNGSKYNPADLLRQAY  
 45 9PP 1 MNKKIIFSMVAAS--IIGSAAMTPSAGTNTGHELTPELFMTLSRVSEMAALS--PDGKTAVY

126PP 55 VGIQWMGDNYVF---IEGDDLVFNKANG-----KSAQTTRFSAAQLNALMPEGCKEQ  
 87PP 16 AIIIRY---NYAS---GKAVDTLFSVER-----ARECPKQIQ--N-----YE  
 65PP 14 SNIDG---S---NTRDLTPFDGVK---ASILNMLKEQK-D-----YM  
 101PP 61 DATDKDLRNVSAADKDGRIAGRKAGSKAERSEMAVYSFALTAEHFAKADIEVFQGGRMSLW  
 9PP 57 AVSFP--DVKKI--NKATRELFTVNLD-----GSGRKQITDTESEN-----EYAPAW

126PP 104 TIDAPPSFRITLDAGRC--LVVLFTQGCIVGFDMLARKVTYL--FTTNEETASLDFSP--  
 87PP 50 VSSTGTHLLFTDMES--IYRHSYRAAVDYDVRNIVKPL--SEHVCKVMIPTESE--  
 65PP 46 IISMNK-----NNPQ---IFEPYKLVNVTGEILTQLYEN---KDAANPIQGYEEDK--  
 101PP 121 IDDKQIGTADSPNSKGDTTLRFSASLSLVPETHLLIKKSIHLEGGTTATDVRVVLNPKTA  
 9PP 98 MADGKR--IAFMSNEGG---SMQLWVNNADGTERRQLSN-----IEGCTTGFLFSE--

126PP 157 -V---G-DRAVAVNNHN-LVITARG--GKLGEGMSRAIAMIIDGTETILVYGA--  
 87PP 103 -G---G-RMVAFAVRDNN-IFIK-----KFDFDTE--VQVHIDGQINSILNGATD  
 65PP 90 -D---G-ELRGYSR-----LVNCHIESELVYKD--  
 101PP 181 RDSSALYPNYTKERLSLKHMMSGTFLSGGSLSPGKYVLTSYRVSRRNKNKPAVTINQLRD  
 9PP 144 -D---E-KQVLETKD-----IKFGKRTKDTIYPPDLDDK

Fig. 6a



12/19

```

126PP 201 -MQRERGGTEKG--TFWSPKGSCLAFYRM-----DQS-MVKPTPIVDYH---PL
87PP 144 WYEEERFGVTNL--MSWADNAFLAFVRS-----DES-AVPEYRMPMYED--KL
65PP 112 -LATGERRELKK--THWDDTFGVIAENYA-----SKN-KDEAYVLINLD--S
101PP 241 AKGNILLNENKEALGMPHEDMLMVFKEGNAKRLVAFDPMGKGEKTLVSNLPESQFRM
9PP 170 ATGRIITDLMYK---HMDWEVETIHPPI-----AN-ATDGMITIGKD---H

126PP 243 EAEKPLLYYPMAGT---PSHHMTVGIYHLA---TG-KTVYLOTGEPKEKFLTNLSWSPDE
87PP 188 YPEDYTKYPKAGE---KNSTVSLHLYNVA---DR-NTKSVSLPIDADGYIPRLAETDNA
65PP 153 DK-TRIVLYDLKQN---K---ITREIFANE---DY-DVSGHLHS-RK---
101PP 301 SPDARYMLFYKQEKGPCKDPLFIHLDPDDRQSDWRDRSQIYLLNAESGVYGPITFGYST
9PP 210 ME-GEPEYEAIPMKPW-----S-GIEDFSWSP---DG--QNIAYASRKKTG---

126PP 296 NIIIVVAE--VNRAQNECKVNAEDAETGTFVVRITLFEVETDKHYVEP--LH-P---LHFLP-
87PP 241 DELAVMT--LNRLOQDFKM--YVHPKSLVPKLLQLQDNKRKYVDSDWIQ-T---LKEFTT-
65PP 188 -R-----N-YEIDLMA--VEGEKSVVVPVSATYKELIKLME-----KEFK--
101PP 361 TYHMDIAPDSKRALIGTLSTDWTRRPFRFATIMEYVNETGKADTLITRDPSIDALQYTPD
9PP 247 -MAYSLS--TN---SDIYIL--YNLASGRTHNISEGMMGYDTYPK-----FSPD

126PP 346 CSNNQFIHWQSR--RDGMNHLIYL-----YDITGRLLIRQVTKGEWEVTNFA---C
87PP 292 CGG--FAYVSE-KDCFAHLYL-----VDNKGVMHRRRIISGNWDVTKLV---C
65PP 224 GKE--FSVM-----D-----YDD
101PP 421 GRH--LIVMGS-ADAFGNIGLNLKSGVTPNSVEKQFFLFDLSIRKATALLKNFNPSVSAG
9PP 287 GKS--IAWISMERDGYES-----DLKRLFVADLATGKRTHVNPTEFDYNVDMI

```

Fig. 6b

```

126PP 389 -FDPKGTRLYFESETEASPLERHFNYCIDKGGKTRDLTP-ESGMHRTQLSPD-GSATIDIF
87PP 333 -VDAAGI-VFYQSAEESPIRRAMVALDAKGRKTK-LSL-NVGTNDALFSGN-YAYYINTY
65PP 235 --DE--I-ILLIAVQSDKLYGYVQFDIR--TK--KFI--LLYD-L
101PP 478 RFDKNN-YYVFAENG-SRQQLYRLDLKLTLEISQITGTEDVVQWFGVAADNGAMWYSGQ
9PP 332 QMAPDSKGHFLACKEA--ETNLWEHILKTCKIRQLTQGQHDYADFSVRND--VMLAKR

126PP 446 QSPTVERKVMVTNIGKGSHTLLEAKNPDGTGYAMPETRTG-----TMAADGQTPLYYKLT
87PP 388 SSAAITPAVVSIFRSKGAKELRTLLEDNVALRERLKAYRYNPKEFTTLKIQSG-LELNAIV
65PP 269 ----MBQLK-----EED-----MAEMRPI-----KFKSRDG-LTIHGFIT
101PP 536 SANNADRLYL DGTGKLVWDLSAEKLANI DFTPAARDWN-----YTA PDG-TVVEGWXY
9PP 387 HSFELEDDLYRVNLKNGAAQAVTAENKVIILDRITPTTCEKR---WMKIIDG-GNMLTWV

126PP 501 MELHEDPAKKYPVLVYVGG--PHADLMTKTWRSVGGWDIYMAQKGYAMFTVDSRGSAN
87PP 447 KFIDEFESRHYPLVMVQVSG--FNSQMLD--RYSFD-WEHYLASKGYVMACV DGRGTGA
65PP 299 LKAALEGKKVPPLVNP HGG--P--QGRD--SMGFNPETQLFAERGYATLQVNFRIISGG
101PP 589 LPPQFDPSKKYPMLVYVYGGTSPINRTLEG--HYSLA---MYAAQGYVMYTLNPSGITG
9PP 443 LPPNFDKNNKYPALILYCQGG--P--QNTVS-QFWSFRWNLRLLMAEQGYHVIAPNRHGVPG

126PP 559 RGAATFEQVIHRRIGQTEVATQMCEDVD-FLKSQSWVDADRIGVHMSYGGFMTINIMLTHG
87PP 502 RGEEMRKCTYMO LGVFESDDQLAAT-AIGQLPYVDAAKIGIMMSYGGYITLMSLCRGN
65PP 353 YGKEFLRAGFKQLGRKANDVEDVLR-VAISQGWDFDRITAIYGASFGGYAILMGLVKITP
101PP 643 YGOEYAAARHVNAWGDRTADDEITGATKEFIRTHSFVNGKKVSGFGASYGGFMLOYTQKT-
9PP 498 FGQRWNEQISGDYGGQNMFDYLTAVD-EMKKEPYVDGDRIGAVGASYGGSVYWLACHHD

```

Fig. 6c

14/19

```

126PP 618 DVFKVGVAGGPMI-----D-----MN--RYEIMYGERVFD--POENPEGYD--AANLLK
87PP 561 GTFKAGIAVAEVA-----D-----MR--FYDSVYITERFMRT--PKENASGYK--MSSALD
65PP 412 DLYACGVYVGVSNITYTFFDSFPEYMK--PFKEMVKEILVLDNPEFAAIAKE-VSPFFQ
101PP 702 DLFAAAVSHAGISSIS-----N-----YMGSGYWGCGYSTVASTDSYPMNPDIVAGHSPLFR
9PP 557 KRFAAFIHAGIFNLEMQYATTEEMWFA-NWDIGGPFWEKDN---VVAQRTYA-TSPHKF

126PP 662 RAGDLKGRIMLTHGATDPVVMVWQHSLFLFDACVKARTYPDYVVPSPSHEHNMVGED-RVHLE
87PP 605 VASQLQGNLITVSGSADDNVHLCNTMLFTEALVQANIPFDMAIYMKNHSHIYGGNTENIL
65PP 469 ID-KINKELFWQGANDPVNNINESDQIVTALRARCFEVEVMVKYNECHGFHREHNSMEL
101PP 755 AD-KIHTPLILLHGSVDITNVPTAESVNLYNALKILGREVEFIEETQDHFILFEFERIRW
9PP 612 VQ-NWDTFTLMIHGELDFRLLASQAMAAFDAAQLRGVPSSEMLIYPPDENHNVLQEQNALLF

126PP 721 VETITRYFTDHTL-----
87PP 665 YTRKAKFLFDNL-----
65PP 528 YRAMLGFFAKHLKK-----
101PP 814 TNSICAWFAFWLQDDPTWNNELYPPVNL
9PP 671 HRIFFGWLDRWLKK-----

```

Fig. 6d

15/19




Fig. 7

16/19

P. gingivalis W 83 PTP sequence

SEQ ID NO: 38 13228 atgaagaagacaatcttccaacaactatctgtctgtttgtgcc  
SEQ ID NO: 30 M K K T I F Q Q L F L S V C A  
13273 cttacagtggccttgccctgttcggctcagtcctcctgaaacgagt  
L T V A L P C S A Q S P E T S  
13318 ggtaaggagtttactcttgagcaactgatgcccggaggaaaagag  
G K E F T L E Q L M P G G K E  
13363 ttttataacttttaccgccgaatacgtgggtcggttgcaatggatg  
F Y N F Y P E Y V V G L Q W M  
13408 ggagacaattatgtctttatcgaggggtgatgatttagttttta  
G D N Y V F I E G D D L V F N  
13453 aaggcgaatggcaaatcggtcagacgaccagattttctgctgcc  
K A N G K S A Q T T R F S A A  
13498 gatctcaatgcactcatgccggagggtgcaaatctcagacgact  
D L N A L M P E G C K F Q T T  
13543 gatgctttcccttcattccgcacactcgatgccggacggggactg  
D A F P S F R T L D A G R G L  
13588 gtcgttctatcttaccgaaggaggattagtcggattcgatatgctt  
V V L F T Q G G L V G F D M L  
13633 gctcgaaagggtgacttatcttttcgataccaatgaggagacggct  
A R K V T Y L F D T N E E T A  
13678 tctttggatttttctcctgtgggagaccgtgttgccctatgtcaga  
S L D F S P V G D R V A Y V R  
13723 aaccataacctttacattgctcgtggagggttaaattgggagaagg  
N H N L Y I A R G G K L G E G  
13768 atgtcacgagctatcgctgtgactatcgatggaactgagactctc  
M S R A I A V T I D G T E T L  
13813 gtatatggccaggccgtacaccagcgtgaattcggtatcgaaaaa  
V Y G Q A V H Q R E F G I E K  
13858 ggtacattctggtctccaaaaggagctgccttgctttctatcga  
G T F W S P K G S C L A F Y R  
13903 atggatcagagtatggtgaagcctaccccgatagtggattatcat  
M D Q S M V K P T P I V D Y H  
13948 ccgctcgaagccgagtccaaaccgctttattaccccatggcagg  
P L E A E S K P L Y Y P M A G  
13993 actccgtcacaccacgttacgggttggtatctatcttgccaca  
T P S H H V T V G I Y H L A T  
14038 ggtaagaccgtctatctacaaacgggtgaacccaaggaaaaattt  
G K T V Y L Q T G E P K E K F  
14083 ctgacgaatttgagttggagtccggacgaaaatatcttgatgta  
L T N L S W S P D E N I L Y V  
14128 gctgaggtgaatcgtgctcaaaacgaatgaaggtaaatagcctat  
A E V N R A Q N E C K V N A Y  
14173 gacgctgagaccggttagattcgtccgtacgctttttgttgaaacc  
D A E T G R F V R T L F V E T  
14218 gataaacattatgtagagccgttacatcccctgacattccttcg  
D K H Y V E P L H P L T F L P

Fig. 7a

17/19

-----

14263 ggaagtaacaatcagttcatttggcagagccgctcgcgacggatgg  
G S N N Q F I W Q S R R D G W

14308 aaccatctctatctgtatgatactacaggctcgtctgatccgctcag  
N H L Y L Y D T T G R L I R Q

14353 gtgacaaaaggggagtgagggttacaaactttgcaggcttcgat  
V T K G E W E V T N F A G F D

14398 cccaaggaacacggctctatttcgaaagtaccgaagccagccct  
P K G T R L Y F E S T E A S P

14443 ctcgaacgccatttttactgtattgatatacaaaggaggaaagaca  
L E R H F Y C I D I K G G K T

14488 aaagatctgactccggagtcgggaatgcaccgcactcagctatct  
K D L T P E S G M H R T Q L S

14533 cctgatgggttctgccataatcgatatttttcagtcacctactgtc  
P D G S A I I D I F Q S P T V

14578 ccgcgtaagggttacagtgacaaatatcggaagggtctcacaca  
P R K V T V T N I G K G S H T

14623 ctcttgagggttaagaaccccgatacgggctatgccatgccggag  
L L E A K N P D T G Y A M P E

14668 atcagaacgggtaccatcatggcgccgatgggcagacacctctt  
I R T G T I M A A D G Q T P L

14713 tattacaagctcacgatgccgcttcatttcgatccggcaaagaaa  
Y Y K L T M P L H F D P A K K

14758 tatectgttattgtctatgtttacggaggacctcatgcccactc  
Y P V I V Y V Y G G P H A Q L

14803 gtaaccaagacatggcgcagctctgtcgggtggatgggatattctat  
V T K T W R S S V G G W D I Y

14848 atggcacagaaaggctatgccgtctttacggtggtatagtcgcgga  
M A Q K G Y A V F T V D S R G

14893 tctgccaatagaggggctgcttttcgagcagggtattcatcgtcgt  
S A N R G A A F E Q V I H R R

14938 ttggggcagaccgagatggccgatcagatgtgcggtgtggatttc  
L G Q T E M A D Q M C G V D F

14983 ctcaagagccaatcatgggtggatgccgatagaataggagtacat  
L K S Q S W V D A D R I G V H

15028 ggctggagctatgggtggctttatgactacgaatctgatgcttacg  
G W S Y G G F M T T N L M L T

15073 cacggcgatgtcttcaaagtcggagtagccggcgggcctgtcata  
H G D V F K V G V A G G P V I

15118 gactggaatcgatatgagattatgtacggtgagcggtattttcgat  
D W N R Y E I M Y G E R Y F D

15163 gcgccacaggaaaatcccgaaggatacgatgctgccaacctgctc  
A P Q E N P E G Y D A A N L L

15208 aaacgagccggtgatctgaaaggacgacttatgctgattcatgga  
K R A G D L K G R L M L I H G

15253 gcgatcgatccggctcgtgggtatggcagcattcactccttttcctt

Fig. 7b

-----

18/19

-----  
A I D P V V V W Q H S L L F L  
15298 gatgcttgcggtgaaggcacgcacctatcctgactattacgtctat  
D A C V K A R T Y P D Y Y V Y  
15343 ccgagccacgaacataatgtgatggggccggacagagtacatttg  
P S H E H N V M G P D R V H L  
15388 tatgaaacaataacccggtatttcacagatcacttatga 15426  
Y E T I T R Y F T D H L \*

Fig. 7c  
-----

19/19

SEQ ID NO:38 ATGAAGAAGACAAATCTTCCAACAACATAATTTCTGTCTGTGTGTGCCCCTTACAGTGGCCTTGCCCTTGTTCCGGC  
TCAGTCTCCTGAAACGAGTGGTAAAGAGTTTACTCTTTGAGCAACTGATGCCCGGAGGAAAGAGTTTATATA  
ACTTTTACCCCGAATACGTGGTCGGTTTGC AATGGATGGAGACAAATATATGCTTTTATCGAGGGTGATGAT  
TTAGTTTTTAATAAGGCGAATGGCAATCGGCTCAGACGACCAAGATTTTCTGCTGCCGATCTCAATGCACAT  
CATCCGGAGGATGCAAAATTTACAGCACTGATGCTTCCCTTCAATTCGGCACACTCGATGCCGGACGGG  
GACTGGTCGTTCTATTTACCC AAGGAGTTAGTCGGATTCGATATGCTTTGCTCGAAAGGTGACTTATCTTT  
TTCGATACCAATGAGGAGACGGCTTCTTTGGATTTTCTCTGTTGGGAGACCGTGTGCTTATGTCAGAAA  
CCATAACCTTTACATTTGCTCGTGGAGGTAATTTGGAGAAAGGTATGTCACGAGCTATCGCTGTGACTATCG  
ATGGAACCTGAGACTCTCGTATATGGCCAGGCCGTACACCAAGCGTGAATTCGGTATCGAAAAAGGTACATTC  
TGGTCTCCAAAAGGGAGCTGCCCTTGTCTTCTATCGAATGGATCAGAGTATGGTGAAGCCTACCCCGATAGT  
GGATTATCATCCGCTCGAAGCCGAGTCCCAAACCGCTTTATTACCCCATGGCAGGTACTCCGTACACCCACG  
TTACGGTTGGGATCTATCATCTGGCCACAGGTAAGACCGTCTATCTACAAAACGGGTGAACCC AAGGAAAAA  
TTTCTGACGAAATTTGAGTTGGAGTCCGGACGAAATATCTTTGATAGTGGTGAAGTGAATCGTGCTCAAAA  
CGAATGTAAGGTAATGCCCTATGACGCTGAGACCCGGTAGATTGCTCCGTACGCTTTTGTGTAACCGGATA  
AACATTATGATAGAGCCGTTACATCCCTGACATTCCTTCCGGGAAGTAACAATCAGTTCAATTTGGCAGAGC  
CGTCGGACGGATGGAACCATCTCTATCTGTATGATATCTACAGTCTGCTGATCCGTCAAGGTGACAAAAAGG  
GGATGGGAGGTTACAAACTTTGACGGCTTCGATCCCAAGGGAACACGGCTCTATTTCGAAAAGTACCGAAG  
CCAGCCCTCTCGAACGCCATTTTACTGTATTGATATCAAGAGGAAAGACAAAAGATCTGACTCCGGAG  
TCGGGAATGCACCCGACTCAGCTATCTCCTGTATGTTCTGCCATATCGATATTTTTCAGTCACTACTGT  
CCCGCTAAGGTTACAGTGACAAATATCGGCAAAAGGTCTCACACTCTTGGAGGCTAAGAACCCCGATA  
CGGGCTATGCCATGCCGGAGATCAGAACGGGTACCATCATGGCGGCCGATGGGCAGACACCTCTTTATTAC  
AAGCTCACGATGCCGCTTCATTTTCGATCCGGCAAAAGAAATATCTCTGTTATTGTCTATGTTTACGGAGGACC  
TCATGCCCAACTCGTAACCAAGACATGGCGCAGCTCTGTCGGTGGATGGGATATCTATATGGCACAGAAAAG  
GCTATGCCGCTCTTACGGTGGATAGTCGGCGGATCTGCCAATAGAGGGGCTGCTTTCGAGCAGGTTATTTCAT  
CGTCGTTTGGGGCAGACCGAGATGGCCGATCAGATGTGCGGTGTGGATTTCTCAAGAGCCCAATCATGGGT  
GGATGCCGATAGAAATAGGAGTACATGGCTGGAGCTATGGTGGCTTTATGACTACGAATCTGATGCTTACGC  
ACGGCGATGTCTTCAAAGTCGGAGTAGCCGGCGGGCTGTCTATAGACTGGAATCGATATGAGATTATGTAC  
GGTGACCGTTATTTTCGATGCCCAACAGGAAATCCCGAAGGATACGATGCTGCCAACCTGTCTCAAAACGAGC  
CGGTGATCTGAAAGGACGACTTATGCTGATTTATGGAGCGATCGATCCGGTCTGTGGTATGGCAGCATTCAC  
TCCTTTTCTCTGATGCTTGGTGAAGGCACGACCATCTCTGACTATTACGCTATCTCCGAGCCACGAAACAT  
AATGTGATGGGGCCGACAGAGTACATTTGTATGAACAATAACCCGTTATTTTCACAGATCACTTATGA

Fig. 7d



## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/05551

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/57 C12N9/48 A61K39/02

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	KIYAMA, M. ET AL.: "Sequence analysis of the Porphyromonas gingivalis dipeptidyl peptidase IV gene" BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1396, no. 1, 4 March 1998 (1998-03-04), pages 39-46, XP000925951 cited in the application the whole document	7
A	---	1-6, 8-16, 18-20
	-/--	

☒ Further documents are listed in the continuation of box C.☐ Patent family members are listed in annex.

## \* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&amp;" document member of the same patent family

Date of the actual completion of the international search

5 October 2000

Date of mailing of the international search report

10.01.01

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Fuchs, U

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/05551

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE WPI Section Ch, Derwent Publications Ltd., London, GB; Class B04, AN 1990-053917 XP002149298 & JP 02 005880 A (SUNSTAR KK), 10 January 1990 (1990-01-10)	7
A	abstract	1-6, 8-16, 18-20
P,X	--- BANBULA, A. ET AL.: "Prolyl Tripetidyl Peptidase from Porphyromonas gingivalis" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 14, April 1999 (1999-04), pages 9246-9252, XP002149297 the whole document	1-16, 18-20
A	--- KABASHIMA, T. ET AL.: "Cloning, Sequencing, and Expression of the Dipeptidyl Peptidase IV Gene from Flavobacterium meningosepticum in Escherichia coli" ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, vol. 320, no. 1, 20 June 1995 (1995-06-20), pages 123-128, XP000925965 the whole document	1-16, 18-20
A	--- KURAMITSU, H.K.: "Proteases of Porphyromonas gingivalis: what don't they do?" ORAL MICROBIOLOGY AND IMMUNOLOGY, vol. 13, no. 5, October 1998 (1998-10), pages 263-270, XP000925947 abstract page 267, column 2, line 34 -page 268, column 1, line 58 -----	1-16, 18-20

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 00/05551

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
  
Although claims 15 and 16 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-16 AND 18-20 COMPLETELY

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

## 1. Claims: 1-16 and 18-20 completely

An isolated prolyl tripeptidyl peptidase, active analog, active fragment, or active modification thereof having amidolytic activity for cleavage of a peptide bond present in a target polypeptide having at least 4 amino acids; an isolated prolyl tripeptidyl peptidase, active analog, active fragment, or active modification thereof being isolated from *Porphyromonas gingivalis*; an isolated polypeptide, active analog, active fragment, or active modification thereof having amidolytic activity for cleavage of a peptide bond present in a target polypeptide having at least 4 amino acids; an isolated polypeptide comprising an amino acid sequence having a percentage amino acid identity of greater than 35% with SEQ ID NO: 30; an isolated nucleic acid fragment encoding a prolyl tripeptidyl peptidase, active analog, active fragment, or active modification thereof having amidolytic activity for cleavage of a peptide bond present in a target polypeptide having at least 4 amino acids, an isolated nucleic acid fragment encoding a polypeptide comprising an amino acid sequence having a percentage amino acid identity of greater than 35% with SEQ ID NO: 30; a method of identifying an inhibitor of a prolyl tripeptidyl peptidase, active analog, active fragment, or active modification thereof; a method of reducing growth of a bacterium comprising inhibiting a prolyl tripeptidyl peptidase, active analog, active fragment, or active modification thereof; an immunogenic composition comprising an isolated prolyl tripeptidyl peptidase, or an antigenic analog, antigenic fragment, or antigenic modification thereof, the prolyl tripeptidyl peptidase having amidolytic activity for cleavage of a peptide bond present in a target peptide having at least 4 amino acids; a composition comprising an inhibitor of an isolated prolyl tripeptidyl peptidase;

## 2. Claim : 17 partially and 21 completely

A method of reducing growth of a bacterium comprising inhibiting a prolyl dipeptidyl peptidase, active analog, active fragment, or active modification thereof; a dipeptidyl peptidase having an amino acid sequence comprising SEQ ID NO: 43;

## 3. Claim : 17 partially and 22 completely

A method of reducing growth of a bacterium comprising inhibiting a prolyl dipeptidyl peptidase, active analog, active fragment, or active modification thereof; a dipeptidyl peptidase having an amino acid sequence comprising SEQ ID NO: 44;

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

4. Claim : 17 partially and 23 completely

A method of reducing growth of a bacterium comprising inhibiting a prolyl dipeptidyl peptidase, active analog, active fragment, or active modification thereof; a dipeptidyl peptidase having an amino acid sequence comprising SEQ ID NO: 45.

### Information on patent family members

PCT/US 00/05551

Form PCT/ISA/210 (patent family annex) (July 1992)

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**